

## ASTRO 2024 Annual Meeting - Committee Disclosure of Relationships

The American Society for Radiation Oncology (ASTRO) is an Accreditation Council for Continuing Medical Education (ACCME) accredited CME provider and complies with the [ACCME Standards for Integrity and Independence in Accredited Continuing Education](#). In accordance with these Standards, the ASTRO Conflict of Interest Policy and the Council for Medical Specialty Societies' Code for Interactions with Companies, ASTRO is disclosing here the relationships between members of the committees charged with planning the Annual Meeting and other entities related to oncology or radiation therapy.

### Explanatory notes:

- ASTRO uses the information disclosed to identify and manage any potential conflicts of interest that may arise in carrying out the responsibilities of the Committees.
- Committee members disclose their own relationships and those of their immediate family members.
- There is no “minimum value” threshold for disclosure.
- Disclosure time period covers relationships held or payments received during the year leading up to the disclosure.
- The disclosure information at this link is relevant only to the planning of the 2024 Annual Meeting and should be considered out-of-date after this time.
- Information at this link may be different from disclosure information provided in other contexts by the Committee members because of variation in the disclosure requests for these other purposes.

**Employment/Leadership Positions** = positions held at the time of disclosure. These include both full- and part-time relationships, whether compensated or uncompensated.

**Compensation/Remuneration/Funding** = includes consultant/advisory roles, honoraria, research funding, travel expenses, in-kind donation, etc. If a Committee member receives an honorarium and donates it to charity, the honorarium is disclosed. If a Committee member declines an honorarium and it is paid directly to charity, the honorarium is not included. Honoraria from accredited CME providers are not included.

**Ownership or Investment Interests** = includes stock, stock options, partnership, royalties, or patents. *Stocks in mutual funds, blind trusts, or other holdings that are not controlled by the individual or an immediate family member are not included.*

**Leadership Positions**= positions held in other organizations or entities.

The ASTRO Conflict of Interest Policies are available at [www.astro.org/coipolicies](http://www.astro.org/coipolicies). Please direct any questions to [annualmeeting@astro.org](mailto:annualmeeting@astro.org).

**ASTRO 2024 Annual Meeting - Annual Meeting Steering Committee Disclosures**

| Member                    | Employment Relationships  |       | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria |          |   |  |  | Ownerships or Investment               | Leadership Positions  |
|---------------------------|---|-------|---|----------|---|--|--|--|---|
|                           | Employment  | Other | Advisory Board  | Research | Consultant/Speaker/Faculty or Other   | Method of Remuneration   | Description of Role  |  |   |
| <b>Beth Beadle</b>        | <b>Stanford University:</b><br>Professor: Employee  | None  | None  | None     | Other - Book writing and journal editing<br>Other - Book writing and journal editorial work | <b>Elsevier:</b> Other - Royalties<br><b>Wolters- Kluwer:</b> Other - Royalties                        | <b>Elsevier:</b> Book/journal publisher: Article writing and journal editorial work: Start Date: 1/1/2016- To Present<br><b>Wolters- Kluwer:</b> Book/journal publisher: Royalties from book writing: Start Date: 1/1/2016- To Present   | None                                   | None  |
| <b>Beth Erickson</b>      | <b>Medical College of Wisconsin:</b> Professor of Radiation Oncology: Employee                      | None  | None  | None     | None  | None   | None   | None                                   | <b>ASTRO:</b> ASTRO Board of Directors: Chair of the Education Council: Help to oversee the educational efforts of ASTRO: Not Compensated<br><b>ASTRO:</b> Fellows Committee: Chair: Oversee the induction of fellows into ASTRO: Not Compensated   |
| <b>Iris Gibbs</b>         | <b>Stanford Medicine:</b> Professor and Associate Dean: Employee                                    | None  | Ongoing: No access to proprietary info                          | None     | None  | <b>Accuray, Inc.:</b> Honoraria: Travel Expenses<br>University of Delaware CAS Dean's Advisory Council | <b>Accuray, Inc.:</b> Honoraria for lectures: Start Date: 08/01/2019- To Present<br><b>University of Delaware CAS Dean's Advisory Council:</b> Alumni advisory board: Start Date: 05/01/2019- To Present   | None                                   | <b>American College of Radiology:</b> Medical organization representing diagnostic and interventional radiologists, radiation oncologists, nuclear medicine physicians and medical physicists.: Member and Chapter leader: Serve on multiple chapters and committees including CARROS, CRS, Diversity Committee: Not Compensated<br><b>ICG Enterprises, Inc.:</b> 501(c)3 non- profit that dispenses educational scholarships and community outreach: Chief Officer: Founder of local non- profit: Not Compensated: Relationship Ended: 1/6/2023<br><b>The Radiosurgery Society:</b> The Radiosurgery Society® (RSS) is an international, medical professional, non- profit society consisting of physicians, physicists and healthcare professionals dedicated to advancing the education, science and clinical practice of stereotactic radiosurgery, stereotactic body radiation therapy and advancing therapies.: Board of Directors: Member of the Board of Directors: Not Compensated |
| <b>Surbhi Grover</b>      | <b>University of Pennsylvania:</b> Associate Professor Radiation Oncology: Employee                 | None  | None  | None     | Consultant  | <b>CDRF Global:</b> Compensation/Pay ment<br><b>GenesisCare:</b> Compensation/Pay ment                 | <b>CDRF Global:</b> NGO working with the State Dept on "Sustainable Dialogue on Peaceful uses of Radiation in Africa": Advising on topics for the dialogue: Start Date: 07/1/23- End Date: 12/1/23<br><b>GenesisCare:</b> Advising on global solutions: Start Date: 11/21/21- End Date: 11/21/23 | <b>Harbinger Health:</b> Stock Options | None  |
| <b>Rachel Jimenez</b>     | <b>Massachusetts General Hospital:</b> Attending Physician: Employee                                | None  | None  | None     | Consultant  | Lilly: Other - None  | <b>Lilly:</b> unpaid consulting: Advised on concurrent RT with systemic therapy in the metastatic setting: Start Date: 1/17/2022- End Date: 10/05/22   | None                                   | <b>American Society of Clinical Oncology:</b> Chair Elect, Ethics Committee: I am the Chair-Elect for the ASCO Ethics Committee. I coordinate and organize an agenda for the Ethics Committee.: Not Compensated<br><b>ASTRO:</b> Advances in Radiation Oncology: Editor-in-Chief: Editor-in-Chief: Not Compensated<br><b>SurvivingBreastCancer.org:</b> This is a non- profit advocacy organization for patients with breast cancer: Medical Advisory Board, Member: I advise the Director of SBC.org on strategy: Not Compensated  |
| <b>Sameer Keole</b>       | <b>Mayo Clinic:</b> Physician: Employee   | None  | None  | None     | None  | None   | None   | None                                   | None  |
| <b>Kenneth Rosenzweig</b> | <b>Mount Sinai:</b> Physician and Chair: Employee<br><b>City of Englewood:</b> Councilman: Employee | None  | None  | None     | None  | None   | None   | None                                   | <b>NRG Data Monitoring Committee:</b> Monitors NRG protocols: Member: Member of Committee: Not Compensated  |

**ASTRO 2024 Annual Meeting - Annual Meeting Steering Committee Disclosures**

| Member                 | Employment Relationships  |       | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria |  |                                     |   |  | Ownerships or Investment | Leadership Positions   |
|------------------------|---|-------|---|--|-------------------------------------|---|--|--------------------------|--|
|                        | Employment  | Other | Advisory Board  | Research   | Consultant/Speaker/Faculty or Other | Method of Remuneration  | Description of Role  |                          |  |
| <b>Howard Sandler</b>  | <b>Cedars-Sinai Medical Center:</b> Chair of Department of Radiation Oncology: Employee | None  | None  | None   | Consultant                          | Janssen: Uncompensated  | Janssen: Pharmaceutical entity: Member, clinical trial steering committee: Start Date: 2015- End Date: 9/23/2023   | None                     | None   |
| <b>Farzan Siddiqui</b> | <b>Henry Ford Health System:</b> Vice-Chair, Radiation Oncology : Employee              | None  | Ongoing: No access to proprietary info                          | My institution receives funding. No salary support in whole or part: site principal investigator             | Consultant Speaker Bureau           | <b>Castle Biosciences, Inc:</b> Honoraria: Travel Expenses<br><b>Varian Medical Systems Inc:</b> Grant/Research Funding: Honoraria: Travel Expenses | <b>Castle Biosciences, Inc:</b> Honorarium for consulting: Start Date: March 2022- To Present<br><b>Varian Medical Systems Inc:</b> Varian Clinical School- Head and neck instructor Varian Noona- Medical Advisory Board member: Start Date: 01/01/2019- To Present | None                     | <b>Henry Ford Cancer Institute:</b> Department of Radiation Oncology: Vice-Chair: Vice- Chair of radiation oncology operations: Not Compensated<br><b>Henry Ford Health:</b> Henry Ford Medical Group: Chair- Elect, HFMG Board of Governors: Conducting board meetings: Not Compensated |
| <b>Nicole Simone</b>   | <b>Thomas Jefferson University:</b> Vice Chair: Employee                                | None  | None  | My institution receives funding. No salary support in whole or part: national/overall principal investigator | None                                | <b>NCI:</b> Grant/Research Funding  | <b>NCI:</b> PI of 2 R01's and a U54: PI: Start Date: 8/1/17- To Present  | None                     | <b>ASTRO:</b> Chair SEPD committee: Chair: Chair SEPD committee: Not Compensated<br><b>RRS:</b> Councilor at Large: Councilor at Large: Councilor at Large: Not Compensated  |



**ASTRO 2024 Annual Meeting - Annual Meeting Education Committee Disclosures**

| Member                   | Employment Relationships   |       | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria                  |   |  |  | Ownerships or Investment Interests   | Leadership Positions |  |
|--------------------------|--|-------|--|---|--|--|--|----------------------|--|
|                          | Employment   | Other | Advisory Board   | Research  | Consultant/Speaker/Faculty or Other                                    | Method of Remuneration   |  |                      | Description of Role  |
| <b>Kevin Albuquerque</b> | <b>Simmons Comprehensive Cancer Center, UTSW:</b> Professor of Radiation Oncology: Employee      | None  | None   | None  | <b>Other</b> - volunteer surveyor<br><b>Other</b> - committee co-chair | <b>ACR:</b> Honoraria: Travel Expenses<br><b>Elsevier Clinical Path:</b> Compensation/Payment  | <b>ACR:</b> Surveyor(volunteer): volunteer surveyor for accreditation: Start Date: five years- To Present<br><b>Elsevier Clinical Path:</b> Clinical Pathways company: Co-Chair and Member of our ClinicalPath Physician Advisory Committee – Gynecological Radiation Oncology.: Start Date: Oct 2022- To Present  | None                 | None   |
| <b>Arya Amini</b>        | <b>City of Hope:</b> Associate professor: Employee   | None  | None   | I receive funding: No salary support in whole or part: national/overall principal investigator                  | Speaker Bureau   | <b>AstraZeneca:</b> Grant/Research Funding<br><b>Genentech:</b> Grant/Research Funding<br><b>RefleXion:</b> Grant/Research Funding<br><b>Takeda Pharmaceuticals:</b> Grant/Research Funding<br><b>Varian:</b> Grant/Research Funding | <b>AstraZeneca:</b> Speakers bureau: Start Date: 1/1/23- To Present<br><b>Genentech:</b> Genentech is providing drug only funding for a phase I trial of SBRT and atezolizumab: Start Date: 4/1/2022- End Date: 12/30/2024<br><b>RefleXion:</b> research funding evaluating role of BgRT in oligoprogressive NSCLC: Start Date: 5/1/2023- End Date: 12/30/2025<br><b>Takeda Pharmaceuticals:</b> Speakers bureau: Start Date: 1/1/2023- To Present<br><b>Varian:</b> grant funding evaluating the role of SBRT for oligoprogressive disease: Start Date: 4/1/2023- End Date: 12/1/25 | None                 | None   |
| <b>Carryn Anderson</b>   | <b>University of Iowa Hospitals &amp; Clinics:</b> Radiation Oncologist: Employee                |       | Ongoing: No access to proprietary info<br>Ongoing: No access to proprietary info | My Institution receives funding: No salary support in whole or part: site principal investigator                | Consultant   | None   | None   | None                 | <b>University of Iowa Hospitals &amp; Clinics:</b> Residency Program Director: Maintain ACGME accreditation for Radiation Oncology program: Not Compensated: Relationship Ended: 3/30/2023 |
| <b>Anthony Apicelli</b>  | <b>Washington University School of Medicine:</b> Asst. Professor of Radiation Oncology: Employee |       | Ongoing: No access to proprietary info<br>Ongoing: No access to proprietary info | My Institution receives funding: No salary support in whole or part: other: Testing drugs in preclinical models | Faculty Consultant   | None   | None   | None                 | <b>University of Iowa Hospitals &amp; Clinics:</b> Residency Program Director: Maintain ACGME accreditation for Radiation Oncology program: Not Compensated: Relationship Ended: 3/30/2023 |









**ASTRO 2024 Annual Meeting - Annual Meeting Education Committee Disclosures**

| Member               | Employment Relationships   |       | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria |  |                                     |   |  | Ownerships or Investment Interests                   | Leadership Positions  |
|----------------------|--|-------|---|--|-------------------------------------|---|--|--|---|
|                      | Employment   | Other | Advisory Board  | Research   | Consultant/Speaker/Faculty or Other | Method of Remuneration  | Description of Role  |  |   |
| <b>Idalid Franco</b> | <b>Brigham and Women's Hospital Dana-Farber CC:</b><br>Radiation Oncologist:<br>Employee | None  | None  | My Institution receives funding:<br>No salary support in whole or part:<br>national/overall principal investigator<br>I recieve funding:<br>No salary support in whole or part:<br>other: Career Development Award<br>My Institution receives funding:<br>No salary support in whole or part:<br>site principal investigator<br>I recieve funding:<br>No salary support in whole or part:<br>site principal investigator | None                                | <b>ASTRO/RTOG NRG Oncology Health Equity Fellowship:</b> Grant/Research Funding<br>Brigham and Women's Hospital Dana-Farber CC: Grant/Research Funding<br><b>Diversity Supplement, National Cancer Institute:</b> Grant/Research Funding<br><b>NIH/NCI Loan Repayment Program:</b> Grant/Research Funding | <b>ASTRO/RTOG NRG Oncology Health Equity Fellowship:</b> National organizations focused on oncology.: PI working on increasing diversity of representation in gynecologic clinical trials.:<br>Start Date: February 2023- To Present<br><b>Brigham and Women's Hospital Dana-Farber CC:</b> Center for Diversity and Inclusion: Career Development Award for Minority Faculty: Start Date: 07/2022 - To Present<br><b>Diversity Supplement, National Cancer Institute:</b> Center to reduce cancer health disparities, National Cancer Institute: Biomarker approaches to high- risk prostate cancer: Start Date: 09/2021- To Present<br><b>NIH/NCI Loan Repayment Program:</b> National Cancer Institute: Cost effectiveness for prostate cancer treatment: Start Date: 07/2022- To Present | None   | <b>American Society of Radiation Oncology ASTRO:</b> Vice Chair of the Health Equity Education Committee: Vice Chair: Vice Chair of the Health Equity Education Committee for the Council on Health Equity Diversity and Inclusion of ASTRO: Not Compensated: Relationship Ended: 10/3/2022<br><b>Association of Residents in Radiation Oncology:</b> Resident branch of ASTRO: Executive Vice Chair: Executive Vice Chair of overall organization and Chair of the Equity and Inclusion Subcommittee: Not Compensated: Relationship Ended: 10/3/2022 |
| <b>Naamit Gerber</b> | <b>NYU Langone Health:</b><br>Associate Professor:<br>Employee                           | None  | Single: No access to proprietary info                           | My Institution receives funding:<br>No salary support in whole or part:<br>other: Research collaboration   | Faculty                             | <b>Accuray:</b> Honoraria<br>John Theurer Cancer Center: Honoraria<br><b>Mount Sinai Icahn School of Medicine:</b> Honoraria<br>PreludeDx: Grant/Research Funding   | <b>Accuray:</b> Accuray breast advisory board at ASTRO 2023: Start Date: 10/1/23- End Date: 10/3/23<br><b>John Theurer Cancer Center: academic institution:</b> SABCS update symposium: Start Date: 01/01/2022- To Present<br><b>Mount Sinai Icahn School of Medicine:</b> Academic institution: grand rounds honoraria: Start Date: 08/05/2022- End Date: 08/05/2022<br><b>PreludeDx:</b> Company: early stage breast cancer: Start Date: 08/01/2022- To Present  | None   | <b>ASTRO:</b> ASTRO APBI Guidelines Committee: member: Serve on ASTRO APBI guidelines committee and chair of one of the key question committees: Not Compensated  |
| <b>Beant Gill</b>    | <b>Associates in Radiation Medicine:</b> Physician:<br>Partner                           | None  | None  | None   | Other - Faculty                     | None  | None   | <b>Associates in Radiation Medicine:</b> Partnership | <b>American College of Radiology:</b> Organization for radiology and radiation oncology: CAC Representative: Representative for local coverage determination review of radiation oncology services: Not Compensated<br><b>Chesapeake Potomac Regional Cancer Center:</b> Community practice for radiation oncology services: Medical Director: Medical director for clinical operations: Not Compensated  |

**ASTRO 2024 Annual Meeting - Annual Meeting Education Committee Disclosures**

| Member         | Employment Relationships  |       | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria |          |                                     |   | Ownerships or Investment Interests                                      | Leadership Positions   |
|----------------|---|-------|---|----------|-------------------------------------|---|---|--|
|                | Employment  | Other | Advisory Board  | Research | Consultant/Speaker/Faculty or Other | Method of Remuneration                          |   |  |
| Scott Glaser   | City of Hope: Radiation Oncologist: Employee  | None  | None  | None     | None                                | None  | None  | None   |
| Vinai Gondi    | Radiation Oncology Consultants, LLC: Physician Partner: Partner   | None  | None  | None     | None                                | None  | None  | None   |
| Craig Grossman | University of South Florida: Associate Professor: Employee<br>Tampa General Hospital: Staff Physician: Employee | None  | None  | None     | None                                | None  | None  | None   |
| Daniel Hamstra | Baylor College of Medicine: Professor and Chairman: Employee  | None  | None  | None     | Consultant                          | Boston Scientific: Uncompensated: Other - Meals | Boston Scientific: Company: Advisory role: Start Date: 2020- To Present | None   |
| Charles Hsu    | Banner- University of Arizona Medical Center: Associate Professor of Radiation Oncology: Employee               | None  | None  | None     | None                                | None  | None  | Univ of Arizona Dept of Radiation Oncology: University of Arizona Cancer Center Department of Radiation Oncology Research: Vice Chairman of Clinical Research: head of clinical research within department of radiation oncology: Not Compensated: Relationship Ended: 6/30/2023<br>University of Arizona Cancer Center: Clinical Trials Office: Medical Director: Medical Director of Clinical Trials Office for Cancer Center: Not Compensated |



**ASTRO 2024 Annual Meeting - Annual Meeting Education Committee Disclosures**

| Member         | Employment Relationships                                |       | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria |   |                                     |  |   | Ownerships or Investment Interests | Leadership Positions   |
|----------------|---|-------|---|---|-------------------------------------|--|---|------------------------------------|--|
|                | Employment  | Other | Advisory Board  | Research  | Consultant/Speaker/Faculty or Other | Method of Remuneration   | Description of Role   |                                    |  |
| Elizabeth Kidd | Stanford University: Associate Professor: Employee      | None  | None  | My Institution receives funding: No salary support in whole or part: site principal investigator  | None                                | Viewray: Grant/Research Funding  | Viewray: Use of viewray for cervix cancer fractionated radiation: Start Date: Feb. 2021- To Present   | None                               | ABS Quality & Safety Standard Committee: Co- Leader: Oversee the ABS Quality and Safety Standards Committee.: Not Compensated  |
| Edward Kim     | University of Washington: Associate Professor: Employee | None  | None  | None  | None                                | None   | None  | None                               | NCCN: Soft tissue sarcoma panel member: NCCN soft tissue sarcoma panel member: Not Compensated   |
| Michelle Kim   | University of Michigan: Professor: Employee             | None  | Ongoing: No access to proprietary info                          | My Institution receives funding: No salary support in whole or part: site principal investigator<br>My Institution receives funding: No salary support in whole or part: national/overall principal investigator<br>My Institution receives funding: No salary support in whole or part: other: Co-investigator | Faculty Consultant<br>Faculty       | ASTRO Annual Meeting Education Committee: Uncompensated<br>BlueEarth Diagnostics: Grant/Research Funding: Honoraria<br>Capital Health: Travel Expenses<br>Nebraska Oncology Society: Honoraria<br>NIH: Grant/Research Funding<br>NIH: Travel Expenses: Salary Support<br>PeerView: Honoraria: Travel Expenses<br>Stanford U54 MetNet Advisory Board: Uncompensated | ASTRO Annual Meeting Education Committee: Chair, ASTRO Annual Meeting Education Committee CNS Track: Start Date: 2023- To Present<br>BlueEarth Diagnostics: Molecular imaging company: Site PI for a national trial, served as a consultant for a one-time workshop (completed): Start Date: 2020- To Present<br>Capital Health: Medical group: Invited speaker for one- time conference (completed): Start Date: 2022- End Date: 2022<br>Nebraska Oncology Society: Professional non profit scientific society: Invited speaker for an educational event (completed): Start Date: 2022- End Date: 2022<br>NIH: Co- investigator of an ongoing NIH- funded research study: Start Date: 2021- End Date: 2026<br>NIH: Principal Investigator, R50 Research Specialist: Start Date: 2023- End Date: 2028<br>PeerView: CME company: Faculty speaker at SNO Annual Meeting at Industry- sponsored educational event: Start Date: 11/16/23- End Date: 11/16/23<br>Stanford U54 MetNet Advisory Board: | None                               | NCCN CNS Guidelines Committee Member: National Comprehensive Cancer Center Guidelines: Member: Member: Not Compensated<br>Neuro-Oncology Editorial Board Member: Neuro- Oncology (Journal) Editorial Board Member: Board Member: Board member: Not Compensated<br>Red Journal: ASTRO Scientific Journal: CNS Section Editor: Section Editor for CNS: Not Compensated |



**ASTRO 2024 Annual Meeting - Annual Meeting Education Committee Disclosures**

| Member                 | Employment Relationships   |       | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria |  |                                     |  | Ownerships or Investment Interests  | Leadership Positions |  |
|------------------------|--|-------|---|--|-------------------------------------|--|---|----------------------|--|
|                        | Employment   | Other | Advisory Board  | Research   | Consultant/Speaker/Faculty or Other | Method of Remuneration   |   |                      | Description of Role  |
| <b>Malcolm Mattes</b>  | <b>Rutgers Cancer Institute of New Jersey:</b> Associate Professor: Employee | None  | None  | I recieve funding: No salary support in whole or part: other: Career Development<br>I recieve funding: No salary support in whole or part: site principal investigator<br>I recieve funding: No salary support in whole or part: national/overall principal investigator | None                                | <b>Bristol Myers Squibb Foundation:</b> Grant/Research Funding<br><b>New Jersey Health Foundation:</b> Grant/Research Funding<br><b>Radiation Oncology Institute:</b> Grant/Research Funding | <b>Bristol Myers Squibb Foundation:</b> Career Development Award: Career Development Award: Start Date: 11/01/2021- End Date: 12/31/2023<br><b>New Jersey Health Foundation:</b> Research Funding: Research Funding: Start Date: 02/15/2022- End Date: 2/14/2024<br><b>Radiation Oncology Institute:</b> Research Funding: Research Funding: Start Date: 11/01/2020- End Date: 10/31/2023 | None                 | <b>ASTRO:</b> Communications Committee: Vice Chair<br>: Communications Committee Vice Chair: Not Compensated<br><b>University Hospital Cancer Center:</b> ACOS CoC Cancer Liaison Physician: Not Compensated |
| <b>Mahta McKee</b>     | <b>Wake Forest UniversitySchool of Medicine:</b> medical Physicist: Employee | None  | None  | None   | None                                | None   | None  | None                 | None   |
| <b>Omar Mian</b>       | <b>Cleveland Clinic:</b> Staff: Employee                                     | None  | None  | My Institution receives funding: No salary support in whole or part: site principal investigator<br>My Institution receives funding: No salary support in whole or part: site principal investigator   | Consultant                          | <b>Bayer:</b> Compensation/Pay ment<br><b>Gilead:</b> Grant/Research Funding<br><b>Varian:</b> Grant/Research Funding  | <b>Bayer:</b> Corporation: Consultant Prostate Cancer: Start Date: Jan 2022- To Present<br><b>Gilead:</b> Company: PI Research (Clinical Trial): Start Date: Dec 2022- To Present<br><b>Varian:</b> Company: PI Research Grant: Start Date: Dec 2022- To Present  | None                 | <b>NCCN:</b> Guidelines: Panel Member: NCCN Panel Member: Not Compensated  |
| <b>George Mikhaeel</b> | <b>Guy's &amp; St Thomas NHS Hospital:</b> Clinical Oncologist: Employee     | None  | None  | None   | Faculty                             | <b>Kite:</b> Honoraria: Travel Expenses  | <b>Kite:</b> Speaker in a scientific meeting: Invited speaker about Role of radiotherapy with CAR-T: Start Date: 5 October 2022 - End Date: 5 October 2022  | None                 | None   |
| <b>Sarah Milgrom</b>   | <b>University of Colorado:</b> Associate Professor: Employee                 | None  | None  | None   | Consultant                          | <b>Bristol Myers Squibb:</b> Uncompensated   | <b>Bristol Myers Squibb:</b> Provided advice regarding PET volumetric research for a pediatric Hodgkin lymphoma study: Provided advice to researchers at Bristol Myers Squibb regarding PET volumetric research for a pediatric Hodgkin lymphoma study: Start Date: 7/1/23- To Present  | None                 | <b>American Radium Society:</b> Appropriate Use Criteria Lymphoma Committee: Vice Chair: work with a committee to develop guidelines regarding lymphoma sub-topics: Not Compensated                          |

**ASTRO 2024 Annual Meeting - Annual Meeting Education Committee Disclosures**

| Member                 | Employment Relationships   |       | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria |  |   |   | Ownerships or Investment Interests  | Leadership Positions |  |
|------------------------|--|-------|---|--|---|---|---|----------------------|--|
|                        | Employment   | Other | Advisory Board  | Research   | Consultant/Speaker/Faculty or Other   | Method of Remuneration  |   |                      | Description of Role  |
| <b>Timur Mitin</b>     | <b>Oregon Health and Science University:</b><br>Associate Professor:<br>Employee                         | None  | Ongoing: No access to proprietary info                          | My Institution receives funding: No salary support in whole or part: national/overall principal investigator<br>My Institution receives funding: No salary support in whole or part: national/overall principal investigator | Speaker<br>BureauFaculty<br>Other - Clinical Events Committee (CEC) for clinical study BP-007<br>ConsultantSpeaker<br>BureauFaculty<br>Other - Chapter author | <b>AstraZeneca:</b> Grant/Research Funding: Honoraria: Travel Expenses<br><b>Bioprotect Ltd.:</b> Honoraria<br><b>Novocure, Inc.:</b> Grant/Research Funding: Honoraria: Travel Expenses: Compensation/Payment<br><b>UpToDate Inc.:</b> Other - Royalties | <b>AstraZeneca:</b> Pharmaceutical Company: Radiation Oncology in management of Stage III NSCLC: Start Date: 3/1/2020- To Present<br><b>Bioprotect Ltd.:</b> Technology platform company that provides innovative bioabsorbable spacers.: CEC primary reviewer: Start Date: 1/1/2022- To Present<br><b>Novocure, Inc.:</b> Oncology company pioneering a novel therapy for solid tumors called Tumor Treating Fields: Prophylactic TTF in SCLC: Start Date: 5/1/2015- To Present<br><b>UpToDate Inc.:</b> Evidence- based clinical resource for practicing clinicians: Chapter Author: "Radiation therapy techniques in cancer treatment": Start Date: 1/1/2014- To Present | None                 | None   |
| <b>Najeeb Mohideen</b> | <b>Northwest Community Hospital, Arlington Heights, IL:</b> Radiation Oncologist: Independent Contractor | None  | None  | None   | None  | None  | None  | None                 | <b>The Radiosurgery Society:</b> The Radiosurgery Society: President: President: Not Compensated |
| <b>Shalini Moningi</b> | <b>Brigham and Women's Hospital:</b> Attending Physician: Employee                                       | None  | None  | None   | None  | None  | None  | None                 | None   |
| <b>Sabin Motwani</b>   | <b>RWJBarnabas Health Medical Group:</b> Radiation Oncologist: Employee                                  | None  | None  | None   | None  | None  | None  | None                 | None   |
| <b>Erin Murphy</b>     | <b>Cleveland Clinic:</b> Associate Professor: Employee   | None  | None  | None   | None  | None  | None  | None                 | None   |
| <b>Chirayu Patel</b>   | <b>MGH:</b> Radiation Oncologist: Employee   | None  | None  | My Institution receives funding: No salary support in whole or part: national/overall principal investigator   | None  | <b>Varian:</b> Grant/Research Funding   | <b>Varian:</b> Radiation technology company: Adaptive Radiation in Lymphoma: Start Date: 10/2023- To Present  | None                 | None   |

**ASTRO 2024 Annual Meeting - Annual Meeting Education Committee Disclosures**

| Member                       | Employment Relationships  |       | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria   |  |  |  | Ownerships or Investment Interests  | Leadership Positions |                     |
|------------------------------|---|-------|---|--|--|--|---|----------------------|---------------------|
|                              | Employment  | Other | Advisory Board  | Research   | Consultant/Speaker/Faculty or Other                            | Method of Remuneration   |   |                      | Description of Role |
| <b>Bradford Perez</b>        | <b>Moffitt Cancer Center:</b><br>Associate Member:<br>Employee                          | None  | Single: No access to proprietary info<br>Single: No access to proprietary info<br>Single: No access to proprietary info | My Institution receives funding:<br>No salary support in whole or part:<br>national/overall principal investigator | Faculty  | <b>AstraZeneca:</b> Compensation/Pay ment<br><b>BMS:</b> Grant/Research Funding<br><b>Daiichi Sankyo:</b> Honoraria<br><b>G1 Therapeutics:</b> Compensation/Pay ment | <b>AstraZeneca:</b> advisory board: Start Date: 11/15/2020- To Present<br><b>BMS:</b> site PI for IIT: Start Date: ongoing- To Present<br><b>Daiichi Sankyo:</b> ASCO Advantage Education Faculty: Start Date: 11/22/22- End Date: 11/22/22<br><b>G1 Therapeutics:</b> advisory board: Start Date: 4/13/2021- End Date: 4/13/2021   | None                 | None                |
| <b>Subha Perni</b>           | <b>The University of Texas MD Anderson Cancer Center:</b> Assistant Professor: Employee | None  | None  | None   | None   | None   | None  | None                 | None                |
| <b>Erqi Pollom</b>           | <b>Stanford:</b> Associate Professor: Employee  | None  | Ongoing: No access to proprietary info<br>Ongoing: No access to proprietary info  | None   | None   | <b>GT Medical Technologies:</b> Compensation/Pay ment<br><b>Varian:</b> Honoraria<br>Vysioneer   | <b>GT Medical Technologies:</b> Gammatile therapy: serve on ad board for use of gamma tiles for brain tumors: Start Date: Sept 1, 2023- To Present<br><b>Varian:</b> honoraria for being an instructor at Varian school: Start Date: Jan 1, 2023- To Present<br><b>Vysioneer:</b> Autosegmentation company: Advisory board, CNS expertise: Start Date: 1/2022- To Present | None                 | None                |
| <b>Christopher Hays Pope</b> | <b>Radiation Oncology Associates P.A.:</b> Vice President: Partner                      | None  | None  | None   | None   | None   | None  | None                 | None                |
| <b>Dominique Rash</b>        | <b>UCSD Health:</b> Radiation oncologist: Employee                                      | None  | None  | None   | Other - Speaker re: Radformation products<br>Speaker<br>Bureau | <b>Radformation:</b> Honoraria<br><b>VisionRT:</b> Honoraria: Travel Expenses  | <b>Radformation:</b> creates radiation planning software products: Discussed EZ fluence and other products at vendor booth: Start Date: 10/26/22- End Date: 10/27/22<br><b>VisionRT:</b> Creates radiation set up prodcuts: discussed use of AlignRT: Start Date 3/2022- End Date: 10/27/2022   | None                 | None                |
| <b>Lei Ren</b>               | <b>University of Maryland:</b> Professor: Employee                                      | None  | None  | None   | None   | None   | None  | None                 | None                |
| <b>Danielle Rodin</b>        | <b>University Health Network:</b> Radiation Oncologist: Employee                        | None  | Ongoing: No access to proprietary info  | None   | Consultant   | <b>Need Inc:</b> Compensation/Pay ment<br><b>Union for International Cancer Control:</b> Travel Expenses: Uncompensated  | <b>Need Inc:</b> company focused on quality assurance in cancer care: provide expertise on breast cancer management: Start Date: June 2022- To Present<br><b>Union for International Cancer Control:</b> non-governmental cancer advocacy organization: Elected member of Board of Directors: Start Date: October 2018- To Present  | None                 | None                |



**ASTRO 2024 Annual Meeting - Annual Meeting Education Committee Disclosures**

| Member                     | Employment Relationships  |       | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria                 |  |                                     |   | Ownerships or Investment Interests  | Leadership Positions  |   |
|----------------------------|---|-------|---|--|-------------------------------------|---|---|---|---|
|                            | Employment  | Other | Advisory Board  | Research   | Consultant/Speaker/Faculty or Other | Method of Remuneration  |   |   | Description of Role   |
| <b>Parag Sanghvi</b>       | <b>University of California, San Diego:</b> Professor: Employee     | None  | None  | None   | None                                | None  | None  | None  |   |
| <b>Stephanie Schaub</b>    | <b>University of Washington:</b> Assistant Professor : Employee     | None  | None  | None   | None                                | None  | None  | None  |   |
| <b>Jonathan Schoenfeld</b> | <b>Brigham and Women's Hospital:</b> Radiation Oncologist: Employee | None  | Ongoing: No access to proprietary info<br>Single: No access to proprietary info | My Institution receives funding: No salary support in whole or part: national/overall principal investigator | Consultant Faculty                  | <b>ACI Clinical:</b> Compensation/Pay ment<br><b>Astellas</b><br><b>Bristol Myers Squibb:</b> Grant/Research Funding<br><b>Castle Biosciences</b><br><b>Debiopharm</b><br><b>EMD Serono:</b> Grant/Research Funding: Compensation/Pay ment<br><b>Genentech:</b> Compensation/Pay ment<br><b>Immunitas:</b> Compensation/Pay ment<br><b>Merck:</b> Grant/Research Funding<br><b>Merck KGaA:</b> Compensation/Pay ment<br><b>Regeneron:</b> Grant/Research Funding<br><b>Sirpant:</b> Compensation/Pay ment | <b>ACI Clinical:</b> DMB: Start Date: 2018- End Date: 2021<br><b>Astellas:</b> Immunotherapy: Start Date: 2021- End Date: 2021<br><b>Genentech:</b> Radiation and immune therapy: Start Date: 2021-End Date: 2022<br><b>Immunitas:</b> Scientific Advisory board: Start Date: 2020- To Present<br><b>Merck:</b> Investigator initiated clinical trial: Start Date: 2016- To Present<br><b>Merck KGaA:</b> Steering committee: Start Date: 2021- To Present<br><b>Regeneron:</b> Radiation and immune therapy: Start Date: 2017- To Present<br><b>Sirpant:</b> Immunotherapy: Start Date: 2022- End Date: 2022 | <b>Doximity:</b> Stock: Relationship Ended: 7/1/2022<br><b>Immunitas:</b> Stock Options | None  |
| <b>Arshin Sheybani</b>     | <b>UnityPoint Health:</b> Physician: Employee                       | None  | None  | My Institution receives funding: No salary support in whole or part: national/overall principal investigator | Speaker Bureau                      | <b>Alliance for Clinical Trials Foundation:</b> Grant/Research Funding: Travel Expenses<br>PRO annual meeting: Honoraria  | <b>Alliance for Clinical Trials Foundation:</b> national network of clinical trials: evaluating the benefit of a course of vit E and trental in implant based PMRT patients: Start Date: 1/2018- End Date: 1/2020<br><b>PRO annual meeting:</b> education session at annual meeting to discuss management of head and neck cancers: invited speaker to discuss work and management of tonsillar cancer in a SA-CME session at annual meeting: Start Date: 10/2021 - End Date: 10/2021   | None  | <b>ASTRO:</b> Nominating Committee: community practice physician: member of ASTRO nominating committee for leadership appointments: Not Compensated<br><b>ASTROnews:</b> magazine publication for ASTRO: editorial board member: select topics for publication: Not Compensated<br><b>IWORC-NCORP:</b> review NCORP grant: board member: voting member to designate inclusion of cancer centers and providers into our NCORP: Not Compensated<br><b>Rectal Anal Task Force:</b> a subcommittee of the NCI GI steering committee: community oncologist representative: a member of the committee with 3 year term. we have monthly meetings to discuss development of clinical trials for rectal and anal cancers: Not Compensated |



**ASTRO 2024 Annual Meeting - Annual Meeting Education Committee Disclosures**

| Member                  | Employment Relationships   |       | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria                  |  |                                     |   | Ownerships or Investment Interests  | Leadership Positions |  |
|-------------------------|--|-------|--|--|-------------------------------------|---|---|----------------------|--|
|                         | Employment   | Other | Advisory Board   | Research   | Consultant/Speaker/Faculty or Other | Method of Remuneration  |   |                      | Description of Role  |
| <b>Mylin Torres</b>     | <b>Emory University:</b><br>Professor: Employee                              | None  | Single: No access to proprietary info  | My Institution receives funding: No salary support in whole or part: national/overall principal investigator<br>My Institution receives funding: No salary support in whole or part: national/overall principal investigator | Consultant/Speaker Bureau           | <b>Genentech:</b> Grant/Research Funding<br><b>Oncohealth:</b> Compensation/Payment<br><b>Pfizer:</b> Grant/Research Funding<br><b>Pfizer Oncology:</b> Honoraria<br><b>Varian Medical Systems:</b> Honoraria | <b>Genentech:</b> IIS research award: PI: Start Date: 10/2020- End Date: 8/2023<br><b>Oncohealth:</b> Utilization management: Utilization management, consultant on radiotherapy toxicity management: Start Date: 11/2020- End Date: 5/2023<br><b>Pfizer:</b> ASPIRE research grant award to fund a clinical trial: PI of a clinical trial: Start Date: 8/2018- To Present<br><b>Pfizer:</b> Pfizer Global Breast Cancer Research Award: PI of Phase II trial: Start Date: 10/2020- End Date: 8/2023<br><b>Pfizer Oncology:</b> Pharmaceutical Company: Advisory role on real world applications of palbociclib: Start Date: 11/2021- End Date: 11/2021<br><b>Varian Medical Systems:</b> Speaker: Breast cancer radiation oncology education: Start Date: 1/3/20 |                      |  |
| <b>C Jillian Tsai</b>   | <b>Princess Margaret Cancer Centre:</b> Staff Radiation Oncologist: Employee | None  | Ongoing: No access to proprietary info<br>Ongoing: No access to proprietary info | None   | None                                | <b>Nanobiotix:</b> Uncompensated<br><b>Varian Medical Inc.:</b> Grant/Research Funding: Honoraria   | <b>Nanobiotix:</b> Provides feedback on clinical trial ideas.: Start Date: 2022- To Present<br><b>Varian Medical Inc.:</b> Speaker and consultant for the company's educational events: Start Date: 2020- To Present  | None                 | <b>Advances in Radiation Oncology:</b> Deputy Editor: Deputy Editor: Not Compensated   |
| <b>Derek Tsang</b>      | <b>University Health Network:</b> Radiation Oncologist: Employee             | None  | None   | None   | Faculty Consultant                  | <b>Elekta:</b> Travel Expenses Need: Compensation/Payment   | <b>Elekta:</b> Radiation equipment vendor: Invited faculty at SOMERA, Mexican radiation oncology society meeting. Travel was supported by Elekta.: Start Date: 12/2022- End Date: 12/2022<br><b>Need:</b> Health care insurance company (https://www.getneed.com): I serve as a consultant regarding pediatric tumour cases for their insurance product: Start Date: 11/2022- To Present  | None                 | None   |
| <b>Alfredo Urdaneta</b> | <b>Virginia Commonwealth University:</b> Assistant Professor: Employee       | None  | None   | None   | None                                | None  | None  | None                 | None   |
| <b>Michael Velec</b>    | <b>University Health Network:</b> Radiation Therapist: Employee              | None  | Ongoing: No access to proprietary info   | None   | None                                | <b>CRUK RadNet Manchester Scientific Advisory Board:</b> Honoraria: Travel Expenses   | <b>CRUK RadNet Manchester Scientific Advisory Board:</b> Research program: Member of scientific advisory board: Start Date: 9/22/2021- To Present   | None                 | None   |
| <b>Edina Wang</b>       | <b>Duke University Hospital:</b> Physician: Employee                         | None  | None   | None   | None                                | None  | None  | None                 | <b>ASTRO Advances in Radiation Oncology:</b> CME Editor and Special Issues Editor: CME Editor and Special Issues Editor: Not Compensated |





**ASTRO 2024 Annual Meeting - Annual Meeting Scientific Committee Disclosures**

| Member                    | Employment Relationships   |       | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria                |  |                                     |   |   | Ownerships or Investment Interests | Leadership Positions   |
|---------------------------|--|-------|--|--|-------------------------------------|---|---|------------------------------------|--|
|                           | Employment   | Other | Advisory Board   | Research   | Consultant/Speaker/Faculty or Other | Method of Remuneration  | Description of Role   |                                    |  |
| <b>Kenneth Rosenzweig</b> | Mount Sinai: Physician and Chair: Employee<br>City of Englewood: Councilman: Employee                    | None  | None   | None   | None                                | None  | None  | None                               | <b>NRG Data Monitoring Committee:</b><br>Monitors NRG protocols: Member:<br>Member of Committee: Not Compensated   |
| <b>Farzan Siddiqui</b>    | Henry Ford Health System: Vice-Chair, Radiation Oncology: Employee                                       | None  | Ongoing: No access to proprietary info   | My Institution receives funding: No salary support in whole or part: site principal investigator | Consultant Speaker Bureau           | Castle Biosciences, Inc: Honoraria: Travel Expenses<br>Varian Medical Systems Inc: Grant/Research Funding: Honoraria: Travel Expenses | Castle Biosciences, Inc: Honorarium for consulting: Start Date: March 2022- To Present<br>Varian Medical Systems Inc: Varian Clinical School- Head and neck instructor Varian Noona- Medical Advisory Board member: Start Date: 01/01/2019- To Present  | None                               | <b>Henry Ford Cancer Institute:</b><br>Department of Radiation Oncology: Vice-Chair: Vice- Chair of radiation oncology operations: Not Compensated<br><b>Henry Ford Health:</b> Henry Ford Medical Group: Chair- Elect, HFMG Board of Governors: Conducting board meetings: Not Compensated  |
| <b>Andrea Ng</b>          | Brigham and Women's Hospital and Dana Farber Cancer Institute: Professor of Radiation Oncology: Employee | None  | None   | None   | None                                | UptoDate: Other - Royalty   | UptoDate: Publishing: Writing contribution: Start Date: to present- To Present  | None                               | <b>American Board of Radiology:</b><br>Medical Board:Trustee: Exam management: Not Compensated   |
| <b>Richard Bakst</b>      | Mount Sinai Hospital: Professor: Employee  | None  | None   | None   | None                                | None  | None  | None                               | None   |
| <b>Leslie Ballas</b>      | Cedars Sinai Medical Center: Physician: Employee   | None  | Single: No access to proprietary info<br>Single: No access to proprietary info | None   | Consultant                          | Blue Earth: Compensation/Pay ment<br>Pfizer: Compensation/Pay ment<br>UpToDate: Honoraria   | Blue Earth: Diagnostic/imaging: new diagnostic agents for PET imaging in prostate cancer: Start Date: 12/7/22- End Date: 12/7/22<br>Pfizer: Drug company: Advisory Board on advanced prostate cancer treatment: Start Date: 11/11/22- End Date: 11/11/22<br>UpToDate: Online educational materials: Edit online educational review materials: Start Date: 12/2023- To Present | None                               | American Board of Radiology: Organization in charge of board certification and maintenance:Chair hematologic malignancy section of oral boards:In charge of heme section of oral exam prep and delivery:Not Compensated<br><b>UroToday:</b> Online resource for urologists/medical oncologists/radiation oncologists for urologic malignancies: Editor: Provide content, reviews, interviews for bladder preservation section of website:Not Compensated |



**ASTRO 2024 Annual Meeting - Annual Meeting Scientific Committee Disclosures**

| Member                 | Employment Relationships  |       | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria |  |  |   |  | Ownerships or Investment Interests     | Leadership Positions  |
|------------------------|---|-------|---|--|--|---|--|--|---|
|                        | Employment  | Other | Advisory Board  | Research   | Consultant/Speaker/Faculty or Other  | Method of Remuneration  | Description of Role  |  |   |
| Daniel Golden          | Rush University Medical Center: Associate Professor: Employee                             | None  | None  | My Institution receives funding: No salary support in whole or part: site principal investigator<br>My Institution receives funding: No salary support in whole or part: national/overall principal investigator | None   | National Institutes of Health: Grant/Research Funding<br>Radiation Oncology Institute: Grant/Research Funding   | National Institutes of Health: Cancer education: Start Date: 2019- End Date: 2023<br>Radiation Oncology Institute: Patient education: Start Date: 2020- End Date: 2023   | RadOncQuestions LLC: Limited Liability | Radiation Oncology Education Collaborative Study G: Non-profit dedicated to improving radiation oncology education worldwide: Chair: Chair of executive committee: Not Compensated  |
| Inga Grills            | Beaumont/Corewell Health: Professor, Chief Thoracic Section, Director GK Center: Employee | None  | None  | None   | None   | None  | None   | None                                   | None  |
| B. Ashleigh Guadagnolo | MD Anderson: Professor: Employee  | None  | None  | None   | None   | None  | None   | None                                   | None  |
| Jillian Gunther        | MD Anderson Cancer Center: Associate Professor: Employee                                  | None  | None  | I receive funding: No salary support in whole or part: other: Researcher   | Faculty Other - I served as an examiner for the Mock Oral board review course. | NIH NCI R25 grant: Grant/Research Funding<br>Osler Institute: Honoraria<br>The Sterling Foundation: Other - Philanthropic donation<br>University of Maryland Board Review Course: Honoraria | NIH NCI R25 grant: R25 grant to support summer medical student research: R25 grant to support summer medical student research: Start Date: 2023- To Present<br>Osler Institute: I served as an examiner for the Mock Oral board review course.: I served as an examiner for the Mock Oral board review course.: Start Date: 3/2020- To Present<br>The Sterling Foundation: Philanthropic funds to support research and education: Philanthropic donation: Start Date: 2021- To Present<br>University of Maryland Board Review Course: I served as an examiner for the Mock Oral board review course.: I served as an examiner for the Mock Oral board review course.: Start Date: 3/2020- To Present | None                                   | Rad Onc Education Collaborative Study Group: International group dedicated to promoting rad onc education: Board Member: Serve as on the leadership team of the organization and the co-lead the UME Working Group: Not Compensated |





**ASTRO 2024 Annual Meeting - Annual Meeting Scientific Committee Disclosures**

| Member            | Employment Relationships   |       | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria |  |                                     |   |  | Ownerships or Investment Interests | Leadership Positions   |
|-------------------|--|-------|---|--|-------------------------------------|---|--|------------------------------------|--|
|                   | Employment   | Other | Advisory Board  | Research   | Consultant/Speaker/Faculty or Other | Method of Remuneration  | Description of Role  |                                    |  |
| <b>Jing Li</b>    | <b>MD Anderson Cancer Center:</b> Associate Professor: Employee          | None  | None  | My Institution receives funding: No salary support in whole or part: national/overall principal investigator<br>My Institution receives funding: No salary support in whole or part: national/overall principal investigator | None                                | <b>BMS:</b> Grant/Research Funding<br><b>Medtronic:</b> Grant/Research Funding  | <b>BMS:</b> Research funding to support clinical trial: funding to support clinical trial with ipi/nivo/brain radiation: Start Date: 2015 to present- To Present<br><b>Medtronic:</b> Research funding to support clinical trial for SSRS and LITT for spine mets: PI for phase II trial investigating combination of LITT and SSRS for spine mets: Start Date: 2015- To Present | None                               | None   |
| <b>John Lucas</b> | <b>St. Jude Children's Research Hospital:</b> Associate Member: Employee | None  | None  | None   | Faculty Consultant<br>Faculty       | <b>Children's Cancer and Leukaemia Group - CCLG:</b> Uncompensated<br>International PPB/DICER1 Registry: Uncompensated<br>Malaysian Society of Paediatric Haem & Onc: Uncompensated |  | None                               | <b>ASTRO Scientific Committee - Pediatric section:</b> Chair: Oversee the pediatric scientific program from year to year.: Not Compensated |

**ASTRO 2024 Annual Meeting - Annual Meeting Scientific Committee Disclosures**

| Member                      | Employment Relationships   |       | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria |   |                                      |  |   | Ownerships or Investment Interests | Leadership Positions   |
|-----------------------------|--|-------|---|---|--------------------------------------|--|---|------------------------------------|--|
|                             | Employment   | Other | Advisory Board  | Research  | Consultant/ Speaker/Faculty or Other | Method of Remuneration   | Description of Role   |                                    |  |
| <b>Raymond Mailhot Vega</b> | <b>University of Florida:</b> Associate Professor: Employee              | None  | None  | My Institution Receives Funding: No salary support in whole or part: national/overall principal investigator My Institution receives funding: No salary support in whole or part: national/overall principal investigator | None                                 | <b>Conquer Cancer Foundation:</b> Grant/Research Funding: Salary Support<br><b>Florida Department of Health:</b> Grant/Research Funding<br><b>Leukemia and Lymphoma Society:</b> Grant/Research Funding<br><b>NIH/NCATS:</b> Grant/Research Funding<br><b>PTCOG:</b> Grant/Research Funding<br><b>Robert A Winn Career Development Award:</b> Grant/Research Funding: Salary Support | <b>Conquer Cancer Foundation:</b> Grant giving wing of ASCO: PI: Start Date: 7/1/2020-End Date:12/31/2021<br><b>Florida Department of Health:</b> PI: Start Date 7/1/2020-End Date 6/30/2024<br><b>Leukemia and Lymphoma Society:</b> Co-I for award seeking to better empower PCPs to advocate for clinical trials: Start Date: 7/1/2021- To Present<br><b>NIH/NCATS:</b> Evaluating radiotherapy receipt in patients receiving NA chemotherapy for breast cancer: Start Date: 7/1/2021- End Date: 06/30/2023<br><b>PTCOG:</b> Determining which patients with Hodgkin lymphoma benefit from particle radiotherapy: Start Date: 1/1/2021- End Date: 12/31/2021<br><b>Robert A Winn Career Development Award:</b> Winn CDA in concert with VCU: Favorable Wilms Tumor Trial: Start Date: 10/16/2023- To Present | None                               | <b>ACR-ARS Appropriateness Criteria Committee:</b> Lymphoma Committee Member: Member: Not Compensated<br><b>Children's Oncology Group:</b> Steering Committee Member: Member of the Hodgkin Lymphoma Steering Committee: Not Compensated<br><b>Particle Therapy Co-Operative Group:</b> Co-operative group focusing on particle therapy: Diversity and Inclusion Chair: DEI Chair: Not Compensated |
| <b>Danielle Margalit</b>    | <b>Brigham &amp; Women's Physician Organization:</b> Physician: Employee | None  | None  | None  | None                                 | None   | None  | None                               | <b>American Radium Society:</b> Chair, Head/Neck Appropriate Use Criteria Comm.: Chair of Committee: Not Compensated<br><b>IJOBP (Red Journal):</b> Section Editor - Head/Neck: Section Editor :Section editor:Not Compensated: Relationship Ended: 10/1/2023  |
| <b>Jyoti Mayadev</b>        | <b>University of California San Diego:</b> Professor: Employee           | None  | Ongoing: No access to proprietary info                          | None  | Consultant                           | <b>AstraZeneca:</b> Honoraria: Compensation/Payment<br><b>KORTUC:</b> Honoraria<br><b>Merck:</b> Honoraria<br><b>Primmune:</b> Honoraria<br><b>Varian Medical Systems:</b> Honoraria   | <b>AstraZeneca:</b> consultant: advisor: Start Date: May 2019- To Present<br><b>KORTUC:</b> Advisor: Clinical trial advisor: Start Date: Jan 2021- To Present<br><b>Merck:</b> Consultant: advisor: Start Date: July 2021- To Present<br><b>Primmune:</b> Advisor: advisory: Start Date: June 2021- To Present<br><b>Varian Medical Systems:</b> Consulting: Advisor to clinical trial development: Start Date: August 2021- To Present   | None                               | <b>American Brachytherapy Society:</b> Board Member: Director-at-large, starting July 2023 for a 3 year term.: Not Compensated<br>NRG Oncology: NCI funded cooperative group: Co-Chair: Grant co chair: Not Compensated  |



**ASTRO 2024 Annual Meeting - Annual Meeting Scientific Committee Disclosures**

| Member                   | Employment Relationships  |       | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria                  |   |                                     |   |  | Ownerships or Investment Interests   | Leadership Positions   |
|--------------------------|---|-------|--|---|-------------------------------------|---|--|--|--|
|                          | Employment  | Other | Advisory Board   | Research  | Consultant/Speaker/Faculty or Other | Method of Remuneration  | Description of Role  |  |  |
| <b>Clifford Robinson</b> | <b>Washington University School of Medicine in St. Louis:</b> Professor: Employee   | None  | Ongoing: No access to proprietary info<br>Ongoing: No access to proprietary info | My Institution receives funding: No salary support in whole or part: national/overall principal investigator<br>My Institution receives funding: No salary support in whole or part: site principal investigator<br>My Institution receives funding: No salary support in whole or part: other: Multiple IITs | Consultant                          | <b>AstraZeneca:</b> Grant/Research Funding: Honoraria<br><b>EMD Serono:</b> Honoraria<br><b>EmpNia:</b> Compensation/Payment<br><b>Merck:</b> Grant/Research Funding<br><b>Quantaras:</b> Other - Stock<br><b>Radialogica:</b> Honoraria: Other - Stock<br><b>Varian:</b> Grant/Research Funding: Honoraria | <b>AstraZeneca:</b> PACIFIC-4 ICI: Start Date: 2018- To Present<br><b>EMD Serono:</b> Ad hoc advisory boards: Start Date: 2018- To Present<br><b>EmpNia:</b> Consulting: Start Date: 2022- To Present<br><b>Merck:</b> Esophageal brachy + pembro phase I trial: Start Date: 2016- To Present<br><b>Quantaras:</b> Ad hoc advisory boards: Start Date: 2019- To Present<br><b>Radialogica:</b> Chief Medical Officer: Start Date: 2016- To Present<br><b>Varian:</b> Consulting on Cardiac Radioablation via Cardialogica, LLC: Start Date: 2019- To Present | <b>Varian:</b> Copyright<br><b>Radialogica:</b> Stock Options<br><b>Quantaras:</b> Stock Options | <b>Radialogica:</b> Chief Medical Officer: Not Compensated   |
| <b>Hina Saeed</b>        | <b>MCW:</b> Assistant Professor: Employee: Relationship ended: 1/20/2022<br><b>Baptist Health South Florida:</b> Deputy Director, BHC: Employee | None  | None   | None  | None                                | <b>Florida Atlantic University:</b> Uncompensated<br><b>Florida International University:</b> Uncompensated<br><b>Medical College of Wisconsin:</b> Uncompensated   | <b>Florida Atlantic University:</b> Clinical affiliate associate professor: Faculty: Start Date: 08/2022 - To Present<br><b>Florida International University:</b> Clinical affiliate associate professor: Faculty: Start Date: 08/2022 - To Present<br><b>Medical College of Wisconsin:</b> Adjunct faculty: Faculty: Start Date: 01/21/2022- To Present   | None   | None   |
| <b>Kilian Salerno</b>    | <b>National Cancer Institute:</b> Staff Clinician, Associate Research Physician: Employee   | None  | None   | None  | None                                | None  | None   | None   | <b>ACR:</b> TXIT<br>Annual In-Service Exam: TXIT<br>Committee Chair: Committee Chair: Not Compensated<br><b>AJCC:</b> Member of the Breast Panel: panel member: Not Compensated<br><b>IJOBP:</b> Senior Editor: Senior Editor for Sarcoma and Pediatrics: Not Compensated<br><b>Journal of Surgical Oncology:</b> Associate Editor: Associate Editor of the Radiation Therapy Section: Not Compensated |

**ASTRO 2024 Annual Meeting - Annual Meeting Scientific Committee Disclosures**

| Member                 | Employment Relationships  |       | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria |          |                                     |   |   | Ownerships or Investment Interests | Leadership Positions  |
|------------------------|---|-------|---|----------|-------------------------------------|---|---|------------------------------------|---|
|                        | Employment  | Other | Advisory Board  | Research | Consultant/Speaker/Faculty or Other | Method of Remuneration  | Description of Role   |                                    |   |
| <b>Naomi Schechter</b> | <b>South Florida Proton Therapy Institute:</b><br>Radiation Oncologist:<br>Independent Contractor<br><b>Rakuten- Medical:</b><br>Medical Director:<br>Employee: Relationship ended: 1/24/2024 | None  | None  | None     | None                                | None  | None  | None                               | <b>American College of Radiology (ACR):</b><br>American College of Radiology: Chair, Practice Parameters Committee, Rad Onc: Chair, Practice Parameters Committee, Radiation Oncology: Not Compensated  |
| <b>Jennifer Schmid</b> | <b>Henry Ford Jackson Radiation Oncology:</b><br>Nurse Practitioner:<br>Employee  | None  | None  | None     | None                                | None  | None  | None                               | None  |
| <b>Charles Simone</b>  | <b>New York Proton Center, Memorial Sloan Kettering:</b> Research Professor and Chief Medical Officer:<br>Employee  | None  | None  | None     | Other - strategic discussions       | <b>Novocure:</b> Honoraria<br><b>Varian Medical System:</b> Honoraria           | <b>Novocure:</b> cancer device maker: strategic discussions: Start Date: 6/29/2018- End Date: 4/21/2022<br><b>Varian Medical System:</b> radiation accelerator maker: strategic discussions: Start Date: 12/29/2015- End Date: 8/03/2022            | None                               | <b>American Radium Society:</b> Chair, Thoracic Appropriate Use Criteria Committee: Chair, Thoracic Appropriate Use Criteria Committee: Not Compensated<br><b>American Society for Radiation Oncology:</b> Chair, Lung Resource Panel; Vice Chair, Lung Track: Chair, Lung Resource Panel; Vice Chair, Lung Track: Not Compensated<br><b>Annals of Palliative Medicine:</b> Editor-in-Chief: Editor-in-Chief: Not Compensated<br><b>NRG Oncology:</b> Chair, Particle Therapy Work Group: Chair, Particle Therapy Work Group: Not Compensated<br><b>Proton Collaborative Group:</b> President of the Board; Chair, Lung Committee: President of the Board; Chair, Lung Committee: Not Compensated |
| <b>Rahul Tendulkar</b> | <b>Cleveland Clinic:</b> Staff: Employee  | None  | Single: No access to proprietary info                           | None     | Faculty                             | <b>Elekta:</b> Compensation/Payment<br><b>Varian Medical Systems:</b> Honoraria | <b>Elekta:</b> Linear accelerator manufacturer: One- time advisory board meeting: Start Date: 2022- End Date: 2022<br><b>Varian Medical Systems:</b> Linear accelerator manufacturer: Honoraria for educational talks: Start Date: 2017- To Present | None                               | None  |

**ASTRO 2024 Annual Meeting - Annual Meeting Scientific Committee Disclosures**

| Member           | Employment Relationships  |       | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria |  |                                     |   | Ownerships or Investment Interests  | Leadership Positions |  |
|------------------|---|-------|---|--|-------------------------------------|---|---|----------------------|--|
|                  | Employment  | Other | Advisory Board  | Research   | Consultant/Speaker/Faculty or Other | Method of Remuneration  |   |                      | Description of Role  |
| Yolanda Tseng    | University of Washington: Associate Professor: Employee             | None  | None  | None   | Faculty                             | ASTRO refresher course: Honoraria   | ASTRO refresher course: ASTRO refresher speaker for lymphoma: Start Date: 03/01/2020- End Date: 03/19/2021  | None                 | ASTRO annual scientific committee: ASTRO annual scientific committee: Chair, Palliative care track: Chair, Palliative care track: Not Compensated<br>PCG: Chair, Lymphoma subcommittee: Chair, Lymphoma subcommittee: Not Compensated<br>PTCOG: Co-chair of lymphoma subcommittee: Co- chair of lymphoma subcommittee: Not Compensated |
| Terence Williams | City of Hope National Medical Center: Professor and Chair: Employee | None  | None  | My Institution receives funding: No salary support in whole or part: national/overall principal investigator<br>My Institution receives funding: No salary support in whole or part: national/overall principal investigator<br>My Institution receives funding: No salary support in whole or part: national/overall principal investigator | Consultant Speaker Bureau           | American Cancer Society: Grant/Research Funding<br>January Therapeutics: Grant/Research Funding<br>National Institutes of Health: Honoraria<br>National Institutes of Health: Grant/Research Funding<br>Reflexion Medical Systems: Honoraria: Travel Expenses: Compensation/Payment | American Cancer Society: research funding: research funding: Start Date: 2021- To Present<br>January Therapeutics: Pharmaceutical company: preclinical research: Start Date: 2021- To Present<br>National Institutes of Health: Radiation Therapeutics and Biology Study Section: Honoraria for reviewing NIH grants.: Start Date: 2017- To Present<br>National Institutes of Health: research funding: research funding: Start Date: 2021- To Present<br>Reflexion Medical Systems: Medical device company: Served as speaker at events.: Start Date: 2021- To Present | None                 | None   |
| Jennifer Wo      | Massachusetts General Hospital: Associate Professor: Employee       | None  | None  | My Institution receives funding: No salary support in whole or part: national/overall principal investigator   | None                                | Genentech: Grant/Research Funding   | Genentech: Research Funding: Phase IB SBRT and Atezo/Bev for Unresectable HCC: Start Date: 7/2020- To Present   | None                 | None   |





## ASTRO 2024 Annual Meeting - Session and Abstract Reviewers' Disclosure of Relationships

The American Society for Radiation Oncology (ASTRO) is an Accreditation Council for Continuing Medical Education (ACCME) accredited CME provider and complies with the [ACCME Standards for Integrity and Independence in Accredited Continuing Education](#). In accordance with these Standards, the ASTRO Conflict of Interest Policy and the Council for Medical Specialty Societies' Code for Interactions with Companies, ASTRO is disclosing here the relationships between members of the session and abstract reviewers' and other entities related to oncology or radiation therapy.

### Explanatory notes:

- ASTRO uses the information disclosed to identify and manage any potential conflicts of interest that may arise in carrying out the responsibilities of the Committees.
- Committee members disclose their own relationships and those of their immediate family members.
- There is no “minimum value” threshold for disclosure.
- Disclosure time period covers relationships held or payments received during the year leading up to the disclosure.
- The disclosure information at this link is relevant only to the planning of the 2024 Annual Meeting and should be considered out-of-date after this time.
- Information at this link may be different from disclosure information provided in other contexts by the Committee members because of variation in the disclosure requests for these other purposes.

**Employment/Leadership Positions** = positions held at the time of disclosure. These include both full- and part-time relationships, whether compensated or uncompensated.

**Compensation/Remuneration/Funding** = includes consultant/advisory roles, honoraria, research funding, travel expenses, in-kind donation, etc. If a Committee member receives an honorarium and donates it to charity, the honorarium is disclosed. If a Committee member declines an honorarium and it is paid directly to charity, the honorarium is not included. Honoraria from accredited CME providers are not included.

**Ownership or Investment Interests** = includes stock, stock options, partnership, royalties, or patents. *Stocks in mutual funds, blind trusts, or other holdings that are not controlled by the individual or an immediate family member are not included.*

**Leadership Positions**= positions held in other organizations or entities.

The ASTRO Conflict of Interest Policies are available at [www.astro.org/coipolicies](http://www.astro.org/coipolicies). Please direct any questions to [annualmeeting@astro.org](mailto:annualmeeting@astro.org).

| ASTRO 2024 Annual Meeting - Annual Meeting Session Reviewers' Disclosures |   |       |   |  |  |  |  |                                    |  |
|---|---|-------|---|--|--|--|--|------------------------------------|--|
| Member  | Employment Relationships  |       | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria |  |  |  |  | Ownerships or Investment Interests | Leadership Positions   |
|   | Employment  | Other | Advisory Board  | Research   | Consultant/Speaker/Faculty or Other                                    | Method of Remuneration   | Description of Role  |                                    |  |
| <b>Mansoor Ahmed</b>  | <b>National Cancer Institute:</b><br>Program Director: Employee                             | None  | None  | None   | None   | None   | None   | None                               | None   |
| <b>Kamran Ahmed</b>   | <b>Moffitt Cancer Center:</b> Associate Member: Employee                                    | None  | Single: No access to proprietary info                           | My Institution receives funding: No salary support in whole or part: national/overall principal investigator | Consultant Speaker Bureau  | <b>Bristol Myers- Squibb:</b> Honoraria<br><b>Bristol Myers- Squibb:</b> Grant/Research Funding<br><b>Cancer Network:</b> Honoraria<br><b>Castle Biosciences:</b> Honoraria<br><b>Eli Lilly:</b> Grant/Research Funding<br><b>Genentech:</b> Grant/Research Funding<br><b>Gilead:</b> Grant/Research Funding | <b>Bristol Myers- Squibb:</b> Honoraria: Speaking honoraria: Start Date: 2020- End Date: 2020<br><b>Bristol Myers- Squibb:</b> Research funding to the institution.: IIT Funding: Start Date: 2018- To Present<br><b>Cancer Network:</b> Honoraria for speaking engagement: Speaking engagement honoraria: Start Date: 2022- End Date: 2022<br><b>Castle Biosciences:</b> Advisory board meeting: Start Date: 2022- End Date: 2022<br><b>Eli Lilly:</b> Funding to the institution for an IIT.: IIT Funding: Start Date: 2021- To Present<br><b>Genentech:</b> Research funding to the institution for two IITs: Research funding for two IITs: Start Date: 2018- To Present<br><b>Gilead:</b> Research funding to the institution for an IIT: IIT funding: Start Date: 2023- To Present | None                               | <b>ABR:</b> ABR Oral Exam Breast Committee Member: Committee Member: Develop questions for oral exam: Not Compensated<br><b>Advances in Radiation Oncology:</b> ARO Editorial Board Member: Editorial Board: Review manuscripts, discuss journal with leadership: Not Compensated<br><b>American Journal of Clinical Oncology:</b> Editorial Board Member: Editorial Board Member: Editorial Board Member: Not Compensated<br><b>Journal of Neuro-Oncology:</b> Member of journal of editorial board: Editorial Board Member: Editorial Board Member: Not Compensated<br><b>Neuro-Oncology Practice:</b> Neuro-Oncology Practice Editorial Board Member: Editorial Board Member: Review manuscripts, discuss journal with leadership.: Not Compensated |
| <b>Safia Ahmed</b>  | <b>Mayo Clinic:</b> Radiation Oncologist: Employee  | None  | None  | None   | None   | None   | None   | None                               | None   |
| <b>Kevin Albuquerque</b>  | <b>Simmons Comprehensive Cancer Center, UTSW:</b> Professor of Radiation Oncology: Employee | None  | None  | None   | <b>Other</b> - volunteer surveyor<br><b>Other</b> - committee co-chair | <b>ACR:</b> Honoraria: Travel Expenses<br><b>Elsevier Clinical Path:</b> Compensation/Pay ment   | <b>ACR:</b> Surveyor(volunteer): volunteer surveyor for accreditation: Start Date: five years- To Present<br><b>Elsevier Clinical Path:</b> Clinical Pathways company: Co-Chair and Member of our ClinicalPath Physician Advisory Committee – Gynecological Radiation Oncology.: Start Date: Oct 2022- To Present  | None                               | None   |
| <b>Arya Amini</b>   | <b>City of Hope:</b> Associate professor: Employee  | None  | None  | I recieve funding: No salary support in whole or part: national/overall principal investigator               | Speaker Bureau   | <b>AstraZeneca:</b> Grant/Research Funding<br><b>Genentech:</b> Grant/Research Funding<br><b>RefleXion:</b> Grant/Research Funding<br><b>Takeda Pharmaceuticals:</b> Grant/Research Funding<br><b>Varian:</b> Grant/Research Funding   | <b>AstraZeneca:</b> Speakers bureau: Start Date: 1/1/23- To Present<br><b>Genentech:</b> Genentech is providing drug only funding for a phase I trial of SBRT and atezolizumab: Start Date: 4/1/2022- End Date: 12/30/2024<br><b>RefleXion:</b> research funding evaluating role of BgRT in oligoprogressive NSCLC: Start Date: 5/1/2023- End Date: 12/30/2025<br><b>Takeda Pharmaceuticals:</b> Speakers bureau: Start Date: 1/1/2023- To Present<br><b>Varian:</b> grant funding evaluating the role of SBRT for oligoprogressive disease: Start Date: 4/1/2023- End Date: 12/1/25   | None                               | None   |

| ASTRO 2024 Annual Meeting - Annual Meeting Session Reviewers' Disclosures |   |       |  |   |                                     |  |   |                                    |   |
|---|---|-------|--|---|-------------------------------------|--|---|------------------------------------|---|
| Member  | Employment Relationships  |       | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria                  |   |                                     |  |   | Ownerships or Investment Interests | Leadership Positions  |
|   | Employment  | Other | Advisory Board   | Research  | Consultant/Speaker/Faculty or Other | Method of Remuneration   | Description of Role   |                                    |   |
| Carryn Anderson   | University of Iowa Hospitals & Clinics: Radiation Oncologist: Employee                    |       | Ongoing: No access to proprietary info<br>Ongoing: No access to proprietary info | My Institution receives funding: No salary support in whole or part: site principal investigator  | Consultant                          | None   | None  | None                               | University of Iowa Hospitals & Clinics: Residency Program Director: Maintain ACGME accreditation for Radiation Oncology program: Not Compensated: Relationship Ended: 3/30/2023   |
| Anthony Apicelli  | Washington University School of Medicine: Asst. Professor of Radiation Oncology: Employee |       | Ongoing: No access to proprietary info<br>Ongoing: No access to proprietary info | My Institution receives funding: No salary support in whole or part: other: Testing drugs in preclinical models   | Faculty Consultant                  | None   | None  | None                               | University of Iowa Hospitals & Clinics: Residency Program Director: Maintain ACGME accreditation for Radiation Oncology program: Not Compensated: Relationship Ended: 3/30/2023   |
| Houda Bahig   | Centre Hospitalier de l'Université de Montréal: Radiation Oncologist: Employee            | None  | Ongoing: No access to proprietary info   | My Institution receives funding: No salary support in whole or part: steering committee<br>I receive funding: No salary support in whole or part: site principal investigator | Faculty Consultant                  | Astra Zeneca: Grant/Research Funding<br>Astra Zeneca: Compensation/Payment<br>Astra Zeneca: Honoraria<br>Sanofi: Honoraria<br>Varian Medical Systems: Grant/Research Funding | Astra Zeneca: Advisory board meetings to discuss on-going and future research projects: Start Date: 2021- To Present<br>Astra Zeneca: co-investigator: Start Date: 2020- End Date: 2022<br>Astra Zeneca: Masterclass on topics related to lung cancer treatment: Start Date: 2022- To Present<br>Sanofi: Cutaneous cancers, review of cases: Start Date: september 2022- To Present<br>Varian Medical Systems: Principal investigator: Start Date: 2020- To Present | None                               | None  |
| Richard Bakst   | Mount Sinai Hospital: Professor: Employee   | None  | None   | None  | None                                | None   | None  | None                               | None  |
| Leslie Ballas   | Cedars Sinai Medical Center: Physician: Employee  | None  | Single: No access to proprietary info<br>Single: No access to proprietary info   | None  | Consultant                          | Blue Earth: Compensation/Payment<br>Pfizer: Compensation/Payment<br>UpToDate: Honoraria  | Blue Earth: diagnostic/imaging: new diagnostic agents for PET imaging in prostate cancer: Start Date: 12/7/22- End Date: 12/7/22<br>Pfizer: Drug company: Advisory Board on advanced prostate cancer treatment: Start Date: 11/11/22- End Date: 11/11/22<br>UpToDate: Online educational materials: Edit online educational review materials: Start Date: 12/2023 - To Present  | None                               | American Board of Radiology: Organization in charge of board certification and maintenance: Chair hematologic malignancy section of oral boards: In charge of heme section of oral exam prep and delivery: Not Compensated<br>UroToday: online resource for urologists/medical oncologists/radiation oncologists for urologic malignancies: Editor: Provide content, reviews, interviews for bladder preservation section of website: Not Compensated |

| ASTRO 2024 Annual Meeting - Annual Meeting Session Reviewers' Disclosures |   |       |   |  |   |   |  |                                    |  |
|---|---|-------|---|--|---|---|--|------------------------------------|--|
| Member  | Employment Relationships  |       | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria   |  |   |   |  | Ownerships or Investment Interests | Leadership Positions   |
|   | Employment  | Other | Advisory Board  | Research   | Consultant/Speaker/Faculty or Other   | Method of Remuneration  | Description of Role  |                                    |  |
| James Balter  | University of Michigan: Professor: Employee                                 | None  | None  | My Institution receives funding: No salary support in whole or part: national/overall principal investigator<br>My Institution receives funding: No salary support in whole or part: national/overall principal investigator | None  | NIH: Grant/Research Funding   | NIH: R01- Optimization of Magnetic Resonance Imaging in Radiation Oncology: I am the Principal Investigator on a NIH R01 for Optimization of Magnetic Resonance Imaging in Radiation Oncology: Start Date: 10/1/13- To Present   | None                               | CSR: Center for Scientific Review (NIH): Chair - SBIR/STTR review Panel: I serve on, and currently chair, a recurring NIH review panel for SBIR and STTR applications: Not Compensated |
| Andrew Baschnagel   | University of Wisconsin: Associate Professor: Employee                      | None  | None  | None   | None  | None  | None   | None                               | None   |
| Mustafa Basree  | University of Wisconsin Hospitals and Clinics: Resident Physician: Employee | None  | None  | None   | None  | None  | None   | None                               | ARRO: National association for radiation oncology residents: Executive Committee Member: Junior chair of the education subcommittee within the executive committee: Not Compensated    |
| James Bates   | Emory University: Assistant Professor: Employee                             | None  | Single: No access to proprietary info<br>Single: No access to proprietary info  | None   | None  | Castle Biosciences Galera Therapeutics  | Castle Biosciences: Advisory board for prognostic product.: Start Date: 2/2022- End Date: 2/2022<br>Galera Therapeutics: Advisory board on radioprotector: Start Date: 10/2021- End Date: 10/2021  | None                               | None   |
| Brian Baumann   | Springfield Clinic: Radiation Oncologist: Employee                          | None  | Ongoing: No access to proprietary info<br>Single: No access to proprietary info<br>Single: No access to proprietary info<br>Single: No access to proprietary info | My Institution receives funding: No salary support in whole or part: national/overall principal investigator   | Consultant  | Boston Scientific: Travel Expenses: Compensation/Payment<br>Galera Therapeutics: Compensation/Payment<br>Mevion: Compensation/Payment<br>Myovant: Compensation/Payment<br>Regeneron: Compensation/Payment<br>Varian: Grant/Research Funding: Compensation/Payment | Boston Scientific: Advisory board service and consulting work: Start Date: 01/01/2021- To Present<br>Galera Therapeutics: served on advisory panel: Start Date: 09/01/21- End Date: 09/01/21<br>Mevion: consultant: Start Date: 05/01/21- End Date: 10/01/21<br>Myovant: advisory board service: Start Date: 09/01/22- End Date: 09/01/22<br>Regeneron: advisory board: Start Date: 05/01/2021- End Date: 10/01/21<br>Varian: Consulting work as physician lead for a Varian-sponsored multi-national trial. Research funding for an investigator-initiated trial where I am PI.: Start Date: 01/01/2021- To Present | None                               | None   |
| Beth Beadle   | Stanford University: Professor: Employee                                    | None  | None  | None   | Other - Book writing and journal editing<br>Other - Book writing and journal editorial work | Elsevier: Other - Royalties<br>Wolters- Kluwer: Other - Royalties   | Elsevier: Book/journal publisher: Article writing and journal editorial work: Start Date: 1/1/2016- To Present<br>Wolters- Kluwer: Book/journal publisher: Royalties from book writing: Start Date: 1/1/2016- To Present   | None                               | None   |







| ASTRO 2024 Annual Meeting - Annual Meeting Session Reviewers' Disclosures |   |       |  |   |   |  |  |                                    |   |
|---|---|-------|--|---|---|--|--|------------------------------------|---|
| Member  | Employment Relationships  |       | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria              |   |   |  |  | Ownerships or Investment Interests | Leadership Positions  |
|   | Employment  | Other | Advisory Board   | Research  | Consultant/Speaker/Faculty or Other                 | Method of Remuneration   | Description of Role  |                                    |   |
| Kevin Du  | Yale School of Medicine:<br>Associate Professor: Employee                   | None  | None   | None  | None  | None   | None   | None                               | None  |
| Ronald Ennis  | Rutgers Cancer Institute of New Jersey: Professor and Vice Chair: Employee  |       |  |   |   | Marathon Asset Management: Honoraria   | Marathon Asset Management: Consultant: Investment firm: Consulted with a firm considering investing in/purchasing Pluvicto regarding the likely financial success of Pluvicto: Start Date: 2/15/2023 - End Date: 5/1/2023  |                                    |   |
| Beth Erickson   | Medical College of Wisconsin: Professor of Radiation Oncology: Employee     | None  | None   | None  | None  | None   | None   | None                               | ASTRO: ASTRO Board of Directors: Chair of the Education Council: Help to oversee the educational efforts of ASTRO: Not Compensated<br>ASTRO: Fellows Committee: Chair: Oversee the induction of fellows into ASTRO: Not Compensated   |
| Alysa Fairchild   | Alberta Health Services: Radiation Oncologist: Independent Contractor       | None  | None   | None  | None  | None   | None   | None                               | None  |
| Eric Ford   | University of Washington: Professor: Employee                               | None  | None   | None  | None  | None   | None   | None                               | None  |
| Ivy Franco  | Brigham and Women's Hospital Dana-Farber CC: Radiation Oncologist: Employee | None  | None   | My Institution receives funding: No salary support in whole or part: national/overall principal investigator I receive funding: No salary support in whole or part: other: Career Development Award My Institution receives funding: No salary support in whole or part: site principal investigator I receive funding: No salary support in whole or part: site principal investigator | None  | ASTRO/ROG NRG Oncology Health Equity Fellowship: Grant/Research Funding Brigham and Women's Hospital Dana-Farber CC: Grant/Research Funding Diversity Supplement, National Cancer Institute: Grant/Research Funding NIH/NCI Loan Repayment Program: Grant/Research Funding | ASTRO/ROG NRG Oncology Health Equity Fellowship: National organizations focused on oncology.: PI working on increasing diversity of representation in gynecologic clinical trials.: Start Date: February 2023- To Present<br>Brigham and Women's Hospital Dana-Farber CC: Center for Diversity and Inclusion: Career Development Award for Minority Faculty: Start Date: 07/2022 - To Present<br>Diversity Supplement, National Cancer Institute: Center to reduce cancer health disparities, National Cancer Institute: Biomarker approaches to high- risk prostate cancer: Start Date: 09/2021- To Present<br>NIH/NCI Loan Repayment Program: National Cancer Institute: Cost effectiveness for prostate cancer treatment: Start Date: 07/2022- To Present | None                               | American Society of Radiation Oncology ASTRO: Vice Chair of the Health Equity Education Committee: Vice Chair: Vice Chair of the Health Equity Education Committee for the Council on Health Equity Diversity and Inclusion of ASTRO: Not Compensated: Relationship Ended: 10/3/2022<br>Association of Residents in Radiation Oncology: Resident branch of ASTRO: Executive Vice Chair: Executive Vice Chair of overall organization and Chair of the Equity and Inclusion Subcommittee: Not Compensated: Relationship Ended: 10/3/2022 |
| Clifton Fuller  | UT MD Anderson Cancer Center: Professor: Employee                           | None  | Ongoing: No access to proprietary info Single: No access to proprietary info | My Institution receives funding: No salary support in whole or part: site principal investigator  | Faculty/Other - Committee Member Consultant/Faculty | American Association of Physicists in Medicine: Honoraria: Travel Expenses   | American Association of Physicists in Medicine: Specialty society.: Speaker/committee member: Start Date: 01/01/2016- To Present   | Kallisis, Inc: Copyright           | American Association of Physicists in Medicine : Specialty Society: Committee Member: Committee member, BDS and TG-263: Not Compensated   |



| ASTRO 2024 Annual Meeting - Annual Meeting Session Reviewers' Disclosures |  |       |   |  |  |   |   |                                    |  |
|---|--|-------|---|--|--|---|---|------------------------------------|--|
| Member  | Employment Relationships                                 |       | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria   |  |  |   |   | Ownerships or Investment Interests | Leadership Positions   |
|   | Employment   | Other | Advisory Board  | Research   | Consultant/Speaker/Faculty or Other  | Method of Remuneration  | Description of Role   |                                    |  |
| Gregory Gan   | None   | None  | My Institution receives funding: No salary support in whole or part: national/overall principal investigator My Institution receives funding: No salary support in whole or part: national/overall principal investigator I receive funding: No salary support in whole or part: other: Subgrant PI My Institution receives funding: No | None   | <b>Aclaris Therapeutics:</b> Grant/Research Funding<br><b>Genentech:</b> Grant/Research Funding: Other - Drug support<br><b>NIH/NIGMS:</b> Grant/Research Funding<br><b>Varian Inc:</b> Grant/Research Funding | <b>Aclaris Therapeutics:</b> Pharma: IIT, translational research: Start Date: 7/1/20- End Date: 6/30/21<br><b>Genentech:</b> Pharma: IIT PI, translational research: Start Date: 8/1/23- End Date: 7/30/23<br><b>NIH/NIGMS:</b> Kansas Institute of Precision Medicine COBRE grant: Subgrant PI, basic science research: Start Date: 8/1/19- End Date: 7/31/22<br><b>Varian Inc:</b> linear accelerator company: PI, IIT: Start Date: 8/1/23- End Date: 7/31/26 | None  | None                               |  |
| Naamit Gerber   | <b>NYU Langone Health:</b> Associate Professor: Employee | None  | Single: No access to proprietary info   | My Institution receives funding: No salary support in whole or part: other: Research collaboration | Faculty  | <b>Accuray:</b> Honoraria John Theurer Cancer Center: Honoraria<br><b>Mount Sinai Icahn School of Medicine:</b> Honoraria PreludeDx: Grant/Research Funding   | <b>Accuray:</b> Accuray breast advisory board at ASTRO 2023: Start Date: 10/1/23- End Date: 10/3/23<br><b>John Theurer Cancer Center: academic institution:</b> SABCS update symposium: Start Date: 01/01/2022- To Present<br><b>Mount Sinai Icahn School of Medicine:</b> Academic institution: grand rounds honoraria: Start Date: 08/05/2022- End Date: 08/05/2022<br><b>PreludeDx:</b> Company: early stage breast cancer: Start Date: 08/01/2022- To Present | None                               | <b>ASTRO:</b> ASTRO APBI Guidelines Committee: member: Serve on ASTRO APBI guidelines committee and chair of one of the key question committees: Not Compensated |

| ASTRO 2024 Annual Meeting - Annual Meeting Session Reviewers' Disclosures |   |       |   |  |                                     |   |  |   |   |
|---|---|-------|---|--|-------------------------------------|---|--|---|---|
| Member  | Employment Relationships  |       | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria |  |                                     |   |  | Ownerships or Investment Interests            | Leadership Positions  |
|   | Employment  | Other | Advisory Board  | Research   | Consultant/Speaker/Faculty or Other | Method of Remuneration  | Description of Role  |   |   |
| Iris Gibbs  | Stanford Medicine: Professor and Associate Dean: Employee                             | None  | Ongoing: No access to proprietary info                          | None   | None                                | Accuray, Inc.: Honoraria: Travel Expenses<br>University of Delaware CAS Dean's Advisory Council               | Accuray, Inc.: Honoraria for lectures: Start Date: 08/01/2019- To Present<br>University of Delaware CAS Dean's Advisory Council: Alumni advisory board: Start Date: 05/01/2019- To Present | None  | American College of Radiology: Medical organization representing diagnostic and interventional radiologists, radiation oncologists, nuclear medicine physicians and medical physicists.: Member and Chapter leader: Serve on multiple chapters and committees including CARROS, CRS, Diversity Committee: Not Compensated<br>ICG Enterprises, Inc.: 501(c)3 non-profit that dispenses educational scholarships and community outreach: Chief Officer: Founder of local non-profit: Not Compensated: Relationship Ended: 1/6/2023<br>The Radiosurgery Society: The Radiosurgery Society® (RSS) is an international, medical professional, non-profit society consisting of physicians, physicists and healthcare professionals dedicated to advancing the education, science and clinical practice of stereotactic radiosurgery, stereotactic body radiation therapy and advancing therapies.: Board of Directors: Member of the Board of Directors: Not Compensated |
| Beant Gill  | Associates in Radiation Medicine: Physician: Partner                                  | None  | None  | None   | Other - Faculty                     | None  | None   | Associates in Radiation Medicine: Partnership | American College of Radiology: Organization for radiology and radiation oncology: CAC Representative: Representative for local coverage determination review of radiation oncology services: Not Compensated<br>Chesapeake Potomac Regional Cancer Center: Community practice for radiation oncology services: Medical Director: Medical director for clinical operations: Not Compensated  |
| David Gius  | University of Texas Science Center San Antonio: Assistant Dean for Research: Employee | None  | None  | I receive funding: No salary support in whole or part: site principal investigator   | None                                | National Cancer Institute: Grant/Research Funding   | National Cancer Institute: Government: PI: Start Date: 02/01/2010- End Date: 04/01/2025  | None  | University of Texas Health Science Center San Antonio: Assistant Dean for Research: Dean for funding portfolio: Not Compensated   |
| Scott Glaser  | City of Hope: Radiation Oncologist: Employee  | None  | None  | None   | None                                | None  | None   | None  | None  |
| Daniel Golden   | Rush University Medical Center: Associate Professor: Employee                         | None  | None  | My Institution receives funding: No salary support in whole or part: site principal investigator<br>My Institution receives funding: No salary support in whole or part: national/overall principal investigator | None                                | National Institutes of Health: Grant/Research Funding<br>Radiation Oncology Institute: Grant/Research Funding | National Institutes of Health: Cancer education: Start Date: 2019- End Date: 2023<br>Radiation Oncology Institute: Patient education: Start Date: 2020- End Date: 2023                     | RadOncQuestions LLC: Limited Liability        | Radiation Oncology Education Collaborative Study G: Non-profit dedicated to improving radiation oncology education worldwide: Chair: Chair of executive committee: Not Compensated  |

| ASTRO 2024 Annual Meeting - Annual Meeting Session Reviewers' Disclosures |   |       |   |  |   |   |  |                                    |   |
|---|---|-------|---|--|---|---|--|------------------------------------|---|
| Member  | Employment Relationships  |       | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria |  |   |   |  | Ownerships or Investment Interests | Leadership Positions  |
|   | Employment  | Other | Advisory Board  | Research   | Consultant/Speaker/Faculty or Other   | Method of Remuneration  | Description of Role  |                                    |   |
| Vinai Gondi   | Radiation Oncology Consultants, LLC: Physician<br>Partner: Partner  | None  | None  | None   | None  | None  | None   | None                               | None  |
| Inga Grills   | Beaumont/Corewell Health:<br>Professor, Chief Thoracic Section,<br>Director GK Center: Employee                       | None  | None  | None   | None  | None  | None   | None                               | None  |
| Craig Grossman  | University of South Florida:<br>Associate Professor: Employee<br>Tampa General Hospital: Staff<br>Physician: Employee | None  | None  | None   | None  | None  | None   | None                               | None  |
| Surbhi Grover   | University of Pennsylvania:<br>Associate Professor Radiation<br>Oncology: Employee                                    | None  | None  | None   | Consultant  | CDRF Global:<br>Compensation/Pay ment<br>GenesisCare:<br>Compensation/Pay ment  | CDRF Global: NGO working with the State Dept on "Sustainable Dialogue on Peaceful uses of Radiation in Africa": Advising on topics for the dialogue: Start Date: 07/1/23- End Date: 12/1/23<br>GenesisCare: Advising on global solutions: Start Date: 11/21/21- End Date: 11/21/23   | Harbinger Health: Stock Options    | None  |
| B. Ashleigh Guadagnolo  | MD Anderson: Professor:<br>Employee   | None  | None  | None   | None  | None  | None   | None                               | None  |
| Jill Gunther  | MD Anderson Cancer Center:<br>Associate Professor: Employee   | None  | None  | I recieve funding: No salary support in whole or part: other: Researcher | Faculty<br>Other - I served as an examiner for the Mock Oral board review course. | NIH NCI R25 grant: Grant/Research Funding<br>Osler Institute: Honoraria<br>The Sterling Foundation: Other - Philanthropic donation<br>University of Maryland Board Review Course: Honoraria | NIH NCI R25 grant: R25 grant to support summer medical student research: R25 grant to support summer medical student research: Start Date: 2023- To Present<br>Osler Institute: I served as an examiner for the Mock Oral board review course.: I served as an examiner for the Mock Oral board review course.: Start Date: 3/2020- To Present<br>The Sterling Foundation: Philanthropic funds to support research and education: Philanthropic donation: Start Date: 2021- To Present<br>University of Maryland Board Review Course: I served as an examiner for the Mock Oral board review course.: I served as an examiner for the Mock Oral board review course.: Start Date: 3/2020- To Present | None                               | Rad Onc Education Collaborative Study Group: International group dedicated to promoting rad onc education: Board Member: Serve as on the leadership team of the organization and the co-lead the UME Working Group: Not Compensated |
| Daniel Hamstra  | Baylor College of Medicine:<br>Professor and Chairman:<br>Employee  | None  | None  | None   | Consultant  | Boston Scientific:<br>Uncompensated: Other - Meals  | Boston Scientific: Company: Advisory role: Start Date: 2020- To Present  | None                               | None  |

| ASTRO 2024 Annual Meeting - Annual Meeting Session Reviewers' Disclosures |   |       |   |   |                                     |   |  |  |  |
|---|---|-------|---|---|-------------------------------------|---|--|--|--|
| Member  | Employment Relationships  |       | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria |   |                                     |   |  | Ownerships or Investment Interests         | Leadership Positions   |
|   | Employment  | Other | Advisory Board  | Research  | Consultant/Speaker/Faculty or Other | Method of Remuneration  | Description of Role  |  |  |
| <b>Kathy Han</b>  | <b>Princess Margaret Cancer Center, University Health Network:</b> Radiation Oncologist: Employee | None  | Single: No access to proprietary info                           | I receive funding: No salary support in whole or part: national/overall principal investigator I receive funding: No salary support in whole or part: site principal investigator | Consultant                          | Advisory Board: Honoraria Grants: Grant/Research Funding Merck Gynecological Cancers National Consultation: Honoraria Princess Margaret Cancer Foundation: Grant/Research Funding | <b>AstraZeneca:</b> Advisory Board: Astra Zeneca Cervical Cancer Radiation Oncology Advisory Board: Astra Zeneca Cervical Cancer Radiation Oncology Advisory Board: Start Date: Oct 2021- To Present Grants: Grant funding - CIHR Project Grant: PI for EN10 trial: Start Date: March 2021- To Present <b>Merck Gynecological Cancers National Consultation:</b> Consultant: Start Date: December 1 2023- To Present <b>Princess Margaret Cancer Foundation:</b> Agnico Eagle Intercept Cancer Grand Challenge Grant: Local pi: Start Date: Feb 2022- To Present | <b>HPV ctDNA patent pending:</b> Copyright | <b>CCTG:</b> Canadian Cancer Trials Group: Endometrial Cancer Working Group Co-Chair: Endometrial Cancer Working Group Co-Chair: Not Compensated <b>MRL Consortium:</b> Breast TSG: Deputy Chair, Breast TSG: Deputy Chair, Breast TSG: Not Compensated: Relationship Ended: 6/30/2021 |
| <b>Matthew Harkenrider</b>  | <b>Loyola University Medical Center:</b> Professor of Radiation Oncology: Employee                | None  | None  | None  | Consultant                          | <b>NEED:</b> Compensation/Payment <b>RTOG Foundation:</b> Compensation/Payment  | <b>NEED:</b> Patient-centered cancer screening and cancer treatment consulting company aimed at provided the best possible cancer outcomes for patients.: Case reviewer: Start Date: 10/1/2023- To Present <b>RTOG Foundation:</b> The RTOG Foundation continues the NCI- funded research of the Radiation Therapy Oncology Group through its membership in NRG Oncology: Case Reviewer: Start Date: 6/1/2022- End Date: 8/1/2023  | None                                       | None   |
| <b>Jona Hattangadi-Gluth</b>  | <b>UC San Diego/Moores Cancer Center:</b> Professor: Employee                                     | None  | None  | None  | None                                | None  | None   | None                                       | None   |
| <b>Maria Hawkins</b>  | <b>University College London:</b> professor: Employee   | None  | None  | None  | None                                | None  | None   | None                                       | <b>CRUK City of London RADNET centre:</b> multiinstitutional programme grant: director: lead and coordinate research in preclinical science research across the teams awarded the grant: Not Compensated   |
| <b>Susan Hiniker</b>  | <b>Stanford University:</b> Assistant Professor: Employee   | None  | None  | None  | None                                | None  | None   | None                                       | None   |
| <b>Ariel Hirsch</b>   | <b>Boston University:</b> Professor of Radiation Oncology: Employee                               | None  | None  | None  | Other - author                      | <b>Uptodate Online:</b> Other - royalties   | <b>Uptodate Online:</b> Update breast cancer chapter on uptodate online: co-author chapter: Start Date: 2017- To Present   | None                                       | None   |
| <b>Brad Hoppe</b>   | <b>Mayo Clinic:</b> Professor of Radiation Oncology: Employee                                     | None  | Ongoing: No access to proprietary info                          | None  | None                                | <b>Merck:</b> Other - Children's Oncology Group funds my scientific advisory board work into a Mayo research PAU  | <b>Merck:</b> drug company: scientific advisory board for AHOD 1822: Start Date: 2019- To Present  | None                                       | <b>NRG lymphoma working group:</b> Co-Chair: co-chair: Not Compensated PTCOG: Secretary: secretary: Not Compensated  |

| ASTRO 2024 Annual Meeting - Annual Meeting Session Reviewers' Disclosures |   |       |   |  |                                     |  |   |                                    |  |
|---|---|-------|---|--|-------------------------------------|--|---|------------------------------------|--|
| Member  | Employment Relationships  |       | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria                 |  |                                     |  |   | Ownerships or Investment Interests | Leadership Positions   |
|   | Employment  | Other | Advisory Board  | Research   | Consultant/Speaker/Faculty or Other | Method of Remuneration   | Description of Role   |                                    |  |
| Charles Hsu   | Banner- University of Arizona Medical Center: Associate Professor of Radiation Oncology: Employee | None  | None  | None   | None                                | None   | None  | None                               | Univ of Arizona Dept of Radiation Oncology: University of Arizona Cancer Center Department of Radiation Oncology Research: Vice Chairman of Clinical Research: head of clinical research within department of radiation oncology: Not Compensated: Relationship Ended: 6/30/2023<br>University of Arizona Cancer Center: Clinical Trials Office: Medical Director: Medical Director of Clinical Trials Office for Cancer Center: Not Compensated |
| Kathryn Huber   | Tufts Medicine Physicians Organization: Attending Physician: Employee                             | None  | None  | None   | None                                | None   | None  | None                               | None   |
| Brandon Imber   | Memorial Sloan Kettering Cancer Center: Assistant Attending Radiation Oncologist: Employee        | None  | Ongoing: No access to proprietary info<br>Single: No access to proprietary info | My Institution receives funding: No salary support in whole or part: site principal investigator<br>My Institution receives funding: No salary support in whole or part: national/overall principal investigator<br>My Institution receives funding: No salary support in whole or part: national/overall principal investigator<br>My Institution receives funding: No salary support in whole or part: national/overall principal investigator | Faculty                             | AstraZeneca: Grant/Research Funding<br>Bayer: Grant/Reserach Funding<br>GT Medical Technologies: Honoraria<br>Kazia Therapeutics: Honoraria<br>Novartis: Honoraria<br>Telix Pharmaceuticals: Honoraria | AstraZeneca: research funding to institution: site PI for international clinical trial: Start Date: 7/2022- To Present<br>Bayer: research funding to institution: national PI of Radium-223 and SBRT study: Start Date: 6/2023- To Present<br>GT Medical Technologies: presented research at SNO 2021: Start Date: November 2021- To Present<br>Kazia Therapeutics: research funding to institution: overall PI for brain metastasis clinical trial: Start Date: 6/2023- To Present<br>Novartis: research funding to institution: PI for IIT where Novartis provided drug: Start Date: 6/2023- To Present<br>Telix Pharmaceuticals: Advisory Board at SNO 2022: Start Date: November 2022- To Present | None                               | None   |
| Daniel Indelicato   | University of Florida: Professor: Employee  | None  | None  | None   | Other - CIRB                        | Honoraria  | NCI CIRB: Member of the NCI CIRB: Start Date: 1/2018- To Present  | None                               | Pediatric Radiation Oncology Society (PROS): Professional Organization: Education Chair- North America: On Executive Committee, responsible for education initiatives throughout North America: Not Compensated  |
| Jerry Jaboin  | University of Oklahoma Health Sciences Center: Professor: Employee                                | None  | None  | None   | None                                | None   | None  | None                               | None   |
| Sachin Jhavar   | The Ohio State University: Associate Professor: Employee  | None  | None  | My Institution receives funding: No salary support in whole or part: national/overall principal investigator   | None                                | Varian Medical Systems: Grant/Research Funding   | Varian Medical Systems: Varian Medical Systems: Oropharyngeal Microbiome: Start Date: 01/01/2019- To Present  | None                               | Enlace Health: Advisory Board: Advisory Board Member: Advisory Board: Not Compensated  |



| ASTRO 2024 Annual Meeting - Annual Meeting Session Reviewers' Disclosures |  |       |   |   |                                     |  |   |                                    |   |
|---|--|-------|---|---|-------------------------------------|--|---|------------------------------------|---|
| Member  | Employment Relationships   |       | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria |   |                                     |  |   | Ownerships or Investment Interests | Leadership Positions  |
|   | Employment   | Other | Advisory Board  | Research  | Consultant/Speaker/Faculty or Other | Method of Remuneration   | Description of Role   |                                    |   |
| <b>Aparna Kesarwala</b>   | <b>Emory University School of Medicine:</b> Assistant Professor: Employee      | None  | None  | I receive funding: No salary support in whole or part: other: PI<br>I receive funding: No salary support in whole or part: other: PI  | None                                | <b>Melanoma Research Alliance:</b> Grant/Research Funding<br><b>National Institutes of Health:</b> Grant/Research Funding  | <b>Melanoma Research Alliance:</b> PI: Start Date: 10/2020- End Date: 09/2023<br><b>National Institutes of Health:</b> PI: Start Date: 9/2019- To Present   | None                               | None  |
| <b>Elizabeth Kidd</b>   | <b>Stanford University:</b> Associate Professor: Employee                      | None  | None  | My Institution receives funding: No salary support in whole or part: site principal investigator  | None                                | <b>Viewray:</b> Grant/Research Funding   | <b>Viewray:</b> Use of viewray for cervix cancer fractionated radiation: Start Date: Feb. 2021- To Present  | None                               | <b>ABS Quality &amp; Safety Standard Committee:</b> Co- Leader: Oversee the ABS Quality and Safety Standards Committee.: Not Compensated  |
| <b>Sungjune Kim</b>   | <b>Mayo Clinic:</b> Director, Preclinical and Translational Research: Employee | None  | None  | My Institution receives funding: No salary support in whole or part: other: directed correlative studies<br>My Institution receives funding: No salary support in whole or part: national/overall principal investigator  | None                                | <b>Astra Zeneca:</b> Grant/Research Funding<br><b>Bristol Myers Squibb:</b> Grant/Research Funding: Salary Support   | <b>Astra Zeneca:</b> co-I for correlative studies for small cell lung cancer trial: Start Date: 06/01/2021- End Date: 06/16/2023<br><b>Bristol Myers Squibb:</b> PI, Phase II randomized study of NIVO plus IPI with or without SBRT in advanced Merkel cell carcinoma: Start Date: 05/01/2017- End Date: 06/16/2023  | None                               | None  |
| <b>Michelle Kim</b>   | <b>University of Michigan:</b> Professor: Employee                             | None  | Ongoing: No access to proprietary info                          | My Institution receives funding: No salary support in whole or part: site principal investigator<br>My Institution receives funding: No salary support in whole or part: national/overall principal investigator<br>My Institution receives funding: No salary support in whole or part: other: Co-investigator | Faculty Consultant Faculty          | <b>ASTRO Annual Meeting Education Committee:</b> Uncompensated<br><b>BlueEarth Diagnostics:</b> Grant/Research Funding: Honoraria<br><b>Capital Health:</b> Travel Expenses<br><b>Nebraska Oncology Society:</b> Honoraria<br><b>NIH:</b> Grant/Research Funding<br><b>NIH:</b> Travel Expenses: Salary Support<br><b>PeerView:</b> Honoraria: Travel Expenses<br><b>Stanford U54 MetNet Advisory Board:</b> Uncompensated | <b>ASTRO Annual Meeting Education Committee:</b> Chair, ASTRO Annual Meeting Education Committee CNS Track: Start Date: 2023- To Present<br><b>BlueEarth Diagnostics:</b> Molecular imaging company: Site PI for a national trial, served as a consultant for a one-time workshop (completed): Start Date: 2020- To Present<br><b>Capital Health:</b> Medical group: Invited speaker for one- time conference (completed): Start Date: 2022- End Date: 2022<br><b>Nebraska Oncology Society:</b> Professional non profit scientific society: Invited speaker for an educational event (completed): Start Date: 2022- End Date: 2022<br><b>NIH:</b> Co- investigator of an ongoing NIH-funded research study: Start Date: 2021- End Date: 2026<br><b>NIH:</b> Principal Investigator, R50 Research Specialist: Start Date: 2023- End Date: 2028<br><b>PeerView:</b> CME company: Faculty speaker at SNO Annual Meeting at Industry-sponsored educational event: Start Date: 11/16/23- End Date: 11/16/23 | None                               | <b>NCCN CNS Guidelines Committee Member:</b> National Comprehensive Cancer Center Guidelines: Member: Member: Not Compensated<br><b>Neuro-Oncology Editorial Board Member:</b> Neuro- Oncology (Journal) Editorial Board Member: Board Member: Board member: Not Compensated<br><b>Red Journal:</b> ASTRO Scientific Journal: CNS Section Editor: Section Editor for CNS: Not Compensated |
| <b>Edward Kim</b>   | <b>University of Washington:</b> Associate Professor: Employee                 | None  | None  | None  | None                                | None   | None  | None                               | <b>NCCN:</b> Soft tissue sarcoma panel member: NCCN soft tissue sarcoma panel member: Not Compensated   |





| ASTRO 2024 Annual Meeting - Annual Meeting Session Reviewers' Disclosures |  |       |   |  |                                     |  |  |                                    |   |
|---|--|-------|---|--|-------------------------------------|--|--|------------------------------------|---|
| Member  | Employment Relationships   |       | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria |  |                                     |  |  | Ownerships or Investment Interests | Leadership Positions  |
|   | Employment   | Other | Advisory Board  | Research   | Consultant/Speaker/Faculty or Other | Method of Remuneration   | Description of Role  |                                    |   |
| Jing Li   | MD Anderson Cancer Center: Associate Professor: Employee                   | None  | None  | My Institution receives funding: No salary support in whole or part: national/overall principal investigator<br>My Institution receives funding: No salary support in whole or part: national/overall principal investigator | None                                | BMS: Grant/Research Funding<br>Medtronic: Grant/Research Funding                                   | BMS: Research funding to support clinical trial: funding to support clinical trial with ipi/nivo/brain radiation: Start Date: 2015 to present- To Present<br>Medtronic: research funding to support clinical trial for SSRS and LITT for spine mets: PI for phase II trial investigating combination of LITT and SSRS for spine mets: Start Date: 2015- To Present | None                               | None  |
| Teh Lin   | Temple University - Fox Chase Cancer Center: Associate Professor: Employee | None  | None  | None   | None                                | None   | None   | None                               | None  |
| Wu Liu  | Stanford University: Associate Professor: Employee                         | None  | None  | None   | None                                | None   | None   | None                               | None  |
| Simon Lo  | University of Washington School of Medicine: Professor: Employee           | None  | None  | My Institution receives funding: No salary support in whole or part: site principal investigator   | None                                | Elekta, AB: Other - Research support: Potential stipend to hire a student to extract research data | Elekta, AB: LINAC manufacturer: Pooled retrospective patient data from multiple sites to answer research questions regarding Gamma Knife ICON SRT for brain tumors: Start Date: Sept 2017- To Present  | None                               | American College of Radiology: Professional Organization: Alternate Councilor: Voting: Not Compensated<br>ASTRO: Advances in Radiation Oncology (Journal): Associate Section Editor: Managing manuscripts: Not Compensated<br>Congress of Neurological Surgeons: Neurosurgery (Journal): Assistant Editor: Managing manuscripts: Not Compensated<br>Radiosurgery Society (RSS): Non- profit professional organization advancing the field of SRS and SBRT: Medical director, SRS/ SBRT<br>Accreditation Program: Development and supervision of the SRS/ SBRT Accreditation Program, which is a joint venture with American College of Radiation Oncology Practice Accreditation Program.: Not Compensated<br>Radiosurgery Society (RSS): Non- profit professional organization advancing the field of SRS and SBRT: Member of Board of Directors: Decision making in the affairs related to RSS: Not Compensated |
| Alexander Louie   | Sunnybrook Health Science Centre: Radiation Oncologist: Employee           | None  | Ongoing: No access to proprietary info                          | None   | Speaker Bureau                      | AstraZeneca: Honoraria   | AstraZeneca: pharmaceutical: participation in speaker's bureau and advisory board: Start Date: sept 2018- To Present   | None                               | None  |

| ASTRO 2024 Annual Meeting - Annual Meeting Session Reviewers' Disclosures |   |       |   |          |   |  |   |                                    |   |
|---|---|-------|---|----------|---|--|---|------------------------------------|---|
| Member  | Employment Relationships  |       | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria |          |   |  |   | Ownerships or Investment Interests | Leadership Positions  |
|   | Employment  | Other | Advisory Board  | Research | Consultant/Speaker/Faculty or Other       | Method of Remuneration   | Description of Role   |                                    |   |
| John Lucas  | St. Jude Children's Research Hospital: Associate Member: Employee | None  | None  | None     | Faculty Consultant Faculty Speaker Bureau | Children's Cancer and Leukaemia Group - CCLG: Uncompensated<br>International PPB/DICER1 Registry: Uncompensated<br>Malaysian Society of Paediatric Haem & Onc: Uncompensated<br>Philips: Uncompensated | Children's Cancer and Leukaemia Group - CCLG: The Children's Cancer and Leukaemia Group is an organization focused on childhood cancer: Lucas Jr., J.T., "State of Radiation Oncology Objectives for High-Risk Neuroblastoma-At St. Jude and Children's Oncology Group". CCLG Radiotherapy Group Meeting September 8-9th, Dublin, Ireland.: Start Date: September 8- End Date: 9th<br>International PPB/DICER1 Registry: The International PPB/DICER1 Registry's mission is to improve outcomes for children and adults with pleuropulmonary blastoma (PPB) and other DICER1- related cancers.: I routinely consult on cases and participate in registry data reviews.: Start Date: 2016- To Present<br>Malaysian Society of Paediatric Haem & Onc: The Malaysian Society of Paediatric Haematology and Oncology was formed in 1994. The objectives of this society are to promote all efforts aimed at the ultimate cure of all children with cancer: Lucas Jr., J.T., Radiotherapy in intracranial germ cell tumors. 26th Virtual Annual Scientific | None                               | ASTRO Scientific Committee - Pediatric section: Chair: Oversee the pediatric scientific program from year to year.: Not Compensated<br>Global Neuroblastoma Network: Radiation Oncology Panel Lead: Participate in case review and panel discussions for the GNN.: Not Compensated<br>Pediatric Cancer Data Commons - NODAL & REACH: Executive Committee member:Construct and devise data sharing agreements and projects for the Pediatric Hodgkin Lymphoma and Retinoblastoma group: Not Compensated<br>St. Jude Children's Research Hospital Continuing Medical Education (CME) Committee: Member: Participate in the construction of the grad rounds curriculum and assist with maintaining CME credentialing for St. Jude providers.:Not Compensated |
| John Lukens   | University of Pennsylvania: Assistant Professor: Employee         | None  | None  | None     | Consultant                                | Acclarent: Compensation/Pay ment   | Acclarent: Johnson & Johnson subsidiary, developing software: Software to track surgical incisions and correlate with CT planning data: Start Date: Jan 2024- To Present  | None                               | NCCN: National Comprehensive Cancer Network: Non- Melanoma Skin Cancer Panelist: Non- Melanoma Skin Cancer Panelist: Not Compensated  |

| ASTRO 2024 Annual Meeting - Annual Meeting Session Reviewers' Disclosures |   |  |  |   |                                     |  |  |                                    |  |
|---|---|--|--|---|-------------------------------------|--|--|------------------------------------|--|
| Member  | Employment Relationships  |  | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria              |   |                                     |  |  | Ownerships or Investment Interests | Leadership Positions   |
|   | Employment  | Other                                      | Advisory Board   | Research  | Consultant/Speaker/Faculty or Other | Method of Remuneration   | Description of Role  |                                    |  |
| <b>Raymond Mailhot Vega</b>   | <b>University of Florida:</b> Associate Professor: Employee                 | None                                       | None   | My Institution receives funding: No salary support in whole or part: national/overall principal investigator<br>My Institution receives funding: No salary support in whole or part: national/overall principal investigator<br>My Institution receives funding: No salary support in whole or part: other: co-investigator<br>My Institution receives funding: No salary support in whole or part: national/overall principal investigator<br>My Institution receives funding: No salary support in whole or part: national/overall principal investigator<br>My Institution receives funding: No salary support in whole or part: national/overall principal investigator | None                                | <b>Conquer Cancer Foundation:</b> Grant/Research Funding: Salary Support<br><b>Florida Department of Health:</b> Grant/Research Funding<br><b>Leukemia and Lymphoma Society:</b> Grant/Research Funding<br><b>NIH/NCATS:</b> Grant/Research Funding<br><b>PTCOG:</b> Grant/Research Funding<br><b>Robert A Winn Career Development Award:</b> Grant/Research Funding: Salary Support | <b>Conquer Cancer Foundation:</b> Grant giving wing of ASCO: PI: Start Date: 7/1/2020- End Date: 12/31/2021<br><b>Florida Department of Health:</b> PI: Start Date: 7/1/2021- End Date: 6/30/2024<br><b>Leukemia and Lymphoma Society:</b> co-I for award seeking to better empower PCPs to advocate for clinical trials: Start Date: 7/1/2021- To Present<br><b>NIH/NCATS:</b> Evaluating radiotherapy receipt in patients receiving NA chemotherapy for breast cancer: Start Date: 7/1/2021- End Date: 06/30/2023<br><b>PTCOG:</b> Determining which patients with Hodgkin lymphoma benefit from particle radiotherapy: Start Date: 1/1/2021- End Date: 12/31/2021<br><b>Robert A Winn Career Development Award:</b> Winn CDA in concert with VCU: Favorable<br><b>Wilms Tumor Trial:</b> Start Date: 10/16/2023- To Present | None                               | <b>ACR-ARS Appropriateness Criteria Committee:</b> Lymphoma Committee Member: Member: Not Compensated<br><b>Children's Oncology Group:</b> Steering Committee Member: Member of the Hodgkin Lymphoma Steering Committee: Not Compensated<br><b>Particle Therapy Co-Operative Group:</b> Co-operative group focusing on particle therapy: Diversity and Inclusion Chair: DEI Chair: Not Compensated |
| <b>Ari Marciscano</b>   | <b>Massachusetts General Hospital:</b> Radiation Oncologist: Employee       | None                                       | None   | None  | None                                | None   | None   | None                               | None   |
| <b>Danielle Margalit</b>  | <b>Brigham &amp; Women's Physician Organization:</b> Physician: Employee    | None                                       | None   | None  | None                                | None   | None   | None                               | <b>American Radium Society:</b> Chair, Head/Neck Appropriate Use Criteria Comm.: Chair of Committee: Not Compensated<br><b>IJROBP (Red Journal):</b> Section Editor - Head/Neck: Section Editor: Section editor: Not Compensated: Relationship Ended: 10/1/2023  |
| <b>Douglas Martin</b>   | <b>The Ohio State University Wexner Medical Center:</b> Professor: Employee | <b>New Century Health:</b> Advisory Board: | <b>Qfix:</b> Other: Delivered presentation with honoraria 3/19/14: Honoraria | <b>Qfix:</b> meeting presentation, brachytherapy suite operations, \$1000 honoraria 3/29/14<br><b>New Century Health:</b> advisory board member on radiation therapy appropriateness criteria: Start Date: 10/23/2015 - 04/15/2016  | None                                | None   | None   | None                               | None   |

| ASTRO 2024 Annual Meeting - Annual Meeting Session Reviewers' Disclosures |  |       |   |  |                                     |   |  |  |  |
|---|--|-------|---|--|-------------------------------------|---|--|--|--|
| Member  | Employment Relationships   |       | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria |  |                                     |   |  | Ownerships or Investment Interests                           | Leadership Positions   |
|   | Employment   | Other | Advisory Board  | Research   | Consultant/Speaker/Faculty or Other | Method of Remuneration  | Description of Role  |  |  |
| Malcolm Mattes  | Rutgers Cancer Institute of New Jersey: Associate Professor: Employee                                      | None  | None  | I receive funding: No salary support in whole or part: other: Career Development<br>I receive funding: No salary support in whole or part: site principal investigator<br>I receive funding: No salary support in whole or part: national/overall principal investigator | None                                | Bristol Myers Squibb Foundation: Grant/Research Funding<br>New Jersey Health Foundation: Grant/Research Funding<br>Radiation Oncology Institute: Grant/Research Funding | Bristol Myers Squibb Foundation: Career Development Award: Start Date: 11/01/2021- End Date: 12/31/2023<br>New Jersey Health Foundation: Research Funding: Research Funding: Start Date: 02/15/2022- End Date: 2/14/2024<br>Radiation Oncology Institute: Research Funding: Research Funding: Start Date: 11/01/2020- End Date: 10/31/2023   | None   | ASTRO: Communications Committee: Vice Chair<br>: Communications Committee Vice Chair: Not Compensated<br>University Hospital Cancer Center: ACOS CoC Cancer Liaison Physician: Not Compensated   |
| Martha Matuszak   | University of Michigan: Professor: Employee  | None  | None  | My Institution receives funding: No salary support in whole or part: national/overall principal investigator   | None                                | Varian: Grant/Research Funding  | Varian: Radiotherapy Vendor: PI: Start Date: November 2023- To Present   | Fuse Oncology: Other - Licensing and Collaboration Agreement | AAPM: American Association of Physicists in Medicine: Member, Board of Directors: Board Member at Large: Not Compensated<br>MROQC: Radiation Oncology Quality Consortium with Blue Cross Blue Shield of Michigan: Co-Director: Executive Leadership: Not Compensated   |
| Jyoti Mayadev   | University of California San Diego: Professor: Employee  | None  | Ongoing: No access to proprietary info                          | None   | Consultant                          | AstraZeneca: Honoraria: Compensation/Pay ment<br>KORTUC: Honoraria<br>Merck: Honoraria<br>Primmune: Honoraria<br>Varian Medical Systems: Honoraria                      | AstraZeneca: consultant: advisor: Start Date: May 2019- To Present<br>KORTUC: advisor: Clinical trial advisor: Start Date: Jan 2021- To Present<br>Merck: consultant: advisor: Start Date: July 2021- To Present<br>Primmune: advisor: advisory: Start Date: June 2021- To Present<br>Varian Medical Systems: Consulting: Advisor to clinical trial development: Start Date: August 2021- To Present | None   | American Brachytherapy Society: Board Member: Director-at-large, starting July 2023 for a 3 year term.: Not Compensated<br>NRG Oncology: NCI funded cooperative group: Co-Chair: Grant co chair: Not Compensated   |
| Mahta McKee   | Wake Forest University School of Medicine: medical Physicist: Employee                                     | None  | None  | None   | None                                | None  | None   | None   | None   |
| Marc Mendonca   | Indiana University School of Medicine, IUPUI: Professor & Associate Vice Chancellor for Research: Employee | None  | None  | None   | Consultant                          | Capture Collective Inc: Compensation/Pay ment   | Capture Collective Inc: Start up company interested in biodosimetry of radiation exposure: Consult on all aspects of radiation biology related to this project.: Start Date: June 2022- To Present   | None   | Radiation Research Society: Radiation Research Society is a 501c3 nonprofit professional organization whose membership is composed of scientist, researchers,staff, and students focused on all aspects of radiation science research, education, and teaching.:Editor-in- Chief of the journal Radiation Research and service on the RRS executive and finance committees: Editor-in-Chief of the journal Radiation Research and service on the RRS executive and finance committees: Not Compensated |

| ASTRO 2024 Annual Meeting - Annual Meeting Session Reviewers' Disclosures |   |   |   |  |   |   |   |                                    |  |
|---|---|---|---|--|---|---|---|------------------------------------|--|
| Member  | Employment Relationships  |   | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria |  |   |   |   | Ownerships or Investment Interests | Leadership Positions   |
|   | Employment  | Other   | Advisory Board  | Research   | Consultant/Speaker/Faculty or Other   | Method of Remuneration  | Description of Role   |                                    |  |
| Omar Mian   | Cleveland Clinic: Staff: Employee   | None  | None  | My Institution receives funding: No salary support in whole or part: site principal investigator<br>My Institution receives funding: No salary support in whole or part: site principal investigator                         | Consultant  | Bayer: Compensation/Payment<br>Gilead: Grant/Research Funding<br>Varian: Grant/Research Funding   | Bayer: Corporation: Consultant Prostate Cancer: Start Date: Jan 2022- To Present<br>Gilead: Company: PI Research (Clinical Trial): Start Date: Dec 2022- To Present<br>Varian: Company: PI Research Grant: Start Date: Dec 2022- To Present   | None                               | NCCN: Guidelines: Panel Member:<br>NCCN Panel Member: Not Compensated  |
| Michelle Mierzwa  | University of Michigan: Associate Professor of Radiation Oncology: Employee | None  | None  | None   | None  | None  | None  | None                               | MROQC: Michigan Radiation Oncology Quality Consortium: Co-lead of Behavioral Health Committee: Co-lead: Not Compensated  |
| George Mikhaeel   | Guy's & St Thomas NHS Hospital: Clinical Oncologist: Employee               | None  | None  | None   | Faculty   | Kite: Honoraria: Travel Expenses  | Kite: Speaker in a scientific meeting: Invited speaker about Role of radiotherapy with CAR-T: Start Date: 5 October 2022 - End Date: 5 October 2022   | None                               | None   |
| Sarah Milgrom   | University of Colorado: Associate Professor: Employee                       | None  | None  | None   | Consultant  | Bristol Myers Squibb: Uncompensated   | Bristol Myers Squibb: Provided advice regarding PET volumetric research for a pediatric Hodgkin lymphoma study: Provided advice to researchers at Bristol Myers Squibb regarding PET volumetric research for a pediatric Hodgkin lymphoma study: Start Date: 7/1/23- To Present   | None                               | American Radium Society: Appropriate Use Criteria Lymphoma Committee: Vice Chair: work with a committee to develop guidelines regarding lymphoma sub-topics: Not Compensated |
| Mark Mishra   | University of Maryland School of Medicine: Professor: Employee              | Family Member: Orthofix:<br>Employee : Employee | None  | None   | Other - Medical expert for patent application   | Humanetics: Honoraria   | Humanetics: Medical expert for patent application: Start Date: 4/1/2023- End Date: 5/1/2023   | None                               | None   |
| Timur Mitin   | Oregon Health and Science University: Associate Professor: Employee         | None  | Ongoing: No access to proprietary info                          | My Institution receives funding: No salary support in whole or part: national/overall principal investigator<br>My Institution receives funding: No salary support in whole or part: national/overall principal investigator | Speaker BureauFaculty<br>Other - Clinical Events Committee (CEC) for clinical study BP-007<br>ConsultantSpeaker BureauFaculty<br>Other - Chapter author | AstraZeneca: Grant/Research Funding: Honoraria: Travel Expenses<br>Bioprotect Ltd.: Honoraria<br>Novocure, Inc.: Grant/Research Funding: Honoraria: Travel Expenses: Compensation/Payment<br>UpToDate Inc.: Other - Royalties | AstraZeneca: Pharmaceutical Company: Radiation Oncology in management of Stage III NSCLC: Start Date: 3/1/2020- To Present<br>Bioprotect Ltd.: Technology platform company that provides innovative bioabsorbable spacers.: CEC primary reviewer: Start Date: 1/1/2022- To Present<br>Novocure, Inc.: Oncology company pioneering a novel therapy for solid tumors called Tumor Treating Fields: Prophylactic TTF in SCLC: Start Date: 5/1/2015- To Present<br>UpToDate Inc.: Evidence- based clinical resource for practicing clinicians: Chapter Author: "Radiation therapy techniques in cancer treatment": Start Date: 1/1/2014- To Present | None                               | None   |

| ASTRO 2024 Annual Meeting - Annual Meeting Session Reviewers' Disclosures |   |       |   |  |  |   |  |   |  |
|---|---|-------|---|--|--|---|--|---|--|
| Member  | Employment Relationships  |       | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria |  |  |   |  | Ownerships or Investment Interests  | Leadership Positions   |
|   | Employment  | Other | Advisory Board  | Research   | Consultant/Speaker/Faculty or Other  | Method of Remuneration  | Description of Role  |   |  |
| <b>Najeeb Mohideen</b>  | <b>Northwest Community Hospital, Arlington Heights, IL:</b> Radiation Oncologist: Independent Contractor                              | None  | None  | None   | None   | None  | None   | None  | <b>The Radiosurgery Society:</b> The Radiosurgery Society: President: President: Not Compensated   |
| <b>Shalini Moningi</b>  | <b>Brigham and Women's Hospital:</b> Attending Physician: Employee  | None  | None  | None   | None   | None  | None   | None  | None   |
| <b>Jean Moran</b>   | <b>Memorial Sloan Kettering Cancer Center:</b> Vice Chair: Employee   | None  | None  | None   | Other - Quality Improvement project; I was the past Associate Director of the Michigan Radiation Oncology Quality Consortium (MROQC) and the lead of the Physics aspects of the project.<br>Other - member of MROQC breast working group Faculty<br>Other - I do not receive any support at my current institution. My prior institution receives grant funding. | <b>Blue Cross Blue Shield of Michigan:</b> Grant/Research Funding<br><b>Blue Cross Blue Shield of Michigan:</b> Travel Expenses<br><b>Sun Nuclear:</b> Travel Expenses<br><b>Varian:</b> A Siemens Healthineers Company | <b>Blue Cross Blue Shield of Michigan:</b> Health insurance company in the state of Michigan: MROQC is a statewide registry focused on quality improvement. I was involved in projects related to the cancer types represented.: Start Date: 01/2011- End Date: 05/2021<br><b>Blue Cross Blue Shield of Michigan:</b> insurance company in the state of Michigan: member of MROQC breast working group: Start Date: 06/2021 - To Present<br><b>Sun Nuclear:</b> Manufacturer of QA equipment and software: Speaker at 2022 QA and Dosimetry Symposium; spoke on IMRT Quality Assurance in a debate format: Start Date: 4/7/21- End Date: 4/9/21<br><b>Varian:</b> A Siemens Healthineers Company: Radiation Oncology Equipment Manufacturer: My past institution holds a grant for a consortium which I lead focused on Automated Quality Assurance for linear accelerators.: Start Date: 1/2015- To Present | <b>Prexient, Inc.:</b> Stock: Partnership<br><b>FuseOncology:</b> Copyright | <b>AAPM:</b> American Association of Physicists in Medicine: Chair Work Group on Report Writing: Chair of group to improve the AAPM report writing process: Not Compensated<br><b>AAPM:</b> American Association of Physicists in Medicine: Chair-Work Group on Science Council EDI: Chair group focused on improving EDI within Science Council and its committees.: Not Compensated<br><b>AAPM:</b> American Association of Physicists in Medicine: Chair-Work Group on Task Group Review Streamlining: Chair of the committee to streamline the review process.: Not Compensated: Relationship Ended: 12/31/2022<br><b>AAPM:</b> American Association of Physicists in Medicine: Working Group on Increasing Equity in Honors and Awards: Chair of group to increase equity in the AAPM Honors and Awards process: Not Compensated<br><b>ROI:</b> Research Committee of the Radiation Oncology Institute: Vice Chair: |
| <b>Sabin Motwani</b>  | <b>RWJBarnabas Health Medical Group:</b> Radiation Oncologist: Employee   | None  | None  | None   | None   | None  | None   | None  | None   |
| <b>Erin Murphy</b>  | <b>Cleveland Clinic:</b> Associate Professor: Employee  | None  | None  | None   | None   | None  | None   | None  | None   |
| <b>Bailey Nelson</b>  | <b>University of Cincinnati:</b> Assistant Professor: Employee<br><b>Cincinnati VA Medical Center:</b> Radiation Oncologist: Employee | None  | None  | None   | None   | None  | None   | None  | <b>Association of Residents in Radiation Oncology:</b> Resident organization: Vice Chair - Education: I run the education subcommittee: Not Compensated  |
| <b>Rahul Parikh</b>   | <b>Rutgers Cancer Institute of New Jersey:</b> Professor: Employee  | None  | None  | None   | Speaker Bureau Consultant  | <b>Mevion Medical Systems:</b> Honoraria<br><b>MyCareGorithm, LLC:</b> Honoraria  | <b>Mevion Medical Systems:</b> Vendor: Speaker fee: Start Date: 2021- End Date: 2021<br><b>MyCareGorithm, LLC:</b> Patient Education: Development of Patient Educational Materials: Start Date: 01/2022- To Present  | None  | None   |
| <b>Chirayu Patel</b>  | <b>MGH:</b> Radiation Oncologist: Employee  | None  | None  | My Institution receives funding: No salary support in whole or part: national/overall principal investigator | None   | <b>Varian:</b> Grant/Research Funding   | <b>Varian:</b> Radiation technology company: Adaptive Radiation in Lymphoma: Start Date: 10/2023- To Present   | None  | None   |



| ASTRO 2024 Annual Meeting - Annual Meeting Session Reviewers' Disclosures |  |       |  |   |  |  |   |  |   |
|---|--|-------|--|---|--|--|---|--|---|
| Member  | Employment Relationships   |       | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria                  |   |  |  |   | Ownerships or Investment Interests   | Leadership Positions  |
|   | Employment   | Other | Advisory Board   | Research  | Consultant/Speaker/Faculty or Other                      | Method of Remuneration   | Description of Role   |  |   |
| Lindsay Puckett   | Medical College of Wisconsin: Physician: Employee<br>Clement J Zablocki Milwaukee VA Medical Center: Physician: Employee | None  | None   | None  | Faculty  | Accuray: Honoraria   | Accuray: Radiation Oncology: Served as speaker and moderator for educational sessions on Synchrony: Start Date: 1/2020- End Date: 5/2022  | None   | Medical College of Wisconsin: Interim Chair of Thoracic Disease Oriented Team: Chair of Thoracic Disease Group: Not Compensated                     |
| Rinaa Punglia   | DFCI/BWH: Attending physician: Employee  | None  | None   | None  | None   | None   | None  | None   | None  |
| Xiangrong Qi  | Department of Radiation Oncology, UCLA: Associate professor: Employee  | None  | None   | I receive funding: No salary support in whole or part: site principal investigator  | None   | Varian Inc.: Grant/Research Funding  | Varian Inc.: Support from Varian.: Evaluation of adaptive solution: Start Date: 1/2020- To Present  | None   | AAPM Journal of Medical Physics: AAPM: Deputy editor of the Journal of Med Phys: American Association of Medical Physics: Not Compensated           |
| Dominique Rash  | UCSD Health: Radiation oncologist: Employee  | None  | None   | None  | Other - Speaker re: Radformation products Speaker Bureau | Radformation: Honoraria<br>VisionRT: Honoraria: Travel Expenses  | Radformation: creates radiation planning software products: Discussed EZ fluence and other products at vendor booth: Start Date: 10/26/22- End Date: 10/27/22<br>VisionRT: Creates radiation set up products: discussed use of AlignRT: Start Date 3/2022- End Date: 10/27/2022   | None   | None  |
| Lei Ren   | University of Maryland: Professor: Employee  | None  | None   | None  | None   | None   | None  | None   | None  |
| Clifford Robinson   | Washington University School of Medicine in St. Louis: Professor: Employee   | None  | Ongoing: No access to proprietary info<br>Ongoing: No access to proprietary info | My Institution receives funding: No salary support in whole or part: national/overall principal investigator<br>My Institution receives funding: No salary support in whole or part: site principal investigator<br>My Institution receives funding: No salary support in whole or part: other: Multiple IITs | Consultant   | AstraZeneca: Grant/Research Funding: Honoraria<br>EMD Serono: Honoraria<br>EmpNia: Compensation/Payment<br>Merck: Grant/Research Funding<br>Quantaras: Other - Stock<br>Radialogica: Honoraria: Other - Stock<br>Varian: Grant/Research Funding: Honoraria | AstraZeneca: PACIFIC-4 ICI: Start Date: 2018- To Present<br>EMD Serono: Ad hoc advisory boards: Start Date: 2018- To Present<br>EmpNia: Consulting: Start Date: 2022- To Present<br>Merck: Esophageal brachy + pembro phase I trial: Start Date: 2016- To Present<br>Quantaras: Ad hoc advisory boards: Start Date: 2019- To Present<br>Radialogica: Chief Medical Officer: Start Date: 2016- To Present<br>Varian: Consulting on Cardiac Radioablation via Cardialogica, LLC: Start Date: 2019- To Present | Varian: Copyright<br>Radialogica: Stock Options<br>Quantaras: Stock Options<br>EmpNia: Stock Options | EmpNia: Chief Medical Officer: Chief Medical Officer: Not Compensated<br>Radialogica: Chief Medical Officer: Chief Medical Officer: Not Compensated |
| Danielle Rodin  | University Health Network: Radiation Oncologist: Employee  | None  | Ongoing: No access to proprietary info   | None  | Consultant   | Need Inc: Compensation/Payment<br>Union for International Cancer Control: Travel Expenses: Uncompensated   | Need Inc: company focused on quality assurance in cancer care: provide expertise on breast cancer management: Start Date: June 2022- To Present<br>Union for International Cancer Control: non-governmental cancer advocacy organization: Elected member of Board of Directors: Start Date: October 2018- To Present  | None   | None  |
| Kenneth Rosenzweig  | Mount Sinai: Physician and Chair: Employee<br>City of Englewood: Councilman: Employee                                    | None  | None   | None  | None   | None   | None  | None   | NRG Data Monitoring Committee: Monitors NRG protocols: Member: Member of Committee: Not Compensated   |







| ASTRO 2024 Annual Meeting - Annual Meeting Session Reviewers' Disclosures |   |       |   |  |                                     |   |  |                                    |   |
|---|---|-------|---|--|-------------------------------------|---|--|------------------------------------|---|
| Member  | Employment Relationships  |       | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria |  |                                     |   |  | Ownerships or Investment Interests | Leadership Positions  |
|   | Employment  | Other | Advisory Board  | Research   | Consultant/Speaker/Faculty or Other | Method of Remuneration  | Description of Role  |                                    |   |
| Arshin Sheybani   | UnityPoint Health: Physician: Employee  | None  | None  | My Institution receives funding: No salary support in whole or part: national/overall principal investigator | Speaker Bureau                      | Alliance for Clinical Trials Foundation: Grant/Research Funding: Travel Expenses PRO annual meeting: Honoraria                        | Alliance for Clinical Trials Foundation: national network of clinical trials: evaluating the benefit of a course of vit E and trental in implant based PMRT patients: Start Date: 1/2018- End Date: 1/2020 PRO annual meeting: education session at annual meeting to discuss management of head and neck cancers: invited speaker to discuss work and management of tonsillar cancer in a SA-CME session at annual meeting: Start Date: 10/2021 - End Date: 10/2021 | None                               | ASTRO: Nominating Committee: community practice physician: member of ASTRO nominating committee for leadership appointments: Not Compensated<br>ASTROnews: magazine publication for ASTRO: editorial board member: select topics for publication: Not Compensated<br>IWORC-NCORP: review NCORP grant: board member: voting member to designate inclusion of cancer centers and providers into our NCORP: Not Compensated<br>Rectal Anal Task Force: a subcommittee of the NCI GI steering committee: community oncologist representative: a member of the committee with 3 year term. we have monthly meetings to discuss development of clinical trials for rectal and anal cancers: Not Compensated |
| Monica Shukla   | Medical College of Wisconsin: Associate Professor of Radiation Oncology: Employee | None  | None  | None   | None                                | None  | None   | None                               | None  |
| Farzan Siddiqui   | Henry Ford Health System: Vice-Chair, Radiation Oncology : Employee               | None  | Ongoing: No access to proprietary info                          | My Institution receives funding: No salary support in whole or part: site principal investigator             | Consultant Speaker Bureau           | Castle Biosciences, Inc: Honoraria: Travel Expenses<br>Varian Medical Systems Inc: Grant/Research Funding: Honoraria: Travel Expenses | Castle Biosciences, Inc: Honorarium for consulting: Start Date: March 2022- To Present<br>Varian Medical Systems Inc: Varian Clinical School- Head and neck instructor Varian Noona- Medical Advisory Board member: Start Date: 01/01/2019- To Present   | None                               | Henry Ford Cancer Institute: Department of Radiation Oncology: Vice-Chair: Vice- Chair of radiation oncology operations: Not Compensated<br>Henry Ford Health: Henry Ford Medical Group: Chair- Elect, HFMG Board of Governors: Conducting board meetings: Not Compensated  |
| Scott Silva   | University of Louisville: Assistant Professor: Employee                           | None  | None  | None   | None                                | None  | None   | None                               | None  |
| Nicole Simone   | Thomas Jefferson University: Vice Chair: Employee                                 | None  | None  | My Institution receives funding: No salary support in whole or part: national/overall principal investigator | None                                | NCI: Grant/Research Funding   | NCI: PI of 2 R01's and a U54: PI: Start Date: 8/1/17- To Present   | None                               | ASTRO: Chair SEPD committee: Chair: Chair SEPD committee: Not Compensated<br>RRS: Councilor at Large: Councilor at Large: Councilor at Large: Not Compensated   |

| ASTRO 2024 Annual Meeting - Annual Meeting Session Reviewers' Disclosures |  |       |   |  |                                     |  |  |                                    |  |
|---|--|-------|---|--|-------------------------------------|--|--|------------------------------------|--|
| Member  | Employment Relationships   |       | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria |  |                                     |  |  | Ownerships or Investment Interests | Leadership Positions   |
|   | Employment   | Other | Advisory Board  | Research   | Consultant/Speaker/Faculty or Other | Method of Remuneration   | Description of Role  |                                    |  |
| Charles Simone  | New York Proton Center, Memorial Sloan Kettering: Research Professor and Chief Medical Officer: Employee | None  | None  | None   | Other - strategic discussions       | Novocure: Honoraria<br>Varian Medical System: Honoraria  | Novocure: cancer device maker: strategic discussions: Start Date: 6/29/2018- End Date: 4/21/2022<br>Varian Medical System: radiation accelerator maker: strategic discussions: Start Date: 12/29/2015- End Date: 8/03/2022   | None                               | American Radium Society: Chair, Thoracic Appropriate Use Criteria Committee: Chair, Thoracic Appropriate Use Criteria Committee: Not Compensated<br>American Society for Radiation Oncology: Chair, Lung Resource Panel; Vice Chair, Lung Track: Chair, Lung Resource Panel; Vice Chair, Lung Track: Not Compensated<br>Annals of Palliative Medicine: Editor-in-Chief: Editor-in-Chief: Not Compensated<br>NRG Oncology: Chair, Particle Therapy Work Group: Chair, Particle Therapy Work Group: Not Compensated<br>Proton Collaborative Group: President of the Board; Chair, Lung Committee: President of the Board; Chair, Lung Committee: Not Compensated |
| Shankar Siva  | Peter MacCallum Cancer Centre: Radiation Oncologist: Employee  | None  | Single: No access to proprietary info                           | My Institution receives funding: No salary support in whole or part: site principal investigator<br>My Institution receives funding: No salary support in whole or part: national/overall principal investigator | Faculty                             | AstraZeneca: Other - Payment to institution<br>Reflexion Medical Systems: Other - payment to institution<br>Varian Medical Systems: Other - Payment to institution | AstraZeneca: Honoraria for Advisory Board, Education: Lung cancer advisory and educational meetings: Start Date: 2021- To Present<br>Reflexion Medical Systems: Device manufacturer: SABR for metastases: Start Date: 2021- End Date: 2022<br>Varian Medical Systems: Device manufacturer: for clinical research activity, educational talks: Start Date: 2021- To Present | None                               | ART committee of IASLC: Advanced Radiotherapy Techniques (ART) committee of the International Association for the Study of Lung Cancer (IASLC): committee member: advisory role: Not Compensated<br>Radiosurgery Society (RSS): Board of Directors of the Radiosurgery Society (RSS): Board Directoy: volunteer role for advisory of the board: Not Compensated  |

| ASTRO 2024 Annual Meeting - Annual Meeting Session Reviewers' Disclosures |  |       |  |   |                                     |   |   |                                    |  |
|---|--|-------|--|---|-------------------------------------|---|---|------------------------------------|--|
| Member  | Employment Relationships   |       | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria                |   |                                     |   |   | Ownerships or Investment Interests | Leadership Positions   |
|   | Employment   | Other | Advisory Board   | Research  | Consultant/Speaker/Faculty or Other | Method of Remuneration  | Description of Role   |                                    |  |
| Heath Skinner   | UPMC Hillman Cancer Center: Chair: Employee<br>University of Pittsburgh: Chair: Employee           | None  | None   | My Institution receives funding: No salary support in whole or part: other: Contact for the grant<br>My Institution receives funding: No salary support in whole or part: national/overall principal investigator<br>My Institution receives funding: No salary support in whole or part: national/overall principal investigator<br>My Institution receives funding: No salary support in whole or part: national/overall principal investigator<br>My Institution receives funding: No salary support in whole or part: national/overall principal investigator<br>My Institution receives funding: No salary support in whole or part: national/overall principal investigator<br>My Institution receives funding: No salary support in whole or part: national/overall principal investigator<br>My Institution receives funding: No salary support in whole or part: national/overall principal investigator<br>My Institution receives funding: No salary support in whole or part: national/overall principal investigator<br>My Institution receives funding: No salary support in whole or part: national/overall principal investigator<br>My Institution receives funding: No salary support in whole or part: national/overall principal investigator | None                                | EMD Sereno: Grant/Research Funding<br>NCI: Grant/Research Funding<br>NIDCR: Grant/Research Funding                                | EMD Sereno: Pharmaceutical company: This grant provides salary support and research funds for 2 fellows performing research in disparities in head and neck cancer. These funds go to the institution and the fellows.: Start Date: 12/2023- To Present<br>NCI: National Cancer Institute: PI of Head and Neck SPORC: Start Date: 9/1/2022- To Present<br>NCI: National Cancer Institute: PI of R01: Start Date: 2/1/2017- End Date: 2/1/2022<br>NIDCR: National Institute of Dental and Craniofacial Research: R01 from NIDCR: Start Date: 12/23/2017- To Present<br>NIDCR: National Institute of Dental and Craniofacial Research: R01 from NIDCR: Start Date: 2/1/2019- To Present<br>NIDCR: National Institute of Dental and Craniofacial Research: This is a grant from the NIH.: Start Date: 7/1/2023- To Present | None                               | Department of Defense: Department of Defense Congressionally Directed Medical Research Program (CDMRP): Programmatic Review Committee Member: Group that provides final decisions for DOD funding of Peer Reviewer Cancer Research Projects and sets goals and funding mechanisms.: Not Compensated<br>NCI: National Cancer Institute: Member of Head and Neck Steering Committee: Serve on committee to evaluate cooperative group clinical trials: Not Compensated<br>UPMC Hillman Cancer Center: Chair of Department: Chair: I run the radiation oncology department: Not Compensated |
| Scott Soltys  | Stanford University: Professor: Employee   | None  | Single: No access to proprietary info<br>Single: No access to proprietary info | My Institution receives funding: No salary support in whole or part: national/overall principal investigator  | Faculty                             | Accuray, Inc.: Honoraria: Travel Expenses<br>Brainlab, Inc.: Travel Expenses<br>Novocure, Inc.: Grant/Research Funding: Honoraria | Accuray, Inc.: Medical Device Manufacturer: Speaker at meeting. 1 hour advisory board.: Start Date: Nov 2022- To Present<br>Brainlab, Inc.: Medical Device Manufacturer: Speaker at Medical Meeting: Start Date: Sept 2023- To Present<br>Novocure, Inc.: Medical Device Manufacturer: Research support to institution.<br>Honoraria to self: Start Date: August 2020- To Present   | None                               | None   |
| Vinita Takiar   | Cincinnati VA Medical Center: Physician: Employee<br>University of Cincinnati: Professor: Employee | None  | None   | None  | None                                | None  | None  | None                               | None   |
| Rahul Tendulkar   | Cleveland Clinic: Staff: Employee  | None  | Single: No access to proprietary info  | None  | Faculty                             | Elekta: Compensation/Pay ment<br>Varian Medical Systems: Honoraria  | Elekta: Linear accelerator manufacturer: One- time advisory board meeting: Start Date: 2022- End Date: 2022<br>Varian Medical Systems: Linear accelerator manufacturer: Honoraria for educational talks: Start Date: 2017- To Present   | None                               | None   |

| ASTRO 2024 Annual Meeting - Annual Meeting Session Reviewers' Disclosures |   |       |  |  |                                     |   |  |                                    |  |
|---|---|-------|--|--|-------------------------------------|---|--|------------------------------------|--|
| Member  | Employment Relationships  |       | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria                  |  |                                     |   |  | Ownerships or Investment Interests | Leadership Positions   |
|   | Employment  | Other | Advisory Board   | Research   | Consultant/Speaker/Faculty or Other | Method of Remuneration  | Description of Role  |                                    |  |
| Reid Thompson   | Oregon Health & Science University: Associate Professor: Employee<br>VA PORTLAND HEALTHCARE SYSTEM: Staff Physician: Employee | None  | None   | None   | None                                | None  | None   | None                               | None   |
| Mylin Torres  | Emory University: Professor: Employee   | None  | Single: No access to proprietary info  | My Institution receives funding: No salary support in whole or part: national/overall principal investigator<br>My Institution receives funding: No salary support in whole or part: national/overall principal investigator | Consultant<br>Speaker Bureau        | Genentech: Grant/Research Funding<br>Oncohealth: Compensation/Pay ment<br>Pfizer: Grant/Research Funding<br>Pfizer Oncology: Honoraria<br>Varian Medical Systems: Honoraria | Genentech: IIS research award: PI: Start Date: 10/2020- End Date: 8/2023<br>Oncohealth: Utilization management: Utilization management, consultant on radiotherapy toxicity managemet: Start Date: 11/2020- End Date: 5/2023<br>Pfizer: ASPIRE research grant award to fund a clinical trial: PI of a clinical trial: Start Date: 8/2018- To Present<br>Pfizer: Pfizer Global Breast Cancer Research Award: PI of Phase II trial: Start Date: 10/2020- End Date: 8/2023<br>Pfizer Oncology: Pharmaceutical Company: Advisory role on real world applications of palbociclib: Start Date: 11/2021- End Date: 11/2021<br>Varian Medical Systems: Speaker: Breast cancer radiation oncology education: Start Date: 1/3/20 |                                    |  |
| C Jillian Tsai  | Princess Margaret Cancer Centre: Staff Radiation Oncologist: Employee   | None  | Ongoing: No access to proprietary info<br>Ongoing: No access to proprietary info | None   | None                                | Nanobiotix: Uncompensated<br>Varian Medical Inc.: Grant/Research Funding: Honoraria   | Nanobiotix: Provides feedback on clinical trial ideas.: Start Date: 2022- To Present<br>Varian Medical Inc.: Speaker and consultant for the company's educational events: Start Date: 2020- To Present   | None                               | Advances in Radiation Oncology: Deputy Editor: Deputy Editor: Not Compensated  |
| Derek Tsang   | University Health Network: Radiation Oncologist: Employee   | None  | None   | None   | Faculty<br>Consultant               | Elekta: Travel Expenses<br>Need: Compensation/Pay ment  | Elekta: Radiation equipment vendor: Invited faculty at SOMERA, Mexican radiation oncology society meeting. Travel was supported by Elekta.: Start Date: 12/2022- End Date: 12/2022<br>Need: Health care insurance company (https://www.getneed.com): I serve as a consultant regarding pediatric tumour cases for their insurance product: Start Date: 11/2022- To Present   | None                               | None   |
| Yolanda Tseng   | University of Washington: Associate Professor: Employee   | None  | None   | None   | Faculty                             | ASTRO refresher course: Honoraria   | ASTRO refresher course: ASTRO refresher speaker for lymphoma: Start Date: 03/01/2020- End Date: 03/19/2021   | None                               | ASTRO annual scientific committee: ASTRO annual scientific committee: Chair, Palliative care track: Chair, Palliative care track: Not Compensated<br>PCG: Chair, Lymphoma subcommittee: Chair, Lymphoma subcommittee: Not Compensated<br>PTCOG: Co-chair of lymphoma subcommittee: Co- chair of lymphoma subcommittee: Not Compensated |







| ASTRO 2024 Annual Meeting - Annual Meeting Session Reviewers' Disclosures |  |       |   |  |   |   |  |                                    |   |
|---|--|-------|---|--|---|---|--|------------------------------------|---|
| Member  | Employment Relationships   |       | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria |  |   |   |  | Ownerships or Investment Interests | Leadership Positions  |
|   | Employment   | Other | Advisory Board  | Research   | Consultant/Speaker/Faculty or Other   | Method of Remuneration  | Description of Role  |                                    |   |
| Jean Wright   | <b>Johns Hopkins University:</b><br>Associate Professor, Radiation Oncology: Employee                        | None  | None  | My Institution receives funding: No salary support in whole or part: site principal investigator<br>My Institution receives funding: No salary support in whole or part: site principal investigator | Other - royalties<br>Other - APEX surveyor<br>Other - Editor<br>Consultant<br>Faculty<br>Consultant | <b>ASTRO:</b> Honoraria<br><b>Elsevier Journals:</b> Honoraria<br><b>Marshall Dennehy:</b> Compensation/Pay ment<br><b>Oncospace:</b> Grant/Research Funding: Salary Support<br>Physicians Education<br>Resource: Honoraria: Travel Expenses<br><b>Prostate Cancer Foundation:</b> Grant/Research Funding: Salary Support<br><b>Wicker Smith:</b> Compensation/Pay ment | <b>ASTRO:</b> National Radiation Oncology Organization: survey radiation oncology departments for accreditation: Start Date: 2016- To Present<br><b>Elsevier Journals:</b> Breast Section Editor, International Journal of Radiation Oncology Biology and Physics: Editor of breast section of journal: Start Date: 1/1/2023- To Present<br><b>Marshall Dennehy:</b> Expert Witness: Expert witness in breast cancer case: Start Date: 2020- End Date: 9/22/22<br><b>Oncospace:</b> Oncospace is a small data analysis company focusing on radiation oncology treatment, outcomes and toxicity: research on utility of platform to identify radiation treatment planning errors: Start Date: 2020- To Present<br><b>Physicians Education Resource:</b> CME provider: speaker on hypofractionated radiotherapy for breast cancer: Start Date: 3/3/2023- End Date: 3/3/2023<br><b>Prostate Cancer Foundation:</b> Prostate Cancer Foundation-Pfizer Health Equity Challenge: Data analysis to identify underserved areas of country with respect to radiation oncology services.: Start Date: 2021- To Present | None                               | <b>American Board of Radiology:</b> Testing for board certification for radiation oncology: Oral Board Examiner: Conduct oral examinations of trainees 1-2 x per year: Not Compensated<br><b>ASTRO:</b> Chair, Clinical Affairs and Quality Committee: chair of committee that oversees guidelines, MDQA and APEX committees.: Not Compensated  |
| Ying Xiao   | <b>University of Pennsylvania:</b><br>Prof.: Employee  | None  | None  | None   | None  | None  | None   | None                               | None  |
| Ying Xiao   | <b>University of Pennsylvania:</b><br>Prof.: Employee  | None  | None  | None   | None  | None  | None   | None                               | None  |
| Lei Xing  | <b>Stanford University Hospital:</b><br>Professor: Employee  | None  | None  | None   | None  | None  | None   | None                               | None  |
| Wensha Yang   | <b>University of California, San Francisco:</b> Associate Professor: Employee                                | None  | None  | None   | None  | None  | None   | None                               | None  |
| Min Yao   | <b>Penn State Cancer Institute:</b><br>Professor: Employee   | None  | None  | None   | None  | None  | None   | None                               | None  |
| Catheryn Yashar   | <b>University of California San Diego:</b> Professor, Radiation Oncology and Chief Medical Officer: Employee | None  | None  | None   | None  | None  | None   | None                               | <b>ABR:</b> American Board of Radiology: Trustee for Breast and GYN: Oversee examinations of written and oral for breast and gynecology:Not Compensated<br><b>kukuna o ka la:</b> small educational organization: chairman of the board: give yearly meeting in hawaii: Not Compensated<br><b>NCCN:</b> National Comprehensive Cancer Network: Vice Chair Cervical and Uterine panel: help run meetings: Not Compensated<br><b>UCSD:</b> University: Chief Medical Officer: quality and safety oversight: Not Compensated |





ASTRO 2024 Annual Meeting - Annual Meeting Abstract Reviewers' Disclosures

| Member                | Employment Relationships   |       | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria                  |  |                                     |  |   | Ownerships or Investment Interests | Leadership Positions   |
|-----------------------|--|-------|--|--|-------------------------------------|--|---|------------------------------------|--|
|                       | Employment   | Other | Advisory Board   | Research   | Consultant/Speaker/Faculty or Other | Method of Remuneration   | Description of Role   |                                    |  |
| Arya Amini            | City of Hope: associate professor: Employee                            | None  | None   | I receive funding: No salary support in whole or part: national/overall principal investigator<br>I receive funding: No salary support in whole or part: national/overall principal investigator<br>I receive funding: No salary support in whole or part: national/overall principal investigator | Speaker Bureau                      | AstraZeneca: Grant/Research Funding<br>Genentech: Grant/Research Funding<br>RefleXion: Grant/Research Funding<br>Takeda: Grant/Research Funding<br>Pharmaceuticals: Grant/Research Funding<br>Varian: Grant/Research Funding | AstraZeneca: speakers bureau: Start Date: 1/1/23- To Present<br>Genentech: Genentech is providing drug only funding for a phase I trial of SBRT and atezolizumab: Start Date: 4/1/2022- End Date: 12/30/2024<br>RefleXion: research funding evaluating role of BgRT in oligoprogressive NSCLC: Start Date: 5/1/2023- End Date: 12/30/2025<br>Takeda Pharmaceuticals: speakers bureau: Start Date: 1/1/2023- To Present<br>Varian: grant funding evaluating the role of SBRT for oligoprogressive disease: Start Date: 4/1/2023- End Date: 12/1/25 | None                               | None   |
| Asma Amjad            | Medical College of Wisconsin: Medical Physics Resident: Employee       | None  | None   | None   | None                                | None   | None  | None                               | None   |
| Yi An                 | Yale University: Assistant Professor: Employee                         | None  | None   | None   | None                                | None   | None  | None                               | None   |
| Bethany Anderson      | University of Wisconsin: Radiation Oncologist: Employee                | None  | None   | None   | Faculty                             | School of Breast Oncology: Honoraria<br>University of Wisconsin  | School of Breast Oncology: Accelerated breast radiation: Start Date: 2022- End Date: 2022<br>University of Wisconsin: No funding; PI for institutional research protocol of MRI-guided adaptive APBI: Start Date: 2021- End Date: 2021  | None                               | ABR: oral board examiner: create & administer oral board exams for breast cancer: Not Compensated<br>Brachytherapy: Medical journal: Section Editor: Breast/Soft Tissue: Not Compensated<br>Clinical Breast Cancer: Medical journal: Associate Editor: Associate Editor: Not Compensated<br>IJROBP: Medical journal: Associate Section Editor: Breast Section: Not Compensated<br>NCCN: Breast Cancer Committee: committee member: Not Compensated |
| Carryn Anderson       | University of Iowa Hospitals & Clinics: Radiation Oncologist: Employee | None  | Ongoing: No access to proprietary info<br>Ongoing: No access to proprietary info | My Institution receives funding: No salary support in whole or part: site principal investigator   | Consultant                          | Galera Therapeutics, Inc: Compensation/Pay ment<br>Galera Therapeutics, Inc: Uncompensated   | Galera Therapeutics, Inc: Pharmaceutical company: Clinical trial and research consultant for oral mucositis in head and neck cancer patients: Start Date: October 2015- To Present<br>Galera Therapeutics, Inc: Pharmaceutical company: Member of consulting focus group for development of healthcare provider and patient education materials related to potential commercial launch of avasopasem manganese for oral mucositis in head and neck cancer patients receiving cisplatin & RT.: Start Date: July 1, 2023- To Present                | None                               | University of Iowa Hospitals & Clinics: Residency Program Director: Maintain ACGME accreditation for Radiation Oncology program: Not Compensated: Relationship Ended: 3/30/2023  |
| Penny Anderson        | Fox Chase Cancer Center: Radiation Oncologist: Employee                | None  | None   | None   | None                                | None   | None  | None                               | None   |
| Sanjay Aneja          | Yale University: Assistant Professor: Employee                         | None  | None   | None   | None                                | None   | None  | None                               | None   |
| Smith Apisarnthanarak | University of Washington: Professor: Employee                          | None  | None   | None   | None                                | None   | None  | None                               | None   |
| Paul Aridgides        | Upstate Medical University: Associate Professor: Employee              | None  | None   | None   | None                                | None   | None  | None                               | None   |
| Katelyn Atkins        | Cedars-Sinai Medical Center: Assistant Professor: Employee             | None  | None   | None   | Faculty                             | OnLive: Honoraria  | OnLive: Educational CME Materials: Speaker, educational: Start Date: 03/2021- End Date: 04/2021   | None                               | None   |

**ASTRO 2024 Annual Meeting - Annual Meeting Abstract Reviewers' Disclosures**

| Member                        | Employment Relationships   |       | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria                |  |                                     |  |   | Ownerships or Investment Interests | Leadership Positions  |
|-------------------------------|--|-------|--|--|-------------------------------------|--|---|------------------------------------|---|
|                               | Employment   | Other | Advisory Board   | Research   | Consultant/Speaker/Faculty or Other | Method of Remuneration   | Description of Role   |                                    |   |
| <b>Vladimir Avkshol</b>       | <b>UT Southwestern Medical Center:</b><br>Assistant Professor:<br>Employee: Relationship ended: 7/28/2023<br><b>Kelsey- Seybold Clinic:</b><br>Radiation Oncologist:<br>Employee | None  | None   | None   | None                                | None   | None  | None                               | None  |
| <b>Musaddiq Awan</b>          | <b>Medical College of Wisconsin:</b> Assistant Professor: Employee   | None  | None   | My Institution receives funding: No salary support in whole or part: national/overall principal investigator<br>My Institution receives funding: No salary support in whole or part: national/overall principal investigator | None                                | <b>Genentech:</b> Other - Drug only support<br><b>NIH:</b> Grant/Research Funding                              | <b>Genentech:</b> Drug company: PI of NCI funded Phase I trial.: Start Date: 1/2021- To Present<br><b>NIH:</b> Government: Phase I Trial of Dose-Escalated Hypofractionated Adaptive Radiation with Adjuvant Atezolizumab: Start Date: 1/2021- To Present   | None                               | <b>NRG Oncology:</b> National Clinical Trial Organization: Committee Member: Serve on Developmental Therapeutics RT subcommittee and Head and Neck General Committee: Not Compensated   |
| <b>B. Ashleigh Guadagnolo</b> | <b>MD Anderson:</b><br>Professor: Employee   | None  | None   | None   | None                                | None   | None  | None                               | None  |
| <b>Shahed Badiyan</b>         | <b>University of Texas Southwestern Medical Center:</b> Associate Professor: Employee  | None  | None   | None   | Consultant                          | <b>Elekta:</b> Compensation/Pay ment<br><b>Merck:</b> Compensation/Pay ment                                    | <b>Elekta:</b> Grant reviewer: Start Date: 9/01/2023- End Date: 10/1/2023<br><b>Merck:</b> Clinical Trial Radiation Quality Assurance.: Start Date: 6-1-2022- To Present  | None                               | None  |
| <b>Richard Bakst</b>          | <b>Mount Sinai Hospital:</b><br>Professor: Employee  | None  | None   | None   | None                                | None   | None  | None                               | None  |
| <b>Ehsan Balagamwala</b>      | <b>Cleveland Clinic:</b> Staff Physician: Employee   | None  | None   | None   | None                                | None   | None  | None                               | <b>Cleveland Clinic:</b> Colorectal cancer program:Co-director: Co-director of the colorectal cancer program for the enterprise: Not Compensated  |
| <b>Leslie Ballas</b>          | <b>Cedars Sinai Medical Center:</b> Physician: Employee  | None  | Single: No access to proprietary info<br>Single: No access to proprietary info | None   | Consultant                          | <b>Blue Earth:</b> Compensation/Pay ment<br><b>Pfizer:</b> Compensation/Pay ment<br><b>UpToDate:</b> Honoraria | <b>Blue Earth:</b> diagnostic/imaging: new diagnostic agents for PET imaging in prostate cancer: Start Date: 12/7/22- End Date: 12/7/22<br><b>Pfizer:</b> Drug company: Advisory Board on advanced prostate cancer treatment: Start Date: 11/11/22- End Date: 11/11/22<br><b>UpToDate:</b> Online educational materials: Edit online educational review materials: Start Date: 12/2023 - To Present | None                               | <b>American Board of Radiology:</b> Organization in charge of board certification and maintenance: Chair hematologic malignancy section of oral boards: In charge of heme section of oral exam prep and delivery: Not Compensated<br><b>UroToday:</b> online resource for urologists/medical oncologists/radiation oncologists for urologic malignancies: Editor: Provide content, reviews, interviews for bladder preservation section of website: Not Compensated |
| <b>James Balter</b>           | <b>University of Michigan:</b><br>Professor: Employee  | None  | None   | My Institution receives funding: No salary support in whole or part: national/overall principal investigator<br>My Institution receives funding: No salary support in whole or part: national/overall principal investigator | None                                | <b>NIH:</b> Grant/Research Funding   | <b>NIH: R01-</b> Optimization of Magnetic Resonance Imaging in Radiation Oncology: I am the Principal Investigator on a NIH R01 for Optimization of Magnetic Resonance Imaging in Radiation Oncology: Start Date: 10/1/13- To Present   | None                               | <b>CSR:</b> Center for Scientific Review (NIH): Chair - SBIR/STTR review Panel: I serve on, and currently chair, a recurring NIH review panel for SBIR and STTR applications: Not Compensated   |



| ASTRO 2024 Annual Meeting - Annual Meeting Abstract Reviewers' Disclosures |  |       |   |  |   |   |   |                                      |   |
|--|--|-------|---|--|---|---|---|--------------------------------------|---|
| Member   | Employment Relationships   |       | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria |  |   |   |   | Ownerships or Investment Interests   | Leadership Positions  |
|  | Employment   | Other | Advisory Board  | Research   | Consultant/Speaker/Faculty or Other                 | Method of Remuneration                            | Description of Role   |                                      |   |
| Ramesh Bilimagga   | Healthcare Global Enterprises: Professor Emeritus: Other: Senior Radiation Oncology Consultant | None  | None  | None   | Consultant  | Healthcare Global Enterprises: Salary Support     | Healthcare Global Enterprises: Ethics Committee: Others: Start Date: Ongoing- To Present  | Healthcare Global Enterprises: Stock | ISO: Indian Society of Oncology - National Organization: President: To advise and steer the activities of ISO national organization for two years.: Not Compensated   |
| Andrew Bishop  | The University of Texas MD Anderson Cancer Center: Associate Professor: Employee               | None  | None  | None   | None  | None  | None  | None                                 | None  |
| Tithi Biswas   | MetroHealth Cancer Center, CWRU: Attending Physician: Employee                                 | None  | None  | None   | Other - EDDOP leadership funding for Clinical trial | NCI: Grant/Research Funding                       | NCI: PI: Start Date: 6/1/2022- End Date: 5/31/23  | None                                 | None  |
| Danielle Bitterman   | Brigham and Women's Hospital: Physician: Employee  | None  | Ongoing: No access to proprietary info                          | None   | None  | Mercurial AI: Compensation/Payment                | Mercurial AI: Tech company: Advisory board member - 30 min/month: Start Date: 01/01/2024- End Date: 01/01/2029                              | None                                 | HemOnc.org: HemOnc.org is the largest freely available medical wiki of interventions, regimens, and general information relevant to the fields of hematology and oncology. It is designed for easy use and intended for healthcare professionals. Any healthcare professional can sign up to contribute; the accuracy and completeness of content is overseen by the Editorial Board.: Associate Editor, Radiation Oncology: Oversee all radiation oncology content, solicit radiation oncology contributors for specialized sections.: Not Compensated |
| Seth Blackburn   | Accuray: SVP, CMO: Employee  | None  | None  | None   | None  | None  | None  | None                                 | None  |
| Rachel Blitzblau   | Duke University Health System: Associate Professor of Radiation Oncology: Employee             | None  | None  | None   | None  | None  | None  | None                                 | None  |
| Melisa Boersma   | University of Kansas Physicians/KUMC: Assistant Professor: Employee                            | None  | None  | None   | None  | None  | None  | None                                 | None  |
| Jeffrey Bogart   | Upstate Cancer Center: Chair, Dept Radiation Oncology: Employee                                | None  | None  | None   | None  | None  | None  | None                                 | None  |
| Thomas Bortfeld  | Massachusetts General Hospital: Division Chief, Radiation Biophysics: Employee                 | None  | None  | None   | None  | None  | None  | None                                 | None  |
| Stephen Bowen  | University of Washington / Fred Hutch Cancer Center: Professor: Employee                       | None  | None  | My Institution receives funding: No salary support in whole or part: national/overall principal investigator | None  | National Cancer Institute: Grant/Research Funding | National Cancer Institute: Federal sponsor of cancer research: I serve as contact PI on R01CA258997.: Start Date: December 2021- To Present | None                                 | None  |





| ASTRO 2024 Annual Meeting - Annual Meeting Abstract Reviewers' Disclosures |   |       |   |  |  |   |  |   |  |
|--|---|-------|---|--|--|---|--|---|--|
| Member   | Employment Relationships  |       | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria |  |  |   |  | Ownerships or Investment Interests  | Leadership Positions   |
|  | Employment  | Other | Advisory Board  | Research   | Consultant/Speaker/Faculty or Other      | Method of Remuneration  | Description of Role  |   |  |
| Zachary Buchwald   | Emory University: Assistant Professor: Employee   | None  | None  | None   | None                                     | None  | None   | None  | None   |
| Michael Buckstein  | Icahn School of Medicine at Mount Sinai: Associate Professor: Employee                                  | None  | None  | None   | None                                     | None  | None   | None  | None   |
| Stuart Burri   | Southeast Radiation Oncology Group: President and Partner: Partner                                      | None  | None  | None   | Other - Data Safety monitoring committee | Novocure: Travel Expenses: Compensation/Pay ment                          | Novocure: Medical Device Company: Member of data safety monitoring board for the METIS trial: Start Date: 2018- End Date: 2023   | Southeast Radiation Oncology Group: Partnership Radiation Oncology Centers of the Carolinas Charlotte Physics Holding FUSE Oncology Holding Oncology Practice Solutions | Atrium Health - Levine Cancer Institute: A large non- profit health system: Chairman of Radiation Oncology: Chairman of Radiation Oncology: Not Compensated  |
| Shauna Campbell  | Cleveland Clinic Foundation: Radiation Oncologist: Employee   | None  | None  | None   | Faculty                                  | Accuray: Travel Expenses  | Accuray: Think Tank presenter.: Start Date: 06/01/22- End Date: 06/15/22   | None  | None   |
| Ning Cao   | University of Washington: Associate Professor: Employee   | None  | None  | None   | None                                     | None  | None   | None  | None   |
| Yue Cao  | University of Michigan: professor: Employee   | None  | None  | My Institution receives funding: No salary support in whole or part: other: co- investigator | Other - AI fellowship during sabbatical  | Acara: Compensation/Pay ment Siemens Healthineers: Grant/Research Funding | Acara: subcontract company working with Digital Technologies and Innovation Center of Siemens Medical Solution of USA: travel and housing during sabbatical: Start Date: 11/01/2023- End Date: 02/29/2024 Siemens Healthineers: Medical device company: Co- investigator to test MRI methodologies: Start Date: 2013- To Present | University of Michigan: Copyright   | None   |
| David Carlson  | Yale University: Professor & Vice Chair: Employee Yale New Haven Health: Director of Physics : Employee | None  | None  | I receive funding: No salary support in whole or part: site principal investigator           | None                                     | Reflexion Medical, Inc.: Grant/Research Funding                           | Reflexion Medical, Inc.: Medical equipment manufacturer in Hayward, California: Funding for several small projects related to Biologically Guided Radiotherapy: Start Date: 4/1/2024- To Present   | None  | ASTRO: Immediate Past Chair, SEPD: Immediate Past Chair of SEPD and member of Science Council: Not Compensated Red Journal: Section Editor, Physics: Senior Editor for the Physics Section of the Red Journal: Not Compensated |
| Keith Cengel   | University of Pennsylvania: professor: Employee   | None  | None  | None   | None                                     | None  | None   | None  | IPA: international photodynamic association: Board: Board: Not Compensated MARF: mesothelioma foundation: board of directors: board member: Not Compensated  |
| Laura Cervino  | Memorial Sloan Kettering Cancer Center: Service Chief, Attending Physicist : Employee                   | None  | Ongoing: No access to proprietary info                          | None   | None                                     | Arquimea Research Center: Advisory Board                                  | Arquimea Research Center: Research Advisory Board Member: Start Date: 01/01/2022- End Date: 02/01/2023   | None  | AAPM: Therapy Imaging Subcommittee: Vice- Chair: Not Compensated   |
| Manjeet Chadha   | Icahn School of Medicine at Mount Sinai: Attending Faculty: Employee                                    | None  | None  | None   | None                                     | None  | None   | None  | None   |
| Daniel Chamberlain   | Sheikh Shakhboub Medical City: Chair: Employee  | None  | None  | None   | None                                     | None  | None   | None  | None   |
| Annie Chan   | MGH: physician: Employee  | None  | None  | None   | None                                     | None  | None   | None  | None   |
| Daniel Chang   | University of Michigan: Professor: Employee   | None  | None  | None   | None                                     | Varian Medican Systems: Honoraria: Travel Expenses                        | Varian Medican Systems: Vendor for radiotherapy machines: Speaker at 2 events in 2023: Start Date: NA - To Present   | None  | None   |

| ASTRO 2024 Annual Meeting - Annual Meeting Abstract Reviewers' Disclosures |  |       |  |  |                                     |  |  |   |   |
|--|--|-------|--|--|-------------------------------------|--|--|---|---|
| Member   | Employment Relationships   |       | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria                  |  |                                     |  |  | Ownerships or Investment Interests  | Leadership Positions  |
|  | Employment   | Other | Advisory Board   | Research   | Consultant/Speaker/Faculty or Other | Method of Remuneration   | Description of Role  |   |   |
| Joe Chang  | MD Anderson Cancer Center: Professor: Employee   | None  | Ongoing: No access to proprietary info   | None   | Consultant                          | IBA: Compensation/Pay ment<br>Regeneron: Compensation/Pay ment   | IBA: Proton manufacturer: Clinical study advisory committee: Start Date: 2022- To Present<br>Regeneron: Pharmaceutical company: Clinical study advisory committee: Start Date: 2023- To Present  | None  | IASLC: International Association of Study of Lung Cancer: Board Director: Board Director Member: Not Compensated<br>NCCN: Thoracic malignancies Guideline Panel: Panel: Voting member: Not Compensated<br>PTCOG: International society for particle therapy: Co-chair for Scientific Program Committee: Organizing society annual meeting: Not Compensated  |
| Samuel Chao  | Cleveland Clinic: Radiation Oncologist: Employee   | None  | None   | My Institution receives funding: No salary support in whole or part: national/overall principal investigator   | Faculty                             | Blue Earth Diagnostics: Honoraria: Travel Expenses: Salary Support<br>Varian Medical Systems: Honoraria  | Blue Earth Diagnostics: PET Tracer Company: Fluciclovine for Diagnosis of Radiation Necrosis: Start Date: 2020- To Present<br>Varian Medical Systems: Review CNS radiation oncology for course: Start Date: 2017- To Present   | None  | None  |
| Christina Chapman  | Baylor College Of Medicine: Assistant of Professor of Radiation Oncology: Employee                   | None  | None   | None   | Faculty                             | Daiichi Sankyo/ASCO Advantage Program: Honoraria: Travel Expenses: Compensation/Pay ment   | Daiichi Sankyo/ASCO Advantage Program: Gave education lectures to pharma (company that manufactures Enhertu) as part of ASCO Advantage Educational Program: Gave education lectures to pharma (company that manufactures Enhertu) as part of ASCO Advantage Educational Program: Start Date: 11/29/22- End Date: 11/30/22  | None  | None  |
| Aadel Chaudhuri  | Mayo Clinic: Associate Professor: Employee   | None  | Ongoing: No access to proprietary info<br>Ongoing: No access to proprietary info | None   | Consultant                          | AlphaSights: Compensation/Pay ment<br>AstraZeneca: Compensation/Pay ment<br>Daiichi Sankyo DeciBio: Compensation/Pay ment<br>Genescopy: Other - Stock options<br>Illumina: Compensation/Pay ment<br>Roche: Honoraria: Travel Expenses: Compensation/Pay ment | AlphaSights: Consulting firm: Liquid biopsy consulting: Start Date: 1/2019- To Present<br>AstraZeneca: Biotechnology company: Lung cancer advising: Start Date: 10/2021 - To Present<br>Daiichi Sankyo: Biotechnology company: Lung cancer advising: Start Date: 10/2021- To Present<br>DeciBio: Consulting firm: Liquid Biopsy consulting: Start Date: 1/2019- To Present<br>Genescopy: Biotechnology company: Stool RNA advising: Start Date: 1/2019- To Present | Genescopy: Stock Options<br>Droplet Biosciences<br>LiquidCell Dx Inc.<br>Patent filings related to cancer biomarkers: Copyright | AI in Precision Oncology: Journal: Editorial Board: Editorial board member: Not Compensated<br>Mayo Clinic Comprehensive Cancer Center: Cancer Center: Co- Director of the Precision Genomics Office: Co-director of precision genomics across the Mayo Clinic enterprise: Not Compensated<br>Mayo Clinic Comprehensive Cancer Center: Cancer Center: Emerging Leader of Early Cancer Detection and Interception: Emerging leader at cancer center: Not Compensated |
| Aileen Chen  | MD Anderson Cancer Center: Associate Professor: Employee   | None  | None   | My Institution receives funding: No salary support in whole or part: site principal investigator<br>My Institution receives funding: No salary support in whole or part: site principal investigator | None                                | Intelligent Automation/BlueHal o: Grant/Research Funding<br>Novocure: Grant/Research Funding   | Intelligent Automation/BlueHal o: NIH SBIR: PROs: Start Date: 9/15/2020- To Present<br>Novocure: Industry: TTFs in lung cancer: Start Date: 11/1/2022- To Present  | None  | None  |
| Peter Chen   | Corewell Beaumont University Hosp, Royal Oak, MI: Professor<br>Oakland U Wm Beaumont SOM: Employee   | None  | None   | None   | None                                | None   | None   | None  | ASTRO Membership Committee, Chair for 2021-2022: Chair<br>2021-2022: Chair of ASTRO Membership Committee: Not Compensated   |
| Ronald Chen  | University of Kansas Medical Center: Professor and Chair, Department of Radiation Oncology: Employee | None  | Ongoing: No access to proprietary info<br>Single: No access to proprietary info  | None   | Consultant                          | Janssen: Honoraria<br>Myovant: Honoraria<br>Seagen: Honoraria  | Janssen: Pharma: Janssen sponsors NRG GU008 clinical trial, for which I am PI: Start Date: 12/8/2021- To Present<br>Myovant: Pharma: Prostate cancer: Start Date: 8/11/2021- End Date: 8/11/2021<br>Seagen: Pharma: Advise on bladder cancer research: Start Date: 11/3/2021- To Present   | None  | None  |
| Yi-Jen Chen  | City of Hope Medical Center: Attending physician: Employee   | None  | None   | None   | None                                | None   | None   | None  | None  |
| Yingxuan Chen  | Thomas Jefferson University: Medical Physicist/ Clinical Assistant Professor: Employee               | None  | None   | My Institution receives funding: No salary support in whole or part: other: Co-investigator  | None                                | Varian Medical System: Grant/Research Funding  | Varian Medical System: Longitudinal CBCT Radiomics Analysis for Lung Cancer Radiotherapy Response and Prognosis Prediction: Start Date: Jan 2024- To Present   | None  | None  |

| ASTRO 2024 Annual Meeting - Annual Meeting Abstract Reviewers' Disclosures |   |       |   |  |   |  |  |                                    |  |
|--|---|-------|---|--|---|--|--|------------------------------------|--|
| Member   | Employment Relationships  |       | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria   |  |   |  |  | Ownerships or Investment Interests | Leadership Positions   |
|  | Employment  | Other | Advisory Board  | Research   | Consultant/Speaker/Faculty or Other         | Method of Remuneration   | Description of Role  |                                    |  |
| Yuhchyan Chen  | University of Rochester Medical Center: Professor and Chair: Employee       | None  | None  | None   | None  | None   | None   | None                               | None   |
| Zhe Chen   | Yale University: Professor: Employee  | None  | None  | None   | None  | None   | None   | None                               | None   |
| Simon Cheng  | Columbia University: Assistant Professor: Employee                          | None  | None  | I receive funding: No salary support in whole or part: other: co- investigator   | Faculty                                     | Janssen: Grant/Research Funding<br>Raysearch: Other - food/beverage  | Janssen: pharmaceutical company: co- investigator in research grant on lung cancer biomarkers: Start Date: 12/22/22- To Present<br>Raysearch: radiation oncology technology: meeting: Start Date: 9/15/2019- End Date: 9/15/2019   | Columbia University: Copyright     | None   |
| Fumiko Chino   | Memorial Sloan Kettering: Assistant Attending, Radiation Oncology: Employee | None  | None  | None   | None  | None   | None   | None                               | None   |
| Steven Chmura  | University of Chicago: Employee   | None  | Single: No access to proprietary info<br>Single: No access to proprietary info  | My Institution receives funding: No salary support in whole or part: national/overall principal investigator<br>My Institution receives funding: No salary support in whole or part: site principal investigator<br>My Institution receives funding: No salary support in whole or part: site principal investigator | None  | bms: Grant/Research Funding<br>GE Medical: Honoraria<br>Genentec: Honoraria<br>Takeda: Grant/Research Funding<br>Varian: Grant/Research Funding: Medical Systems   | bms: pharma: PI for COSINR: Start Date: 7/2016- To Present<br>GE Medical: PET tracer: Ad board for pET tracers: Start Date: 12/5/2022- End Date: 12/5/2022<br>Genentec: pARMA: adboard: Start Date: 7/2022- End Date: 7/2022<br>Takeda: Pharma: PI Tak636: Start Date: 7/2021- To Present<br>Varian: Medical Systems: PI: Start Date: 7/2021- To Present   | None                               | None   |
| Kevin Chua   | National Cancer Centre Singapore: Senior Consultant: Employee               | None  | Single: No access to proprietary info<br>Single: No access to proprietary info<br>Single: No access to proprietary info<br>Single: No access to proprietary info<br>Single: No access to proprietary info<br>Single: No access to proprietary info<br>Single: No access to proprietary info | None   | Speaker Bureau<br>Faculty<br>Speaker Bureau | AstraZeneca: Honoraria<br>MSD: Honoraria<br>Peer Voice: Honoraria<br>Regeneron: Honoraria<br>Roche Singapore: Honoraria<br>Seagen: Honoraria<br>Takeda: Honoraria<br>Varian Medical System: Honoraria: Travel Expenses | AstraZeneca: Pharmaceutical: Speaking role and participation in advisory board: Start Date: Nov 2018- To Present<br>MSD: Pharmaceutical: Advisory board meeting: Start Date: Aug 2023- To Present<br>Peer Voice: Medical Education: Speaking role and curriculum development: Start Date: Jan 2021- To Present<br>Regeneron: Pharmaceutical company: Advisory board: Start Date: Sep 23- To Present<br>Roche Singapore: Pharmaceutical: Participation in advisory board: Start Date: Dec 2022- To Present<br>Seagen: Pharmaceutical: Advisory board: Start Date: June 23 - To Present<br>Takeda: Pharmaceutical: Advisory board meeting: Start Date: March 23- To Present<br>Varian Medical System: Radiotherapy and software company: Invited speaker: Start Date: Nov 23- To Present | None                               | ASNO: Asian Society for Neuro- Oncology: Executive board member: Member of Communications committee; Member of Outreach and Education committee<br>Member of Nomination committee: Not Compensated<br>Brain Tumour Society Singapore: Patient advocacy: Medical Advisor: Not Compensated<br>Lung Cancer Consortium Singapore: Bring together clinical and research community to advance diagnosis and management of lung cancer in Singapore: Member: Member of scientific committee: Not Compensated<br>National Cancer Centre Singapore: Co-chair of CNS Cancer Service Line Development<br>Workgroup: Co-chair: Co-chair of CNS Cancer Service Line Development<br>Workgroup: Not Compensated<br>Singapore Society for Neuro- Oncology: Society to promote Neuro- Oncology research and education in Singapore: Founding member & Board member: Founding member & Board member: Not Compensated |



**ASTRO 2024 Annual Meeting - Annual Meeting Abstract Reviewers' Disclosures**

| Member                  | Employment Relationships  |       | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria |  |   |   |   | Ownerships or Investment Interests | Leadership Positions  |
|-------------------------|---|-------|---|--|---|---|---|------------------------------------|---|
|                         | Employment  | Other | Advisory Board  | Research   | Consultant/Speaker/Faculty or Other         | Method of Remuneration  | Description of Role   |                                    |   |
| <b>Kiri Cook</b>        | <b>Oregon Health and Science University:</b> Assistant Professor: Employee: Relationship ended: 1/6/2023<br><b>Compass Oncology:</b> Radiation Oncologist: Employee | None  | None  | None   | None  | None  | None  | None                               | None  |
| <b>Mark Corkum</b>      | <b>The Ottawa Hospital, University of Ottawa:</b> Radiation Oncologist: Independent Contractor  | None  | <b>Tersera:</b> Advisory Board                                  | None   | Consultant Faculty                          | <b>Tersera:</b> Consultant<br><b>Knight Pharmaceutical:</b> Consultant: Honoraria<br><b>Tolmar pharmaceuticals:</b> Travel Expenses   | <b>Tersera:</b> Multidisciplinary Journal Club: Start Date: 02/2022 - To Present<br><b>Knight Pharmaceutical:</b> Multidisciplinary Journal Club: Start Date: 12/2022 - To Present<br><b>Tolmar pharmaceuticals:</b> pharmaceutical: education session re: ASTRO 2023 to oncologists in Ottawa: Start Date: 7/2022 - To Present   | None                               | None  |
| <b>Pippa Cosper</b>     | <b>University of Wisconsin-Madison:</b> Assistant Professor: Employee   | None  | None  | I receive funding: No salary support in whole or part: national/overall principal investigator   | Consultant                                  | <b>Guidepoint network:</b> Compensation/Payment<br><b>NIH:</b> Grant/Research Funding   | <b>Guidepoint network:</b> Consulting firm: sometimes consult for them regarding head and neck cancer biology or trials.: Start Date: 10/01/2023- To Present<br><b>NIH:</b> K08 career development award: PI: Start Date: 7/2021- End Date: 7/2026  | None                               | None  |
| <b>Jennifer Croke</b>   | <b>Princes Margaret Cancer Centre:</b> Radiation Oncologist: Employee   | None  | None  | None   | Faculty                                     | <b>Merck:</b> Honoraria   | <b>Merck:</b> Provided education to healthcare providers in the area of breast cancer radiotherapy and immunotherapy: Provided education to healthcare providers in the area of breast cancer radiotherapy and immunotherapy: Start Date: November 2022- To Present   | None                               | None  |
| <b>Kyle Cuneo</b>       | <b>University of Michigan:</b> Faculty: Employee  | None  | None  | None   | None  | None  | None  | None                               | None  |
| <b>Roi Dagan</b>        | <b>University of Florida, College of Medicine:</b> Associate Professor, Radiation Oncology: Employee  | None  | None  | None   | None  | <b>UptoDate:</b> Honoraria  | <b>UptoDate:</b> Publisher: Author: Start Date: 2014- To Present  | None                               | None  |
| <b>Megan Daly</b>       | <b>University of California Davis:</b> Professor of Clinical Radiation Oncology: Employee   | None  | Ongoing: No access to proprietary info                          | My Institution receives funding: No salary support in whole or part: national/overall principal investigator<br>My Institution receives funding: No salary support in whole or part: national/overall principal investigator<br>My Institution receives funding: No salary support in whole or part: site principal investigator | Consultant Faculty<br>Faculty<br>Consultant | <b>Astra Zeneca:</b> Honoraria<br><b>Curio:</b> Honoraria<br><b>Dava:</b> Honoraria<br><b>EMD Serono:</b> Grant/Research Funding<br><b>Genentech:</b> Grant/Research Funding<br><b>Merck:</b> Grant/Research Funding<br><b>Novocure:</b> Honoraria<br><b>Prelude Corporation:</b> Honoraria | <b>Astra Zeneca:</b> Pharma company: Attended single advisory board meeting on stage 3 NSCLC, separately attended single consulting session, and separately served as a speaker (provided my own content) at an educational meeting.: Start Date: Dec 2022- To Present<br><b>Curio:</b> Education company: Spoke at online meeting about stage 3 NSCLC: Start Date: Nov 2022- To Present<br><b>Dava:</b> Education company: Spoke at online meeting on stage 3 NSCLC: Start Date: Oct 2022- To Present<br><b>EMD Serono:</b> Pharma Company: IIT funding radiation + avelumab NSCLC: Start Date: 2017- End Date: 2020<br><b>Genentech:</b> Pharma Company: Prior funding/drug for ITTs (served as co-PI) and funding for SWOG trial that I serve as PI on: Start Date: 2017- To Present | None                               | <b>Clinical Lung Cancer:</b> Journal: Editorial board member: Radiation oncology editor for CLC journal: Not Compensated<br><b>JROBP:</b> Journal: Associate Editor: Member of thoracic team: Not Compensated |
| <b>Savita Dandapani</b> | <b>City of Hope:</b> associate professor: Employee  | None  | None  | I receive funding: No salary support in whole or part: national/overall principal investigator<br>I receive funding: No salary support in whole or part: other: provides imaging agent for my research investigator initiated trial  | None  | <b>Bayer:</b> Grant/Research Funding<br><b>imaginab:</b> Grant/Research Funding: Other - provides imaging agent for my IIT  | <b>Bayer:</b> radium223 oligomet prostate: radium223 oligomet prostate: Start Date: 2017- To Present<br><b>imaginab:</b> provides imaging agent for my IIT: Start Date: 1/2021- To Present  | None                               | None  |

| ASTRO 2024 Annual Meeting - Annual Meeting Abstract Reviewers' Disclosures |   |       |   |  |                                     |  |   |                                    |  |
|--|---|-------|---|--|-------------------------------------|--|---|------------------------------------|--|
| Member   | Employment Relationships  |       | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria |  |                                     |  |   | Ownerships or Investment Interests | Leadership Positions   |
|  | Employment  | Other | Advisory Board  | Research   | Consultant/Speaker/Faculty or Other | Method of Remuneration   | Description of Role   |                                    |  |
| Indra Das  | Northwestern Memorial Hospital: Director of Medical Physics: Employee   | None  | None  | None   | Other - Book Royalty                | CRC/ Taylor and Francis: Other<br>Springer nature: Other   | CRC/ Taylor and Francis: Publisher: Book Royalty: Start Date: Jan 2020- To Present<br>Springer nature: Publisher: Book Royalty: Start Date: Jan 2020- To Present  | None                               | AAPM: Member society: Committee Member: Committee members of several group in AAPM: Not Compensated<br>Br J Radiology: Publisher: Associate Editor: Associate Editor: Not Compensated<br>IOP, Publishing: Institute of physics: Chair of the Board: Chair of the board: Not Compensated<br>J Clinical Medicine: Journal: Editor: Editor: Not Compensated<br>Journal of radiation Research: Publisher: Associate editor: Associate editor: Not Compensated<br>Medical Physics: Journal: Sr AE: Senior Associate Editor: Not Compensated |
| Emily Daugherty  | University of Cincinnati: Associate Professor: Employee   | None  | None  | None   | Speaker Bureau                      | Varian Medical Systems: Honoraria  | Varian Medical Systems: Honoraria received for 2/2022 talk: Talk given at Varian Australasian Summit 2/2022: Start Date: 2/1/2022- End Date: 2/1/2022   | None                               | None   |
| Laura Dawson   | Princess Margaret: Clinician scientist: Employee<br>University of Toronto, Dept. of Radiation Oncology: Chair: Employee | None  | None  | My Institution receives funding: No salary support in whole or part: other: coinvestigator   | Faculty                             | Astro Zeneca: Honoraria<br>Merck: Grant/Research Funding   | Astro Zeneca: speaker on liver cancer: Start Date: 2023- End Date: 2023<br>Merck: ITT research clinical trial PEMRAD: coinvestigator. Radiation oncology PI. Trial is an ITT, only open at our center, investigating Pembrolizumab and SBRT for HCC patients.: Start Date: 2018- End Date: 2022   | None                               | None   |
| John DeMarco   | Cedars-Sinai Department of Radiation Oncology: Chief of Clinical Physics: Employee                                      | None  | None  | None   | None                                | None   | None  | None                               | None   |
| Jun Deng   | Yale University: Professor: Employee  | None  | None  | None   | None                                | None   | None  | None                               | None   |
| Kristopher Dennis  | Ontario Ministry of Health and Long Term Care: Radiation oncologist: Independent Contractor                             | None  | None  | None   | None                                | None   | None  | None                               | None   |
| Neil Desai   | University of Texas Southwestern: Physician employee: Employee  | None  | Ongoing: No access to proprietary info                          | My Institution receives funding: No salary support in whole or part: national/overall principal investigator<br>My Institution receives funding: No salary support in whole or part: national/overall principal investigator | Consultant Faculty                  | Boston Scientific: Grant/Research Funding: Compensation/Pay ment<br>Society Urologic Nursing (SUNA): Honoraria<br>Society Urologic Oncology: Honoraria<br>Tellix: Grant/Research Funding | Boston Scientific: Healthcare company: Research funding of trial ; consulting annual limit by university management plan of this COI: Start Date: 8/2017- To Present<br>Society Urologic Nursing (SUNA): Nursing/APP society: Annual meeting invited talk: Start Date: 7/2022- End Date: 7/2022<br>Society Urologic Oncology: Talk honoraria annual meeting: Talk at annual meeting: Start Date: 12/2021- End Date: 12/2022<br>Tellix: Healthcare company: Anticipated funding of project in 2023: Start Date: 3/2023- To Present | None                               | NCCN: Guideline committee: Institutional representative prostate cancer: Institutional representative prostate cancer: Not Compensated   |
| Eric Deutsch   | University Paris-Saclay: Professor: Employee<br>gustave roussy: professor: Employee                                     | None  | None  | None   | None                                | None   | None  | None                               | None   |
| Kavita Dharmarajan   | Mount Sinai: Associate Professor: Employee  | None  | None  | None   | None                                | None   | None  | None                               | None   |
| Virginia Diavolitsis   | Riverside Radiation Oncology: Physician: Partner  | None  | None  | None   | None                                | None   | None  | None                               | None   |
| Roberto Diaz   | Moffitt Cancer Center: Senior Member: Employee  | None  | None  | None   | Consultant                          | Lumicell: Travel Expenses: Compensation/Pay ment   | Lumicell: Consultant to assess the benefits for patients by removing residual cancer left behind after the standard lumpectomy procedure, specifically, from negative margin orientations that would have not been addressed by a second surgery.: Start Date: 1/10/24- End Date: 3/5/24  | None                               | None   |

**ASTRO 2024 Annual Meeting - Annual Meeting Abstract Reviewers' Disclosures**

| Member                   | Employment Relationships   |       | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria |  |                                     |  |  | Ownerships or Investment Interests  | Leadership Positions  |
|--------------------------|--|-------|---|--|-------------------------------------|--|--|---|---|
|                          | Employment   | Other | Advisory Board  | Research   | Consultant/Speaker/Faculty or Other | Method of Remuneration   | Description of Role  |   |   |
| <b>Dayssy Diaz Pardo</b> | <b>The Ohio State University:</b> Associate Professor: Employee      | None  | None  | None   | Faculty                             | <b>ASCO:</b> Honoraria<br><b>ASTRO:</b> Honoraria  | <b>ASCO:</b> Speaker best of journals: DEI in GU: Start Date: 02/17/22- End Date: 02/19/22<br><b>ASTRO:</b> Speaker ASTRO refresher 2023: Start Date: 04/26/23- End Date: 04/26/23   | None  | <b>The Ohio State University:</b> Vice-Chair of DEI: I am the Vice- Chair of DEI: Not Compensated   |
| <b>Adam Dicker</b>       | <b>Thomas Jefferson University:</b> SVP, Prof and Chair: Employee    | None  | Ongoing: No access to proprietary info                          | My Institution receives funding: No salary support in whole or part: national/overall principal investigator   | Consultant                          | <b>Empirica Lab:</b> Uncompensated: Other - Stock option<br><b>Janssen:</b> Compensation/Pay ment<br><b>Oncohost:</b> Compensation/Pay ment<br><b>Oranomed:</b> Compensation/Pay ment<br><b>Prostate Cancer Foundation:</b> Grant/Research Funding<br><b>SBR Bio:</b> Compensation/Pay ment  | <b>Empirica Lab:</b> Startup focused on learning: Advisor for learning system: Start Date: 09/2022 - To Present<br><b>Janssen:</b> Pharma: Data Safety monitoring: Start Date: 06/2019 - To Present<br><b>Oncohost:</b> Startup-Diagnostic: Clinical Advisor/CMO: Start Date: 09/2019- To Present<br><b>Oranomed:</b> Radiopharmaceutic al: Advisory board, 1-2X a year: Start Date: 06/2020- To Present<br><b>Prostate Cancer Foundation:</b> Research Grant: Start Date: 06/2018 - To Present<br><b>SBR Bio:</b> Therapy for mucositis: Clinical Advisor: Start Date: 10/2022- To Present  | None  | None  |
| <b>Maximilian Diehn</b>  | <b>Stanford University:</b> Professor: Employee                      | None  | Ongoing: No access to proprietary info                          | My Institution receives funding: No salary support in whole or part: national/overall principal investigator<br>My Institution receives funding: No salary support in whole or part: national/overall principal investigator<br>My Institution receives funding: No salary support in whole or part: site principal investigator<br>My Institution receives funding: No salary support in whole or part: national/overall principal investigator | Consultant<br>Faculty<br>Consultant | <b>AstraZeneca:</b> Grant/Research Funding: Honoraria: Travel Expenses: Salary Support<br><b>Boehringer Ingelheim:</b> Honoraria<br><b>Bristol Myers Squibb:</b> Honoraria<br><b>Genentech:</b> Grant/Research Funding: Honoraria<br><b>Gritstone Oncology:</b> Honoraria: Other - stock options<br><b>illumina:</b> Honoraria: Travel Expenses: In-kind Donations - reagents<br><b>Novartis:</b> Honoraria<br><b>Varian Medical Systems:</b> Grant/Research Funding | <b>AstraZeneca:</b> radiation therapy; liquid biopsy: Start Date: July 2018- To Present<br><b>Boehringer Ingelheim:</b> liquid biopsy: Start Date: March 2021- To Present<br><b>Bristol Myers Squibb:</b> liquid biopsy: Start Date: July 2022- To Present<br><b>Genentech:</b> liquid biopsy: Start Date: November 2020- To Present<br><b>Gritstone Oncology:</b> liquid biopsy: Start Date: June 2020- To Present<br><b>illumina:</b> DNA sequencing: Start Date: July 2019- To Present<br><b>Novartis:</b> liquid biopsy: Start Date: March 2020- To Present<br><b>Varian Medical Systems:</b> anti-TGFB plus RT: Start Date: September 2012 - To Present | <b>CiberMed</b><br><b>Foresight Diagnostics</b><br><b>Gritstone Oncology:</b> Stock Options<br><b>Roche:</b> Copyright<br><b>Foresight Diagnostics:</b> Copyright | Foresight Diagnostics: Uncompensated board member: Not Compensated  |
| <b>Sonja Dieterich</b>   | <b>University of California, Davis:</b> Professor: Employee          | None  | None  | My Institution receives funding: No salary support in whole or part: other: Co-PI  | None                                | <b>Siemens Healthineers:</b> Grant/Research Funding  | <b>Siemens Healthineers:</b> Co- PI, motion management: Start Date: 01/01/2022- End Date: 12/31/2023   | <b>Elsevier:</b> Copyright  | <b>AAPM:</b> Secretary: Secretary, duties per Rules and Bylaws of AAPM: Not Compensated: Relationship Ended: 12/31/2026<br><b>AAPM:</b> Therapy Physics Committee: Chair: Chair, Therapy Physics Committee, AAPM.: Not Compensated: Relationship Ended: 12/31/2023<br><b>ABR:</b> Therapy Physics IC Oral Board Writing Committee: Member: Oral board exam question writer for therapy physics: Not Compensated<br><b>Medical Physics Journal:</b> Deputy Editor, AAPM Scientific Report Editor: DE for AAPM Scientific Reports: Not Compensated<br><b>ROILS:</b> Ro-HAC: Member: Member of RO-HAC: Not Compensated |
| <b>Thomas Dilling</b>    | <b>Moffitt Cancer Center:</b> Senior Member: Employee                | None  | Ongoing: No access to proprietary info                          | None   | Consultant                          | <b>AstraZeneca:</b> Honoraria  | <b>AstraZeneca:</b> advisory board re: clinical care questions for patients with lung cancer: Start Date: 2020- To Present   | <b>Moderna:</b> Stock   | NCCN: NSCLC, meso, and thymoma tx guideline committees: Have received travel reimbursement in the past. Have also received compensation for teaching session at NCCN Annual Meeting: Not Compensated  |
| <b>Thomas DiPetrillo</b> | <b>Tufts Medical Center:</b> Vice Chair Radiation Oncology: Employee | None  | None  | None   | None                                | None   | None   | <b>PointSource:</b> Copyright   | None  |







| ASTRO 2024 Annual Meeting - Annual Meeting Abstract Reviewers' Disclosures |  |       |   |  |   |  |   |                                    |  |
|--|--|-------|---|--|---|--|---|------------------------------------|--|
| Member   | Employment Relationships   |       | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria   |  |   |  |   | Ownerships or Investment Interests | Leadership Positions   |
|  | Employment   | Other | Advisory Board  | Research   | Consultant/Speaker/Faculty or Other   | Method of Remuneration   | Description of Role   |                                    |  |
| Clifton Fuller   | UT MD Anderson Cancer Center: Professor: Employee                  | None  | Ongoing: No access to proprietary info Single: No access to proprietary info Ongoing: No access to proprietary info | My Institution receives funding: No salary support in whole or part: site principal investigator My Institution receives funding: No salary support in whole or part: national/overall principal investigator My Institution receives funding: No salary support in whole or part: other: NIH Sub-awardee  | Faculty/Other - Committee Member Consultant/Faculty Other - Task Force Member | American Association of Physicists in Medicine: Honoraria: Travel Expenses<br>Elekta AB: Grant/Research Funding: Honoraria: Travel Expenses: In-kind Donations - Computer and software support<br>Emory University: Honoraria: Travel Expenses<br>European Society of Radiation Oncology: Honoraria: Travel Expenses<br>National Institutes of Health: Grant/Research Funding: Honoraria: Travel Expenses: Salary Support<br>NRG Oncology: Uncompensated<br>Oncospace, inc.: Grant/Research Funding<br>Philips Medical Systems: Grant/Research Funding: Travel Expenses: In-kind Donations - Computer and software support<br>Varian/Siemens Healthineers: In-kind Donations - Software support: Uncompensated | American Association of Physicists in Medicine: Specialty society.: Speaker/committee member: Start Date: 01/01/2016- To Present<br>Elekta AB: Commercial device vendor: MR-Linac Development: Start Date: 01/01/2015- To Present<br>Emory University: Academic medical center: Visiting Professor: Start Date: 09/25/2022- End Date: 09/26/2022<br>European Society of Radiation Oncology: Specialty Society: Teaching faculty for ESTRO courses: Start Date: 01/01/2021- To Present<br>National Institutes of Health: Federal agency: Research grants support; study section service: Start Date: 08/01/2016- To Present<br>NRG Oncology: Cooperative Group: Member of NRG Xcode/mCode task group: Start Date: 01/01/2022- To Present<br>Oncospace, inc.: Software vendor: NTCP model validation: Start Date: 01/01/2021- To Present<br>Philips Medical Systems: Commercial device vendor: MR-LinAc Development: Start Date: 01/01/2019- To Present<br>Varian/Siemens Healthineers: Commercial medical device vendor: Technical advisory committee member: Start Date: 08/01/2022- To Present | Kalliso, Inc: Copyright            | American Association of Physicists in Medicine: Specialty Society: Committee Member: Committee member, BDS and TG-263: Not Compensated<br>American Society of Clinical Oncology: Specialty Society: Editorial Board Member: Associate Editor, JCO Clinical Cancer Informatics: Not Compensated<br>University of Texas System Shine Academy: State university health education scholarly society: Committee member: Promotion of health education within the UT System: Not Compensated |
| Thomas Galloway  | Fox Chase Cancer Center: Professor: Employee                       | None  | None  | None   | Consultant  | EMD Serono: Honoraria  | EMD Serono: Pharmaceutical company: Management of head and neck cancer: Start Date: August 1 2022- To Present   | None                               | None   |
| Mauricio Gamez   | Mayo Clinic: MD: Employee  | None  | None  | None   | None  | None   | None  | None                               | None   |
| Gregory Gan  | University of Kansas Medical Center: Assistant Professor: Employee | None  | None  | My Institution receives funding: No salary support in whole or part: national/overall principal investigator My Institution receives funding: No salary support in whole or part: other: Subgrant PI My Institution receives funding: No salary support in whole or part: national/overall principal investigator I receive funding: No salary support in whole or part: other: Subgrant PI My Institution receives funding: No salary support in whole or part: national/overall principal investigator | None  | Aclaris Therapeutics: Grant/Research Funding<br>Genentech: Grant/Research Funding: Other - Drug support<br>NIH/NIGMS: Grant/Research Funding<br>Varian Inc: Grant/Research Funding   | Aclaris Therapeutics: Pharma: IIT, translational research: Start Date: 7/1/20- End Date: 6/30/21<br>Genentech: Pharma: IIT PI, translational research: Start Date: 8/1/23- End Date: 7/30/23<br>NIH/NIGMS: Kansas Institute of Precision Medicine COBRE grant: Subgrant PI, basic science research: Start Date: 8/1/19- End Date: 7/31/22<br>Varian Inc: linear accelerator company: PI, IIT: Start Date: 8/1/23- End Date: 7/31/26   | None                               | None   |
| Hao Gao  | University of Kansas: Associate Professor: Employee                | None  | None  | None   | None  | None   | None  | None                               | None   |
| Hiram Gay  | Washington University in Saint Louis: Professor: Employee          | None  | None  | None   | Consultant  | BSCI: Honoraria  | BSCI: Boston Scientific.: Consultant for clinical trial in development. Does not present a conflict with any existing GU treatments.: Start Date: 2022- To Present  | None                               | None   |
| Yaorong Ge   | UNC Charlotte: Professor: Employee                                 | None  | None  | None   | None  | None   | None  | None                               | None   |
| Daphna Gelblum   | Memorial Sloan Kettering Cancer Center: Attending: Employee        | None  | None  | My Institution receives funding: No salary support in whole or part: site principal investigator   | None  | Merck  | Merck: institutional PI of clinical trial: institutional PI for M-3475: Start Date: 05/30/2022- To Present  | None                               | None   |



| ASTRO 2024 Annual Meeting - Annual Meeting Abstract Reviewers' Disclosures |  |       |   |  |                                     |   |   |                                    |  |
|--|--|-------|---|--|-------------------------------------|---|---|------------------------------------|--|
| Member   | Employment Relationships   |       | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria |  |                                     |   |   | Ownerships or Investment Interests | Leadership Positions   |
|  | Employment   | Other | Advisory Board  | Research   | Consultant/Speaker/Faculty or Other | Method of Remuneration  | Description of Role   |                                    |  |
| Chelain Goodman  | University of Texas MD Anderson Cancer Center: Assistant Professor: Employee   | None  | None  | My Institution receives funding: No salary support in whole or part: national/overall principal investigator<br>My Institution receives funding: No salary support in whole or part: national/overall principal investigator<br>My Institution receives funding: No salary support in whole or part: national/overall principal investigator<br>I receive funding: No salary support in whole or part: national/overall principal investigator | None                                | ASTRO- BCRF: Grant/Research Funding: Travel Expenses: Salary Support<br>Menarini Silicon biosystems: In-kind Donations - Circulating Tumor Cell Kits<br>NIH: Grant/Research Funding: Salary Support<br>UT MD Anderson Cancer Center: Grant/Research Funding | ASTRO- BCRF: Career Development Award to End Breast Cancer: Career Development Award: Start Date: 2021- To Present<br>Menarini Silicon biosystems: In-Kind Materials for Career Development Award: Start Date: 2022- To Present<br>NIH: K12 Clinical Scientist Institutional Career Development Award: Career Development Award: Start Date: 2022- To Present<br>UT MD Anderson Cancer Center: MDACC Institutional Research Grant: Institutional Research Grant: Start Date: 2023- To Present | None                               | American Society for Radiation Oncology (ASTRO): Association of Residents in Radiation Oncology (ARRO) Executive Committee: Chair: Executive Committee Member (2018-20219)<br>Chair (2019-2020)<br>Immediate Past Chair (2020-2021): Not Compensated: Relationship Ended: 4/15/2021<br>American Society for Radiation Oncology (ASTRO): ASTRO Workforce Subcommittee: Committee Member: Committee Member: Not Compensated<br>American Society for Radiation Oncology (ASTRO): Early Career Committee: Committee Member :Committee Member: Not Compensated<br>Radiation Oncology Initiative (ROI): Development Committee: Committee Member: Committee Member: Not Compensated |
| Elizabeth Gore   | Medical College of Wisconsin: MD: Employee   | None  | None  | None   | None                                | None  | None  | None                               | None   |
| Daniel Gorovets  | Memorial Sloan Kettering Cancer Center: Assistant attending physician: Employee  | None  | None  | None   | None                                | None  | None  | None                               | ACRO: GU disease site chair for standards committee: Lead team to establish standards of care and provide accreditation to radiation oncology practices: Not Compensated   |
| Clemens Grassberger  | Massachusetts General Hospital: Assistant Professor: Employee: Relationship ended: 11/30/2022<br>University of Washington: Associate Professor: Employee | None  | Ongoing: No access to proprietary info                          | None   | None                                | Nanolive SA: Advisory Board   | Nanolive SA: Developing 3D Microscope for label-free live cell imaging: Scientific Advisory Board member: Start Date: 2018- To Present  | Nanolive SA: Stock<br>OncAI: Stock | W inter Institute of Medical Physics: organizes yearly conferences in Medical Physics: Member of Planning Committee: Member of Winter Institute of Medical Physics Planning Committee: Not Compensated   |
| Katherine Griem  | Retired: Partner   | None  | None  | None   | None                                | None  | None  | None                               | None   |
| Inga Grills  | Beaumont/Corewell Health: Professor, Chief Thoracic Section, Director GK Center: Employee  | None  | None  | None   | None                                | None  | None  | None                               | None   |
| Tamara Vern-Gross  | Mayo Clinic: Radiation Oncologist: Employee  | None  | None  | None   | None                                | None  | None  | None                               | None   |
| Aaron Grossberg  | Oregon Health & Science University: Assistant Professor: Employee  | None  | None  | None   | None                                | None  | None  | None                               | None   |
| Craig Grossman   | University of South Florida: Associate Professor: Employee<br>Tampa General Hospital: Staff Physician: Employee  | None  | None  | None   | None                                | None  | None  | None                               | None   |
| Matthias Guckenberger  | University Hospital Zurich: Chairman and Full Professor: Employee  | None  | Single: No access to proprietary info                           | None   | None                                | Astra Zeneca: Compensation/Payment  | Astra Zeneca: Advisory Board about stage III NSCLC: Participation in Ad board: Start Date: 01.01.2024- End Date: 30.06.2024   | None                               | ESTRO: President elect: ESTRO:President elect and board member: Not Compensated  |





| ASTRO 2024 Annual Meeting - Annual Meeting Abstract Reviewers' Disclosures |  |       |   |  |                                     |   |   |  |  |
|--|--|-------|---|--|-------------------------------------|---|---|--|--|
| Member   | Employment Relationships   |       | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria                 |  |                                     |   |   | Ownerships or Investment Interests   | Leadership Positions   |
|  | Employment   | Other | Advisory Board  | Research   | Consultant/Speaker/Faculty or Other | Method of Remuneration  | Description of Role   |  |  |
| <b>Bradford Hoppe</b>  | <b>Mayo Clinic:</b> Professor of Radiation Oncology: Employee  | None  | Ongoing: No access to proprietary info  | None   | None                                | <b>Merck:</b> Other - Children's Oncology Group funds my scientific advisory board work into a Mayo research PAU  | <b>Merck:</b> drug company: scientific advisory board for AHOD 1822: Start Date: 2019- To Present   | None   | <b>NRG lymphoma working group:</b> Co-Chair: co-chair: Not Compensated<br><b>PTCOG:</b> Secretary: secretary: Not Compensated  |
| <b>Charles Hsu</b>   | <b>Banner- University of Arizona Medical Center:</b> Associate Professor of Radiation Oncology: Employee | None  | None  | None   | None                                | None  | None  | None   | <b>Univ of Arizona Dept of Radiation Oncology:</b> University of Arizona Cancer Center Department of Radiation Oncology Research: Vice Chairman of Clinical Research: head of clinical research within department of radiation oncology: Not Compensated: Relationship Ended: 6/30/2023<br><b>University of Arizona Cancer Center:</b> Clinical Trials Office: Medical Director: Medical Director of Clinical Trials Office for Cancer Center: Not Compensated |
| <b>Geoffrey Hugo</b>   | <b>Washington University:</b> Professor: Employee  | None  | None  | My Institution receives funding: No salary support in whole or part: national/overall principal investigator<br>My Institution receives funding: No salary support in whole or part: national/overall principal investigator   | Consultant                          | <b>Siemens:</b> Grant/Research Funding<br><b>Varian Medical Systems:</b> Compensation/Pay ment<br><b>ViewRay:</b> Grant/Research Funding  | <b>Siemens:</b> siemens: 4DCT sorting evaluation: Start Date: 2022- To Present<br><b>Varian Medical Systems:</b> Varian: Cardiac radioablation: Start Date: 2019- To Present<br><b>ViewRay:</b> ViewRay: utilization of MRgRT: Start Date: 2018- End Date: 2022   | <b>Varian Medical Systems:</b> Copyright   | None   |
| <b>Florence Huguet</b>   | <b>AP-HP:</b> Hospital: Employee<br><b>Sorbonne University:</b> University: Employee                     | None  | Single: No access to proprietary info   | None   | Faculty Consultant Faculty          | <b>Amgen:</b> Honoraria<br><b>BMS:</b> Honoraria: Travel Expenses<br><b>Merck Serono:</b> Honoraria: Travel Expenses<br><b>MSD:</b> Honoraria: Travel Expenses<br><b>Servier:</b> Honoraria   | <b>Amgen:</b> Rectal cancer: Start Date: 25/11/2021-End Date: 25/11/2021<br><b>BMS:</b> Head and neck cancer Oesophageal cancer: Start Date: 01/01/2017- To Present<br><b>Merck Serono:</b> Head and neck cancer: Start Date: 01/01/2013- To Present<br><b>MSD:</b> Head and neck cancer: Start Date: 01/0/2014- To Present<br><b>Servier:</b> Rectal cancer: Start Date: 27/09/2018- End Date 9/27/2018  | None   | None   |
| <b>Zain Husain</b>   | <b>Southern California Permanente Medical Group:</b> Physician: Employee                                 | None  | Single: No access to proprietary info   | None   | None                                | <b>EMD Serono:</b> Honoraria: Travel Expenses   | <b>EMD Serono:</b> Discuss landscape of clinical trials in HN cancer: Start Date: Jan 2024- To Present  | None   | None   |
| <b>Brandon Imber</b>   | <b>Memorial Sloan Kettering Cancer Center:</b> Assistant Attending Radiation Oncologist: Employee        | None  | Ongoing: No access to proprietary info<br>Single: No access to proprietary info | My Institution receives funding: No salary support in whole or part: site principal investigator<br>My Institution receives funding: No salary support in whole or part: national/overall principal investigator<br>My Institution receives funding: No salary support in whole or part: national/overall principal investigator<br>My Institution receives funding: No salary support in whole or part: national/overall principal investigator | Faculty                             | <b>AstraZeneca:</b> Grant/Research Funding<br><b>Bayer:</b> honoraria<br><b>GT Medical Technologies:</b> Honoraria<br><b>Kazia Therapeutics:</b> Honoraria<br><b>Novartis:</b> Honoraria<br><b>Telix Pharmaceuticals:</b> Honoraria | <b>AstraZeneca:</b> research funding to institution: site PI for international clinical trial: Start Date: 7/2022- To Present<br><b>Bayer:</b> research funding to institution: national PI of Radium-223 and SBRT study: Start Date: 6/2023- To Present<br><b>GT Medical Technologies:</b> presented research at SNO 2021: Start Date: November 2021- To Present<br><b>Kazia Therapeutics:</b> research funding to institution: overall PI for brain metastasis clinical trial: Start Date: 6/2023- To Present<br><b>Novartis:</b> research funding to institution: PI for IIT where Novartis provided drug: Start Date: 6/2023- To Present<br><b>Telix Pharmaceuticals:</b> Advisory Board at SNO 2022: Start Date: November 2022- To Present | None   | None   |
| <b>Puneeth Iyengar</b>   | <b>MSKCC:</b> Attending and Director of Metastatic Service: Employee                                     | None  | None  | My Institution receives funding: No salary support in whole or part: national/overall principal investigator   | None                                | <b>Incyte:</b> Grant/Research Funding: Salary Support   | <b>Incyte:</b> Research funding to the UTSW Med Center for phase clinical trial in cancer cachexia space.: Overall PI.: Start Date: 2021- To Present  | <b>AstraZeneca:</b> Other - One off Advisory Board: Relationship Ended: 11/13/2023 | None   |

**ASTRO 2024 Annual Meeting - Annual Meeting Abstract Reviewers' Disclosures**

| Member           | Employment Relationships  |       | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria |  |  |  |  | Ownerships or Investment Interests | Leadership Positions   |
|------------------|---|-------|---|--|--|--|--|------------------------------------|--|
|                  | Employment  | Other | Advisory Board  | Research   | Consultant/Speaker/Faculty or Other    | Method of Remuneration   | Description of Role  |                                    |  |
| Salma Jabbour    | Rutgers University: M.D.: Employee  | None  | None  | My Institution receives funding: No salary support in whole or part: site principal investigator<br>My Institution receives funding: No salary support in whole or part: site principal investigator | Consultant                             | Beigene: Grant/Research Funding<br>IMX Medical: Compensation/Payment<br>Merck & Co, Inc: Grant/Research Funding: Compensation/Payment<br>Novocure: Compensation/Payment<br>Radialogica: Compensation/Payment<br>Syntactx: Compensation/Payment | Beigene: Research grant: Start Date: to present- To Present<br>IMX Medical: review of cases: Start Date: 2018- To Present<br>Merck & Co, Inc: research consultant: Start Date: to present- To Present<br>Novocure: consultant: Start Date: April 2022- To Present<br>Radialogica: review of RT cases: Start Date: Jan 2022- To Present<br>Syntactx: adjudication committee: Start Date: 2020- To Present | None                               | IUROBP Deputy Editor D: Deputy Editor: Edit articles for IROBP: Not Compensated  |
| William Jackson  | University of michigan: assistant professor: Employee   | None  | None  | None   | None                                   | None   | None   | None                               | None   |
| Naresh Jegadeesh | Cook Radiation Oncology: Partner: Partner   | None  | None  | None   | None                                   | None   | None   | None                               | None   |
| Richard Jennelle | County of Los Angeles: Physician: Employee<br>University of Southern California: Professor of Clinical Radiation Oncology: Employee | None  | None  | None   | None                                   | None   | None   | None                               | None   |
| Krishan Jethwa   | Mayo Clinic, Rochester, MN: Physician: Employee   | None  | None  | None   | Other - Editor                         | RadOncQuestions.com, LLC: Honoraria  | RadOncQuestions.com, LLC: GI disease site editor: Start Date: 2017- End Date: 2/2023   | None                               | American Board of Radiology: Board Examiner: Written board examiner for the American Board of Radiology: Not Compensated   |
| Xun Jia          | Johns Hopkins University: Professor and Chief of medical physics: Employee  | None  | None  | I recieve funding: No salary support in whole or part: national/overall principal investigator   | None                                   | NIH/NCI and NIH/NIBIB: Grant/Research Funding  | NIH/NCI and NIH/NIBIB: PI, medical physics: Start Date: 2012- To Present   | Velox AI: Copyright                | None   |
| Rachel Jimenez   | Massachusetts General Hospital: Attending Physician: Employee   | None  | None  | None   | Consultant                             | Lilly: Other - None  | Lilly: unpaid consulting: Advised on concurrent RT with systemic therapy in the metastatic setting: Start Date: 1/17/2022- End Date: 10/05/22  | None                               | American Society of Clinical Oncology: Chair Elect, Ethics Committee:I am the Chair-Elect for the ASCO Ethics Committee. I coordinate and organize an agenda for the Ethics Committee.:Not Compensated<br>ASTRO: Advances in Radiation Oncology: Editor-in-Chief: Editor-in-Chief: Not Compensated<br>SurvivingBreastCancer.org: This is a non-profit advocacy organization for patients with breast cancer: Medical Advisory Board, Member: I advise the Director of SBC.org on strategy: Not Compensated |
| Skyler Johnson   | University of Utah School of Medicine: Assistant Professor: Employee  | None  | None  | None   | None                                   | None   | None   | None                               | None   |
| Kimberly Johung  | Yale University School of Medicine: Associate Professor: Employee   | None  | None  | None   | None                                   | None   | None   | None                               | None   |
| Nikhil Joshi     | Rush University Medical Center: Medical Director and Associate Professor: Employee  | None  | None  | None   | Other - one time advisory board member | Castle Biosciences: Honoraria  | Castle Biosciences: Commercial entity developing prognostic gene signatures for cancer: advised company on skin cancer gene signature once last year: Start Date: 11/2023- End Date: 11/2023   | None                               | None   |
| Melissa Joyner   | M.D. Anderson Cancer Center: Professor: Employee  | None  | None  | None   | None                                   | None   | None   | None                               | MD Anderson Cancer Center: Ancillary site: Associate Director Clinical Operations West Houston: Manage radiation related clinical operations: Not Compensated  |



**ASTRO 2024 Annual Meeting - Annual Meeting Abstract Reviewers' Disclosures**

| Member           | Employment Relationships  |       | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria                  |  |   |   |  | Ownerships or Investment Interests | Leadership Positions  |
|------------------|---|-------|--|--|---|---|--|------------------------------------|---|
|                  | Employment  | Other | Advisory Board   | Research   | Consultant/Speaker/Faculty or Other                         | Method of Remuneration  | Description of Role  |                                    |   |
| Jenna Kahn       | Kaiser NW Permanent: Radiation Oncologist: Employee   | None  | None   | None   | None  | None  | None   | None                               | ASTRO: Communication Committee: Chair: Communications committee chair: Not Compensated<br>ASTRO: Early Career Committee: Committee Member: Committee Member: Not Compensated<br>ROI: committee member: Committee member Research and Development: Not Compensated   |
| Anusha Kalbasi   | Stanford University: Associate Professor: Employee<br>UCLA: Assistant Professor: Employee: Relationship ended: 11/30/2022 | None  | Ongoing: No access to proprietary info<br>Ongoing: No access to proprietary info | I recieve funding: No salary support in whole or part: site principal investigator   | None  | Certis Oncology: Other - stock<br>Highlight Therapeutics: Grant/Research Funding<br>T Cure Therapeutics: Compensation/Pay ment  | Certis Oncology: biotech company: sarcoma & immunology/immun otherapy: Start Date: 2020- To Present<br>Highlight Therapeutics: Biotech company: research clinical trial investigator: Start Date: 2019- To Present<br>T Cure Therapeutics: Biotech company: advisory board member; T cell immunotherapy / sarcoma: Start Date: 2019- To Present  | None                               | None  |
| Sophia Kamran    | MGH: Assistant Professor: Radiation Oncology: Employee  | None  | None   | I recieve funding: No salary support in whole or part: national/overall principal investigator<br>I recieve funding: No salary support in whole or part: national/overall principal investigator     | Faculty<br>Other - speaker                                  | DAVA Oncology: Honoraria: Travel Expenses<br>NRG Oncology: Grant/Research Funding: Travel Expenses<br>Prostate Cancer Foundation: Grant/Research Funding<br>Varian: Honoraria | DAVA Oncology: SBRT in RCC<br>Trimodality Therapy for Muscle-Invasive Bladder Cancer: Start Date: 11/10/2022- End Date: 11/13/2022<br>NRG Oncology: NRG Oncology: health equity fellowship: Start Date: 01/01/2023- To Present<br>Prostate Cancer Foundation: Prostate Cancer Foundation Young Investigator: Start Date: 12/31/2021- End Date: 12/30/2024<br>Varian: Speaker: Character, Courage, and Commitment: Spotlighting Women in Radiation Oncology: Start Date: 7/25/2022- End Date: 7/25/2022 | None                               | American Board of Radiology: American Board of Radiology Radiation Oncology Certifying Exam Genitourinary Committee: American Board of Radiology Radiation Oncology Certifying Exam Genitourinary Committee: Not Compensated<br>ASCO: Annual GU Symposium: Chair- Renal and Rare Tumors Track: Not Compensated<br>MGH: Department of Radiation Oncology: Director of Diversity, Equity & Inclusion: Director of Diversity, Equity & Inclusion for the Department: Not Compensated |
| Mitchell Kamrava | Cedars Sinai: Professor: Employee   | None  | Ongoing: No access to proprietary info   | None   | Consultant<br>Other - DSMB member<br>Other - book royalties | Adaptiiv: Compensation/Pay ment<br>Alessa: Compensation/Pay ment<br>GammaTile: Compensation/Pay ment<br>Springer: Compensation/Pay ment<br>theragenics: Honoraria             | Adaptiiv: 3D printing: Start Date: 6/2023- To Present<br>Alessa: DSMB: DSMB member: Start Date: 2022- To Present<br>GammaTile: DSMB member: DSMB member: Start Date: 2022- To Present<br>Springer: Book royalties: book royalties: Start Date: 2000- To Present<br>theragenics:: advisory board regarding product development: Start Date: 2/2021- To Present  | None                               | ABR Gyn examiner: ABR Gyn oral examiner: ABR Gyn oral examiner: Not Compensated<br>ABS: Board of Directors, Member-at-large: Board of Directors, president elect: Not Compensated<br>ADROP: President: ADROP Immediate Past President: Not Compensated  |
| Hyejoo Kang      | Loyola University Chicago: Assistant Professor: Employee  | None  | None   | None   | None  | None  | None   | None                               | None  |
| Benjamin Kann    | Brigham and Women's Hospital: Assistant Professor: Employee   | None  | None   | My Institution receives funding: No salary support in whole or part: site principal investigator<br>My Institution receives funding: No salary support in whole or part: site principal investigator | None  | NIH: Grant/Research Funding<br>RSNA: Grant/Research Funding   | NIH: Head and neck cancer imaging: Start Date: 1/1/2021- To Present<br>RSNA: Foundation: Head and neck cancer imaging: Start Date: 6/1/2020- To Present  | None                               | None  |
| Nirav Kapadia    | Dartmouth Health: Associate Professor of Radiation Oncology and Applied Sciences: Employee                                | None  | None   | None   | None  | None  | None   | None                               | Northern New England Clinical Oncology Society: Consortium of oncology providers / practices serving patients in NH, VT and ME: Treasurer; Board/Executive Committee Member: Treasurer: Not Compensated   |



| ASTRO 2024 Annual Meeting - Annual Meeting Abstract Reviewers' Disclosures |   |       |   |   |                                     |   |  |   |  |
|--|---|-------|---|---|-------------------------------------|---|--|---|--|
| Member   | Employment Relationships  |       | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria |   |                                     |   |  | Ownerships or Investment Interests  | Leadership Positions   |
|  | Employment  | Other | Advisory Board  | Research  | Consultant/Speaker/Faculty or Other | Method of Remuneration  | Description of Role  |   |  |
| <b>Hyun Kim</b>  | <b>Washington University School of Medicine:</b> Associate Professor: Employee  | None  | None  | I receive funding: No salary support in whole or part: site principal investigator I receive funding: No salary support in whole or part: national/overall principal investigator   | Consultant Faculty                  | <b>Novartis:</b> Compensation/payment<br><b>Varian:</b> Grant/Research Funding: Honoraria<br><b>ViewRay:</b> Grant/Research Funding: Honoraria  | <b>Novartis:</b> Consultant regarding radiopharmaceuticals: Start Date: 12/2022- End Date: 12/2022<br><b>Varian:</b> Varian: Ethos imaging (CBCT); adaptive research: Start Date: 08/2017 - To Present<br><b>ViewRay:</b> ViewRay: Research funding: Start Date: 08/2019- To Present   | <b>GlobalART:</b> Limited Liability   | <b>IUROBP:</b> GI Editorial Board: Associate Editor: Associate Editor: Not Compensated   |
| <b>Jinkoo Kim</b>  | <b>Stony Brook University Hospital:</b> Medical Physicist: Employee   | None  | None  | None  | None                                | None  | None   | None  | None   |
| <b>Joshua Kim</b>  | <b>Henry Ford Health:</b> Medical Physicist: Employee   | None  | None  | None  | Consultant                          | <b>ViewRay:</b> Travel Expenses: Compensation/Payment   | <b>ViewRay:</b> Vendor that specializes in MR- guided radiotherapy machines: Served as a consultant for a clinical trial sponsored by VR related to adaptive MRgRT treatments for pancreatic cancer patients.: Start Date: 8/1/2019- To Present  | None  | None   |
| <b>Michelle Kim</b>  | <b>University of Michigan:</b> Professor: Employee  | None  | Ongoing: No access to proprietary info                          | My Institution receives funding: No salary support in whole or part: site principal investigator My Institution receives funding: No salary support in whole or part: national/overall principal investigator My Institution receives funding: No salary support in whole or part: other: Co-investigator | Faculty Consultant Faculty          | <b>ASTRO Annual Meeting Education Committee:</b> Uncompensated<br><b>BlueEarth Diagnostics:</b> Grant/Research Funding: Honoraria<br><b>Capital Health:</b> Travel Expenses<br><b>Nebraska Oncology Society:</b> Honoraria<br><b>NIH:</b> Grant/Research Funding<br><b>NIH:</b> Travel Expenses: Salary Support<br><b>PeerView:</b> Honoraria: Travel Expenses<br><b>Stanford US4 MetNet:</b> Advisory Board: Uncompensated | <b>ASTRO Annual Meeting Education Committee:</b> Chair, ASTRO Annual Meeting Education Committee CNS Track: Start Date: 2023- To Present<br><b>BlueEarth Diagnostics:</b> Molecular imaging company: Site PI for a national trial, served as a consultant for a one-time workshop (completed): Start Date: 2020- To Present<br><b>Capital Health:</b> Medical group: Invited speaker for one- time conference (completed): Start Date: 2022- End Date: 2022<br><b>Nebraska Oncology Society:</b> Professional non profit scientific society: Invited speaker for an educational event (completed): Start Date: 2022- End Date: 2022<br><b>NIH:</b> Co- investigator of an ongoing NIH- funded research study: Start Date: 2021- End Date: 2026<br><b>NIH:</b> Principal Investigator, R50 Research Specialist: Start Date: 2023- End Date: 2028<br><b>PeerView:</b> CME company: Faculty speaker at SNO Annual Meeting at Industry- sponsored educational event: Start Date: 11/16/23- End Date: 11/16/23<br><b>Stanford US4 MetNet Advisory Board:</b> External Advisory Board Member for Stanford US4 Grant: Start Date: 2023- To Present  | None  | <b>NCCN CNS Guidelines Committee Member:</b> National Comprehensive Cancer Center Guidelines: Member: Member: Not Compensated<br><b>Neuro-Oncology Editorial Board Member:</b> Neuro- Oncology (Journal) Editorial Board Member: Board Member: Board member: Not Compensated<br><b>Red Journal:</b> ASTRO Scientific Journal: CNS Section Editor: Section Editor for CNS: Not Compensated                          |
| <b>Martin King</b>   | <b>Brigham and Women's Physician's Organization:</b> Physician: Employee  | None  | None  | My Institution receives funding: No salary support in whole or part: national/overall principal investigator  | None                                | <b>Bayer Healthcare:</b> Grant/Research Funding<br><b>Palette Life Sciences:</b> Grant/Research Funding: Salary Support   | <b>Bayer Healthcare:</b> Principal investigator: Start Date: 1/1/2019- To Present<br><b>Palette Life Sciences:</b> Coordinating investigator: Start Date: 1/1/2020- To Present   | None  | None   |
| <b>Youlia Kirova</b>   | <b>Institut Curie:</b> Associate Professor Medical Doctor: Employee   | None  | None  | None  | None                                | None  | None   | None  | None   |
| <b>David Kirsch</b>  | <b>Duke University Medical Center:</b> Barbara Levine University Professor/Radiation Oncologist: Employee: Relationship ended: 4/30/2023<br><b>PRINCESS MARGARET CANCER CENTRE/UNIVERSITY HEALTH NETWORK:</b> Head, Department of Radiation Oncology & Radiation Medicine Program: Employee | None  | Ongoing: No access to proprietary info                          | None  | Consultant                          | <b>Bristol Myers Squibb:</b> Grant/Research Funding<br><b>Lumicell Diagnostics:</b> Merck: Grant/Research Funding<br><b>Merck Investigators Study Program:</b> Grant/Research Funding<br><b>Varian Medical Systems:</b> Grant/Research Funding<br><b>XRAD Therapeutics:</b> Grant/Research Funding  | <b>Bristol Myers Squibb:</b> Targeting Epigenetic Dysregulation in Pediatric Cancer: he Kirsch lab will test combinations of BMS-986158 and HDAC inhibitors in sarcoma cell lines in vitro and in primary sarcomas in vivo. Duke will enroll patients in the first-in-child clinical trial of BMS-986158.: Start Date: 2018 - End Date: 2023<br><b>Lumicell Diagnostics:</b> Scientific Advisory Board for Lumicell Inc. (a company commercializing intraoperative imaging technology): Advisory Board and Consultant; Licensee and Royalties, Patent issued for imaging device, Consulting fee- payment to me, Stock and Stock options: Start Date: 2009- To Present<br><b>Varian Medical Systems:</b> Radiation and Immunotherapy for Genetically Engineered Mouse Models of Soft Tissue Sarcoma: This study investigates whether the intratumoral injection of CpG and the agonistic OX40 antibody can enhance the efficacy of radiation therapy and anti- PD-1 therapy: Start Date: 2019- End Date: 2021<br><b>XRAD Therapeutics:</b> Developing Radiosensitizers: To evaluate kinase inhibitors for their ability to radiosensitize tumor cells without significantly increasing toxicity to normal cells: Start Date: 2016- End Date: 2020<br><b>Merck:</b> Dissecting Mechanisms of T cell Exhaustion in Autochthonous Tumors: The overall goal of this project is to use sophisticated genetically engineered mouse models to express tumor-specific neoantigens in primary tumors and define novel mechanisms of T cell exhaustion. Start Date: 2021- End Date: 2024<br><b>Merck Investigators Study Program:</b> Neoadjuvant Pembrolizumab & Radiotherapy for Soft Tissue Sarcomas of the Extremity: The overall goal of this project is to carry out a randomized clinical trial for localized sarcoma patients at high-risk for developing metastasis comparing neoadjuvant radiation therapy and surgery with neoadjuvant radiation therapy plus pembrolizumab followed by surgery and adjuvant pembrolizumab. Start Date: 2016- End Date: 2021 | <b>XRAD Therapeutics:</b> Stock: Stock Options: Copyright<br><b>Lumicell Diagnostics:</b> Stock: Stock Options: Copyright | <b>PRINCESS MARGARET CANCER CENTRE/UNIVERSITY HEALTH NETWORK:</b> Head of the Department of Radiation Oncology, UHN<br>Head of the Radiation Medicine Program, Princess Margaret Cancer Centre: Head, Department of Radiation Oncology & Radiation Medicine Program: Head of the Department of Radiation Oncology, UHN<br>Head of the Radiation Medicine Program, Princess Margaret Cancer Centre: Not Compensated |





**ASTRO 2024 Annual Meeting - Annual Meeting Abstract Reviewers' Disclosures**

| Member                 | Employment Relationships   |       | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria                  |  |  |   |  | Ownerships or Investment Interests  | Leadership Positions  |
|------------------------|--|-------|--|--|--|---|--|---|---|
|                        | Employment   | Other | Advisory Board   | Research   | Consultant/Speaker/Faculty or Other  | Method of Remuneration  | Description of Role  |   |   |
| <b>Simon Lo</b>        | University of Washington School of Medicine: Professor: Employee | None  | None   | My Institution receives funding: No salary support in whole or part: site principal investigator   | None   | <b>Elekta, AB:</b> Other - Research support: Potential stipend to hire a student to extract research data   | <b>Elekta, AB:</b> LINAC manufacturer: Pooled retrospective patient data from multiple sites to answer research questions regarding Gamma Knife ICON SRT for brain tumors: Start Date: Sept 2017- To Present   | None  | American College of Radiology<br>:Professional Organization<br>:Alternate Councilor<br>:Voting:Not Compensated<br><b>ASTRO:</b> Advances in Radiation Oncology (Journal):Associate Section Editor:<br>Managing manuscripts: Not Compensated<br><b>Congress of Neurological Surgeons:</b><br>Neurosurgery (Journal): Assistant Editor:<br>Managing manuscripts: Not Compensated<br><b>Radiosurgery Society (RSS):</b> Non- profit professional organization advancing the field of SRS and SBRT: Medical director, SRS/ SBRT<br>Accreditation Program: Development and supervision of the SRS/ SBRT Accreditation Program, which is a joint venture with American College of Radiation Oncology Practice Accreditation Program.: Not Compensated<br><b>Radiosurgery Society (RSS):</b> Non- profit professional organization advancing the field of SRS and SBRT: Member of Board of Directors: Decision making in the affairs related to RSS: Not Compensated |
| <b>Alexander Louie</b> | Sunnybrook Health Science Centre: Radiation Oncologist: Employee | None  | Ongoing: No access to proprietary info   | None   | Speaker Bureau   | <b>AstraZeneca:</b> Honoraria   | <b>AstraZeneca:</b> pharmaceutical: participation in speaker's bureau and advisory board: Start Date: sept 2018- To Present  | None  | None  |
| <b>Daniel Low</b>      | UCLA: Professor: Employee  | None  | Ongoing: No access to proprietary info<br>Ongoing: No access to proprietary info | My Institution receives funding: No salary support in whole or part: site principal investigator<br>I receive funding: No salary support in whole or part: site principal investigator<br>My Institution receives funding: No salary support in whole or part: site principal investigator | Other - Founding member<br>Consultant<br>Other - Founding member<br>Consultant | <b>Pulmonum LLC:</b> Compensation/Pay ment<br><b>TAE Life Sciences:</b> Compensation/Payment<br><b>Triplet State LLC:</b> Grant/Research Funding<br><b>Ursus Arctos:</b> Uncompensated<br><b>Varian:</b> Grant/Research Funding: Salary Support | <b>Pulmonum LLC:</b> Radiation Therapy Software Development Company: President and founder. Company has not yet obtained funding but will work in the radiation oncology domain, specifically in 4DCT applications.: Start Date: 2020- To Present<br><b>TAE Life Sciences:</b> Boron neutron capture therapy startup: SAB member: Start Date: 2019- To Present | <b>Ursus Arctos LLC:</b> Limited Liability<br><b>Triplet State LLC:</b> Limited Liability<br><b>Pulmonum LLC:</b> Limited Liability | None  |



| ASTRO 2024 Annual Meeting - Annual Meeting Abstract Reviewers' Disclosures |  |       |   |  |   |   |  |  |  |
|--|--|-------|---|--|---|---|--|--|--|
| Member   | Employment Relationships   |       | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria |  |   |   |  | Ownerships or Investment Interests                           | Leadership Positions   |
|  | Employment   | Other | Advisory Board  | Research   | Consultant/Speaker/Faculty or Other                               | Method of Remuneration  | Description of Role  |  |  |
| Anand Mahadevan  | NYU Grossman School of Medicine: Radiation Oncologist: Employee  | None  | None  | None   | None  | None  | None   | None   | None   |
| Kimberley Mak  | Boston Medical Center: Assistant Professor: Employee<br>VA Boston Healthcare System: Attending Physician: Employee | None  | None  | None   | Speaker Bureau<br>Other - Investigator Workshop<br>Speaker Bureau | Curio Science / Vaniam Group: Honoraria<br>Merck: Travel Expenses<br>Total Health Conferencing: Honoraria   | Curio Science / Vaniam Group: Healthcare communications company: Participant in "Opinions in Unresectable Stage III Lung Cancer: An Interactive Local Workshop": Start Date: 11/14/22- End Date: 11/14/22<br>Merck: Attended investigator workshop for clinical trial KeyVibe-006: Start Date: 2/9/24- End Date: 2/9/24<br>Total Health Conferencing: Medical information company providing cancer education: Participation as panelist on "What Changes Monday Morning Post ASCO Q&A" for non-small cell lung cancer discussing research presented at ASCO 2021: Start Date: 6/17/2021- End Date: 6/17/2021 | None   | None   |
| Gerassimos Makrigiorgos  | DANA FARBER CANCER INSTITUTE: PROFESSOR: Employee  | None  | None  | None   | None  | None  | None   | None   | DANA FARBER CANCER INSTITUTE AND BRIGHAM AND WOMENS HOSPITAL: Academic Medical Centers/Hospitals Department of Radiation Oncology: Director Medical Physics and Biophysics Division: Division Director Department of Radiation Oncology: Not Compensated             |
| Ariel Marciscano   | Massachusetts General Hospital: Radiation Oncologist: Employee   | None  | None  | None   | None  | None  | None   | None   | None   |
| Danielle Margalit  | Brigham & Women's Physician Organization: Physician: Employee  | None  | None  | None   | None  | None  | None   | None   | American Radium Society: Chair, Head/Neck Appropriate Use Criteria Comm.: Chair of Committee: Not Compensated<br>JROBP (Red Journal): Section Editor - Head/Neck: Section Editor: Section editor: Not Compensated: Relationship Ended: 10/1/2023                     |
| Stephanie Markovina  | Washington University: Assistant Professor: Employee   | None  | None  | None   | Faculty   | NCCN: Travel Expenses   | NCCN: Panel member, NCCN, Thyroid Cancer Guidelines: Member of NCCN Thyroid Cancer Panel, recently traveled to in- person panel meeting, received reimbursement for travel expenses for this meeting: Start Date: 2019- To Present   | None   | National Cancer Institute, NIH: K08 Career Development Award: Research Grants, Other: PI: Not Compensated<br>Tesaro Inc.: Oncology-focused business within Glasco Smith Kline: Research Grants, Other: PI: Not Compensated   |
| Neil Martin  | Brigham and Women's Hospital: Physician: Employee  | None  | None  | None   | None  | None  | None   | None   | None   |
| Malcolm Mattes   | Rutgers Cancer Institute of New Jersey: Associate Professor: Employee  | None  | None  | I receive funding: No salary support in whole or part: other: Career Development<br>I receive funding: No salary support in whole or part: site principal investigator<br>I receive funding: No salary support in whole or part: national/overall principal investigator | None  | Bristol Myers Squibb Foundation: Grant/Research Funding<br>New Jersey Health Foundation: Grant/Research Funding<br>Radiation Oncology Institute: Grant/Research Funding | Bristol Myers Squibb Foundation: Career Development Award: Career Development Award: Start Date: 11/01/2021- End Date: 12/31/2023<br>New Jersey Health Foundation: Research Funding: Research Funding: Start Date: 02/15/2022- End Date: 2/14/2024<br>Radiation Oncology Institute: Research Funding: Research Funding: Start Date: 11/01/2020- End Date: 10/31/2023   | None   | ASTRO: Communications Committee: Vice Chair: Communications Committee Vice Chair: Not Compensated<br>University Hospital Cancer Center: ACOS CoC Cancer Liaison Physician: ACOS CoC Cancer Liaison Physician: Not Compensated  |
| Martha Matuszak  | University of Michigan: Professor: Employee  | None  | None  | My Institution receives funding: No salary support in whole or part: national/overall principal investigator   | None  | Varian: Grant/Research Funding  | Varian: Radiotherapy Vendor: PI: Start Date: November 2023- To Present   | Fuse Oncology: Other - Licensing and Collaboration Agreement | AAPM: American Association of Physicists in Medicine: Member, Board of Directors: Board Member at Large: Not Compensated<br>MROQC: Radiation Oncology Quality Consortium with Blue Cross Blue Shield of Michigan: Co-Director: Executive Leadership: Not Compensated |



| ASTRO 2024 Annual Meeting - Annual Meeting Abstract Reviewers' Disclosures |   |       |  |   |                                     |   |  |                                    |  |
|--|---|-------|--|---|-------------------------------------|---|--|------------------------------------|--|
| Member   | Employment Relationships  |       | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria                  |   |                                     |   |  | Ownerships or Investment Interests | Leadership Positions   |
|  | Employment  | Other | Advisory Board   | Research  | Consultant/Speaker/Faculty or Other | Method of Remuneration  | Description of Role  |                                    |  |
| <b>Jyoti Mayadev</b>   | <b>University of California San Diego:</b> Professor: Employee  | None  | Ongoing: No access to proprietary info   | None  | Consultant                          | <b>AstraZeneca:</b> Honoraria: Compensation/Pay ment<br><b>KORTUC:</b> Honoraria<br><b>Merck:</b> Honoraria<br><b>Primmune:</b> Honoraria<br><b>Varian Medical Systems:</b> Honoraria | <b>AstraZeneca:</b> consultant: advisor: Start Date: May 2019- To Present<br><b>KORTUC:</b> advisor: Clinical trial advisor: Start Date: Jan 2021- To Present<br><b>Merck:</b> consultant: advisor: Start Date: July 2021- To Present<br><b>Primmune:</b> advisor: advisory: Start Date: June 2021- To Present<br><b>Varian Medical Systems:</b> Consulting: Advisor to clinical trial development: Start Date: August 2021- To Present  | None                               | <b>American Brachytherapy Society:</b> Board Member: Director-at-large, starting July 2023 for a 3 year term.: Not Compensated<br><b>NRG Oncology:</b> NCI funded cooperative group: Co-Chair: Grant co chair: Not Compensated   |
| <b>Charles Mayo</b>  | <b>University of Michigan:</b> Professor: Employee  | None  | Ongoing: No access to proprietary info<br>Ongoing: No access to proprietary info | None  | None                                | CodeX Steering Committee<br>EPIC Radiation Oncology Steering Board  | <b>CodeX Steering Committee:</b> Multi- Institutional group organized by HL7 and Miter Corporation facilitating development of HL7-FHIR interfaces to improve interoperable data exchange: Member of steering committee having oversight of CodeX projects.: Start Date: 1/1/2023- To Present<br><b>EPIC Radiation Oncology Steering Board:</b> Manufacturer of Electronic Health Care Records System: Advocate for use of standardization methods being developed via professional societies into EPICs interfaces. Coordinate connections between EPIC and other clinical stakeholders regarding standardizations. There is no remuneration or other financial benefit from this participation: Start Date: 1/1/2020- To Present | None                               | <b>American Association of Physicists in Medicine:</b> Professional society representing role of physics in medicine: Chair Big Data Subcommittee: Chair Big Data Subcommittee: Not Compensated<br><b>American Association of Physicists in Medicine:</b> Professional society representing the role of physics in medicine: Vice Chair Data Science Committee: Vice Chair Data Science Committee: Not Compensated   |
| <b>Sean McBride</b>  | <b>Memorial Sloan Kettering Cancer Center:</b> Employee   | None  | None   | None  | None                                | None  | None   | None                               | None   |
| <b>Beryl McCormick</b>   | <b>Memorial Sloan Kettering:</b> Cancer Center: Employee  | None  | None   | None  | None                                | None  | None   | None                               | None   |
| <b>Andrew McDonald</b>   | <b>University of Alabama at Birmingham:</b> Assistant Professor: Employee   | None  | None   | None  | None                                | None  | None   | None                               | None   |
| <b>Mark McDonald</b>   | <b>Winship Cancer Institute of Emory University:</b> Professor of Radiation Oncology: Employee  | None  | None   | None  | Faculty                             | <b>Varian Medical Systems:</b> Honoraria  | <b>Varian Medical Systems:</b> Radiation oncology medical device and software manufacturer: moderator, Varian Users Meeting, PTCOG 2022: Start Date: 2022- End Date: 2022  | None                               | <b>Georgia ProtonCare Center, Inc.:</b> d/b/a Emory Proton Therapy Center, a not-for-profit cancer treatment center providing proton radiation therapy services: Medical Director: approve, direct and provide oversight, evaluate and set standards for patient care at the center: Not Compensated   |
| <b>Lachlan Joseph McDowell</b>   | <b>Princess Alexandra Hospital:</b> Radiation Oncologist: Employee<br><b>Peter MacCallum Cancer Centre:</b> Radiation Oncologist: Employee: Relationship ended: 10/7/2022 | None  | Single: No access to proprietary info  | None  | None                                | <b>MSD:</b> Compensation/Pay ment   | <b>MSD:</b> Pharma: Advisory board for study design; Paid to institution: Start Date: April 2023- To Present   | None                               | <b>Head and Neck Cancer International Group:</b> International collaboration of Head and Neck research groups: Co-Chair Young Investigator subcommittee: Co-Chair of Young Investigator subcommittee: Not Compensated<br><b>Head and Neck Cancer International group:</b> International collaboration of Head and Neck research groups:Deputy Chair Guidelines and Protocols Committee: Co-chair of subcommittee: Not Compensated<br><b>Trans Tasman Radiation Oncology Group:</b> Research Group: Deputy Chair Head and Neck/Skin Working Party: Organisation, no compensation: Not Compensated |
| <b>Susan McDuff</b>  | <b>Duke Cancer Center Department of Radiation Oncology:</b> Assistant Professor: Employee   | None  | None   | None  | None                                | None  | None   | None                               | None   |
| <b>Ronald McGarry</b>  | <b>University of Kentucky:</b> Professor: Employee  | None  | None   | I recieve funding: No salary support in whole or part: steering committee | None                                | <b>Veteran's Adminstration:</b> Honoraria   | <b>Veteran's Administration:</b> National VA study of SBRT vs. Surgery. DSMC member: DSMC member, national clinical trial: Start Date: 2016 to present- To Present   | None                               | None   |
| <b>Heather McGee</b>   | <b>City of Hope:</b> Assistant Professor: Employee  | None  | None   | None  | Consultant                          | <b>Reflexion:</b> Honoraria   | <b>Reflexion:</b> Consultant: served as a consultant for Reflexion to advise them on ways to incorporate immunotherapy with biologically guided radiation therapy: Start Date: 2019-2021- End Date: 2021   | None                               | None   |

| ASTRO 2024 Annual Meeting - Annual Meeting Abstract Reviewers' Disclosures |   |       |   |  |   |  |  |                                    |   |
|--|---|-------|---|--|---|--|--|------------------------------------|---|
| Member   | Employment Relationships  |       | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria |  |   |  |  | Ownerships or Investment Interests | Leadership Positions  |
|  | Employment  | Other | Advisory Board  | Research   | Consultant/Speaker/Faculty or Other   | Method of Remuneration   | Description of Role  |                                    |   |
| James McIntyre   | MGH: Chief, Rad Onc, Mass General/North Shore CC: Employee                  | None  | None  | None   | None  | None   | None   | None                               | None  |
| Christopher McLaughlin   | University of Virginia: Assistant Professor: Employee                       | None  | None  | None   | None  | None   | None   | None                               | None  |
| Icro Meattini  | University of Florence: Associate Professor: Employee                       | None  | None  | None   | None  | None   | None   | None                               | None  |
| Teresa Meier   | University of Cincinnati: Assistant Professor: Employee                     | None  | None  | None   | None  | None   | None   | None                               | None  |
| Jeffrey Meyer  | Johns Hopkins University School of Medicine: Physician: Employee            | None  | None  | None   | Other - Sponsored research support, funds paid to institution<br>Other - Editorial activities and published book royalties. | Boston Scientific: Other - Sponsored research support, funds paid to institution<br>Springer: Honoraria<br>UpToDate, Inc.: Honoraria | Boston Scientific: Sponsored research support, funds paid to institution: Start Date: ~2019- End Date: ~2021<br>Springer: Editorial activities and published books.: Start Date: ~2017- To Present<br>UpToDate, Inc.: Contribution to site: Start Date:~2009- To Present | None                               | None  |
| Omar Mian  | Cleveland Clinic: Staff: Employee   | None  | None  | My Institution receives funding: No salary support in whole or part: site principal investigator<br>My Institution receives funding: No salary support in whole or part: site principal investigator | Consultant  | Bayer: Compensation/Pay ment<br>Gilead: Grant/Research Funding<br>Varian: Grant/Research Funding                                     | Bayer: Corporation: Consultant Prostate Cancer: Start Date: Jan 2022- To Present<br>Gilead: Company: PI Research (Clinical Trial): Start Date: Dec 2022- To Present<br>Varian: Company: PI Research Grant: Start Date: Dec 2022- To Present                              | None                               | MCCN: Guidelines:Panel Member: NCCN Panel Member: Not Compensated   |
| Michelle Mierzwa   | University of Michigan: Associate Professor of Radiation Oncology: Employee | None  | None  | None   | None  | None   | None   | None                               | MROQC: Michigan Radiation Oncology Quality Consortium: Co-lead of Behavioral Health Committee: Co-lead: Not Compensated   |
| Dimitris Mihailidis  | University of Pennsylvania: Associate Professor: Employee                   | None  | None  | None   | None  | None   | None   | None                               | AAPM: Therapy Physics Committee: Vice Chair: Manage therapy physics subcommittees, working groups and task groups.: Not Compensated: Relationship Ended: 5/26/2023<br>AAPM Task Group 261: management of dental and maxillofacial CBCT technologies: Provide document with recommendations and guidelines to manage dental and maxillofacial CBCT technologies: Chair: manage and produce the guidelines: Not Compensated<br>AAPM Task Group 359: FLASH beam dosimetry: Manage and coordinate expert investigation on FLASH beam dosimetry issues, make recommendations and provide guidance in FLASH beam dosimetry.: Chair: Manage and coordinate, guide the group to producing recommendations and guidance through a manuscript: Not Compensated<br>Doody Enterprise Inc: Source, expert reviews of newly published books, print and electronic, in the health sciences.: Member of the Editorial Board: Book review editor for Medical Physics division: Not Compensated<br>The American Board of Medical Physics: Board certification for medical and |
| George Mikhael   | Guy's & St Thomas NHS Hospital: Clinical Oncologist: Employee               | None  | None  | None   | Faculty   | Kite: Honoraria: Travel Expenses   | Kite: Speaker in a scientific meeting: Invited speaker about Role of radiotherapy with CAR-T: Start Date: 5 October 2022- End Date: 5 October 2022   | None                               | None  |

| ASTRO 2024 Annual Meeting - Annual Meeting Abstract Reviewers' Disclosures |  |   |   |  |   |   |   |   |  |
|--|--|---|---|--|---|---|---|---|--|
| Member   | Employment Relationships   |   | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria |  |   |   |   | Ownerships or Investment Interests  | Leadership Positions   |
|  | Employment   | Other                                       | Advisory Board  | Research   | Consultant/Speaker/Faculty or Other           | Method of Remuneration  | Description of Role   |   |  |
| Sarah Milgrom  | University of Colorado: Associate Professor: Employee  | None  | None  | None   | Consultant                                    | Bristol Myers Squibb: Uncompensated   | Bristol Myers Squibb: Provided advice regarding PET volumetric research for a pediatric Hodgkin lymphoma study; Provided advice to researchers at Bristol Myers Squibb regarding PET volumetric research for a pediatric Hodgkin lymphoma study: Start Date: 7/1/23- To Present   | None  | American Radium Society: Appropriate Use Criteria Lymphoma Committee: Vice Chair: work with a committee to develop guidelines regarding lymphoma sub-topics: Not Compensated |
| Jacob Miller   | Cleveland Clinic Foundation: Associate Staff: Employee   | None  | None  | None   | None  | None  | None  | None  | None   |
| Jessica Miller   | University of Wisconsin - Madison: Associate Professor: Employee   | None  | Ongoing: No access to proprietary info                          | My Institution receives funding: No salary support in whole or part: other: collaborator<br>My Institution receives funding: No salary support in whole or part: site principal investigator | None  | GE Healthcare Collaboration: Grant/Research Funding<br>Siemens Healthiness Collaboration: Grant/Research Funding<br>UWADCL: Advisory Board: Uncompensated | GE Healthcare Collaboration: Collaboration agreement with GE Healthcare: Collaborator/Bone Marrow Imaging: Start Date: 2021- To Present<br>Siemens Healthiness Collaboration: Collaboration agreement with Siemens Healthineers.: PI/DECT: Start Date: 2017- To Present<br>UWADCL: Advisory Board: University of Wisconsin Accredited Dosimetry Calibration Laboratory Advisory Board Committee: Board Member: Start Date: 2017- To Present | None  | None   |
| Giuseppe Minniti   | University of Rome Sapienza: Professor: Employee   | None  | None  | None   | None  | Brainlab: Travel Expenses   | Brainlab: honoraria 2.000 euros: speaker: Start Date: 2022- End Date: 2023  | None  | None   |
| Mark Mishra  | University of Maryland School of Medicine: Professor: Employee   | Family Member: Orthofix: Employee: Employee | None  | None   | Other - Medical expert for patent application | Humanetics: Honoraria   | Humanetics: Medical expert for patent application: Start Date: 4/1/2023- End Date: 5/1/2023   | None  | None   |
| Melissa Mitchell   | MD Anderson: Physician: Employee   | None  | None  | I receive funding: No salary support in whole or part: national/overall principal investigator   | None  | NRG, ARTIDIS, SABCS: Grant/Research Funding: Travel Expenses: Salary Support  | NRG, ARTIDIS, SABCS: NRG investigator on BR008<br>Funding from ARTIDIS SABCS speaker DAVA Oncology speaker<br>Travel funds from VisionRT: co-PI for NRG BR008<br>Speaker at SABCS 2022<br>Research trial supported by ARTIDIS<br>Speaker at DAVA Oncology with financial support for travel<br>Attended VisionRT SGRT meeting with financial support for travel: Start Date: 01/2022- To Present  | None  | None   |
| Devarati Mitra   | University of Texas MD Anderson Cancer Center: Assistant Professor: Employee   | None  | None  | None   | None  | None  | None  | None  | None   |
| Kathryn Mittauer   | Miami Cancer Institute: Senior Medical Physician: Employee<br>Florida International University: Associate Professor: Other: Academic affiliate | None  | None  | I receive funding: No salary support in whole or part: national/overall principal investigator   | Consultant<br>Speaker Bureau                  | ViewRay Inc: Grant/Research Funding: Honoraria: Travel Expenses: Compensation/Payment   | ViewRay Inc: radiotherapy device company: Honoraria for speaking engagement on A3i UI, travel and compensation for consulting for A3i UI: Start Date: 7/1/2015- End Date: 10/25/2023  | MR Guidance LLC: Partnership: Limited Liability: Relationship Ended: 12/31/2023 | None   |
| David Miyamoto   | Massachusetts General Hospital: Physician Investigator: Employee   | None  | None  | My Institution receives funding: No salary support in whole or part: site principal investigator   | None  | Cardiff Oncology: Grant/Research Funding  | Cardiff Oncology: Biotech company: Molecular signatures of response to onvansertib and abiraterone in circulating tumor cells from men with metastatic prostate cancer.: Start Date: 4/29/2021- End Date: 4/30/2022   | None  | None   |
| Everett Moding   | Stanford University: Assistant Professor: Employee   | None  | None  | None   | Consultant                                    | Gerson Lehrman Group: Compensation/Payment<br>Guidepoint: Compensation/Payment  | Gerson Lehrman Group: Expert consultant network.: Consulted on projects related to oncology and genomic technologies.: Start Date: 10/20/2023- To Present<br>Guidepoint: Expert consulting network.: Consulted on projects related to oncology and genomic technologies.: Start Date: 7/13/2023- To Present   | None  | None   |

ASTRO 2024 Annual Meeting - Annual Meeting Abstract Reviewers' Disclosures

| Member                  | Employment Relationships  |       | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria |  |                                     |   |   | Ownerships or Investment Interests | Leadership Positions   |
|-------------------------|---|-------|---|--|-------------------------------------|---|---|------------------------------------|--|
|                         | Employment  | Other | Advisory Board  | Research   | Consultant/Speaker/Faculty or Other | Method of Remuneration  | Description of Role   |                                    |  |
| <b>Osama Mohamad</b>    | University of California San Francisco: assistant professor: Employee: Relationship ended: 6/30/2023<br>Md Anderson cancer center, Houston: Assistant professor: Employee | None  | None  | None   | None                                | None  | None  | None                               | None   |
| <b>Pranshu Mohindra</b> | University of Maryland School of Medicine: Associate Professor: Employee: Relationship ended: 1/17/2023   | None  | None  | None   | Consultant                          | White Plains Hospital: Compensation/Pay ment  | White Plains Hospital: Hospital with cancer center: Review of clinical operations, one time consultation, no ongoing relationship.: Start Date: 11/1/2021- End Date: 12/31/2021   | None                               | <b>Alliance for Clinical Trials in Oncology:</b> NCI Cooperative Group: Member, Board of Director: Board activities: Not Compensated: Relationship Ended: 2/1/2023<br><b>American Brachytherapy Society:</b> Professional society:Vice-Chair International Committee: Assist with International Committee activities.: Not Compensated: Relationship Ended: 8/31/2022<br><b>American College of Radiology:</b> Professional Society: Panel Chair- Thoracic Section: Finalize test items for the ACR Radiation Oncology In-Training Examination: Not Compensated<br><b>ASTRO:</b> Professional Society: Chair, Workforce Subcommittee: Lead regular teleconferences, participate in work groups and help with other activities of the subcommittee: Not Compensated<br><b>IASLC:</b> Society, Lung Cancer: Chair, Education Committee: Lead activities of Education Committee within IASLC: Not Compensated<br><b>Ulman Foundation:</b> Not for profit foundation for Cancer In Young Adults: Member, Board of Directors: Participate in various activities of the foundation |
| <b>Vitali Moiseenko</b> | UC San Diego: Medical Physicist: Employee   | None  | None  | None   | None                                | None  | None  | None                               | None   |
| <b>Dominic Moon</b>     | UT Southwestern Medical Center: Assistant Professor: Employee   | None  | None  | I recieve funding: No salary support in whole or part: national/overall principal investigator<br>I recieve funding: No salary support in whole or part: national/overall principal investigator | None                                | <b>Gateway For Cancer Research:</b> Grant/Research Funding<br><b>The Cary Council:</b> Grant/Research Funding | <b>Gateway For Cancer Research:</b> Non-profit organization funding early phase clinical trials: Research funding for phase I trial: Start Date: 7/2021- To Present<br><b>The Cary Council:</b> Non-profit organization funding research: Research funding for a translational research project: Start Date: 12/2022 - To Present | None                               | None   |

| ASTRO 2024 Annual Meeting - Annual Meeting Abstract Reviewers' Disclosures |  |       |   |  |  |  |   |   |  |
|--|--|-------|---|--|--|--|---|---|--|
| Member   | Employment Relationships   |       | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria                 |  |  |  |   | Ownerships or Investment Interests                            | Leadership Positions   |
|  | Employment   | Other | Advisory Board  | Research   | Consultant/Speaker/Faculty or Other  | Method of Remuneration   | Description of Role   |   |  |
| Jean Moran   | Memorial Sloan Kettering Cancer Center: Vice Chair: Employee   | None  | None  | None   | Other - Quality Improvement project; I was the past Associate Director of the Michigan Radiation Oncology Quality Consortium (MROQC) and the lead of the Physics aspects of the project. Other - member of MROQC breast working group Faculty Other - I do not receive any support at my current institution. My prior institution receives grant funding. | Blue Cross Blue Shield of Michigan: Grant/Research Funding<br>Blue Cross Blue Shield of Michigan: Travel Expenses<br>Sun Nuclear: Travel Expenses<br>Varian: A Siemens Healthineers Company  | Blue Cross Blue Shield of Michigan: Health insurance company in the state of Michigan: MROQC is a statewide registry focused on quality improvement. I was involved in projects related to the cancer types represented.: Start Date: 01/2011- End Date: 05/2021<br>Blue Cross Blue Shield of Michigan: insurance company in the state of Michigan: member of MROQC breast working group: Start Date: 06/2021 - To Present<br>Sun Nuclear: Manufacturer of QA equipment and software: Speaker at 2022 QA and Dosimetry Symposium; spoke on IMRT Quality Assurance in a debate format: Start Date: 4/7/21- End Date: 4/9/21<br>Varian: A Siemens Healthineers Company: Radiation Oncology Equipment Manufacturer: My past institution holds a grant for a consortium which I lead focused on Automated Quality Assurance for linear accelerators.: Start Date: 1/2015- To Present  | Prexient, Inc.: Stock: Partnership<br>FuseOncology: Copyright | AAPM: American Association of Physicists in Medicine: Chair Work Group on Report Writing; Chair of group to improve the AAPM report writing process: Not Compensated<br>AAPM: American Association of Physicists in Medicine: Chair-Work Group on Science Council EDI: Chair group focused on improving EDI within Science Council and its committees.: Not Compensated<br>AAPM: American Association of Physicists in Medicine: Chair-Work Group on Task Group Review Streamlining: Chair of the committee to streamline the review process.: Not Compensated: Relationship Ended: 12/31/2022<br>AAPM: American Association of Physicists in Medicine: Working Group on Increasing Equity in Honors and Awards: Chair of group to increase equity in the AAPM Honors and Awards process: Not Compensated<br>ROI: Research Committee of the Radiation Oncology Institute: Vice Chair: Vice Chair of Research Committee of the ROI: Not Compensated |
| Rosalyn Morrell  | CenterPoint Radiation Oncology, Inc: Owner: Partner  | None  | None  | None   | None   | None   | None  | None  | None   |
| Waleed Mourad  | University of Kentucky/Markey Cancer Center: Professor: Employee   | None  | None  | None   | None   | None   | None  | None  | None   |
| Kent Mouw  | Brigham & Women's Hospital: Assistant Professor of Radiation Oncology: Employee<br>Dana-Farber Cancer Institute: Assistant Professor of Radiation Oncology: Employee   | None  | Ongoing: No access to proprietary info<br>Single: No access to proprietary info | My Institution receives funding: No salary support in whole or part: national/overall principal investigator<br>My Institution receives funding: No salary support in whole or part: national/overall principal investigator | Faculty Consultant   | Pfizer: Grant/Research Funding<br>Riva Therapeutics: Compensation/Pay ment<br>UpToDate: Honoraria<br>UroGen: Honoraria   | Pfizer: bladder cancer clinical trial; bladder cancer clinical trial: Start Date: 1/2018- To Present<br>Riva Therapeutics: Drug discovery: drug development consultant: Start Date: 8/2022- To Present<br>UpToDate: professional material development: bladder cancer professional media: Start Date: 1/2021- To Present<br>UroGen: device and drug development: device and drug development consultant: Start Date: 10/2021- End Date: 10/2021   | Riva Therapeutics: Ownership Equity: Co-founder               | None   |
| Yvonne Mowery  | Duke Health: Assistant Professor of Radiation Oncology: Employee: Relationship ended: 5/31/2023<br>UPMC Hillman Cancer Center/University of Pittsburgh: Associate Professor of Radiation Oncology : Employee | None  | None  | My Institution receives funding: No salary support in whole or part: national/overall principal investigator<br>My Institution receives funding: No salary support in whole or part: national/overall principal investigator | Consultant<br>Faculty Consultant<br>Grant/Research Funding   | Bayer: In-kind Donations - BAY 1895344 provided for preclinical experiments<br>SU2C: Charitable organization providing grant funding for cancer research: Start Date: 05/2017 - To Present<br>UpToDate: UpToDate is a subscription-based resource designed to provide: physicians access to current clinical information. It addresses specific clinical issues in the form of topic reviews. Start Date: 12/16/2019 - To Present<br>Catalys Pacific LLC: Compensation/Pay ment<br>Damon Runyon Cancer Foundation: Grant/Research Funding: Travel Expenses<br>NID CR/NIH: Grant/Research Funding: : Start Date: 07/2020 - To Present<br>NCI/NIH: Federal government's principal agency for cancer research and training: Start Date: September 2020 - To Present<br>John R. Flanagan Charitable Foundation: Grant/Research Funding: Start Date: 01/2020 - To Present | Bayer: Pharmaceutical company: Supports research evaluating radiosensitizing and immunomodulatory effects of ATR inhibitor BAY 1895344: Start Date: January 2021 - To Present<br>SU2C: Funding SU2C-SARC032 and correlative studies: Start Date: 05/2017 - To Present<br>UpToDate: Co-author of article: "Treatment of early (stage I and II) head and neck cancer: The hypopharynx: Start Date: 12/16/2019 - To Present: Start Date: 09/2018 - 10/2020<br>Catalys Pacific LLC: A venture capital firm that invests in life sciences innovation in early-stage start-ups. Reviewed slides from Galera Therapeutics regarding Avasopasem, related literature, and literature related to potential competitor. Summarized these findings and provided input on potential for FDA approval and clinical benefit for Avasopasem. Start Date: 12/15/2022 - End Date: 01/16/2023<br>Damon Runyon Cancer Foundation: Foundation supporting cancer research: Basic, translational and clinical research focused on studying radiation resistance in head and neck cancer: Start Date: 07/2020 - To Present<br>NID CR/NIH: Grant/Research Funding: Studying radiation resistance in mouse models of head and neck cancer and evaluating anti-PD-1 therapy with ATR inhibitor and radiation for head and neck cancer in preclinical studies: Start Date: 07/2020 - To Present<br>NCI/NIH: Supports opening phase I trial on BAY 1895344, reirradiation, pembrolizumab for recurrent HNSCC at Duke: Start Date: September 2020 - To Present<br>John R. Flanagan Charitable Foundation: supports postdoc salary: Start Date: 01/2020 - To Present | None  | Center for Cancer Immunotherapy: Duke Cancer Institute Center for Cancer Immunotherapy: To identify cancer immunotherapy discoveries related to radiation therapy that show promise and facilitate a team to translate the finding into a drug that can be tested in a clinical trial. End Date: 05/31/2023  |



**ASTRO 2024 Annual Meeting - Annual Meeting Abstract Reviewers' Disclosures**

| Member                       | Employment Relationships  |       | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria |  |                                     |   |  | Ownerships or Investment Interests | Leadership Positions  |
|------------------------------|---|-------|---|--|-------------------------------------|---|--|------------------------------------|---|
|                              | Employment  | Other | Advisory Board  | Research   | Consultant/Speaker/Faculty or Other | Method of Remuneration  | Description of Role  |                                    |   |
| <b>Chika Nwachukwu</b>       | <b>University of California, San Diego:</b> Assistant Professor: Employee   | None  | None  | None   | None                                | None  | None   | None                               | None  |
| <b>Nitin Ohri</b>            | <b>Albert Einstein College of Medicine, Montefiore Me:</b> Associate Professor, Attending Physician: Employee: Relationship ended: 10/7/2023<br><b>Albert Einstein College of Medicine, Montefiore Me:</b> Professor, Attending Physician: Employee | None  | None  | My Institution receives funding: No salary support in whole or part: site principal investigator | Consultant                          | <b>AstraZeneca:</b> Grant/Research Funding: Honoraria<br><b>Genentech:</b> Compensation/Pay ment<br><b>Regeneron:</b> Compensation/Payment  | <b>AstraZeneca:</b> Pharmaceutical Company: Lung Cancer: Start Date: 1/1/2021- To Present<br><b>Genentech:</b> Pharmaceutical Company: Consultant: Start Date: 11/1/2021- To Present<br><b>Regeneron:</b> Pharmaceutical Company: Consulting: Start Date: 10/1/2023- To Present  | None                               | None  |
| <b>Christian Okoye</b>       | <b>Mercy Medical Center:</b> Radiation Oncologist / Physician: Employee<br><b>St. Bernards Medical Center:</b> Radiation Oncologist / Physician: Employee: Relationship ended: 12/11/2020   | None  | None  | None   | None                                | None  | None   | None                               | None  |
| <b>Oluwadamilola Oladeru</b> | <b>Mayo Clinic Florida:</b> Assistant Professor of Radiation Oncology: Employee   | None  | None  | I recieve funding: No salary support in whole or part: national/overall principal investigator   | None                                | <b>ASCO/Pfizer Competitive Research Gran:</b> Grant/Research Funding<br><b>ASCO/Winn Clinical Investigator Leadership Award:</b> Salary Support<br><b>Bristol Myers Squibb Foundation/Winn CDA:</b> Grant/Research Funding<br><b>Florida Breast Cancer Foundation:</b> Grant/Research Funding<br><b>NRG Oncology:</b> Grant/Research Funding<br><b>Radiation Oncology Institute:</b> Grant/Research Funding | <b>ASCO/Pfizer Competitive Research Gran:</b> metastatic breast cancer research grant: Start Date: 12/2021- End Date: 12/2023<br><b>ASCO/Winn Clinical Investigator Leadership Award:</b> Salary support during program participation: Start Date: 1/2024- To Present<br><b>Bristol Myers Squibb Foundation/Winn CDA:</b> Career Development Award: Start Date: 10/2021- To Present<br><b>Florida Breast Cancer Foundation:</b> NGO: Service grant: Start Date: 02/2023- End Date: 12/2023<br><b>NRG Oncology:</b> Research grant: Start Date: 07/2021 - To Present<br><b>Radiation Oncology Institute:</b> Research grant: Start Date: 07/2020 - To Present | None                               | <b>Rayos Contra Cancer:</b> Non profit organization dedicated to improving global health inequities in the field of radiation oncology.: Director of Education: I oversee educational content and course development for radiation oncology clinicians across the globe offered by volunteer physician and physicist partners of the organization.: Not Compensated |
| <b>Carol Oliveira</b>        | <b>McGill University Health Centre:</b> Radiation Oncologist: Independent Contractor  | None  | None  | None   | None                                | None  | None   | None                               | None  |
| <b>Kenneth Olivier</b>       | <b>Mayo Clinic:</b> faculty: Employee   | None  | None  | None   | None                                | None  | None   | ViewRay: Stock                     | None  |

| ASTRO 2024 Annual Meeting - Annual Meeting Abstract Reviewers' Disclosures |   |       |   |  |                                     |  |  |                                    |   |
|--|---|-------|---|--|-------------------------------------|--|--|------------------------------------|---|
| Member   | Employment Relationships  |       | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria |  |                                     |  |  | Ownerships or Investment Interests | Leadership Positions  |
|  | Employment  | Other | Advisory Board  | Research   | Consultant/Speaker/Faculty or Other | Method of Remuneration   | Description of Role  |                                    |   |
| Jeffrey Olsen  | University of Colorado: Professor: Employee   | None  | Ongoing: No access to proprietary info                          | None   | None                                | NAMSA: Compensation/payment  | NAMSA: I review clinical events for an ongoing clinical trial of MR guided RT for pancreatic cancer). As of 8/2023 the company has transitioned from Syntactx to NAMSA, updated here: I review clinical events for Syntactx (review AE attributions for an ongoing clinical trial of MR guided RT for pancreatic cancer): Start Date: 1/2019- To Present                                     | None                               | ASTRO: Guidelines Committee: Member: Guidelines Committee Member: Not Compensated<br>IJOBP: GI Section Editor:Service as GI section editor for IJOBP - my term ended after ASTRO 2023, although am continuing to handle several manuscripts that were under review with completion in 12/2023: Not Compensated: Relationship Ended: 12/31/2023<br>RO-HAC: Service on RO-HAC: Service on RO-HAC: I serve on the ASTRO RO-HAC, and receive honorarium in this regard: Not Compensated |
| Adam Olson   | UPMC Hillman Cancer Center: Assistant Professor: Employee                             | None  | None  | None   | None                                | None   | None   | None                               | None  |
| Eenas Omari  | The Medical College of Wisconsin: Assistant Professor: Employee                       | None  | None  | None   | Faculty                             | The Medical College of Wisconsin: Travel Expenses  | The Medical College of Wisconsin: Faculty: Research presentations travel funds: Start Date: 07/01/2020- To Present   | None                               | None  |
| Evan Osmundson   | Vanderbilt University Medical Center: Associate Professor, Medical Director: Employee | None  | None  | My Institution receives funding: No salary support in whole or part: national/overall principal investigator   | None                                | Varian / Siemens Health Care: Grant/Research Funding   | Varian / Siemens Health Care: Radiotherapy- based clinical trial: Start Date: 2022- To Present   | None                               | None  |
| Dawn Owen  | Mayo Clinic: Physician: Employee  | None  | None  | My Institution receives funding: No salary support in whole or part: national/overall principal investigator<br>My Institution receives funding: No salary support in whole or part: national/overall principal investigator | Other - honorarium                  | Astra Zeneca: Grant/Research Funding<br>UpToDate: Honoraria<br>Varian: Grant/Research Funding              | Astra Zeneca: Research funding: PI of 10 patient Phase I trial: Start Date: 10/1/2021- To Present<br>UpToDate: Author: Author on Radiation Pneumonitis section: Start Date: 6/1/2020- To Present<br>Varian: Corporation: Phase I trial: Start Date: 10/1/2021- To Present  | None                               | None  |
| Oscar Padilla  | Icahn School of Medicine at Mount Sinai: Assistant Professor : Employee               | None  | None  | None   | None                                | None   | None   | None                               | None  |
| David Palma  | London Health Sciences Centre: Radiation Oncologist: Independent Contractor           | None  | None  | None   | Consultant                          | Need Inc: Honoraria<br>UpToDate.com: Honoraria   | Need Inc: Need Inc is a company providing a virtual platform that encourages screening and cancer prevention and allows multidisciplinary review of cancer cases.: Consultant regarding quality of care and improving outcomes.: Start Date: Sept 2020- To Present<br>UpToDate.com: Online medical information resource: I receive royalties from UpToDate: Start Date: Jan 2021- To Present | Need Inc: Stock                    | None  |
| Joshua Palmer  | The Ohio State University: Associate Professor: Employee                              | None  | None  | My Institution receives funding: No salary support in whole or part: national/overall principal investigator<br>My Institution receives funding: No salary support in whole or part: national/overall principal investigator | Consultant                          | Carbofix: Honoraria<br>ICOTEC: Honoraria<br>The Ohio State University<br>Varian Medical Systems: Honoraria | Carbofix: Spine Hardware company: honoraria for speaking: Start Date: 7/2022- To Present<br>ICOTEC:<br>Spine Hardware company: Consultant and honoraria for speaking.: Start Date: 6/2019- To Present<br>The Ohio State University: Trial funding: Start Date: 7/2021- To Present<br>Varian Medical Systems: trial funding, and honoraria for speaking: Start Date: 6/2019- To Present       | None                               | None  |





| ASTRO 2024 Annual Meeting - Annual Meeting Abstract Reviewers' Disclosures |  |       |  |  |                                     |   |  |                                    |   |
|--|--|-------|--|--|-------------------------------------|---|--|------------------------------------|---|
| Member   | Employment Relationships   |       | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria                  |  |                                     |   |  | Ownerships or Investment Interests | Leadership Positions  |
|  | Employment   | Other | Advisory Board   | Research   | Consultant/Speaker/Faculty or Other | Method of Remuneration  | Description of Role  |                                    |   |
| Shilpen Patel  | <b>Good Samaritan:</b><br>Radiation Oncologist:<br>Independent Contractor<br><b>Gilead Sciences:</b><br>Executive Medical Director: Employee:<br>Relationship ended: 10/6/2023<br><b>Bristol Meyers Squib:</b><br>Executive Medical Director: Employee | None  | Ongoing: No access to proprietary info   | None   | Faculty                             | <b>Travera:</b> Compensation/Pay ment<br><b>Unviersity of Washington:</b><br>Uncompensated  | <b>Travera:</b> Ad Board: Provide Advice: Start Date: 11/1/22- End Date: 5/1/23<br><b>Unviersity of Washington:</b> On faculty: Start Date: 9/1/13- To Present   | None                               | <b>American Medical Association:</b> AMA: Delegate/Reference Committee/Council member: AMA: Not Compensated<br><b>Horizons Foundation:</b> Non Profit: Board Member: Board Member: Not Compensated<br><b>Phi Chi Medical Foundation:</b> Non Profit: Chairman Executive Trustees: Non Profit: Not Compensated<br><b>RADAID:</b> Non Profit: Director: Non Profit: Not Compensated<br><b>Radiating Hope:</b> Non Profit: Board Member: Not Compensated |
| Ima Paydar   | <b>Merck:</b> Clinical Director: Employee  | None  | None   | None   | None                                | None  | None   | <b>Merck:</b> Stock                | None  |
| Angelica Perez-Andujar   | <b>Memorial Sloan Kettering:</b> Associate Attending Physician: Employee   | None  | None   | None   | Faculty                             | <b>Invited Speaker:</b> Travel Expenses   | <b>Sun Nuclear QADS symposium:</b> Invited Speaker to conference, sponsored/reimbur sed travel: Start Date: April 8, 2022- To Present  | None                               | <b>AAPM:</b> Vice Chair of the DREAM subcommittee:AAPM DREAM Vice Chair: Evaluate applications from underrepresented students for the AAPM DREAM program: Not Compensated   |
| Gabrielle Peters   | <b>Yale School of Medicine:</b> Assistant Professor: Employee  | None  | None   | None   | None                                | None  | None   | None                               | None  |
| Jennifer Peterson  | <b>Mayo Clinic:</b> MD: Employee   | None  | None   | None   | None                                | None  | None   | None                               | None  |
| Kenneth Pitter   | <b>The Ohio State University:</b> Assistant Professor: Employee  | None  | None   | None   | None                                | None  | None   | None                               | None  |
| Matthew Podgorsak  | <b>Roswell Park Comprehensive Cancer Center:</b> Chief Physician: Employee   | None  | Ongoing: No access to proprietary info   | None   | None                                | <b>American College of Radiation Oncology (ACRO):</b><br>Uncompensated  | <b>American College of Radiation Oncology (ACRO):</b> Member - Physics advisory committee for the ACRO Practice Accreditation Program: Advise ACRO on physics standards for their practice accreditation program: Start Date: 01/01/2010- To Present   | None                               | <b>American Board of Radiology:</b> Chair - Board of Trustees, Member - Board of Governors, Trustee - Therapy Medical Physics: Chair - Board of Trustees, Member - Board of Governors, Trustee - Therapy Medical Physics: Not Compensated   |
| Kelli Pointer  | <b>Dartmouth- Hitchcock Medical Center:</b> Assistant Professor: Employee<br><b>University of Chicago:</b> Resident: Employee:<br>Relationship ended: 6/30/2022  | None  | Ongoing: No access to proprietary info   | I recieve funding: No salary support in whole or part: national/overall principal investigator<br>I recieve funding: No salary support in whole or part: site principal investigator<br>My Institution receives funding: No salary support in whole or part: national/overall principal investigator<br>I recieve funding: No salary support in whole or part: national/overall principal investigator | None                                | <b>ACS-IRG grant:</b> Grant/Research Funding<br><b>Dartmouth Cancer Center Shared Resources:</b> Uncompensated<br>Lab start up funding: Grant/Research Funding<br><b>Radiation Research Foundation:</b> Grant/Research Funding<br><b>RSNA grant:</b> Grant/Research Funding | <b>ACS-IRG grant:</b> IRG-21-136-36-IRG Grant- Defining a Molecular Signature of Glioblastoma Cancer Stem Cell Acquired Radiation Resistance: Defining a Molecular Signature of Glioblastoma Cancer Stem Cell Acquired Radiation Resistance: Start Date: 12/15/2022 - To Present<br><b>Dartmouth Cancer Center Shared Resources:</b> Advisory board for cancer center shared resources: advisory board member for shared resources: Start Date: 1/1/2023- To Present<br><b>Lab start up funding:</b> Overcoming radiation resistance in cancer.: Start Date: 9/2022- To Present<br><b>Radiation Research Foundation:</b> research funding for radiation resistance in glioma: Start Date: 12/1/2023- End Date: 11/30/2024<br><b>RSNA grant:</b> Grant during residency: Targeting HR to improve radiation resistance: Start Date: 7/2021- End Date: 7/2022 | None                               | <b>ASTRO:2022 - 2023 Annual Meeting Track - Biology and CNS tracks:</b> abstract reviewer: Not Compensated  |
| Daniel Polan   | <b>University of Michigan:</b> Assistant Professor: Employee   | None  | None   | None   | None                                | None  | None   | None                               | Winter Insitute of Medical Physics :Co-Director:Co- Director of Conference:Not Compensated  |
| Erqi Pollom  | <b>Stanford:</b> Associate Professor: Employee   | None  | Ongoing: No access to proprietary info<br>Ongoing: No access to proprietary info | None   | None                                | <b>GT Medical Technologies:</b> Compensation/Pay ment<br>Varian: Honoraria<br>Vysioneer   | <b>GT Medical Technologies:</b> Gammatile therapy: serve on ad board for use of gamma tiles for brain tumors: Start Date: Sept 1, 2023- To Present<br><b>Varian:</b> honoraria for being an instructor at Varian school: Start Date: Jan 1, 2023- To Present<br><b>Vysioneer:</b> Autosegmentation company: Advisory board, CNS expertise: Start Date: 1/2022- To Present  | None                               | None  |



**ASTRO 2024 Annual Meeting - Annual Meeting Abstract Reviewers' Disclosures**

| Member          | Employment Relationships   |       | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria |  |  |   |  | Ownerships or Investment Interests | Leadership Positions  |
|-----------------|--|-------|---|--|--|---|--|------------------------------------|---|
|                 | Employment   | Other | Advisory Board  | Research   | Consultant/Speaker/Faculty or Other  | Method of Remuneration  | Description of Role  |                                    |   |
| Shyam Rao       | University Of California, Davis: Associate Professor: Employee   | None  | None  | None   | None   | None  | None   | None                               | None  |
| Dominique Rash  | UCSD Health: Radiation oncologist: Employee  | None  | None  | None   | Other - Speaker re:Radformation products Speaker Bureau  | Radformation: Honoraria<br>VisionRT: Honoraria: Travel Expenses   | Radformation: creates radiation planning software products: Discussed EZ fluence and other products at vendor booth: Start Date: 10/26/22- End Date: 10/27/22<br>VisionRT: Creates radiation set up products: discussed use of AlignRT: Start Date 3/2022- End Date: 10/27/2022  | None                               | None  |
| Jay Paul Reddy  | MD Anderson Cancer Center: Assistant Professor: Employee   | None  | None  | None   | None   | None  | None   | None                               | None  |
| Kristin Redmond | Johns Hopkins University: physician: Employee  | None  | None  | My Institution receives funding: No salary support in whole or part: site principal investigator<br>My Institution receives funding: No salary support in whole or part: site principal investigator<br>My Institution receives funding: No salary support in whole or part: site principal investigator<br>My Institution receives funding: No salary support in whole or part: site principal investigator | Other - Data safety monitoring board for a trial<br>Other - They supported travel to a meeting<br>Consultant | Accuray: Grant/Research Funding: Honoraria: Travel Expenses<br>Biomimetix: Compensation/Payment<br>Brainlab: Travel Expenses<br>Canon: Grant/Research Funding<br>Elekta AB: Grant/Research Funding: Travel Expenses<br>Gamma tile: Compensation/Payment<br>Icotec: Grant/Research Funding: Compensation/Payment | Accuray: I am the PI for a small single arm pilot study receiving modest support from Accuray. In addition they covered travel expenses and gave an honorarium for participation at the AERO meeting a few years ago: Start Date: 2017- To Present<br>Biomimetix: data safety monitoring board for a trial: Start Date: 2020- To Present<br>Brainlab: Travel to a meeting: They supported travel to a meeting: Start Date: 2018- End Date: 2018<br>Canon: radiogenomics for chordoma: Start Date: 2022- To Present<br>Elekta AB: Multi-institutional research consortium funded by electa: Start Date: 2017- To Present<br>Gamma tile: consulting: Start Date: 2023- To Present<br>icotec: carbon fiber instrumentation: Funding for research on carbon fiber spine implants: Start Date: 2023- To Present | None                               | Camp Kesem: Camp for children whose parent has cancer: Advisory board: advisory board: Not Compensated              |
| Lei Ren         | University of Maryland: Professor: Employee  | None  | None  | None   | None   | None  | None   | None                               | None  |
| Marsha Reyngold | Memorial Sloan Kettering Cancer Center: assistant attending: Employee  | None  | None  | My Institution receives funding: No salary support in whole or part: national/overall principal investigator<br>My Institution receives funding: No salary support in whole or part: national/overall principal investigator   | Speaker Bureau   | Elekta: Grant/Research Funding: Honoraria<br>Varian: Grant/Research Funding   | Elekta: lecturer: Start Date: 2022- To Present<br>Varian: PI pancreatic cancer clinical research: Start Date: 2022- End Date: 2022   | None                               | NCCN Pancreatic Cancer Guidelines: panel: panel member: represent my institution in the NCCN panel: Not Compensated |
| Shayna Rich     | Veterans Administration: Hospice and Palliative Medicine Section Head: Employee: Relationship ended: 10/13/2023<br>Haven Hospice: Associate Medical Director: Employee | None  | None  | None   | Faculty  | University of Central Florida: Uncompensated  | University of Central Florida: Honorary Professor: Start Date: 12/01/2022- To Present  | None                               | Fast Facts: Reviewer: Review blinded versions of proposed Fast Facts: Not Compensated                               |







| ASTRO 2024 Annual Meeting - Annual Meeting Abstract Reviewers' Disclosures |   |       |  |   |                                     |   |  |                                    |  |
|--|---|-------|--|---|-------------------------------------|---|--|------------------------------------|--|
| Member   | Employment Relationships  |       | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria  |   |                                     |   |  | Ownerships or Investment Interests | Leadership Positions   |
|  | Employment  | Other | Advisory Board   | Research  | Consultant/Speaker/Faculty or Other | Method of Remuneration  | Description of Role  |                                    |  |
| Reinhard Schulte   | Loma Linda University: Professor; Employee  | None  | None   | None  | None                                | None  | None   | None                               | <p><b>National Center for Particle Beam Radiation Therapy Research:</b> A non-profit organization established in 2015 with support of a P20 grant from the NCI.: Executive Director: I work on promoting individual research projects and technology developments that will make PBRT more effective, less costly, and more widely available in the United States.: Not Compensated</p> <p><b>University of California San Francisco:</b> Academic Institution: Visiting Professor: Development of funding applications and conduct of NIH funded research in Particle Beam Radiation Therapy Research.: Not Compensated</p> |
| Suresh Senan   | Amsterdam University Medical Centers: Professor, radiation oncology: Employee   | None  | Ongoing: No access to proprietary info Single: No access to proprietary info Single: No access to proprietary info Ongoing: No access to proprietary info Ongoing: No access to proprietary info | My Institution receives funding: No salary support in whole or part: steering committee My Institution receives funding: No salary support in whole or part: other: investigator- initiated trial My Institution receives funding: No salary support in whole or part: other: investigator- initiated trial My Institution receives funding: No salary support in whole or part: other: lung advisory board | Faculty Consultant Speaker Bureau   | <p><b>AstraZeneca:</b> Grant/Research Funding: Honoraria</p> <p><b>BMS:</b> Grant/Research Funding: Honoraria</p> <p><b>MSD:</b> Honoraria</p> <p><b>Varian Medical Systems:</b> Grant/Research Funding</p> <p><b>ViewRay Inc.:</b> Grant/Research Funding: Honoraria</p> | <p><b>AstraZeneca:</b> Pharmaceutical: Steering committee member for a phase III clinical trial; DSMB member for an ongoing phase III trial: Start Date: 2019- To Present</p> <p><b>BMS:</b> pharmaceutical: Research in immunotherapy for lung cancer: Start Date: 2019- To Present</p> <p><b>MSD:</b> pharmaceutical: Member of toxicity adjudication committee for 2 ongoing phase III trials in lung cancer.: Start Date: 2020- To Present</p> <p><b>Varian Medical Systems:</b> manufacturer of linacs: For conduct of a clinical trial using online adaptive palliative radiotherapy: Start Date: 2021- To Present</p> <p><b>ViewRay Inc.:</b> Manufacturer of MR-linacs: Grant for translational laboratory research. Speaker at ViewRay symposia and a live meeting.: Start Date: 2019- To Present</p> | None                               | None   |
| Youngho Seo  | University of California, San Francisco: Professor: Employee<br>University of California, Berkeley: Professor: Employee<br>Lawrence Berkeley National Laboratory: Physicist Faculty Scientist: Employee | None  | None   | None  | Other - Co-Founder Consultant       | <p><b>TensoroFazo, Inc.:</b> Uncompensated</p> <p><b>Ziteo, Inc.:</b> Compensation/Pay ment</p>   | <p><b>TensoroFazo, Inc.:</b> X-ray imaging instrumentation development: Co- Founder: Start Date: 2018- To Present</p> <p><b>Ziteo, Inc.:</b> Medical imaging instrumentation development: Consulting: Start Date: 2022- To Present</p>   | Fortis Therapeutics, Inc.          | <p><b>IEEE NPSS Nuclear Medical and Imaging Sciences Council:</b> Oversight Technical Committee for Annual Medical Imaging Conference under IEEE NPSS: Chair: Vice Chair (2022-2023), Chair (2024-2025), Past Chair (2026-2027): Not Compensated</p>   |
| Jinsil Seong   | Yonsei university Yonsei cancer center: professor: Employee   | None  | None   | None  | None                                | None  | None   | None                               | <p><b>Asia pacific primary liver cancer expert association:</b> Academic society on liver cancer:president: leading role in scope of academic activity and policy making: Not Compensated: Relationship Ended: 7/31/2022</p> <p><b>Korean Cancer Association:</b> An academic society regarding clinical and laboratory research on cancer: president: leading KCA in scope of academic activity and policy making: Not Compensated: Relationship Ended: 5/31/2023</p>   |







**ASTRO 2024 Annual Meeting - Annual Meeting Abstract Reviewers' Disclosures**

| Member                  | Employment Relationships   |       | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria |  |                                     |   |  | Ownerships or Investment Interests | Leadership Positions   |
|-------------------------|--|-------|---|--|-------------------------------------|---|--|------------------------------------|--|
|                         | Employment   | Other | Advisory Board  | Research   | Consultant/Speaker/Faculty or Other | Method of Remuneration  | Description of Role  |                                    |  |
| <b>Rebecca Shulman</b>  | <b>Fox Chase Cancer Center:</b> Resident physician: Employee: Relationship ended: 6/30/2023<br><b>Fox Chase Cancer Center:</b> Assistant Professor: Employee | None  | None  | None   | None                                | None  | None   | None                               | None   |
| <b>David Shultz</b>     | <b>Princess Margaret Cancer Centre:</b> Clinician Investigator: Employee   | None  | None  | None   | None                                | None  | None   | None                               | None   |
| <b>Farzan Siddiqui</b>  | <b>Henry Ford Health System:</b> Vice-Chair, Radiation Oncology: Employee  | None  | Ongoing: No access to proprietary info                          | My Institution receives funding: No salary support in whole or part: site principal investigator | Consultant Speaker Bureau           | <b>Castle Biosciences, Inc:</b> Honoraria: Travel Expenses<br><b>Varian Medical Systems Inc:</b> Grant/Research Funding: Honoraria: Travel Expenses | <b>Castle Biosciences, Inc:</b> Honorarium for consulting: Start Date: March 2022- To Present<br><b>Varian Medical Systems Inc:</b> Varian Clinical School- Head and neck instructor Varian Noona- Medical Advisory Board member: Start Date: 01/01/2019- To Present | None                               | <b>Henry Ford Cancer Institute:</b> Department of Radiation Oncology: Vice-Chair: Vice-Chair of radiation oncology operations: Not Compensated<br><b>Henry Ford Health:</b> Henry Ford Medical Group: Chair- Elect, HFMG Board of Governors: Conducting board meetings: Not Compensated                                    |
| <b>Jeffrey Siebers</b>  | <b>University of Virginia:</b> Professor: Employee   | None  | None  | None   | Faculty                             | <b>American Association of Physicists in Medicine:</b> Honoraria  | <b>American Association of Physicists in Medicine:</b> Speaker in annual physics review course: Start Date: 2017- To Present   | <b>Various:</b> Copyright          | <b>American Association of Physicists in Medicine:</b> Various: Brachytherapy Subcommittee (Member) Calibration Laboratory Accreditation Executive Committee (Member) Calibration Laboratory Accreditation Subcommittee (Chair) Therapy Physics Committee (Member) WG on Brachytherapy Dosimetry (Member): Not Compensated |
| <b>Malika Siker</b>     | <b>Medical College of Wisconsin:</b> Associate Professor: Employee   | None  | None  | None   | None                                | None  | None   | None                               | None   |
| <b>Scott Silva</b>      | <b>University of Louisville:</b> Assistant Professor: Employee   | None  | None  | None   | None                                | None  | None   | None                               | None   |
| <b>Joshua Silverman</b> | <b>NYU Langone Health:</b> Associate Professor, Department of Radiation Oncology: Employee   | None  | None  | None   | None                                | None  | None   | None                               | None   |
| <b>Aaron Simon</b>      | <b>UC Irvine Health/Chao Family Comprehensive Cancer:</b> Assistant Professor: Employee  | None  | None  | None   | Consultant                          | <b>Courage Health:</b> Compensation/Payment   | <b>Courage Health:</b> LLC developing prognostic models for cancer patients and providers: Assisted with development of prognostic models: Start Date: 07/01/2019- End Date: 07/01/2020  | None                               | None   |

| ASTRO 2024 Annual Meeting - Annual Meeting Abstract Reviewers' Disclosures |  |       |  |  |                                     |   |   |  |   |
|--|--|-------|--|--|-------------------------------------|---|---|--|---|
| Member   | Employment Relationships   |       | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria                |  |                                     |   |   | Ownerships or Investment Interests         | Leadership Positions  |
|  | Employment   | Other | Advisory Board   | Research   | Consultant/Speaker/Faculty or Other | Method of Remuneration  | Description of Role   |  |   |
| <b>Charles Simone</b>  | <b>New York Proton Center, Memorial Sloan Kettering:</b> Research Professor and Chief Medical Officer: Employee                | None  | None   | None   | Other - strategic discussions       | <b>Novocure:</b> Honoraria<br><b>Varian Medical System:</b> Honoraria   | <b>Novocure:</b> cancer device maker: strategic discussions: Start Date: 6/29/2018- End Date: 4/21/2022<br><b>Varian Medical System:</b> radiation accelerator maker: strategic discussions: Start Date: 12/29/2015- End Date: 8/03/2022  | None                                       | <b>American Radium Society:</b> Chair, Thoracic Appropriate Use Criteria Committee: Chair, Thoracic Appropriate Use Criteria Committee: Not Compensated<br><b>American Society for Radiation Oncology:</b> Chair, Lung Resource Panel; Vice Chair, Lung Track: Chair, Lung Resource Panel; Vice Chair, Lung Track: Not Compensated<br><b>Annals of Palliative Medicine:</b> Editor-in-Chief: Editor-in-Chief: Not Compensated<br><b>NRG Oncology:</b> Chair, Particle Therapy Work Group: Chair, Particle Therapy Work Group: Not Compensated<br><b>Proton Collaborative Group:</b> President of the Board; Chair, Lung Committee: President of the Board; Chair, Lung Committee: Not Compensated |
| <b>Nicole Simone</b>   | <b>Thomas Jefferson University:</b> Vice Chair: Employee   | None  | None   | My Institution receives funding: No salary support in whole or part: national/overall principal investigator   | None                                | <b>NCI:</b> Grant/Research Funding  | <b>NCI:</b> PI of 2 R01's and a U54: PI: Start Date: 8/1/17- To Present   | None                                       | <b>ASTRO:</b> Chair SEPD committee: Chair: Chair SEPD committee: Not Compensated<br><b>RRS:</b> Councilor at Large: Councilor at Large: Councilor at Large: Not Compensated   |
| <b>Benjamin Sintay</b>   | <b>Cone Health:</b> Executive Director & Chief Physicist: Employee<br><b>Fuse Oncology:</b> Chief Innovation Officer: Employee | None  | None   | None   | None                                | None  | None  | <b>Fuse Oncology:</b> Stock: Stock Options | <b>Fuse Oncology:</b> Board Member: Board Member: Not Compensated   |
| <b>Terence Sio</b>   | <b>Mayo Clinic Arizona:</b> Radiation Oncologist: Employee   | None  | Single: No access to proprietary info<br>Single: No access to proprietary info | None   | Speaker Bureau                      | <b>Galera Therapeutics:</b> Honoraria<br><b>Novocure, Inc.:</b> Honoraria: Travel Expenses  | <b>Galera Therapeutics:</b> Galera Therapeutics is a company which focuses on developing novel mechanism-based therapies for improving both treatment and outcomes for cancer patients.: To discuss their ongoing clinical trials in symptom control for head and neck cancer patients: Start Date: 1/1/2021- End Date: 6/31/2022<br><b>Novocure, Inc.:</b> Novocure, Inc. is a company that manufactures the Optune device, a treatment for patients with GBM: Scientific advisory board and commercialization of their products, Optune device for patients with GBM: Start Date: 1/1/2018- End Date: 6/31/2022 | None                                       | <b>Advances in Radiation Oncology:</b> Associate Editor, Education Editor: Associate Editor, Education Editor: Associate Editor, Education Editor: Not Compensated<br><b>Alliance Symptom Intervention Health Disparities Subcommittee:</b> Co- chair, Alliance SI Health Disparities: Co-chair, Alliance SI Health Disparities: Co-chair, Alliance SI Health Disparities: Not Compensated<br><b>American Board of Radiology (ABR):</b> GI oral board examiner: GI oral board examiner: GI oral board examiner: Not Compensated   |
| <b>Shankar Siva</b>  | <b>Peter MacCallum Cancer Centre:</b> Radiation Oncologist: Employee   | None  | Single: No access to proprietary info  | My Institution receives funding: No salary support in whole or part: site principal investigator<br>My Institution receives funding: No salary support in whole or part: national/overall principal investigator | Faculty                             | <b>AstraZeneca:</b> Other - Payment to institution<br><b>Reflexion Medical Systems:</b> Other - payment to institution<br><b>Varian Medical Systems:</b> Other - Payment to institution | <b>AstraZeneca:</b> Honoraria for Advisory Board, Education: Lung cancer advisory and educational meetings: Start Date: 2021- To Present<br><b>Reflexion Medical Systems:</b> Device manufacturer: SABR for metastases: Start Date: 2021- End Date: 2022<br><b>Varian Medical Systems:</b> Device manufacturer: for clinical research activity, educational talks: Start Date: 2021- To Present   | None                                       | <b>ART committee of IASLC:</b> Advanced Radiotherapy Techniques (ART) committee of the International Association for the Study of Lung Cancer (IASLC): committee member: advisory role: Not Compensated<br><b>Radionavigation Society (RSS):</b> Board of Directors of the Radionavigation Society (RSS): Board Director: volunteer role for advisory of the board: Not Compensated   |

| ASTRO 2024 Annual Meeting - Annual Meeting Abstract Reviewers' Disclosures |   |       |   |   |   |  |   |  |  |
|--|---|-------|---|---|---|--|---|--|--|
| Member   | Employment Relationships  |       | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria |   |   |  |   | Ownerships or Investment Interests   | Leadership Positions   |
|  | Employment  | Other | Advisory Board  | Research  | Consultant/Speaker/Faculty or Other                           | Method of Remuneration   | Description of Role   |  |  |
| Heath Skinner  | UPMC Hillman Cancer Center: Chair: Employee<br>University of Pittsburgh: Chair: Employee  | None  | None  | My Institution receives funding: No salary support in whole or part: other: Contact for the grant<br>My Institution receives funding: No salary support in whole or part: national/overall principal investigator<br>My Institution receives funding: No salary support in whole or part: national/overall principal investigator<br>My Institution receives funding: No salary support in whole or part: national/overall principal investigator<br>My Institution receives funding: No salary support in whole or part: national/overall principal investigator<br>My Institution receives funding: No salary support in whole or part: national/overall principal investigator<br>My Institution receives funding: No salary support in whole or part: national/overall principal investigator | None  | EMD Sereno: Grant/Research Funding<br>NCI: Grant/Research Funding<br>NIDCR: Grant/Research Funding | EMD Sereno: Pharmaceutical company: This grant provides salary support and research funds for 2 fellows performing research in disparities in head and neck cancer. These funds go to the institution and the fellows.: Start Date: 12/2023- To Present<br>NCI: National Cancer Institute: PI of Head and Neck SPORE: Start Date: 9/1/2022- To Present<br>NCI: National Cancer Institute: PI of R01: Start Date: 2/1/2017- End Date: 2/1/2022<br>NIDCR: National Institute of Dental and Craniofacial Research: R01 from NIDCR: Start Date: 12/23/2017- To Present<br>NIDCR: National Institute of Dental and Craniofacial Research: R01 from NIDCR: Start Date: 2/1/2019- To Present<br>NIDCR: National Institute of Dental and Craniofacial Research: This is a grant from the NIH.: Start Date: 7/1/2023- To Present | None   | Department of Defense: Department of Defense Congressionally Directed Medical Research Program (CDMRP):<br>Programmatic Review Committee Member: Group that provides final decisions for DOD funding of Peer Reviewer Cancer Research Projects and sets goals and funding mechanisms.: Not Compensated<br>NCI: National Cancer Institute: Member of Head and Neck Steering Committee:Serve on committee to evaluate cooperative group clinical trials: Not Compensated<br>UPMC Hillman Cancer Center: Chair of Department: Chair: I run the radiation oncology department: Not Compensated |
| Lindsey Sloan  | University of Minnesota: Assistant Professor: Employee  | None  | Ongoing: No access to proprietary info                          | My Institution receives funding: No salary support in whole or part: site principal investigator  | Other - PI for clinical trial<br>Consultant<br>Speaker Bureau | GT Medical Technologies: Salary Support  | GT Medical Technologies: Medical device company: GammaTile Clinical Trials: Start Date: 01/01/2024- To Present  | None   | None   |
| Ben Slotman  | AmsterdamUMC: Professor, chairman: Employee   | None  | None  | None  | None  | None   | None  | None   | ESTRO: Past- president: Past- president: Not Compensated<br>RSS: Radiosurgery Society: President: President: Not Compensated   |
| Felicia Snead  | UPMC Hillman Cancer Center: Clinical Associate Professor of Radiation Oncology: Employee  | None  | None  | None  | None  | None   | None  | None   | None   |
| Quaovi Sodji   | University of Wisconsin-Madison: Assistant Professor: Employee  | None  | None  | None  | None  | None   | None  | None   | None   |
| Jerry Soen   | Medical Radiation Concepts, Inc.: President: Employee   | None  | None  | None  | None  | None   | None  | None   | None   |
| Timothy Solberg  | University of Washington: Senior Advisor: Employee<br>American Association of Physicists in Medicine: Deputy Editor: Independent Contractor | None  | None  | None  | None  | None   | None  | Foretell Medical: Limited Liability<br>Global Radiosurgery: Partnership: Limited Liability | None   |
| William Song   | Virginia Commonwealth University: Medical Physicist: Employee   | None  | None  | I recieve funding: No salary support in whole or part: national/overall principal investigator  | Speaker Bureau  | Varian: Grant/Research Funding<br>ViewRay: Honoraria   | Varian: Varian: PI, investigate novel applicators for brachytherapy: Start Date: 6/1/2020- End Date: 9/30/2023<br>ViewRay: ViewRay: Invited to speak at their events and booths: Start Date: 7/1/2022- End Date: 10/1/2023  | None   | None   |
| Corey Speers   | University Hospitals: Vice Chair of Research: Employee  | None  | None  | None  | Consultant  | Exact Sciences: Compensation/Payment   | Exact Sciences: paid consultant for Exact Sciences: Start Date: 04/15/2020- To Present  | None   | None   |

| ASTRO 2024 Annual Meeting - Annual Meeting Abstract Reviewers' Disclosures |  |       |   |  |  |  |  |  |  |
|--|--|-------|---|--|--|--|--|--|--|
| Member   | Employment Relationships   |       | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria   |  |  |  |  | Ownerships or Investment Interests   | Leadership Positions   |
|  | Employment   | Other | Advisory Board  | Research   | Consultant/Speaker/Faculty or Other                              | Method of Remuneration   | Description of Role  |  |  |
| Daphna Spiegel   | Beth Israel Deaconess Medical Center: Assistant Professor: Employee              | None  | None  | None   | None   | None   | None   | None   | None   |
| Bradley Stish  | Mayo Clinic: Consultant Physician: Employee                                      | None  | None  | My Institution receives funding: No salary support in whole or part: site principal investigator             | Faculty  | Minnesota Society of Clinical Oncology: Honoraria<br>Honoraria: Travel Expenses<br>Varian: Grant/Research Funding  | Minnesota Society of Clinical Oncology: Professional Organization for Oncology Clinicians: Featured speaker at conference: Start Date: 09/2022- End Date: 09/2022<br>Kansas Society of Clinical Oncology: Invited speaker at Annual Meeting: Start Date: 10/2023- End Date: 10/2023<br>Varian: Manufacturer of Radiation Oncology Equipment and Technology: 3 year research grant to develop and conduct a research protocol.: Start Date: 06/2021- To Present   | None   | None   |
| Lisa Sudmeier  | Emory University Winship Cancer Institute: Assistant Professor: Employee         | None  | None  | None   | None   | None   | None   | None   | None   |
| Gita Suneja  | University of Utah: Associate Professor: Employee                                | None  | None  | My Institution receives funding: No salary support in whole or part: national/overall principal investigator | Faculty  | American Brachytherapy Society: Uncompensated<br>American College of Radiation Oncology: Travel Expenses<br>Binayara Foundation: Travel Expenses<br>NIH/NCI: Grant/Research Funding  | American Brachytherapy Society: ABS Gyn School: Course Director: Start Date: 2/2022- End Date: 2/2022<br>American College of Radiation Oncology: ACRO Annual Meeting: Panel speaker, residency cases: Start Date: 3/2023- End Date: 3/2023<br>Binayara Foundation: Health Equity Meeting: Health Equity: Start Date: 4/2023- End Date: 4/2023<br>NIH/NCI: Federal funding: Health equity, HIV malignancies: Start Date: 9/2018- End Date: 9/2023   | None   | Radiation Oncology Institute: Non-profit: Vice-Chair: Vice-Chair of the Board: Not Compensated |
| Chad Tang  | MD Anderson Cancer Center: Hospital: Employee                                    | None  | Ongoing: No access to proprietary info<br>Single: No access to proprietary info<br>Single: No access to proprietary info<br>Single: No access to proprietary info<br>Single: No access to proprietary info<br>Single: No access to proprietary info | I receive funding: No salary support in whole or part: national/overall principal investigator               | Consultant   | Boston Scientific: Honoraria: Travel Expenses<br>Diffusion Pharmaceutical: Honoraria<br>Lantheus: Honoraria: Travel Expenses<br>Merck: Grant/Research Funding<br>Molli Surgical: Honoraria<br>Siemen Helathineer: Honoraria: Travel Expenses<br>Telix: Honoraria | Boston Scientific: Participate in device development workshop: Start Date: 9/24/23- End Date: 9/25/23<br>Diffusion Pharmaceutical: Member of scientific advisory board: Start Date: 1/1/2022- To Present<br>Lantheus: Member of advisory board: Start Date: 5/12/23- End Date: 5/12/23<br>Merck: Received research drug for a study: Start Date: 10/1/22- To Present<br>Molli Surgical: Advisory board meeting: Start Date: 10/2/23- End Date: 10/2/23<br>Siemen Helathineer: Member of advisory board: Start Date: 1/11/23- End Date: 1/11/23<br>Telix: Advisory board with multiple meetings: Start Date: 7/24/23- End Date: 10/1/23   | Stanford Office of Technology Licensing: Copyright<br>Wolter Kluwer: Copyright<br>Osler: Copyright | None   |
| Kekoa Taparra  | Stanford Health Care: Resident Physician: Employee                               | None  | None  | None   | Other - Invited commentary<br>Other - Invited lecturer           | Lancet: Honoraria<br>MDACC: Honoraria<br>Stanford CARE: Honoraria  | Lancet: Honorarium for invited commentary published "Data aggregation hides Pacific Islander health disparities": Honorarium for invited commentary published "Data aggregation hides Pacific Islander health disparities": Start Date: 6/2022- End Date: 6/2022<br>MDACC: Honorarium for Faculty Diversity, Equity and Inclusion & the Division of Radiation Oncology Presents: Thought Leaders on Diversity and Inclusion Lecture Series.: Faculty Diversity, Equity and Inclusion & the Division of Radiation Oncology Presents: Thought Leaders on Diversity and Inclusion Lecture Series: Start Date: 5/2023- End Date: 5/2023<br>Stanford CARE: Honorarium for Stanford Center for Asian Health Research and Education Community Health Talk: Speaker invitation for Stanford CARE lecture series.<br>Honorarium for Stanford Center for Asian Health Research and Education Community Health Talk: Start Date: 3/2023- End Date: 3/2023 | None   | None   |
| Leila Tchelebi   | Northwell Health: Attending Physician: Employee                                  | None  | None  | None   | Other - Chart reviewer for facilities seeking ACRO accreditation | American College of Radiation Oncology: Compensation/payment   | American College of Radiation Oncology: American College of Radiation Oncology (ACRO) chart reviewer on the gastrointestinal subcommittee: I review charts relevant to GI oncology for completeness/accuracy as part of the process by which facilities seek ACRO accreditation: Start Date: 2020- To Present  | None   | None   |
| Sewit Teckie   | New York City Health and Hospitals: System Chief of Radiation Oncology: Employee | None  | None  | None   | None   | None   | None   | None   | None   |
| Rahul Tendulkar  | Cleveland Clinic: Staff: Employee  | None  | Single: No access to proprietary info   | None   | Faculty  | Elekta: Compensation/Payment<br>Varian Medical Systems: Honoraria  | Elekta: Linear accelerator manufacturer: One- time advisory board meeting: Start Date: 2022- End Date: 2022<br>Varian Medical Systems: Linear accelerator manufacturer: Honoraria for educational talks: Start Date: 2017- To Present  | None   | None   |

| ASTRO 2024 Annual Meeting - Annual Meeting Abstract Reviewers' Disclosures |   |       |   |  |  |   |   |   |   |
|--|---|-------|---|--|--|---|---|---|---|
| Member   | Employment Relationships  |       | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria |  |  |   |   | Ownerships or Investment Interests            | Leadership Positions  |
|  | Employment  | Other | Advisory Board  | Research   | Consultant/Speaker/Faculty or Other              | Method of Remuneration  | Description of Role   |   |   |
| Kundan Thind   | Henry Ford Health: Senior Physicist, Radiation Oncology: Employee   | None  | None  | None   | None   | None  | None  | None  | None  |
| Charles Thomas   | AMA: Deputy Editor: Independent Contractor  | None  | None  | None   | None   | None  | None  | None  | None  |
| Reid Thompson  | Oregon Health & Science University: Associate Professor: Employee<br>VA PORTLAND HEALTHCARE SYSTEM: Staff Physician: Employee | None  | None  | None   | None   | None  | None  | None  | None  |
| Christopher Tien   | Yale School of Medicine: Associate Professor: Employee<br>Yale-New Haven Hospital: Medical Physicist: Employee                | None  | None  | None   | None   | None  | None  | None  | American Association of Physicists in Medicine: Board of Directors: As a member of BoD, I contribute to, vote on, and discuss decisions for AAPM.: Not Compensated  |
| Martin Tom   | The University of Texas MD Anderson Cancer Center: Assistant Professor : Employee   | None  | None  | None   | Other - Editorial Content Contributor Consultant | Elsevier: Compensation/Pay ment<br>ViewRay: Compensation/Pay ment   | Elsevier: Company: Editorial Content Contributor to PracticeUpdate Brain Center: Start Date: 3/2021- End Date: 12/2022<br>ViewRay: Company: CNS Research Consortium: Start Date: 3/2021- End Date: 8/2022   | None  | None  |
| Wolfgang Tome  | Montefiore Medical Center: Professor and Chief, Division of Physics: Employee   | None  | None  | None   | None   | None  | None  | Archeus Inc: Stock Options<br>WARF: Copyright | None  |
| Mylin Torres   | Emory University: Professor: Employee   | None  | Single: No access to proprietary info                           | My Institution receives funding: No salary support in whole or part: national/overall principal investigator<br>My Institution receives funding: No salary support in whole or part: national/overall principal investigator<br>My Institution receives funding: No salary support in whole or part: national/overall principal investigator | Consultant Speaker Bureau                        | Genentech: Grant/Research Funding<br>Oncohealth: Compensation/Pay ment<br>Pfizer: Grant/Research Funding<br>Pfizer Oncology: Honoraria<br>Varian Medical Systems: Honoraria | Genentech: IIS research award: PI: Start Date: 10/2020- End Date: 8/2023<br>Oncohealth: Utilization management: Utilization management, consultant on radiotherapy toxicity management: Start Date: 11/2020- End Date: 5/2023<br>Pfizer: ASPIRE research grant award to fund a clinical trial: PI of a clinical trial: Start Date: 8/2018- To Present<br>Pfizer: Pfizer Global Breast Cancer Research Award: PI of Phase II trial: Start Date: 10/2020- End Date: 8/2023<br>Pfizer Oncology: Pharmaceutical Company: Advisory role on real world applications of palbociclib: Start Date: 11/2021- End Date: 11/2021<br>Varian Medical Systems: Speaker: Breast cancer radiation oncology education: Start Date: 1/3/2022- To Present | None  | None  |
| Alexei Trofimov  | Massachusetts General Hospital: Physicist: Employee   | None  | None  | None   | None   | None  | None  | None  | American Association of Physicists in Medicine: Professional association: Vice-chair of Workgroup on Particle Beams: Vice- chair of a workgroup charged with reviewing policy documents, facilitating educational and professional guidance initiatives related to particle radiation therapy practice: Not Compensated                     |
| Yolanda Tseng  | University of Washington: Associate Professor: Employee   | None  | None  | None   | Faculty  | ASTRO refresher course: Honoraria   | ASTRO refresher course: ASTRO refresher speaker for lymphoma: Start Date: 03/01/2020- End Date: 03/19/2021  | None  | ASTRO annual scientific committee: ASTRO annual scientific committee: Chair, Palliative care track: Chair, Palliative care track: Not Compensated<br>PCG: PCG: Chair, Lymphoma subcommittee: Chair, Lymphoma subcommittee: Not Compensated<br>PTCOG: Co-chair of lymphoma subcommittee: Co- chair of lymphoma subcommittee: Not Compensated |

**ASTRO 2024 Annual Meeting - Annual Meeting Abstract Reviewers' Disclosures**

| Member                       | Employment Relationships  |       | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria |   |                                     |  |  | Ownerships or Investment Interests | Leadership Positions   |
|------------------------------|---|-------|---|---|-------------------------------------|--|--|------------------------------------|--|
|                              | Employment  | Other | Advisory Board  | Research  | Consultant/Speaker/Faculty or Other | Method of Remuneration   | Description of Role  |                                    |  |
| <b>Katherine Tzou</b>        | <b>University of Colorado:</b> Associate Professor of Radiation Oncology: Employee<br><b>Mayo Clinic Florida:</b> Associate Professor of Radiation Oncology: Employee: Relationship ended: 6/1/2022 | None  | None  | None  | None                                | None   | None   | None                               | None   |
| <b>James Urbanic</b>         | <b>University of California San Diego:</b> Professor: Employee  | None  | None  | None  | None                                | None   | None   | None                               | None   |
| <b>Andrew Vassil</b>         | <b>Cleveland Clinic:</b> Staff physician: Employee  | None  | None  | None  | None                                | None   | None   | None                               | None   |
| <b>Raymond Mailhot Vega</b>  | <b>University of Florida:</b> Associate Professor: Employee   | None  | None  | My Institution receives funding: No salary support in whole or part: national/overall principal investigator<br>My Institution receives funding: No salary support in whole or part: national/overall principal investigator<br>My Institution receives funding: No salary support in whole or part: other: co-investigator<br>My Institution receives funding: No salary support in whole or part: national/overall principal investigator<br>My Institution receives funding: No salary support in whole or part: national/overall principal investigator<br>My Institution receives funding: No salary support in whole or part: other: Career Development Award | None                                | <b>Conquer Cancer Foundation:</b> Grant/Research Funding: Salary Support<br><b>Florida Department of Health:</b> Grant/Research Funding<br><b>Leukemia and Lymphoma Society:</b> Grant/Research Funding<br><b>NIH/NCATS:</b> Grant/Research Funding<br><b>PTCOG:</b> Grant/Research Funding<br><b>Robert A Winn Career Development Award:</b> Grant/Research Funding: Salary Support | <b>Conquer Cancer Foundation:</b> Grant giving wing of ASCO: PI: Start Date: 7/1/2020- End Date: 12/31/2021<br><b>Florida Department of Health:</b> PI: Start Date: 7/1/2021- End Date: 6/30/2024<br><b>Leukemia and Lymphoma Society:</b> co-I for award seeking to better empower PCPs to advocate for clinical trials: Start Date: 7/1/2021- To Present<br><b>NIH/NCATS:</b> Evaluating radiotherapy receipt in patients receiving NA chemotherapy for breast cancer: Start Date: 7/1/2021- End Date: 06/30/2023<br><b>PTCOG:</b> Determining which patients with Hodgkin lymphoma benefit from particle radiotherapy: Start Date: 1/1/2021- End Date: 12/31/2021<br><b>Robert A Winn Career Development Award:</b> Winn CDA in concert with VCU: Favorable<br><b>Wilms Tumor Trial:</b> Start Date: 10/16/2023- To Present | None                               | <b>ACR-ARS Appropriateness Criteria Committee:</b> Lymphoma Committee Member: Member: Not Compensated<br><b>Children's Oncology Group:</b> Steering Committee Member: Member of the Hodgkin Lymphoma Steering Committee: Not Compensated<br><b>Particle Therapy Co-Operative Group:</b> Co-operative group focusing on particle therapy: Diversity and Inclusion Chair: DEI Chair: Not Compensated |
| <b>Michael Velec</b>         | <b>University Health Network:</b> Radiation Therapist: Employee   | None  | Ongoing: No access to proprietary info                          | None  | None                                | <b>CRUK RadNet Manchester Scientific Advisory Board:</b> Honoraria: Travel Expenses  | <b>CRUK RadNet Manchester Scientific Advisory Board:</b> Research program: Member of scientific advisory board: Start Date: 9/22/2021- To Present  | None                               | None   |
| <b>Gregory Videtic</b>       | <b>Cleveland Clinic:</b> Staff Physician: Employee  | None  | None  | None  | None                                | None   | None   | None                               | None   |
| <b>Yevgeniy Vinogradskiy</b> | <b>Thomas Jefferson University:</b> Professor and Director of Medical Physics: Employee   | None  | None  | I receive funding: No salary support in whole or part: national/overall principal investigator<br>I receive funding: No salary support in whole or part: national/overall principal investigator  | None                                | <b>MIM Software:</b> Other - Software Only<br><b>NIH:</b> Grant/Research Funding   | <b>MIM Software:</b> Company: Lung function imaging for lung cancer patients: Start Date: 01/01/2020- End Date: 12/31/2025<br><b>NIH:</b> National Institute of Health: PI of grant looking at lung function imaging for lung cancer patients: Start Date: 01/01/2020- End Date: 12/31/2025  | None                               | <b>AAPM:</b> Medical Physics Professional Group: Chair of Multi-lesion srs task group: Chair of Multi-lesion srs task group: Not Compensated   |
| <b>Lucas Vizthum</b>         | <b>Stanford University:</b> Radiation Oncologist: Employee  | None  | None  | My Institution receives funding: No salary support in whole or part: site principal investigator  | None                                | <b>Reflexion Medical:</b> Grant/Research Funding   | <b>Reflexion Medical:</b> Biology- Guided Radiotherapy Treatment Technology Company: Principal investigator: Start Date: 8/8/2020- To Present  | None                               | None   |





| ASTRO 2024 Annual Meeting - Annual Meeting Abstract Reviewers' Disclosures |   |       |   |  |                                     |  |  |   |  |
|--|---|-------|---|--|-------------------------------------|--|--|---|--|
| Member   | Employment Relationships  |       | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria |  |                                     |  |  | Ownerships or Investment Interests          | Leadership Positions   |
|  | Employment  | Other | Advisory Board  | Research   | Consultant/Speaker/Faculty or Other | Method of Remuneration   | Description of Role  |   |  |
| <b>Christopher Wilke</b>   | <b>University of Minnesota:</b> Assistant Professor: Employee: Relationship ended: 2/17/2023<br><b>UPMC:</b> Clinical Assistant Professor: Employee                   | None  | Ongoing: No access to proprietary info                          | None   | Consultant                          | <b>ASTRO:</b> Uncompensated<br><b>Kalliso:</b> Compensation/Pay ment   | <b>ASTRO:</b> ASTRO NRC Subcommittee: Member of ASTRO NRC subcommittee: Start Date: 2020- To Present<br><b>Kalliso:</b> Medical device start-up manufacturing custom 3D printed oral stents for use in head and neck radiotherapy.: Consultant to provide clinical expertise for product R&D.: Start Date: 2/1/2024- To Present  | <b>MD Anderson Cancer Center:</b> Copyright | <b>ASTRO:</b> IJROBP Editorial board - H&N section: Associate Section Editor: Manage peer review process for manuscripts submitted to the journal: Not Compensated |
| <b>Henning Willers</b>   | <b>Massachusetts General Hospital:</b> Associate Radiation Oncologist: Employee   | None  | None  | My Institution receives funding: No salary support in whole or part: national/overall principal investigator<br>I receive funding: No salary support in whole or part: national/overall principal investigator<br>I receive funding: No salary support in whole or part: national/overall principal investigator                             | None                                | <b>Department of Defense:</b> Grant/Research Funding<br><b>NIH/NCI:</b> Grant/Research Funding   | <b>Department of Defense:</b> PI, Chromatin effect of proton response: Start Date: 2022- To Present<br><b>NIH/NCI:</b> PI, Molecular Targeted Radiosensitizers; P01 Project Co- Lead, Variable Proton RBE: Start Date: 2018- To Present  | None  | None   |
| <b>Terence Williams</b>  | <b>City of Hope National Medical Center:</b> Professor and Chair: Employee  | None  | None  | My Institution receives funding: No salary support in whole or part: national/overall principal investigator<br>My Institution receives funding: No salary support in whole or part: national/overall principal investigator<br>My Institution receives funding: No salary support in whole or part: national/overall principal investigator | Consultant<br>Speaker Bureau        | <b>American Cancer Society:</b> Grant/Research Funding<br><b>January Therapeutics:</b> Grant/Research Funding<br><b>National Institutes of Health:</b> Honoraria<br><b>National Institutes of Health:</b> Grant/Research Funding<br><b>Reflexion Medical Systems:</b> Honoraria: Travel Expenses: Compensation/Payment | <b>American Cancer Society:</b> research funding: research funding: Start Date: 2021- To Present<br><b>January Therapeutics:</b> Pharmaceutical company: preclinical research: Start Date: 2021- To Present<br><b>National Institutes of Health:</b> Radiation Therapeutics and Biology Study Section: Honoraria for reviewing NIH grants.: Start Date: 2017- To Present<br><b>National Institutes of Health:</b> research funding: research funding: Start Date: 2021- To Present<br><b>Reflexion Medical Systems:</b> Medical device company: Served as speaker at events.: Start Date: 2021- To Present | None  | None   |
| <b>Vonetta Williams</b>  | <b>Memorial Sloan Kettering Cancer Center:</b> Assistant Attending: Employee  | None  | None  | None   | None                                | None   | None   | None  | None   |
| <b>Casey Williamson</b>  | <b>Oregon Health &amp; Science University:</b> Assistant Professor: Employee  | None  | None  | None   | None                                | None   | None   | None  | None   |
| <b>Lydia Wilson</b>  | <b>St. Jude Children's Research Hospital:</b> Instructor: Employee: Relationship ended: 6/1/2023<br><b>Thomas Jefferson University:</b> Assistant Professor: Employee | None  | None  | None   | None                                | None   | None   | None  | None   |
| <b>Brian Winey</b>   | <b>Massachusetts General Hospital:</b> Associate Professor of Medical Physics: Employee   | None  | None  | My Institution receives funding: No salary support in whole or part: other: Investigator   | None                                | <b>NIH:</b> Salary Support   | <b>NIH:</b> NIH NCI Grant: R01 CA229178: Researching adaptive proton therapy. I help lead the aim looking at CBCT correction methods.: Start Date: 2019- To Present  | <b>Patent:</b> US8855738: Copyright         | <b>ASTRO:</b> Vice-Chair of SEPD Subcommittee: Help to organize the subcommittee business and assist with annual meeting program development.: Not Compensated     |

| ASTRO 2024 Annual Meeting - Annual Meeting Abstract Reviewers' Disclosures |   |       |   |  |   |  |   |                                    |  |
|--|---|-------|---|--|---|--|---|------------------------------------|--|
| Member   | Employment Relationships  |       | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria |  |   |  |   | Ownerships or Investment Interests | Leadership Positions   |
|  | Employment  | Other | Advisory Board  | Research   | Consultant/Speaker/Faculty or Other   | Method of Remuneration   | Description of Role   |                                    |  |
| Jennifer Wo  | Massachusetts General Hospital: Associate Professor: Employee                                     | None  | None  | My Institution receives funding: No salary support in whole or part: national/overall principal investigator   | None  | Genentech: Grant/Research Funding  | Genentech: Research Funding: Phase IB SBRT and Atezo/Bev for Unresectable HCC: Start Date: 7/2020- To Present   | None                               | None   |
| Andrzej Wojcieszynski  | Colorado Permanente Medical Group: Radiation Oncologist: Employee                                 | None  | None  | None   | None  | None   | None  | None                               | None   |
| Julia Wong   | Brigham and Women's Physician Organization: Radiation Oncologist: Employee                        | None  | None  | None   | Other - Co-Author   | Wolters Kluwer: Honoraria  | Wolters Kluwer: UpToDate: Co-Author for DCIS subsection: Start Date: 2011- To Present   | None                               | None   |
| William Woods  | University of Mississippi Medical Center: Nurse Practitioner/Faculty Administrator: Employee      | None  | None  | None   | None  | None   | None  | None                               | None   |
| Jean Wright  | Johns Hopkins University: Associate Professor, Radiation Oncology: Employee                       | None  | None  | My Institution receives funding: No salary support in whole or part: site principal investigator<br>My Institution receives funding: No salary support in whole or part: site principal investigator | Other - royalties<br>Other - APEX surveyor<br>Other - Editor<br>Consultant<br>Faculty<br>Consultant | ASTRO: Honoraria<br>Elsevier Journals: Honoraria<br>Marshall Dennehy: Compensation/Payment<br>Oncospace: Grant/Research Funding: Salary Support<br>Physicians Education Resource: Honoraria: Travel Expenses<br>Prostate Cancer Foundation: Grant/Research Funding: Salary Support<br>Wicker Smith: Compensation/Payment | ASTRO: National Radiation Oncology Organization: survey radiation oncology departments for accreditation: Start Date: 2016- To Present<br>Elsevier Journals: Breast Section Editor, International Journal of Radiation Oncology Biology and Physics: Editor of breast section of journal: Start Date: 1/1/2023- To Present<br>Marshall Dennehy: Expert Witness: Expert witness in breast cancer case: Start Date: 2020- End Date: 9/22/22<br>Oncospace: Oncospace is a small data analysis company focusing on radiation oncology treatment, outcomes and toxicity: research on utility of platform to identify radiation treatment planning errors: Start Date: 2020- To Present<br>Physicians Education Resource: CME provider: speaker on hypofractionated radiotherapy for breast cancer: Start Date: 3/3/2023- End Date: 3/3/2023<br>Prostate Cancer Foundation: Prostate Cancer Foundation-Pfizer Health Equity Challenge: Data analysis to identify underserved areas of country with respect to radiation oncology services.: Start Date: 2021- To Present<br>Wicker Smith: Law firm: Expert witness in defense of clinical radiation oncologist: Start Date: 11/1/23- End Date: 11/20/23 | None                               | American Board of Radiology: Testing for board certification for radiation oncology: Oral Board Examiner: Conduct oral examinations of trainees 1-2 x per year: Not Compensated<br>ASTRO: Chair, Clinical Affairs and Quality Committee: chair of committee that oversees guidelines, MDQA and APEX committees.: Not Compensated |
| Abraham Wu   | Memorial Sloan Kettering Cancer Center: Associate Attending: Employee                             | None  | Ongoing: No access to proprietary info                          | My Institution receives funding: No salary support in whole or part: national/overall principal investigator   | Consultant  | CivaTech Oncology, Inc.: Grant/Research Funding<br>Nanovi A/S: Honoraria<br>Simphotek, Inc.: Compensation/payment  | CivaTech Oncology, Inc.: Medical device company: Research grant for study involving company product (CivaSheet) paid to institution: Start Date: 2016- To Present<br>Nanovi A/S: Medical devices company: One-time consulting fee: Start Date: June 2021- To Present<br>Simphotek, Inc.: Medical device/software company: Scientific advisory board, compensated with restricted stock: Start Date: August 2020- To Present   | Simphotek, Inc.: Stock Options     | None   |
| Ying Xiao  | University of Pennsylvania: Prof.: Employee   | None  | None  | None   | None  | None   | None  | None                               | None   |
| David Yang   | Brigham and Women's Hospital: Attending Physician: Employee                                       | None  | None  | None   | None  | None   | None  | None                               | None   |
| Gary Yang  | Loma Linda University Health: Professor and Del E Webb Endowed Chair in Proton Research: Employee | None  | None  | None   | None  | None   | None  | None                               | Journal Of Gastrointestinal Oncology: PubMed & SCI-indexed Journal: Editor-in-Chief: Editor-in-Chief: Not Compensated  |
| Joanna Yang  | Washington University in St. Louis: Asst Attending: Employee                                      | None  | None  | None   | Faculty<br>Other - Reviewer,<br>Health Equity Research Program<br>Faculty                           | ASTCT: Uncompensated<br>Leukemia and Lymphoma Society: Honoraria<br>NCCN: Honoraria<br>Society for Immunotherapy of Cancer: Uncompensated<br>Washington University Continuing Medical Education: Honoraria   | ASTCT: Non- profit: speaker in webinar: Start Date: 10/25/22- End Date: 10/25/22<br>Leukemia and Lymphoma Society: Non-profit: Grant reviewer for Health Equity Research Program: Start Date: 2/27/23- End Date: 2/27/23<br>NCCN: Non- profit: Speaker in educational webinar: Start Date: 12/14/22- End Date: 12/14/22<br>Society for Immunotherapy of Cancer: Non-profit: speaker in SITC webinar: Start Date: 12/18/21- End Date: 12/18/21<br>Washington University Continuing Medical Education: Non- profit: speaker in CME course: Start Date: 1/28/23- End Date: 1/28/23   | None                               | ASCO: American Society of Clinical Oncology: Government Relations Committee member: member of GRC: Not Compensated   |

| ASTRO 2024 Annual Meeting - Annual Meeting Abstract Reviewers' Disclosures |   |       |   |  |   |   |  |                                     |   |
|--|---|-------|---|--|---|---|--|-------------------------------------|---|
| Member   | Employment Relationships  |       | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria                 |  |   |   |  | Ownerships or Investment Interests  | Leadership Positions  |
|  | Employment  | Other | Advisory Board  | Research   | Consultant/Speaker/Faculty or Other       | Method of Remuneration  | Description of Role  |                                     |   |
| Jonathan Yang  | University of Washington: Associate Professor: Employee   | None  | Single: No access to proprietary info<br>Ongoing: No access to proprietary info | My Institution receives funding: No salary support in whole or part: national/overall principal investigator<br>My Institution receives funding: No salary support in whole or part: site principal investigator<br>My Institution receives funding: No salary support in whole or part: site principal investigator     | Consultant                                | AstraZeneca: Grant/Research Funding<br>Cantex Therapeutics: Grant/Research Funding<br>Debiopharm: Grant/Research Funding<br>Kazia Therapeutics: Grant/Research Funding: Compensation/Pay ment<br>Nanocan Therapeutics: Compensation/Pay ment<br>Plus Therapeutics: Compensation/Pay ment  | AstraZeneca: research funding: Start Date: 2018- To Present<br>Cantex Therapeutics: GBM clinical trial: Start Date: 1/2024- To Present<br>Debiopharm: research funding for prospective trial: Start Date: 5/2023- To Present<br>Kazia Therapeutics: research funding and advisory board for drug development: Start Date: 2019- To Present<br>Nanocan Therapeutics: advisory board member: Start Date: 2021- To Present<br>Plus Therapeutics: DSMC member: Start Date: 2022- To Present  | Nanocan Therapeutics: Stock Options | None  |
| Wensha Yang  | University of California, San Francisco: Associate Professor: Employee                                | None  | None  | None   | None                                      | None  | None   | None                                | None  |
| Min Yao  | Penn State Cancer Institute: Professor: Employee  | None  | None  | None   | None                                      | None  | None   | None                                | None  |
| Catheryn Yashar  | University of California San Diego: Professor, Radiation Oncology and Chief Medical Officer: Employee | None  | None  | None   | None                                      | None  | None   | None                                | ABR: American Board of Radiology: Trustee for Breast and GYN: Oversee examinations of written and oral for breast and gynecology: Not Compensated<br>kukuna o ka la: small educational organization: chairman of the board: give yearly meeting in hawaii: Not Compensated<br>NCCN: National Comprehensive Cancer Network: Vice Chair Cervical and Uterine panel: help run meetings: Not Compensated<br>UCSD: University: Chief Medical Officer: quality and safety oversight: Not Compensated  |
| Jason Ye   | Keck School of Medicine of USC: Associate Professor of Clinical Radiation Oncology: Employee          | None  | None  | None   | Consultant                                | Cardinal health: Honoraria  | Cardinal health: Attended oncology summit to give input: Start Date: 10/6/23- End Date: 10/8/23  | None                                | Los Angeles Radiological Society: Academic Organization: Continuing Education Committee Chair: Manage and organize CME events: Not Compensated  |
| Debra Yeboa  | Univ of Texas MD Anderson Cancer Center: Associate Professor: Employee                                | None  | None  | My Institution receives funding: No salary support in whole or part: national/overall principal investigator<br>My Institution receives funding: No salary support in whole or part: other: collaborator<br>My Institution receives funding: No salary support in whole or part: national/overall principal investigator | Other - Academic journal associate editor | Brockman Foundation/ Medical research Grant: Grant/Research Funding<br>MD Anderson Institutional Research Grant Funding: Grant/Research Funding<br>Novartis: Other - 1 percent effort paid to the MD Anderson institution, not personally, as a potential Radonc collaborator for a clinical trial. The neurologist is the site PI, and we are not the lead site.<br>Practical Radiation Oncology Journal: Uncompensated<br>Robert Wood Johnson: Grant/Research Funding | Brockman Foundation/ Medical research Grant: Medical research foundation grant: Medical research foundation grant: Start Date: 2020- To Present<br>MD Anderson Institutional Research Grant Funding: Institutional Research Grant, Shirley Stein Award, and/or Division of RadOnc Grants: Start Date: 09/01/2017- To Present<br>Novartis: 1 percent effort paid to the MD Anderson institution, not personally, as a potential Radonc collaborator for a clinical trial. The neurologist is the site PI, and we are not the lead site.: Start Date: 09/1/2023- To Present<br>Practical Radiation Oncology Journal: Academic journal associate editor: academic journal associate editor: Start Date: 2022- To Present<br>Robert Wood Johnson: Medical research foundation: Medical research foundation grant: Start Date: 2023- To Present | None                                | ACR Radiation Oncology In-Training Exam: Text writing committee: In service test writing: Not Compensated: Relationship Ended: 12/1/2022<br>American Radium Society: Annual Meeting Planning Committee member: Annual Meeting Planning Committee member for review of abstracts: Not Compensated: Relationship Ended: 9/1/2023<br>ASCO/SNO Brain Mets Conference: Annual Meeting Planning Committee member: Annual Meeting Planning Committee member/ abstract reviewer: Not Compensated: Relationship Ended: 9/1/2024<br>Radiosurgery Society (RSS): Annual Planning Committee member & MD Anderson liason: Annual Planning Committee: Not Compensated<br>Society of Neuro-Oncology: Radiation Sciences Co-chair: Co-chair for radiation sciences education track and part of planning committee: Not Compensated: Relationship Ended: 12/1/2023 |

| ASTRO 2024 Annual Meeting - Annual Meeting Abstract Reviewers' Disclosures |  |       |   |   |  |   |  |                                    |  |
|--|--|-------|---|---|--|---|--|------------------------------------|--|
| Member   | Employment Relationships   |       | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria |   |  |   |  | Ownerships or Investment Interests | Leadership Positions   |
|  | Employment   | Other | Advisory Board  | Research  | Consultant/Speaker/Faculty or Other                                | Method of Remuneration  | Description of Role  |                                    |  |
| Raphael Yechieli   | University of Miami: Associate Professor: Employee   | None  | None  | None  | None   | None  | None   | None                               | None   |
| Divya Yerramilli   | Memorial Sloan Kettering Cancer Center: Assistant Attending: Employee  | None  | None  | None  | None   | None  | None   | None                               | None   |
| Stephanie Yoon   | City of Hope Medical Center: Assistant Professor : Employee  | None  | None  | None  | None   | None  | None   | None                               | None   |
| Ellen Yorke  | Memorial Sloan Kettering Cancer Center: Attending Physicist and Member, Emeritus: Employee                     | None  | None  | None  | None   | None  | None   | None                               | AAPM: Member of Awards and Honors Committee and of Biological Effects Subcommittee of AAPM: Committee member: Participate in discussions and votes on AAPM members to receive awards: Not Compensated  |
| Emi Yoshida  | UCSF: Assistant Professor: Employee  | None  | None  | None  | Faculty  | Varian: Honoraria   | Varian: Educational speaker on palliative SBRT: Start Date: 3/1/21- End Date: 3/26/21  | None                               | None   |
| Kristina Young   | The Oregon Clinic: Radiation Oncologist: Partner   | None  | Ongoing: No access to proprietary info                          | I receive funding: No salary support in whole or part: other: SRA PI<br>My Institution receives funding: No salary support in whole or part: other: SRA PI<br>My Institution receives funding: No salary support in whole or part: other: IIT through Exist<br>My Institution receives funding: No salary support in whole or part: other: IIT PI | Consultant   | BMS: Grant/Research Funding<br>Corbus Therapeutics: Grant/Research Funding: Salary Support: Compensation/Pay ment<br>Eli Lilly: Grant/Research Funding<br>IMV Inc: Grant/Research Funding<br>Synthis Bio: Other - Shareholder           | BMS: Pharma: PI: Start Date: 2020- To Present<br>Corbus Therapeutics: Pharmaceutical company: 1) Clinical trial design consultant. 2) SRA for pre- clinical work with some salary support testing combination radiation and CRB-622: Start Date: 9/2023- To Present<br>Eli Lilly: Pharmaceutical Company: Partial funding for investigator-initiated clinical trial: Start Date: 2015- End Date: 2021<br>IMV Inc: Pharma: IIT PI: Start Date: 2021- To Present<br>Synthis Bio: Pharmaceutical Company: Scientific Advisor: Start Date: 10/2022 - To Present                                    | Kristina Young: Copyright          | The Oregon Clinic: Medical Practice: Medical Director and Managing Partner: Medical Director and Managing Partner: Not Compensated   |
| Melissa Young  | Yale University: Associate Professor, Medical Director of Yale New Haven Radiation Oncology Services: Employee | None  | Ongoing: No access to proprietary info                          | None  | None   | Xequel Bio: Compensation/Pay ment   | Xequel Bio: A clinical stage biopharmaceutical company exploring a CT1 peptide technology platform to develop drugs that will revolutionize the way the body responds to injury.: Advisory board member: Start Date: 11/29/2022- To Present  | None                               | None   |
| David Yu   | Emory University School of Medicine: Associate Professor: Employee   | None  | None  | None  | Other - Reviewer Speaker Bureau<br>Other - Reviewer Speaker Bureau | DOD: Honoraria: Travel Expenses<br>GW School of Medicine: Honoraria: Travel Expenses<br>MCW: Travel Expenses<br>NIH: Honoraria: Travel Expenses<br>University of Kentucky: Honoraria: Travel Expenses<br>University of Miami: Honoraria | DOD: Department of Defense: Reviewer: Start Date: 2014- To Present<br>GW School of Medicine: Medical School: Speaker: Start Date: 2021- End Date: 2021<br>MCW: Medical School: Speaker: Start Date: 2022- End Date: 2022<br>NIH: Reviewer: Reviewer: Start Date: 2015- To Present<br>University of Kentucky: University of Kentucky: Speaker: Start Date: 2022 - End Date: 2022<br>University of Miami: University of Miami: Speaker: Start Date: 2021- End Date: 2021   | None                               | Cancer Research: Journal: Editorial Board: Editorial Board: Not Compensated<br>International Journal of Radiation Biology: Journal: Associate Editor: Not Compensated<br>Journal of Molecular Cell Biology: Journal: Editorial Board: Editorial Board: Not Compensated |
| Hsiang-Hsuan Yu  | Moffitt Cancer Center: Senior Member: Employee   | None  | Single: No access to proprietary info                           | My Institution receives funding: No salary support in whole or part: other: Site Co- investigator   | Speaker Bureau<br>Other - Author of a chapter/section              | BMS: Salary Support<br>BrainLab: Honoraria: Travel Expenses<br>Novocure: Honoraria: Travel Expenses<br>UpToDate: Honoraria  | BMS: A pharmaceutical company: Site co- investigator to accrue patients and collect clinical data: Start Date: 06/01/2018- End Date: 08/30/2021<br>BrainLab: A medical devise company: Invited to speak at a regional conference: Start Date: 09/01/2018- End Date: 09/30/2018<br>Novocure: A medical device company: Attended an advisory meeting to provide medical expertise: Start Date: 10/01/2019- End Date: 10/31/2020<br>UpToDate: Online medical learning resources: Author a section on bone metastasis and provide annual update on the chapter: Start Date: 01/01/2017- To Present | None                               | None   |

| ASTRO 2024 Annual Meeting - Annual Meeting Abstract Reviewers' Disclosures |  |       |   |  |                                     |  |  |                                    |  |
|--|--|-------|---|--|-------------------------------------|--|--|------------------------------------|--|
| Member   | Employment Relationships   |       | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria                 |  |                                     |  |  | Ownerships or Investment Interests | Leadership Positions   |
|  | Employment   | Other | Advisory Board  | Research   | Consultant/Speaker/Faculty or Other | Method of Remuneration   | Description of Role  |                                    |  |
| James Yu   | Connecticut Radiation Oncology: Radiation Oncologist: Employee                     | None  | Ongoing: No access to proprietary info<br>Single: No access to proprietary info | I receive funding: No salary support in whole or part: national/overall principal investigator   | Speaker Bureau                      | Boston Scientific: Honoraria: Compensation/Pay ment<br>Pfizer / Myovant: Grant/Research Funding: Honoraria<br>Reflexion Medical: Honoraria   | Boston Scientific: Medical Device Company: Ongoing advisory board. Past speaking on behalf of the company.: Start Date: 2018- To Present<br>Pfizer / Myovant: Pharmaceutical Company: Served on an advisory board and was compensated. Spoke in an educational panel and compensated by Pfizer/Myovant. PI of a funded trial as part of the Pfizer/Myovant funded 2022 ASTRO/Pfizer/Myo vant challenge grant.: Start Date: 2020- To Present<br>Reflexion Medical: Medical device / LINAC company: Spoke at 2021 ASTRO meeting at a Reflexion sponsored event.: Start Date: October 2021- To Present  | Modifi Bio: Stock                  | None   |
| Jennifer Yu  | Cleveland Clinic: Staff: Employee  | None  | None  | My Institution receives funding: No salary support in whole or part: national/overall principal investigator<br>My Institution receives funding: No salary support in whole or part: national/overall principal investigator<br>My Institution receives funding: No salary support in whole or part: national/overall principal investigator | None                                | Case Comprehensive Cancer Center: Grant/Research Funding<br>Cleveland Clinic: Grant/Research Funding<br>NIH: Grant/Research Funding  | Case Comprehensive Cancer Center: cancer center: PI: Start Date: 2020- To Present<br>Cleveland Clinic: hospital: PI: Start Date: 2011- To Present<br>NIH: government agency: PI: Start Date: 2013- To Present  | None                               | Frontiers in Oncology: journal: Associate Editor: Not Compensated<br>International Journal of Hyperthermia: journal: Associate Editor: Associate Editor: Not Compensated<br>Molecular Carcinogenesis: journal: Associate Editor: Not Compensated |
| Nathan Yu  | Mayo Clinic: Radiation Oncologist: Employee  | None  | None  | None   | None                                | None   | None   | None                               | None   |
| Ning Yue   | Rutgers University: Professor, Executive Vice Chair and Chief of Physics: Employee | None  | None  | None   | None                                | None   | None   | None                               | SANTRO: Radiation oncology network between US and China:Board member:Board Member:Not Compensated  |
| Nicholas Zaorsky   | University Hospitals: Radiation Oncologist: Employee                               | None  | None  | My Institution receives funding: No salary support in whole or part: national/overall principal investigator<br>I receive funding: No salary support in whole or part: national/overall principal investigator   | Consultant                          | American Cancer Society: Grant/Research Funding<br>American College of Radiation Oncology: Compensation/Pay ment<br>NIH: Grant/Research Funding<br>Springer Nature: Other - NGZ received remuneration from Springer Nature for his textbook, Absolute Clinical Radiation Oncology Review | American Cancer Society: Grant: Tri State CEOs Against Cancer Clinician Scientist Development Grant, CSDG-20- 013-01-CCE: Start Date: 03/2020- To Present<br>American College of Radiation Oncology: chart review and accreditation of radiation oncology facilities nationally: chart review and accreditation of radiation oncology facilities nationally: Start Date: 2019- To Present<br>NIH: Grant: LRP 1 L30 CA231572-01: Start Date: 2018- End Date: 2022<br>Springer Nature: remuneration from Springer Nature for textbook, Absolute Clinical Radiation Oncology Review: NGZ received remuneration from Springer Nature for his textbook, Absolute Clinical Radiation Oncology Review: Start Date: 2019- End Date: 2021 | None                               | None   |
| Jing Zeng  | University of Washington: Professor: Employee                                      | None  | Single: No access to proprietary info<br>Ongoing: No access to proprietary info | My Institution receives funding: No salary support in whole or part: national/overall principal investigator<br>My Institution receives funding: No salary support in whole or part: national/overall principal investigator<br>My Institution receives funding: No salary support in whole or part: national/overall principal investigator | Consultant<br>Consultant/Faculty    | AstraZeneca: Grant/Research Funding: Honoraria: Compensation/Pay ment<br>Gilead: Grant/Research Funding<br>IBA: Grant/Research Funding: Honoraria: Compensation/Pay ment   | AstraZeneca: Pharmaceutical company: Radiation and immunotherapy for lung cancer: Start Date: 01/01/2018- To Present<br>Gilead: Pharmaceutical company: Testing radiation with immunotherapy in mouse model: Start Date: 01/01/2021- To Present<br>IBA: Makes proton therapy units: Proton radiation for cancer treatment: Start Date: 01/01/2017- To Present  | None                               | None   |
| Chi Zhang  | University of Nebraska Medical Center: Associate Professor: Employee               | None  | None  | I receive funding: No salary support in whole or part: national/overall principal investigator   | None                                | AstraZeneca: Grant/Research Funding: Salary Support  | AstraZeneca: Principal investigator on a IIT: Start Date: July 2022- To Present  | ZCure LLC: Limited Liability       | GT Medical Technologies, Inc.: Practitioner Society member: Meeting participant: Not Compensated: Relationship Ended: 4/29/2023  |

**ASTRO 2024 Annual Meeting - Annual Meeting Abstract Reviewers' Disclosures**

| Member                 | Employment Relationships                               |       | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria |          |                                     |                                  |   | Ownerships or Investment Interests | Leadership Positions |
|------------------------|--|-------|---|----------|-------------------------------------|----------------------------------|---|------------------------------------|----------------------|
|                        | Employment   | Other | Advisory Board  | Research | Consultant/Speaker/Faculty or Other | Method of Remuneration           | Description of Role   |                                    |                      |
| <b>Hong Zhang</b>      | URMC: Professor, Chief of Highland Radiation: Employee | None  | None  | None     | None                                | None                             | None  | None                               | None                 |
| <b>Jim Zhong</b>       | Emory University: Associate PProfessor: Employee       | None  | None  | None     | None                                | None                             | None  | None                               | None                 |
| <b>X. Ronald Zhu</b>   | MD Anderson Cancer Center: Professor: Employee         | None  | Ongoing: No access to proprietary info                          | None     | None                                | Mevion Medical System: Honoraria | Mevion Medical System: Technical and Clinical Advisory Committee: Member of advisory board: Start Date: 3/1/2018- To Present        | None                               | None                 |
| <b>Zachary Zumsteg</b> | Cedars-Sinai Medical Center: Employee                  | None  | None  | None     | Consultant                          | EMD Serono: Honoraria            | EMD Serono: Pharmaceutical company: Advisory board meeting regarding Merkel cell carcinoma: Start Date: 12/2016 - End Date: 12/2016 | None                               | None                 |

## ASTRO 2024 Annual Meeting - Faculty and Presenters' Disclosure of Relationships

The American Society for Radiation Oncology (ASTRO) is an Accreditation Council for Continuing Medical Education (ACCME) accredited CME provider and complies with the [ACCME Standards for Integrity and Independence in Accredited Continuing Education](#). In accordance with these Standards, the ASTRO Conflict of Interest Policy and the Council for Medical Specialty Societies' Code for Interactions with Companies, ASTRO is disclosing here the relationships between faculty and presenters and other entities related to oncology or radiation therapy.

### Explanatory notes:

- ASTRO uses the information disclosed to identify and manage any potential conflicts of interest that may arise in carrying out the responsibilities of the Committees.
- Committee members disclose their own relationships and those of their immediate family members.
- There is no “minimum value” threshold for disclosure.
- Disclosure time period covers relationships held or payments received during the year leading up to the disclosure.
- The disclosure information at this link is relevant only to the planning of the 2024 Annual Meeting and should be considered out-of-date after this time.
- Information at this link may be different from disclosure information provided in other contexts by the Committee members because of variation in the disclosure requests for these other purposes.

**Employment/Leadership Positions** = positions held at the time of disclosure. These include both full- and part-time relationships, whether compensated or uncompensated.

**Compensation/Remuneration/Funding** = includes consultant/advisory roles, honoraria, research funding, travel expenses, in-kind donation, etc. If a Committee member receives an honorarium and donates it to charity, the honorarium is disclosed. If a Committee member declines an honorarium and it is paid directly to charity, the honorarium is not included. Honoraria from accredited CME providers are not included.

**Ownership or Investment Interests** = includes stock, stock options, partnership, royalties, or patents. *Stocks in mutual funds, blind trusts, or other holdings that are not controlled by the individual or an immediate family member are not included.*

**Leadership Positions**= positions held in other organizations or entities.

The ASTRO Conflict of Interest Policies are available at [www.astro.org/coipolicies](http://www.astro.org/coipolicies). Please direct any questions to [annualmeeting@astro.org](mailto:annualmeeting@astro.org).



**ASTRO 2024 Annual Meeting - Faculty and Presenters' Disclosures**

| First Name | Last Name      | Employment Relationships  | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria   | Ownerships/Investments/Intellectual Property   | Leadership/Positions of Authority  |
|------------|----------------|---|---|--|--|
| Scout      | .              | National LGBT Cancer Network: Director: Employee  | None  | None   | None   |
| Roxolyana  | Abdah-Bortnyak | Rambam Health Care Campus   | None  | None   | None   |
| May        | Abdel-Wahab    | IAEA: Director, Division of Human Health: Employee  | None  | None   | None   |
| Reine      | Abou Zeidane   | Department of Radiation Oncology, University Hospitals Seidman Cancer Center and Case Western Reserve University  | None  | None   | None   |
| Elham      | Abouei         | Emory University  | None  | None   | None   |
| Brad       | Ackerson       | Duke University Medical Center, Department of Radiation Oncology  | None  | None   | None   |
| Charu      | Aggarwal       | Department of Hematology and Oncology, University of Pennsylvania   | Lilly, Merck, Daiichi Sankyo/Astra Zeneca, Regeneron/Sanofi, Pfizer, Janssen, Boehringer Ingelheim: Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Honoraria: Consultant: Ongoing<br><b>AstraZeneca, Genentech, Incyte, Loxo@Lilly, Macrogenics, Medimmune, and Merck Sharp &amp; Dohme:</b> Research: Recipient: My Institution: Salary Support: Yes: national/overall principal investigator: clinical trial: Salary support: PI, Sub I: Ongoing  | None   | None   |
| Ajay       | Aggarwal       | Guy's & St. Thomas NHS Trust: Consultant Clinical Oncologist: Employee<br><b>London School of Hygiene and Tropical Medicine:</b> Associate Professor: Employee  | <b>National Cancer Institute:</b> Research: Recipient: My Institution: Salary Support: Yes: national/overall principal investigator: International multicentre prospective study appraising Artificial Intelligence for radiotherapy treatment: Grant/research funding: International multicentre prospective study appraising Artificial Intelligence for radiotherapy treatment: Aug 2026<br><b>National Institute for Health Research:</b> Research: Recipient: Me: Salary Support: Yes: national/overall principal investigator: Health Services Research focused on outcomes and equity of cancer care delivery: Grant/research funding: Health Services Research focused on outcomes and equity of cancer care delivery: Feb 2025<br><b>Rising Tide Foundation:</b> Research: Recipient: My Institution: Salary Support: Yes: national/overall principal investigator: International multicentre prospective study appraising Artificial Intelligence for radiotherapy treatment: Grant/research funding: International multicentre prospective study appraising Artificial Intelligence for radiotherapy treatment: Aug 2026 | None   | None   |
| Todd       | Aguilera       | UT Southwestern: Assistant Professor: Employee  | None  | <b>Akso Biosciences:</b> Stock: Shares at start of company<br><b>Avelas Biosciences:</b> Stock: Shares at start of company.<br><b>Stanford University:</b> Copyright/Patent/License/Royalty: Patent royalties<br><b>UC San Diego:</b> Copyright/Patent/License/Royalty: Patent royalties | None   |
| Mansoor    | Ahmed          | <b>Albert Einstein College of Medicine:</b> Professor: Employee<br><b>National Cancer Institute:</b> Program Director: Employee<br><b>National Cancer Institute:</b> Special Volunteer: Special Volunteer | None  | None   | None   |
| Ahmet      | Ahunbay        | University of Wisconsin-Madison   | None  | None   | None   |
| Hikmat     | Al-Ahmadie     | Memorial Sloan Kettering Cancer Center  | <b>Paige.AI:</b> Consultant: Compensation/Payment: consultation on bladder cancer matters: ongoing<br><b>Pfizer:</b> Consultant: Compensation/Payment: consultation on bladder cancer matters: ongoing  | None   | None   |
| Francesca  | Albertini      | ETH Zurich: Teaching Assistant: Independent Contractor<br><b>Paul Scherrer Institute:</b> Medical Physicist: Employee   | <b>RAPTOR:</b> Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: Real Time adaptive particle therapy: Grant/research funding: Real Time adaptive particle therapy: Ongoing  | None   | None   |
| Sara       | Alcorn         | University of Minnesota: Associate professor: Employee  | <b>Prostate Cancer Foundation-Pfizer:</b> Research: Recipient: Me: Salary Support: No: national/overall principal investigator: Identifying "radiotherapy deserts": Grant/research funding: PI for project identifying "radiotherapy deserts": present<br><b>Radiation Oncology Institute:</b> Research: Recipient: Me: Salary Support: No: site principal investigator: Grading radiation skin reaction: Grant/research funding: PI for project grading radiation skin reaction: 11/2023   | None   | <b>American Radium Society:</b> Professional organization: Committee member, ARS AUC Guidelines Committee: Committee member for development of ARS AUC Guidelines Committee for Palliative Radiation: Compensation? No<br><b>ASTRO:</b> Professional organization: Bone Metastases Guidelines Committee Vice Chair: Bone Metastases Guidelines Committee: Compensation? No<br><b>IJOBP:</b> Academic Journal: Breast Section Associate Editor: Breast Section Associate Editor: Compensation? No<br><b>Society for Palliative Radiotherapy:</b> Professional society: Vice President: Vice President: Compensation? No |

**ASTRO 2024 Annual Meeting - Faculty and Presenters' Disclosures**

| First Name | Last Name       | Employment Relationships   | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria   | Ownerships/Investments/Intellectual Property | Leadership/Positions of Authority   |
|------------|-----------------|--|---|--|---|
| Prasanna   | Alluri          | UT Southwestern Medical Center: Assistant Professor: Employee  | Department of Defense: Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: Translational Breast Cancer Research: Grant/research funding: PI on Breast Cancer Research Program Breakthrough Award: Present<br><b>METAvisor</b> : Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: Breast cancer: Grant/research funding: PI on METAvisor Translational Breast Cancer Research Award: 05/31/2025                                 | None   | UT Southwestern Breast Center: Member, Breast Program Leadership Committee: Member: Compensation? No  |
| Nima       | Almassi         | Cleveland Clinic: Staff Urologic Oncologist: Employee  | None  | None   | None  |
| Michelle   | Alonso-Basanta  | University of Pennsylvania: Faculty: Employee  | <b>Varian</b> : Research, Other-invited speaker: Recipient: My Institution: Salary Support: No: site principal investigator: Travel expenses: Hypersight: To present  | None   | None  |
| Sudha      | Amarnath        | Cleveland Clinic Foundation: Staff Physician: Employee   | None  | None   | None  |
| Robert     | Amdur           | ASTRO: Editor in Chief of PRO: Employee<br>University of Florida: Professor: Employee  | None  | None   | Practical Radiation Oncology and ASTRO: Editor-in-Chief: Editor-in-Chief: Editor-in-Chief: Compensation? No   |
| Beatriz    | Amendola        | Innovative Cancer Institute: Medical Director: Partner   | <b>Varian</b> : Speaker's Bureau: Honoraria, Travel expenses: member of Speaker's Bureau: 12/31/2030  | None   | None  |
| Uri        | Amit            | University of Pennsylvania: Research Scholar: Employee   | None  | None   | None  |
| Asma       | Amjad           | Medical College of Wisconsin: Medical Physics Resident: Employee   | None  | None   | None  |
| Bethany    | Anderson        | University of Wisconsin: Radiation Oncologist: Employee  | School of Breast Oncology: Education/Meeting Faculty: Honoraria: Accelerated breast radiation: 2022   | None   | <b>ABR</b> : oral board examiner: create & administer oral board exams for breast cancer: Compensation? No<br><b>Brachytherapy</b> : Medical journal: Section Editor: Breast/Soft Tissue: Compensation? No<br><b>Clinical Breast Cancer</b> : Medical journal: Associate Editor: Associate Editor: Compensation? Yes<br><b>IJOBP</b> : Medical journal: Associate Section Editor: Breast Section: Compensation? No<br><b>NCCN</b> : Breast Cancer Committee: committee member: Compensation? No |
| Carryn     | Anderson        | Heartland Anesthesia: Chief Operating Officer: Employee<br>University of Iowa Hospitals & Clinics: Radiation Oncologist: Employee                | <b>Galera Therapeutics, Inc.</b> : Consultant, Research: Recipient: My Institution: Salary Support: No: site principal investigator: Drug development to mitigate oral mucositis: Compensation/Payment, Uncompensated: Member of consulting focus group for development of healthcare provider and patient education materials related to potential commercial launch of avasopasem manganese for oral mucositis in head and neck cancer patients receiving cisplatin & RT.: Present  | None   | University of Iowa Hospitals & Clinics: Residency Program Director: Maintain ACGME accreditation for Radiation Oncology program: Compensation? No: Relationship ended 03/30/2023  |
| Hidefumi   | Aoyama          | Hokkaido University: Professor: Employee   | None  | None   | None  |
| Smith      | Apisarnthanarax | University of Washington: Professor: Employee  | None  | None   | None  |
| Paul       | Aridgides       | Upstate Medical University: Associate Professor: Employee  | None  | None   | None  |
| Andrew     | Arifin          | The University of Texas MD Anderson Cancer Center: Fellow: Employee  | None  | None   | Canadian Radiation Oncology Foundatio: Board member: Board member for charitable foundation: Compensation? No   |
| Gregory    | Armstrong       | St Jude Children's Research Hospital: Chair: Employee  | None  | None   | None  |
| Alexander  | Assaley         | None   | None  | None   | None  |
| Katelyn    | Atkins          | Cedars-Sinai Medical Center: Assistant Professor: Employee   | None  | None   | None  |
| Sarah      | Atkinson        | University of Washington: Assistant Professor: Employee  | None  | None   | None  |
| Musaddiq   | Awan            | Medical College of Wisconsin: Assistant Professor: Employee  | <b>Genentech</b> : Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: RT + Atezolizumab in Locally Advanced HNC: Other-Drug only support: PI of NCI funded Phase I trial.: Present<br><b>NIH</b> : Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: RT + Atezolizumab in Locally Advanced HNC: Grant/research funding: Phase I Trial of Dose-Esclated Hypofractionated Adaptive Radiation with Adjuvant Atezolizumab: Present | None   | <b>NRG Oncology</b> : National Clinical Trial Organization: Committee Member: Serve on Developmental Therapeutics RT subcommittee and Head and Neck General Committee: Compensation? No   |
| Hannah     | Ayettey Anie    | National Radiotherapy Oncology & Nuclear Medicine Center; National Radiotherapy Oncology and Nuclear Medicine Centre, Korle Bu Teaching Hospital | None  | None   | None  |
| Omar       | Azem            | Rush University Medical Center   | None  | None   | None  |
| Cordelia   | Baffic          | University of Pennsylvania Health System   | None  | None   | None  |

**ASTRO 2024 Annual Meeting - Faculty and Presenters' Disclosures**

| First Name | Last Name | Employment Relationships  | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria  | Ownerships/Investments/Intellectual Property  | Leadership/Positions of Authority   |
|------------|-----------|---|--|---|---|
| Houda      | Bahig     | Centre Hospitalier de l'Université de Montréal: Radiation Oncologist: Employee                                      | <b>Astra Zeneca:</b> Advisory Board, Education/Meeting Faculty, Research: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Recipient: My Institution: Salary Support: No: steering committee: Metastatic lung cancer oligoprogression: Grant/research funding, Honoraria, Compensation/Payment: co-investigator: Present<br><b>Varian Medical Systems:</b> Research: Recipient: Me: Salary Support: No: site principal investigator: Lung cancer treatment, adaptive radiotherapy in HN: Grant/research funding: Principal investigator: | None  | None  |
| Yun        | Bai       | Department of Radiation Oncology, Peking University First Hospital  | None   | None  | None  |
| Gopal      | Bajaj     | Radiation Oncology Associates of the National Capital Region: Partner/President: Partner                            | None   | <b>Bajaj Ventures:</b> Ownership equity: Bajaj Ventures is an LLC vehicle I use to angel invest in early stage startups, primarily in the digital health space<br><b>Theralife Clinics North America:</b> Ownership equity: I am the co-CMO of Theralife Clinics NA. This is a company which focuses on expanding the role of functional radiotherapy for benign clinical conditions in the US.<br><b>Totipotent Capital:</b> Partnership: DHA is an angel group of investors based in DC that focus on early stage syndicated investments in new | None  |
| Justin     | Baker     | Stanford University School of Medicine  | None   | None  | None  |
| Richard    | Bakst     | Mount Sinai Hospital: Professor: Employee   | None   | None  | None  |
| Tracy      | Balboni   | Department of Radiation Oncology, Dana-Farber Cancer Institute/Brigham and Women's Hospital, Harvard Medical School | None   | None  | None  |
| Elizabeth  | Baldini   | Brigham and Women's Hospital: Physician: Employee   | <b>UpToDate:</b> Other-writer and editor for educational content: Compensation/Payment: writer and editor for educational topics pertaining to sarcoma and lung cancer: Present  | None  | None  |
| Leslie     | Ballas    | Cedars Sinai Medical Center: Physician: Employee  | <b>Blue Earth:</b> Advisory Board: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Compensation/Payment: new diagnostic agents for PET imaging in prostate cancer: 12/7/22<br><b>Pfizer:</b> Advisory Board: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Compensation/Payment: Advisory Board on advanced prostate cancer treatment: 11/11/22<br><b>UpToDate:</b> Consultant: Honoraria: Edit online educational review materials: To present          | None  | <b>American Board of Radiology:</b> Organization in charge of board certification and maintenance: Chair hematologic malignancy section of oral boards: In charge of heme section of oral exam prep and delivery: Compensation? No<br><b>UroToday:</b> online resource for urologists/medical oncologists/radiation oncologists for urologic malignancies: Editor: Provide content, reviews, interviews for bladder preservation section of website: Compensation? No |
| James      | Balter    | University of Michigan: Professor: Employee   | <b>NIH:</b> Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: Automated brain met detection and delineation: Grant/research funding: PI for Automated brain met detection and delineation study: Present   | None  | <b>CSR:</b> Center for Scientific Review (NIH): Chair - SBIR/STTR review Panel: I serve on, and currently chair, a recurring NIH review panel for SBIR and STTR applications: Compensation? No  |
| Claire     | Baniel    | Stanford: Resident Physician: Employee  | None   | None  | <b>Society for Women in Radiation Oncology:</b> Vice Chair/Chair: Gender minority advocacy group: Compensation? No  |

**ASTRO 2024 Annual Meeting - Faculty and Presenters' Disclosures**

| First Name  | Last Name  | Employment Relationships  | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria  | Ownerships/Investments/Intellectual Property | Leadership/Positions of Authority  |
|-------------|------------|---|--|--|--|
| Christopher | Barker     | Memorial Sloan Kettering Cancer Center: Associate Member: Employee          | <p><b>Alpha Tau Medical:</b> Research: Recipient: My Institution: Salary Support: No: site principal investigator: Skin cancer: Grant/research funding: Site PI for company-sponsored clinical trial: To present</p> <p><b>Amgen:</b> Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: Skin cancer: Grant/research funding: I am overall PI for an investigator initiated clinical trial financially supported by the entity: To present</p> <p><b>Elekta:</b> Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: Skin cancer: Grant/research funding: I am the overall PI for an investigator initiated clinical trial financially supported by the entity: To present</p> <p><b>EMD Serono:</b> Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: Skin cancer: Grant/research funding: I am overall PI for investigator initiated trial that is financially supported by the entity: To present</p> <p><b>Merck:</b> Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: Skin cancer: Grant/research funding: I was the overall PI for an investigator initiated clinical trial financially supported by the entity: 10/12/22</p> <p><b>National Institutes of Health/National Cancer Institute:</b> Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: Skin cancer: Grant/research funding: I am the overall PI of an investigator initiated trial financially supported by the NIH/NCI through subcontract with Physical Sciences, Inc.: To present</p> <p><b>Regeneron:</b> Advisory Board, Research: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Recipient: My Institution:</p> | None   | <p>Memorial Sloan Kettering Cancer Center: Cancer center: Vice Chair for Clinical Research: Lead clinical research program: Compensation? No</p> <p>National Comprehensive Cancer Network: Cancer guideline organization: Panel member: Melanoma panel member: Compensation? No</p>  |
| Justin      | Barnes     | Barnes Jewish Hospital: Resident: Employee                                  | None   | None   | None   |
| Parul       | Barry      | UPMC Radiation Oncology: Clinical Assistant Professor: Employee             | <p><b>ACRO faculty:</b> Education/Meeting Faculty: Travel expenses: I have been faculty for multiple topics at the annual meeting for several years now: To present</p> <p><b>ACRO New Practitioner grant:</b> Research: Recipient: Me: Salary Support: No: national/overall principal investigator: : Grant/research funding: ACRO NP Grant: To present</p> <p><b>ASTRO faculty:</b> Education/Meeting Faculty: Travel expenses: ASTRO speaker: To present</p> <p><b>ASTRO Minority Summer Fellowship:</b> Research: Recipient: Me: Salary Support: No: mentor: mentor: Grant/research funding: Assessment of Clinical Outcomes of Black and Hispanic Women who receive RT as part of their curative treatment for Endometrial Cancer; mentor: Present</p> <p><b>Beckwith Foundation:</b> Research: Recipient: Me: Salary Support: Yes: site principal investigator: Grant/research funding: Present</p> <p><b>El-Sevier Pathways Consultant:</b> Consultant: Honoraria: El-Sevier Pathways consultant: To present</p> <p><b>NCTN - 5UG1CA233184-06:</b> Grant/research funding: Barry (Co-I): Present</p> <p><b>Silverlon:</b> Research: Recipient: Me: Salary Support: No: site principal investigator: : Grant/research funding: funding for IIT evaluating acute RT dermatitis in breast cancer pts for which i am the PI: Present</p>  | None   | <p><b>ACRO board of chancellors:</b> ACRO Board: member and chair of membership: Member of ACRO Board of Chancellors: Compensation? No</p> <p><b>ASTRO:</b> HEDI Council: Chair of Education: Chair of Education for HEDI: Compensation? No</p> <p><b>Rare Tumors:</b> Journal on Rare Tumors: Senior Associate Editor: Senior Associate Editor: Compensation? No</p> <p><b>SWRO:</b> Senior Advisory Committee: Senior Advisory Committee member: Compensation? No</p> <p><b>Women in Medicine Summit:</b> Director of Research and of Scientific Program: Director of Research and of Scientific Program: Compensation? No</p> |
| Andrew      | Baschnagel | Department of Human Oncology, University of Wisconsin-Madison               | None   | None   | None   |
| Mustafa     | Basree     | University of Wisconsin Hospitals and Clinics: Resident Physician: Employee | None   | None   | <b>ARRO:</b> national association for radiation oncology residents: Executive Committee Member: Junior chair of the education subcommittee within the executive committee: Compensation? No  |
| James       | Bates      | Emory University: Assistant Professor: Employee                             | None   | None   | None   |
| Julie       | Bauman     | George Washington University Cancer Center                                  | <p><b>Aveo:</b> Research: Recipient: My Institution: Salary Support: No: steering committee: Ficluzumab in head and neck cancer: Other-Steering committee payment to institution: Phase III trial of cetuximab plus ficluzumab vs. placebo in advanced head and neck cancer: Ongoing</p> <p><b>Bluedot Bio:</b> Consultant: Other-Payment to institution: Preclinical</p>  | None   | None   |
| Hansel      | Bauman     | Hansel Bauman Architecture + Planning: Principal: Independent Contractor    | None   | None   | None   |

**ASTRO 2024 Annual Meeting - Faculty and Presenters' Disclosures**

| First Name | Last Name     | Employment Relationships   | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria  | Ownerships/Investments/Intellectual Property | Leadership/Positions of Authority   |
|------------|---------------|--|--|--|---|
| Brian      | Baumann       | Springfield Clinic: Radiation Oncologist: Employee   | <b>Boston Scientific:</b> Advisory Board, Consultant: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Travel expenses, Compensation/Payment: Advisory board service and consulting work: Present<br><b>Varian:</b> Consultant, Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: Consulting work as physician lead for a Varian-sponsored multi-national trial. Research funding for an investigator-initiated trial where I am PI.: Grant/research funding, Compensation/Payment: Consulting work as physician lead for a Varian-sponsored multi-national trial. Research funding for an investigator-initiated trial where I am PI.: Present | None   | None  |
| Farhang    | Bayat         | University of Colorado School of Medicine  | None   | None   | None  |
| Jose       | Bazan         | City of Hope: Associate Professor: Employee  | <b>ASTRO VA Breast Panel:</b> Consultant: Honoraria: Member of the VA panel that updates pathways for breast cancer: Ongoing   | None   | <b>American Board of Radiology:</b> Oral exam committee - Breast: Member: Member of oral exam committee: Compensation? No<br><b>International Journal of Radiation Onc/Biol/Phys:</b> Journal: Associate Editor: Breast section associate editor: Compensation? No  |
| Soha       | Baziar        | University of Maryland Medical Center: Resident Physician: Employee                                | <b>RSNA:</b> Research: Recipient: Me: Salary Support: No: national/overall principal investigator: Ultra-high Dose Rate Sparing of Lung Tissue During Radiation Therapy: Grant/research funding: I am PI for the 1-yr RSNA resident research grant to evaluate the sparing effect of electron ultra-high dose radiation therapy on murine lung models.: 6/30/2024  | None   | None  |
| Beth       | Beadle        | Stanford University: Professor: Employee   | <b>Elsevier:</b> Other-Book writing and journal editing: Other-Royalties: Article writing and journal editorial work: Ongoing<br><b>Wolters-Kluwer:</b> Other-Book writing and journal editorial work: Other-Royalties: Royalties from book writing: Ongoing   | None   | None  |
| Emilio     | Beatley       | ASTRO: Health Policy Analyst: Employee   | None   | None   | None  |
| Manpreet   | Bedi          | Medical College of Wisconsin: Associate Professor: Employee  | <b>Accuray:</b> Consultant: Honoraria: Consultant and speaker for Accuray: Present<br><b>Varian:</b> Education/Meeting Faculty: Honoraria, Travel expenses: Speaker at the annual SPECTRUM Interventional Radiology meeting on Radiation Oncology Topics: Present  | None   | None  |
| Brett      | Bell          | Albert Einstein College of Medicine: MD/PhD Candidate: Employee                                    | None   | None   | None  |
| Colin      | Belliveau     | Centre Hospitalier de l'Université de Montréal: Resident Doctor: Employee                          | None   | None   | None  |
| Carmen     | Bergom        | Washington University School of Medicine: Associate Professor: Employee                            | None   | None   | None  |
| Sushil     | Beriwal       | Allegheny health network: Academic chief: Employee<br><b>Varian:</b> VP, medical affairs: Employee | <b>Elsivier:</b> Consultant: Compensation/Payment: Clinical pathways: Ongoing<br><b>Varian:</b> Other-Employer: Salary support: VP medical affairs: Ongoing  | None   | None  |
| Vincent    | Bernard Pagan | MD Anderson Cancer Center: Resident: Trainee   | None   | None   | None  |
| Michael    | Binkley       | Department of Radiation Oncology, Stanford University School of Medicine                           | None   | None   | None  |
| Andrew     | Bishop        | The University of Texas MD Anderson Cancer Center: Associate Professor: Employee                   | None   | None   | None  |
| Danielle   | Bitterman     | Brigham and Women's Hospital: Physician: Employee  | <b>Mercurial AI:</b> Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Compensation/Payment: Advisory board member - 30 min/month: 01/01/2029  | None   | <b>HemOnc.org:</b> HemOnc.org is the largest freely available medical wiki of interventions, regimens, and general information relevant to the fields of hematology and oncology. It is designed for easy use and intended for healthcare professionals. Any healthcare profession: Associate Editor, Radiation Oncology: Oversee all radiation oncology content, solicit radiation oncology contributors for specialized sections.: Compensation? No |
| Omar       | Bohoudi       | Amsterdam UMC: Post doc researcher: Employee   | None   | None   | None  |
| Casey      | Bojchko       | University of California San Diego: Assistant Clinical Professor: Employee                         | <b>Varian Medical Systems:</b> Education/Meeting Faculty: Compensation/Payment: Teach a course on how to use Varian adaptive products.: To present   | None   | None  |
| Anirudh    | Bommireddy    | Department of Radiation Oncology, Cleveland Clinic Foundation                                      | None   | None   | None  |
| Ryan       | Bonate        | Medical College of Wisconsin: Graduate Student: Employee   | None   | None   | None  |
| Pierluigi  | Bonomo        | Radiation Oncology, Careggi University Hospital, University of Florence                            | None   | None   | None  |

**ASTRO 2024 Annual Meeting - Faculty and Presenters' Disclosures**

| First Name | Last Name  | Employment Relationships   | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria   | Ownerships/Investments/Intellectual Property   | Leadership/Positions of Authority  |
|------------|------------|--|---|--|--|
| Victor     | Bourel     | BRAQUI srl: Medical Physicist: Partner<br>Universidad Favaloro: Professor: Employee  | None  | None   | ALATRO: Scientific Society: Board Member: southern zone representative: Compensation? No   |
| Kristin    | Bradley    | University of Wisconsin: Physician: Employee   | NCCN: Other-Member, gynecologic committee: Travel expenses: Member, gynecologic committee: Present  | None   | American Brachytherapy Society: organization promoting the use & education in the treatment of cancer: Treasurer, Board of Directors: Travel expenses to meetings: Compensation? Yes |
| Jessica    | Brady      | Guy's and St Thomas NHS Trust: Consultant Clinical Oncologist: Employee<br>Guy's and St Thomas' NHS foundation: Consultant Clinical Oncologist: Employee | None  | None   | None   |
| Scott      | Bratman    | Adela, Inc.: Co-Founder and CIO: Employee<br>University Health Network: Staff Radiation Oncologist - Clinician Scientist: Employee                       | EMD Serono: Advisory Board: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Honoraria: Ad board member for head and neck cancer therapy: November 2023  | Adela, Inc.:<br>Copyright/Patent/License/Royalty: Inventor on patent licensed to Adela related ctDNA detection; Co-founder and stockholder of Adela, a UHN spin-out company.: Stock: Inventor on patent licensed to Adela related ctDNA detection; Co-founder and stockholder of Adela, a UHN spin-out company.:<br>Copyright/Patent/License/Royalty: Inventor on patent licensed to Adela related ctDNA detection; Co-founder and stockholder of Adela, a UHN spin-out company.<br>Roche:<br>Copyright/Patent/License/Royalty: Inventor on patent licensed to Roche | None   |
| Steve      | Braunstein | University of California San Francisco: Associate Professor: Employee  | Elekta: Research: Recipient: My Institution: Salary Support: No: site principal investigator: SRS: Grant/research funding: As above, research on SRS: To present<br>Icotec: Education/Meeting Faculty: Travel expenses, Compensation/Payment: Speaking on topic of spine RT and carbon fiber implants: To present   | None   | None   |
| William    | Breen      | Mayo Clinic: Radiation Oncologist: Employee  | GE Healthcare: Advisory Board: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Compensation/Payment, Other-Paid to institution: Discussion of development of novel PET/CT radiotracers, all funds paid to department.: January 2023<br>Miltenyi: Advisory Board: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Compensation/Payment, Other-Paid to institution: CAR-T development for CNS lymphoma: 5/29/24 | None   | None   |
| Kristy     | Brock      | The University of Texas MD Anderson Cancer Center: Professor: Employee   | RaySearch Laboratories: Advisory Board, Research: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Recipient: My Institution: Salary Support: No: Research investigator: Dose accumulation: Grant/research funding: Dose  | RaySearch Laboratories:<br>Copyright/Patent/License/Royalty: DIR software  | None   |
| Julianna   | Bronk      | University of Texas MD Anderson Cancer Center: Assistant Professor: Employee   | None  | None   | None   |

**ASTRO 2024 Annual Meeting - Faculty and Presenters' Disclosures**

| First Name   | Last Name  | Employment Relationships   | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria  | Ownerships/Investments/Intellectual Property  | Leadership/Positions of Authority   |
|--------------|------------|--|--|---|---|
| Anna         | Brown      | Barton Associates: Board-Certified Radiation Oncologist: Independent Contractor  | Pfizer: Advisory Board: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Travel expenses: Advisory board on Relugolix for men with prostate cancer: 11/05/2023 | None  | <p><b>Accelerators Podcast:</b> Accelerators Podcast: Co-founder and co-host: Co-founder and co-host for Seasons 1 and 2 of this global radiation oncology podcast: Compensation? No: Relationship ended 10/02/2023</p> <p><b>American College of Radiation Oncology:</b> American College of Radiation Oncology (ACRO): Board of Chancellors Member, Communications Liaison to the GREC (Government Relations and Economics Committee), and member of the New Practitioners Committee: Board of Chancellors Member and member of the GREC (Government Relations and Economics Committee) as well as Communications Committee Liaison to the GREC and member of the New Practitioners Committee: Compensation? No</p> <p><b>American Medical Association:</b> American Medical Association: Alternate Delegate to the House of Delegates for the American College of Radiation Oncology and on the Nominating Committee for the Radiology Section Council: Alternate Delegate of the American College of Radiation Oncology and on the Nominating Committee of the Radiology Section Council: Compensation? No</p> <p><b>ASTRO:</b> Early Career Committee: Community Building Lead: Leader of the Community Building Subcommittee of the ASTRO Early Career Committee: Compensation? No</p> <p><b>ASTRO:</b> CUAC Committee: Member of the CUAC Committee: Compensation? No</p> <p><b>ASTRO:</b> HEDI Council: Member of the Advocacy and Education subcommittees: Member of the HEDI Council Education and Advocacy committees: Compensation? No</p> <p><b>CARROS:</b> Council of Affiliated Regional Radiation Oncology Societies: Communications Committee Lead: Communications Committee Lead; responsible for developing Instagram and Twitter content and coordinating strategy for maximal engagement and impact: Compensation? No</p> <p><b>NRG Oncology Podcast:</b> Official podcast of NRG Oncology: Guest: Will be a guest on the NRG Oncology Podcast in Sept 2024 focusing on ways that NRG Oncology and other organizations such as the AMA, ACR, and ACRO can collaborate on helping boost minority and rural patient enrollment on clinical trials: Compensation? No</p> <p><b>ROECSG:</b> Radiation Oncology Education Collaborative Study Group: Founder and Editor in Chief of the ROECSG Report Periodical and Co-Lead of the Patient Education Working Group: ROECSG Report periodical founder and editor in chief, and Co-Lead of the Patient Education Working Group: Compensation? No</p> <p><b>SOAP Podcast:</b> Spotlight on Advocacy and Policy (SOAP) podcast, an official podcast of ACRO: Founder and lead anchor: The vision for this podcast is to feature critical updates on advocacy and policy issues in the field of radiation oncology and to unify efforts in this space: Compensation? No</p> |
| Matthew      | Brown      | University of Maryland: Physician: Employee  | None   | None  | None  |
| Jeremy       | Brownstein | Ohio State University: Assistant Professor: Employee   | None   | None  | None  |
| Deborah      | Bruner     | Emory University: Senior Vice President for Research: Employee   | None   | None  | None  |
| Thomas       | Brunner    | Medical University of Graz: Chair radiation oncology: Employee<br>Medical University of Graz: Head of Department: Employee | None   | None  | None  |
| John Michael | Bryant     | H. Lee Moffitt Cancer Center & Research Institute  | None   | None  | None  |
| John         | Buatti     | University of Iowa   | None   | None  | None  |
| Jeffrey      | Buchsbaum  | NCI: Medical Officer: Employee   | None   | None  | None  |
| Zachary      | Buchwald   | Emory University: Assistant Professor: Employee  | None   | None  | None  |
| Michael      | Buckstein  | Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai  | None   | None  | None  |
| Jessica      | Burlike    | Mayo Clinic: Resident Physician: Employee  | None   | None  | None  |
| Stuart       | Burri      | Southeast Radiation Oncology Group: President and Partner: Partner   | Novocure: Other-Data Safety monitoring committee: Travel expenses, Compensation/Payment: Member of data safety monitoring board for the METIS trial: 2023  | <p><b>Charlotte Physics Holding:</b> Ownership equity: Partial owner of holding company that owns an interest in a physics staffing company</p> <p><b>FUSE Oncology Holding:</b> Ownership equity: Own a partial stake of a holding company that owns a portion of FUSE Oncology</p> <p><b>Oncology Practice Solutions:</b> Ownership equity: Own a portion and am a managing partner of Oncology Practice Solutions</p> <p><b>Radiation Oncology Centers of the Carolinas:</b> Ownership equity: Partial owner</p> | <p><b>Atrium Health - Levine Cancer Institute:</b> A large non-profit health system: Chairman of Radiation Oncology: Chairman of Radiation Oncology: Compensation? No</p>   |
| Brook        | Byrd       | Penn Medicine Radiation Oncology Abramson Cancer Center  | NIH: Research: Recipient: My Institution: Salary Support: Yes: Post-doctoral researcher: Cherenkov imaging: Grant/research funding: Post-doctoral researcher on Cherenkov imaging during EBRT:   | None  | None  |

**ASTRO 2024 Annual Meeting - Faculty and Presenters' Disclosures**

| First Name   | Last Name   | Employment Relationships  | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria  | Ownerships/Investments/Intellectual Property   | Leadership/Positions of Authority   |
|--------------|-------------|---|--|--|---|
| Bin          | Cai         | University of Texas Southwestern Medical Center: Associate Professor: Employee  | <b>Reflexion Medical:</b> Research, Other-invited to provide feedback to product improvement.: Recipient: My Institution: Salary Support: No: site co-investigator on a data registry: Prospective Data Registry and Quality of Life Assessment of Patients Undergoing Radiotherapy with the Reflexion Medical Radiotherapy System: Grant/research funding, Compensation/Payment, Other-Salary for student: Feasibility of BgRT planning from diagnostic PET images on various treatment sites: 06/03/2024<br><b>Reflexion Medical:</b> Research, Other-Panelist discussion 06.16: Recipient: My Institution: Salary Support: No: site principal investigator: Biology guided RT planning outside lung and bone: Grant/research funding, Travel expenses: Research grant; Speaker at Reflexion user meeting in 06/16/2022 and 07/24/2023.: Dec,2023<br><b>Varian Medical System:</b> Other-Speaker AAPM user meeting: Honoraria: present Halcyon experience 07/21/2023 | None   | None  |
| Chang        | Cai         | Ruijin Hospital, Shanghai JiaoTong University School of Medicine,   | None   | None   | None  |
| Joseph       | Califano    | University of California: Professor: Employee   | None   | None   | None  |
| Kristin      | Cambell     | University of British Columbia: Professor: Employee   | <b>Canadian Association of Pharmacy in Oncology:</b> Education/Meeting Faculty: Honoraria, Travel expenses: Plenary speaker at annual meeting: 4/13/2024<br><b>Pfizer Canada:</b> Education/Meeting Faculty: Honoraria: plenary speaker at annual meeting: 4/13/2024   | <b>Abcellera:</b> Stock: stock holder  | None  |
| Shauna       | Campbell    | Cleveland Clinic Foundation: Radiation Oncologist: Employee   | None   | None   | None  |
| Yue          | Cao         | Departments of Radiology and Biomedical Engineering, University of Michigan   | None   | None   | None  |
| Chad         | Caraway     | Johns Hopkins University: Research Technologist: Employee: Relationship ended 06/01/2023  | None   | None   | None  |
| Higinia      | Cardenes    | Weill Cornell Medicine - Radiation Oncology: Professor: Employee  | None   | None   | None  |
| David        | Carlson     | <b>Yale New Haven Health:</b> Director of Physics: Employee<br><b>Yale University:</b> Professor & Vice Chair: Employee                                 | <b>Reflexion Medical, Inc.:</b> Research: Recipient: Me: Salary Support: No: site principal investigator: BGRT: Grant/research funding: Funding for several small projects related to Biologically Guided Radiotherapy: Present  | None   | <b>ASTRO:</b> Immediate Past Chair, SEPD: Immediate Past Chair of SEPD and member of Science Council: Compensation? No<br><b>Red Journal:</b> Section Editor, Physics: Senior Editor for the Physics Section of the Red Journal: Compensation? Yes                        |
| Patrick      | Carriere    | The University of Texas MD Anderson Cancer Center: Resident Physician: Employee   | None   | None   | None  |
| Claudia      | Carvajal    | Clínica Alemana de Santiago: Radiation Oncologist: Employee   | None   | None   | <b>SOCHIRA:</b> Sociedad chilena de radioterapia oncológica: Chairman: SOCHIRAS's president: Compensation? No   |
| Matthew      | Case        | Department of Radiation Oncology, Emory University: Radiation Oncology Resident: Employee   | None   | None   | None  |
| Katherine    | Castle      | Mary Bird Perkins: Rad Onc: Independent Contractor  | None   | <b>One Oncology:</b> Ownership equity: Through MBP relationship with One Oncology the MD receive shares in | <b>MARY Bird Perkins Cancer Center:</b> Free standing community cancer center: Medical director: oversee rad onc program + leadership with the cancer center: Compensation? Yes<br><b>SLROG:</b> Rad Onc Group: medical director: oversee group of MDs: Compensation? Yes |
| Andrea       | Cercek      | MSKCC: Assistant Professor: Employee  | None   | None   | None  |
| Laura        | Cervino     | Memorial Sloan Kettering Cancer Center: Service Chief, Attending Physicist: Employee  | None   | None   | <b>AAPM:</b> Therapy Imaging Subcommittee: Vice-Chair: Compensation? No   |
| Manjeet      | Chadha      | Icahn School of Medicine at Mount Sinai: Attending Faculty: Employee  | None   | None   | None  |
| Molly        | Chakraborty | Memorial Sloan Kettering Cancer Center: Medical Student Researcher: Employee  | None   | None   | None  |
| Ibrahim      | Chamseddine | Massachusetts General Hospital: Instructor: Employee<br><b>Massachusetts General Hospital:</b> Research Fellow: Employee: Relationship ended 10/31/2022 | <b>Dubai Harvard Foundation for Medical Research:</b> Research: Recipient: Me: Salary Support: Yes: national/overall principal investigator: AI for outcome: Grant/research funding: AI for outcome: Present<br><b>Mass Gen Hospital and Brigham and Women's:</b> Research: Recipient: Me: Salary Support: Yes: national/overall principal investigator: AI for outcome modelling: Grant/research funding: AI  | None   | <b>American Association of Physicists in Medicine:</b> Profession Organization: Member of Global Research and Scientific Innovation Committee: Helping establish the Global Student and Trainee Research program: Compensation? No  |
| Mark Ka Heng | Chan        | Department of Radiation Oncology, University Nebraska Medical Center  | None   | None   | None  |
| Daniel       | Chang       | Stanford University   | None   | None   | None  |



**ASTRO 2024 Annual Meeting - Faculty and Presenters' Disclosures**

| First Name     | Last Name      | Employment Relationships   | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria  | Ownerships/Investments/Intellectual Property   | Leadership/Positions of Authority   |
|----------------|----------------|--|--|--|---|
| Samuel         | Chao           | Cleveland Clinic: Radiation Oncologist: Employee   | Blue Earth Diagnostics: Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: Fluciclovine for Diagnosis of Radiation Necrosis: Honoraria, Travel expenses, Salary support: Fluciclovine for Diagnosis of Radiation Necrosis: To present<br>GE Healthcare: Education/Meeting Faculty: Honoraria: Speaker for Workflow: October 2023<br>Varian Medical Systems: Education/Meeting Faculty: Honoraria:   | None   | None  |
| K. S. Clifford | Chao           | China Medical University: Distinguished Professor: Employee<br>China Medical University Hospital: Dean: Employee           | None   | None   | None  |
| Christina      | Chapman        | Baylor College Of Medicine: Assistant of Professor of Radiation Oncology: Employee   | Daiichi Sankyo/ASCO Advantage Program: Education/Meeting Faculty: Honoraria, Travel expenses, Compensation/Payment: Gave education lectures to pharma (company that manufactures Enhertu) as part of ASCO Advantage Educational Program:   | None   | None  |
| Youssef        | Charara        | Howard University: Adjunct professor: Employee: May 2024<br>Virginia Cancer Specialists: Chief Medical Physicist: Employee | Novartis/aaa: Consultant: Compensation/Payment, Other-TBD: consultant on RLT experience: Present   | None   | None  |
| Oi Wai         | Chau           | UCSF: Resident: Independent Contractor   | None   | None   | None  |
| Adel           | Chaudhuri      | Mayo Clinic: Associate Professor: Employee   | AlphaSights: Consultant: Compensation/Payment: Liquid biopsy consulting: Present<br>AstraZeneca: Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Compensation/Payment: Lung cancer advising: Present<br>Daiichi Sankyo: Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Compensation/Payment: Lung cancer advising: Present<br>DeciBio: Consultant: Compensation/Payment: Liquid Biopsy consulting: Present<br>Geneoscopy: Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Other-Stock options: Stool RNA advising: Present<br>Guidepoint: Consultant: Compensation/Payment: Liquid biopsy consulting: Present<br>Illumina: Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Compensation/Payment: Other-Research supplies: Cell-free RNA research support: Present<br>Roche: Other-Research supplies: Other-Research supplies: Honoraria, Travel expenses, Compensation/Payment: Liquid biopsy cell-free DNA advising: Present<br>Tempus Labs: Consultant: Grant/research funding, Compensation/Payment: Grant/research funding: Grant/research funding, Compensation/Payment: Liquid biopsy cell-free DNA advising: Present | Droplet Biosciences: Ownership equity: Board of Directors<br>Geneoscopy: Stock options: Advisory Board<br>LiquidCell Dx Inc.: Ownership equity: Board of Directors<br>Patent filings related to cancer biomarkers:<br>Copyright/Patent/License/Royalty: Patent filings | AI in Precision Oncology: Journal: Editorial Board: Editorial board member: Compensation? No<br>AI in Precision Oncology: Journal: Editorial Board: Editorial Board Member: Compensation? No<br>AI in Precision Oncology: Journal: Editorial Board: Editorial board member: Compensation? No<br>Mayo Clinic Comprehensive Cancer Center: Cancer Center: Co-Director of the Precision Genomics Office: Co-Director of precision genomics across the Mayo enterprise: Compensation? Yes<br>Mayo Clinic Comprehensive Cancer Center: Cancer Center: Emerging Leader: Emerging leader for early cancer detection and interception at the cancer center: Compensation? Yes<br>Mayo Clinic Department of Radiation Oncology: Radiation oncology department: Vice Chair of Translational Research: Vice Chair of Translational Research: Compensation? No<br>Molecular Diagnosis & Therapy: Journal: Editorial Board: Editorial Board Member: Compensation? No<br>NIH Liquid Biopsy Interest Group: NIH Liquid Biopsy Interest Group: Co-Chair: Co-Chair of NIH Liquid Biopsy Interest Group: Compensation? No<br>NSCLC Multidisciplinary Advisory Council: AstraZeneca advisory council: Member of the advisory council: Advise on matters related to NSCLC biomarkers: Compensation? No<br>PLOS Medicine: Journal: Editorial Board: Editorial Board Member: Compensation? No<br>Siteman Cancer Center ctDNA Working Group: ctDNA working group at Siteman Cancer Center: Leader: Leader of this group within the cancer center: Compensation? No<br>Translational Lung Cancer Research: Journal: Editorial Board: Editorial Board Member: Compensation? No |
| Pradeep        | Chauhan        | Department of Radiation Oncology, Mayo Clinic  | None   | Cancer biomarker Patent:<br>Copyright/Patent/License/Royalty:  | None  |
| Avinash        | Chaurasia      | Radiation Oncology Branch, National Cancer Institute, NIH  | None   | None   | None  |
| Jessica        | Chavez Noguera | Instituto Mexicano del Seguro Social: Medical Society: Employee  | Boehringer inghelheim: Advisory Board: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No:   | None   | Sociedad mexicana de oncologia: Medical society: Board Member: Treasurer: Compensation? Yes   |
| Monica         | Chelius        | Department of Radiation Oncology, Hospital of the University of Pennsylvania   | None   | None   | None  |
| Ronald         | Chen           | University of Kansas Medical Center: Professor and Chair, Department of Radiation Oncology: Employee                       | Janssen: Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Honoraria: Janssen sponsors NRG GU008 clinical trial, for which I am PI: To present<br>Seagen: Consultant: Honoraria: Advise on bladder cancer research: Ongoing  | None   | None  |
| Ming           | Chen           | State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center: Dr.: Employee                       | None   | None   | None  |

**ASTRO 2024 Annual Meeting - Faculty and Presenters' Disclosures**

| First Name     | Last Name | Employment Relationships  | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria  | Ownerships/Investments/Intellectual Property                         | Leadership/Positions of Authority  |
|----------------|-----------|---|--|--|--|
| Peter          | Chen      | Corewell Beaumont University Hosp, Royal Oak, Mi: Professor, Oakland U Wm Beaumont SOM: Employee  | None   | None   | ASTRO Membership Committee, Chair for 2021-2022: Chair 2021-2022: Chair of ASTRO Membership Committee: Compensation? No: Relationship ended 06/30/2023   |
| William        | Chen      | Department of Radiation Oncology, University of California San Francisco  | None   | None   | None   |
| Xianyan        | Chen      | Thoracic Oncology Ward, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University   | None   | None   | None   |
| Yao            | Chen      | Thayer School of Engineering, Dartmouth College   | None   | None   | None   |
| Yen-Lin Evelyn | Chen      | Mass General Brigham: Associate Professor: Employee   | None   | None   | None   |
| Yingxuan       | Chen      | Thomas Jefferson University: Medical Physicist/ Clinical Assistant Professor: Employee  | Varian Medical System: Research: Recipient: My Institution: Salary Support: No: Co-investigator: CBCT Radiomics Analysis for Lung Cancer Patients: Grant/research funding: Longitudinal CBCT Radiomics Analysis for Lung Cancer Radiotherapy Response and Prognosis Prediction: To present   | None   | None   |
| Bhisham        | Chera     | Medical University of South Carolina: Professor, Vice Chair, Endowed Chair: Employee  | None   | Naveris: Copyright/Patent/License/Royalty: Scientific Advisory Board | ABR, Radiation Oncology Head/Neck/skin: Committee Member: Develop and administer written and oral examinations: Compensation? No<br>American College of Radiology: ACR Journal Advisor Editor: Write monthly commentary on seminal literature in the field of head and neck oncology.: Compensation? No<br>ASTRO: Head and Neck Resource Panel member: Provide expert review/opinion regarding issues related to head and neck radiation oncology: Compensation? No<br>NRG: Head and Neck Core Committee Member: Voting member: Compensation? No<br>Practical Radiation Oncology: Section Editor: Editor: Compensation? No |
| Hua-Ren        | Cherng    | University of Maryland Medical Center: Resident Physician: Employee   | None   | None   | None   |
| Indrin         | Chetty    | Cedars-Sinai Medical Center: Professor and Director of Medical Physics: Employee<br>Henry Ford Health System: Professor and Director: Medical Physics: Employee: Relationship ended 09/08/2023  | None   | None   | AAPM: AAPM Board of Directors - Member at Large: AAPM Board of Directors - Member at Large: AAPM Board of Directors - Member at Large: Compensation? No: Relationship ended 12/31/2023<br>AAPM Awards and Honors Committee: Member of the AAPM Awards and Honors Committee: Member - AAPM Awards and Honors Committee: Member - AAPM Awards and Honors Committee: Compensation? No<br>Indian American Society of Medical Physics (IASMP) - Board Member: Board Member of the IASMP: Board Member of the IASMP: Board Member of the IASMP: Compensation? No   |
| Walter         | Chin      | Department of Radiation Oncology, Winship Cancer Institute of Emory University  | None   | None   | None   |
| Junzo          | Chino     | Duke University Health System: Associate Professor: Employee  | GOG Foundation: Other-Received Stipend for writing (GOG foundation book): Honoraria: Honoraria for writing: 4/10/23<br>Guidepoint: Consultant: Compensation/Payment: Investment Consulting - Platinum Therapy: 10/9/23<br>KM Pharmaceutical Consulting LLC: Other-Data and Safety Monitoring Board for ongoing trial: Honoraria: Data and Safety Monitoring Board for ongoing trial for Cervical Cancer: To present<br>Merck: Advisory Board: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Grant/research funding: Pembrolizumab in Cervical Cancer: 1/22/24<br>Stryker: Consultant: Honoraria: Airo CT Consulting: 4/30/23 | None   | American Brachytherapy Society: Medical Society: Board Member: Board Member: Compensation? No  |
| Fumiko         | Chino     | MD Anderson: Assistant Professor, Radiation Oncology: Employee<br>Memorial Sloan Kettering: Assistant Attending, Radiation Oncology: Employee: Relationship ended 08/02/2024<br>Memorial Sloan Kettering: Assistant Attending, Radiation Oncology: Employee | None   | None   | None   |
| Elena Gabriela | Chiorean  | Division of Hematology Oncology, University of Washington/Fred Hutchinson Cancer Center.  | AfiniT, Lonza, Mirati, Erasca: Research: Recipient: Me: Salary Support: Yes: site principal investigator: GI Cancer: Grant/research funding: National PI: 04/2024  | None   | None   |

**ASTRO 2024 Annual Meeting - Faculty and Presenters' Disclosures**

| First Name | Last Name        | Employment Relationships   | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria  | Ownerships/Investments/Intellectual Property | Leadership/Positions of Authority  |
|------------|------------------|--|--|--|--|
| Steven     | Chmura           | Department of Medicine, University of North Carolina   | <p><b>bms:</b> Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: SBRT and IPI/Nivo: Grant/research funding: PI for COSINR: Present</p> <p><b>GE Medical:</b> Advisory Board: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Honoraria: Ad board for pET tracers: 12/5/2022</p> <p><b>Serier:</b> Education/Meeting Faculty, Advisory Board: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Honoraria, Travel expenses: Speaking on low grade glioma: 10/25/2024</p> <p><b>Takeda:</b> Research: Recipient: My Institution: Salary Support: No: site principal investigator: SBRT and STING: Grant/research funding: PI Tak636: Present</p> <p><b>Varian:</b> Research: Recipient: My Institution: Salary Support: Yes: site principal investigator: SBRT: Grant/research funding: PI</p>   | None   | None   |
| Karen      | Choi             | <p><b>MDACC:</b> Associate Professor of Otolaryngology: Employee</p> <p><b>Penn State University:</b> Assistant Professor of Surgery, Div of Otolaryngology: Employee: Relationship ended 12/31/2022</p> | <p><b>Cardinal Health:</b> Consultant: Honoraria: Medical Device/Supply: Current</p> <p><b>Intuitive Surgical:</b> Education/Meeting Faculty: Travel expenses: Medical Device/ Training: Current</p>   | None   | <p><b>AHNS:</b> National HN surgical Society: Education Chair for Cutaneous Section of HNS: Educational Agenda for Society Meetings: Compensation? No</p> <p><b>AHNS:</b> National HN surgical Society: Vice Chair of Women in HNS service: Leadership role for HN society: Compensation? No</p> <p><b>Texas Association of Otolaryngology:</b> State Surgical Sub specialty society: Board Member: Oversee/participate in state regulations for specialty: Compensation? No</p>   |
| Ariel      | Choi             | Department of Radiation Oncology, Wake Forest University School of Medicine  | None   | None   | None   |
| Isabelle   | Choi             | The New York Proton Center: Director of Research, Clinical Director: Employee  | None   | None   | <p><b>National Association of Proton Therapy:</b> Member, BoD; Chair, Physician Advisory Committee: Provide input and guidance on goals and initiatives of organization.: Compensation? No</p> <p><b>Proton Collaborative Group:</b> Organization furthering the research mission in proton therapy through multiinstitution clinical trials to help further understanding of the impact of proton therapy on survivorship and quality of life for cancer patients.: Chair of Publications Committee: Oversee and provide guidance for new and existing research protocols, ensure best practices for organization research endeavors.: Compensation? No</p> |
| Julie      | Choi             | Lawrence Hospital  | None   | None   | None   |
| Casey      | Chollet-Lipscomb | <p><b>Tennessee Oncology:</b> Managing Partner: Partner</p> <p><b>Varian:</b> Physicist: Employee</p>  | <p><b>Ideology Health:</b> Education/Meeting Faculty: Honoraria: Educational speaker on lung and thyroid cancer: 8/16/23</p>   | None   | <b>Tennessee Oncology:</b> Board of Directors: Member: Managing Partner, Radiation Oncology: Compensation? No  |
| Supriya    | Chopra           | ACTREC Tata Memorial Centre: Doctor: Employee  | <p><b>Elekta:</b> Research: Recipient: My Institution: Salary Support: No: site principal investigator: Brachytherapy devices: Grant/research funding: gynecological cancers: Present</p> <p><b>Varian:</b> Research: Recipient: My Institution: Salary Support: No: site principal investigator: RT devices: Grant/research funding, Honoraria: Gynecological cancers: Ongoing</p>  | None   | <b>ESTRO focus group:</b> scientific: Member: Advisory: Compensation? No   |
| Ananya     | Choudhury        | University of Manchester and The Christie NHS Foundation Trust: Professor: Employee  | <p><b>BMJ:</b> Other-Editor in Chief: Grant/research funding: Editor in Chief of BMJ Oncology: To present</p> <p><b>Cancer Research UK:</b> Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: Biomarkers: Grant/research funding: Research grant: To present</p> <p><b>Elekta AB:</b> Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: Advanced radiotherapy: Grant/research funding: Research funding: To present</p> <p><b>Merck:</b> Education/Meeting Faculty: Honoraria: Delivery of education: 01/24</p> <p><b>NIHR:</b> Research: Recipient: My Institution: Salary Support: Yes: site principal investigator: Advanced RT: Grant/research funding: Research funder: To present</p> <p><b>Prostate cancer UK:</b> Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: Biomarkers: Grant/research funding: Research funding: To present</p> <p><b>UKRI:</b> Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: Advanced radiotherapy: Grant/research funding: Research funding: To present</p> | None   | <p><b>ESTRO:</b> European Society of Therapeutic Radiation Oncology: Member: Member of Radiobiology Committee: Compensation? No</p> <p><b>National Institute of Clinical Excellence, UK:</b> National body: Expert member for guidelines and appraisal of treatment: Expert member for guidelines and appraisal of treatment: Compensation? No</p> <p><b>Royal College of Radiologists, UK:</b> Professional body: Chair of Academic Committee: Chair of Academic Committee: Compensation? No</p>  |
| Mudit      | Chowdhary        | Northside Hospital: Radiation Oncologist: Employee   | None   | None   | None   |
| Jared      | Christensen      | Department of Radiology, University of Michigan  | None   | None   | None   |

**ASTRO 2024 Annual Meeting - Faculty and Presenters' Disclosures**

| First Name | Last Name | Employment Relationships  | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria   | Ownerships/Investments/Intellectual Property              | Leadership/Positions of Authority  |
|------------|-----------|---|---|---|--|
| Peter      | Chung     | University Health Network: Radiation Oncologist: Independent Contractor                 | <b>AbbVie:</b> Advisory Board: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Honoraria, Compensation/Payment: Advisory board with respect to use of product and relationship to marketing: November 2022<br><b>Knigh Therapeutics:</b> Advisory Board: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Honoraria: Provide insight into use of medication in prostate cancer: November 2022<br><b>Pfizer:</b> Education/Meeting Faculty: Honoraria, Travel expenses: Education talk provided at urothelial cancer meeting: November 2022<br><b>Terseera:</b> Research: Recipient: My Institution: Salary Support: No: site principal investigator: Radiotherapy for prostate cancer: Grant/research funding: Prostate cancer research: Present<br><b>Tolmar:</b> Other-Fellowship funding: Grant/research funding: Clinical fellow funding: Present  | None  | None   |
| Christine  | Chung     | Alta Bates Comprehensive Cancer Center; H. Lee Moffitt Cancer Center                    | None  | None  | None   |
| Michael    | Chuong    | Baptist Health South Florida: physician: Employee                                       | <b>Novocure:</b> Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: pancreas cancer: Grant/research funding: PI: Present<br><b>Sirtex:</b> Speaker's Bureau: Honoraria: participate in educational presentations: 01/01/2024<br><b>StratPharma:</b> Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: radiation dermatitis: Grant/research funding: PI: present<br><b>ViewRay:</b> Consultant, Research, Speaker's Bureau: Recipient: My Institution: Salary Support: No: national/overall principal investigator: pancreas cancer: Grant/research funding, Honoraria, Travel expenses, in-kind donations, Compensation/Payment: Clinical and research activities involving MRIdian: 10/25/2023<br><b>ViewRay, Inc.:</b> Consultant, Research, Speaker's Bureau: Recipient: My Institution: Salary Support: Yes: national/overall principal investigator: MRI-guided radiation therapy: Grant/research funding, Honoraria, Travel expenses: collaborated on clinical research, participated in speaking events: October 2023 | None  | <b>Proton Collaborative Group:</b> Board of Directors member: Board of Directors member: Compensation? No<br><b>Proton Collaborative Group:</b> Board of Directors Member: Board of Directors Member: Compensation? No |
| Megan      | Clark     | Dartmouth College: PhD Student: Employee  | <b>DoseOptics LLC:</b> Consultant: Compensation/Payment: Consultant: Present  | None  | None   |
| Payton     | Clark     | Cleveland Clinic  | None  | None  | None   |
| Callisia   | Clarke    | Medical College of Wisconsin: Associate Professor of Surgery: Employee                  | None  | None  | <b>Academy of Academic Surgeons:</b> National organization for Academic Surgery: President-Elect: National meeting assembly, Oversee operations, establish partnerships with other organizations.: Compensation? No    |
| Lauren     | Colbert   | Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center     | None  | None  | None   |
| Sean       | Collins   | Department of Radiation Medicine, MedStar Georgetown University Hospital                | <b>Accuray:</b> Consultant: Honoraria: clinical consultation: Present   | None  | None   |
| Eileen     | Connolly  | Columbia University Medical Center: Assistant Professor of Radiation Oncology: Employee | <b>Eisai:</b> Research: Recipient: Me: Salary Support: No: national/overall principal investigator: Investigator initiated grant: Grant/research funding: Biomarker grant: To present<br><b>Merck:</b> Research: Recipient: Me: Salary Support: No: national/overall principal investigator: Investigator initiated grant: Grant/research funding: Phase I clinical trial: To present   | <b>BMS:</b> Stock: Associate director of drug development | None   |
| Cheryl     | Connors   | Johns Hopkins: Program Director of Organizational Resilience: Employee                  | None  | None  | None   |
| Louis      | Constine  | University of Rochester Medical Center: Professor: Employee                             | <b>National Cancer Institute PDQ pediatric board:</b> Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Honoraria, Travel expenses: advisory board: 2026<br><b>Up-to-date:</b> Consultant: Honoraria: consultant: 2026   | None  | None   |
| Kimberly   | Corbin    | Mayo Clinic: Physician: Employee  | <b>National Consortium of Breast Canters:</b> Education/Meeting Faculty: Travel expenses: Co-Chair clinical planning committee. Travel to national meeting reimbursed by NCBC: present  | None  | None   |
| German     | Corredor  | Emory University  | None  | None  | None   |
| Kelsey     | Corrigan  | UT MD Anderson Cancer Center: Resident: Employee  | None  | None  | None   |
| June       | Corry     | GenesisCare: Radiation Oncologist: Employee   | None  | None  | None   |

**ASTRO 2024 Annual Meeting - Faculty and Presenters' Disclosures**

| First Name  | Last Name | Employment Relationships   | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria  | Ownerships/Investments/Intellectual Property  | Leadership/Positions of Authority  |
|-------------|-----------|--|--|---|--|
| Christopher | Corso     | SERO: Physician: Partner   | None   | <b>Oncology Practice Solutions:</b><br>Ownership equity: I am a silent partial owner of OPS which is manages SERO's non-medical business including HR, practice support, revenue cycle etc. This was a spin off from the SERO business office that now offers services to other groups. I am not involved in the affairs of this company at all.<br><b>Radiation Oncology Centers Holdings:</b> Ownership equity: As a SERO partner, I had the opportunity to buy in to the technical component | Added column N. 09/17  |
| Pippa       | Cosper    | University of Wisconsin-Madison: Assistant Professor: Employee   | <b>Guidepoint network:</b> Consultant: Compensation/Payment: sometimes consult for them regarding head and neck cancer biology or trials.: Present<br><b>NIH:</b> Research: Recipient: Me: Salary Support: Yes: national/overall principal investigator: chromosomal instability: Grant/research funding: PI: 7/2026   | None  | None   |
| Laurence    | Court     | Department of Radiation Physics, The University of Texas MD Anderson Cancer Center<br>The University of Texas MD Anderson Cancer Center<br>UTHealth Houston Graduate School of Biomedical Sciences | None   | None  | None   |
| Matthew     | Cousins   | Self Regional Healthcare: Radiation Oncologist: Employee   | None   | None  | University of Michigan: Academic: Adjunct Clinical Assistant Professor: Unpaid faculty member: Compensation? No  |
| Elizabeth   | Covington | University of Alabama at Birmingham: Adjunct Faculty: Adjunct Faculty<br>University of Michigan: Associate Professor: Employee   | None   | None  | American Association of Physicist in Medicine: Chair of Task Group TG-263U1: Chair of task group on standardized nomenclature in radiation oncology: Compensation? No                        |
| Juanita     | Crook     | BCancer: Radiation Oncologist: Employee  | <b>Astellas:</b> Advisory Board: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Honoraria: Embark data discussion: Nov 24, 2023<br><b>Tersera:</b> Advisory Board: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Honoraria: Uptake of Zoladex by province: Nov 2022   | None  | None   |
| Sunan       | Cui       | Department of Radiation Oncology, University of Washington/ Fred Hutchinson Cancer Center  | None   | None  | None   |
| Kaylie      | Cullison  | Department of Radiation Oncology, Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami  | None   | None  | None   |
| Karen       | Curnow    | Georgetown University  | None   | None  | None   |
| Walter      | Curran    | GenesisCare: Global Chief Medical Officer: Employee  | <b>AstraZeneca:</b> Consultant: Compensation/Payment: I serve on an Astra Zeneca data monitoring committee for several of their ongoing clinical trials: Present<br><b>Bristol Myers Squibb:</b> Consultant: Compensation/Payment: I chair one of their data monitoring committees for ongoing clinical trials: Present<br><b>CPRIT:</b> Consultant: Compensation/Payment: I serve on a grant review committee for CPRIT grants: Present<br><b>Roswell Park Cancer Institute:</b> Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Compensation/Payment: I serve on an advisory board for a research program at RPCI: Present<br><b>University of Pittsburgh:</b> Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Compensation/Payment: I serve on the Hillman UPMC Cancer Center External Advisory Board: Present<br><b>UT MD Anderson CC:</b> Consultant: Compensation/Payment: I review grant applications on behalf of MD Anderson: Present<br><b>Washington University:</b> Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: | <b>Arterra:</b> Stock options: none other than owning stock options<br><b>GenesisCare:</b> Stock: I serve as the Global CMO and own stock in this company<br><b>Nantworks:</b> Stock: none other than stock ownership   | <b>Georgia Proton Center:</b> proton facility: board member: serve on board: Compensation? No<br><b>RTOG Foundation:</b> research foundation: Board Member: serve on board: Compensation? No |

**ASTRO 2024 Annual Meeting - Faculty and Presenters' Disclosures**

| First Name | Last Name       | Employment Relationships  | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria   | Ownerships/Investments/Intellectual Property | Leadership/Positions of Authority   |
|------------|-----------------|---|---|--|---|
| Elliott    | Czarnecki       | Department of Radiation Oncology, Henry Ford Cancer Institute   | None  | None   | None  |
| Luqman     | Dad             | Columbia University Irving Medical Center: Assistant Professor: Employee  | None  | None   | None  |
| Shraddha   | Dalwadi         | UT Health San Antonio: Assistant Professor: Employee  | None  | None   | None  |
| Savita     | Dandapani       | City of Hope: Associate professor: Employee   | <b>Bayer:</b> Research: Recipient: Me: Salary Support: No: national/overall principal investigator: Grant/research funding: radium223 oligomet prostate: Ongoing<br><b>imaginab:</b> Research: Recipient: Me: Salary Support: No: provides imaging agent for my research investigator initiated trial: : Grant/research funding, Other-provides imaging agent for my IIT: provides imaging agent for my IIT: Ongoing  | None   | None  |
| Subhadip   | Das             | Alberta Health Services, Alberta: Clinical Fellow: Employee: Relationship ended 11/09/2022<br>Provincial Health Services Authority, British Columbia: Clinical Fellow: Employee | None  | None   | None  |
| Emily      | Daugherty       | University of Cincinnati: Associate Professor: Employee   | None  | None   | None  |
| Samantha   | Dawes           | American Society for Radiation Oncology   | None  | None   | None  |
| Laura      | Dawson          | Princess Margaret Cancer Centre, UHN: Staff Physician: Employee   | <b>AstraZeneca:</b> Education/Meeting Faculty: Honoraria: Speaker at liver cancer meeting: 11/2023<br><b>Elekt:</b> Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Other-No compensation to date, but expect honoraria in the future: Provide advice on future of radiation. oncology: Ongoing   | None   | None  |
| M. Dolores | De La Mata Moya | CENTRO MEDICO ABC: HEAD OF RADIOTHERAPY: Employee<br>TEC MONTERREY MEDICINE FACULTY: PROFESSOR: Employee  | <b>ASTRA ZENECA:</b> Speaker's Bureau: Honoraria, Travel expenses: LUNG CANCER RADIOTHERAPY: To present<br><b>C-RAD:</b> Education/Meeting Faculty: Uncompensated: webinar: To present<br><b>ELEKTA:</b> Advisory Board, Consultant, Education/Meeting Faculty, Speaker's Bureau: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Honoraria, Travel expenses: SMART CLINIC developer reference training center in LATAM: To present  | None   | <b>CENTRO MEDICO ABC:</b> radiotherapy and oncology invesments in Mexico: HEAD OF RADIOTHERAPY, Tumor Comittees director: salary head of RT, no for Comittee: Compensation? No<br><b>LATIN AMERICA RADIOTHERAPY SOCIETY:</b> SOMERA, IBLA: secretary: secreatry societies: Compensation? No |
| Kamel      | Debbi           | APHP. Radiation Oncology Department and Henri Mondor Breast Center. Henri Mondor University Hospital. University of Paris East Creteil (UPEC). INSERM U955 (i-Biot), IMRB       | None  | None   | None  |
| Savannah   | Decker          | Thayer School of Engineering, Dartmouth College   | <b>DoseOptics, LLC:</b> Consultant: Compensation/Payment: Research and Development Consultant: Present  | None   | None  |
| Sandra     | Demaria         | Weill Cornell Medicine: Professor: Employee   | <b>Boheringer Ingelheim:</b> Research: Recipient: My Institution: Salary Support: No: Research: ReseaContract for preclinical studies: Compensation/Payment: Research contract for preclinical studies: 12/2024<br><b>Johnson &amp; Johnson:</b> Advisory Board: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Honoraria: Scientific Advisory Board member for immuno-oncology drug: 02/2023<br><b>Lytix Biopharma:</b> Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Honoraria: Scientific Advisory Board member for immuno-oncology drug: 03/25/2024 | None   | None  |
| Nicolas    | Demogeot        | CLRCC Institut de Cancérologie de Lorraine  | <b>Astellas:</b> Advisory Board: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Honoraria: Radiotherapist needed:  | None   | None  |

| ASTRO 2024 Annual Meeting - Faculty and Presenters' Disclosures |              |   |  |  |   |
|---|--------------|---|--|--|---|
| First Name  | Last Name    | Employment Relationships  | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria  | Ownerships/Investments/Intellectual Property | Leadership/Positions of Authority   |
| Neil  | Desai        | University of Texas Southwestern: Physician employee: Employee                                | <b>Astellas/Pfizer:</b> Research: Recipient: My Institution: Salary Support: No: co-PI (overall; not coordinating PI): Antibody drug conjugate combination with radiotherapy in bladder cancer: Grant/research funding: Co-P.I. (single center investigator initiated study); not coordinating PI: 9/2027<br><b>Boston Scientific:</b> Advisory Board, Consultant, Research: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Recipient: My Institution: Salary Support: No: national/overall principal investigator: Prostate SBRT trial focusing on sexual function: Grant/research funding, Compensation/Payment: Research funding of trial ; consulting: annual limit by university management plan of this COI: To present<br><b>Reflexion:</b> Research: Recipient: My Institution: Salary Support: Yes: national/overall principal investigator: Technical development of PSMA-11 68Ga (Illucix) imaging on Reflexion treatment/imaging system: Grant/research funding, Salary support: Overall P.I. (single center investigator initiated study): 9/2026<br><b>Society Urologic Oncology:</b> Education/Meeting Faculty: Honoraria: Talk at annual meeting: 12/2022<br><b>Telix:</b> Advisory Board, Research: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Recipient: My Institution: Salary Support: No: national/overall principal investigator: PET in prostate cancer: Grant/research funding, Compensation/Payment: PI of investigator initiated study activated 2024; Consulting - Ad Board 2023 x1 per management plan from university for COI: | None   | <b>NCCN:</b> Guideline committee: Institutional representative prostate cancer: Institutional representative prostate cancer: Compensation? No  |
| Jay   | Detsky       | Sunnybrook Hospital: Staff radiation oncologist: Independent Contractor                       | <b>Elekta:</b> Speaker's Bureau: Honoraria: Educational presentation: Dec 2023<br><b>Novocure:</b> Advisory Board: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Honoraria: Advisory board: Sept 2023<br><b>Sumitomo:</b> Speaker's Bureau: Honoraria: Educational presentation: June 2024   | None   | None  |
| Curtiland   | Deville      | Johns Hopkins University: Associate Professor: Employee                                       | None   | None   | <b>ASTRO:</b> Vice Chair, Council on Health Equity, Diversity & Inclusion: Board of Directors: Compensation? No<br><b>ASTRO Red Journal:</b> Deputy Editor: Deputy Editor: Compensation? No |
| Kavita  | Dharmarajan  | Mount Sinai: Associate Professor: Employee  | None   | None   | None  |
| Vishal  | Dhere        | Emory University: Assistant Professor: Employee   | None   | None   | None  |
| Virginia  | Diavolitsis  | Ohio State University: Physician: Partner<br>Riverside Radiation Oncology: Physician: Partner | None   | None   | None  |
| Roberto   | Diaz         | Moffitt Cancer Center: Senior Member: Employee  | <b>Lumicell:</b> Consultant: Travel expenses, Compensation/Payment: Consultant to assess the benefits for patients by removing residual cancer left behind after the standard lumpectomy procedure, specifically, from negative margin orientations that would have not been addressed by a second surgery.: 3/5/24  | None   | None  |
| Dayssy  | Diaz Pardo   | The Ohio State University: Associate Professor: Employee                                      | <b>ASTRO:</b> Education/Meeting Faculty: Honoraria: Speaker ASTRO refresher 2023: 04/26/23   | None   | <b>The Ohio State University:</b> Vice-Chair of DEI: I am the Vice-Chair of DEI: Compensation? No   |
| Adam  | Dicker       | Thomas Jefferson University: SVP, Prof and Chair: Employee                                    | <b>Empirica Lab:</b> Consultant: Uncompensated, Other-Stock option: Advisor for learning system: To present<br><b>Janssen:</b> Consultant: Compensation/Payment: Data Safety monitoring: To present<br><b>Oncohost:</b> Consultant: Compensation/Payment: Clinical Advisor/CMO: To present<br><b>Oranomed:</b> Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Compensation/Payment: Advisory board, 1-2X a year: To present<br><b>Prostate Cancer Foundation:</b> Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: : Grant/research funding: Research Grant: To present<br><b>SBR Bio:</b> Consultant: Compensation/Payment: Clinical Advisor: To present  | None   | None  |
| Daniel  | Dickstein    | Mt Sinai Hospital: Resident Physician: Employee   | <b>American Society of Clinical Oncology:</b> Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: Clinical oncology: Grant/research funding: Principal investigator: 06/30/2024  | None   | None  |
| Eric  | Diffenderfer | University of Pennsylvania: Assistant Professor: Employee                                     | <b>IBA:</b> Research: Recipient: My Institution: Salary Support: No: Researcher: Proton: Grant/research funding: Proton: Present   | None   | None  |

**ASTRO 2024 Annual Meeting - Faculty and Presenters' Disclosures**

| First Name | Last Name  | Employment Relationships   | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria  | Ownerships/Investments/Intellectual Property | Leadership/Positions of Authority   |
|------------|------------|--|--|--|---|
| Thomas     | Dilling    | Moffitt Cancer Center: Senior Member: Employee   | AstraZeneca: Advisory Board, Consultant: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Honoraria: advisory board re: clinical care questions for patients with lung   | Moderna: Stock: stock owner                  | NCCN: NSCLC, meso, and thymoma tx guideline committees: Have received travel reimbursement in the past. Have also received compensation for teaching session at NCCN Annual Meeting: Compensation? No   |
| Jason      | Domogauer  | New York University, School of Medicine: Attending: Employee   | Novartis: Consultant: Compensation/Payment: Consulting on clinical trial protocol inclusion.: 9/22/23  | None   | None  |
| Olga       | Dona Lemus | University of Rochester: Assistant Professor: Employee   | None   | None   | None  |
| Lei        | Dong       | Hospital of the University of Pennsylvania: Professor: Employee  | None   | None   | None  |
| Eric       | Donnelly   | Northwestern Medicine: Associate Professor, Director of Brachytherapy: Employee  | None   | None   | None  |
| Anna       | Dornisch   | Department of Radiation Medicine and Applied Sciences, UC San Diego  | None   | None   | None  |
| Jennifer   | Dorth      | University Hospitals Seidman Cancer Center: Associate Professor: Employee  | None   | None   | None  |
| Kevin      | Du         | Yale School of Medicine: Associate Professor: Employee   | None   | None   | None  |
| Rongxu     | Du         | Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital & Institute | None   | None   | None  |
| Piotr      | Dubrowski  | Stanford University: Clinical Instructor: Employee   | None   | None   | None  |
| Stephanie  | Dudzinski  | MD Anderson Cancer Center: Resident Physician: Employee<br>The University of Texas MD Anderson Cancer Center: Resident Physician: Employee                                   | None   | None   | None  |
| Neal       | Dunlap     | University of Louisville: Professor and Chair: Employee  | AstraZeneca: Speaker's Bureau: Compensation/Payment: Use of radiation in stage III NSCLC: to present   | None   | None  |
| Michelle   | Echevarria | Moffitt Cancer Center: Radiation Oncologist: Employee  | None   | None   | None  |
| Bradley    | Eckelmann  | Department of Human Oncology, University of Wisconsin Hospitals and Clinics  | None   | None   | None  |
| Carolyn    | Eckrich    | University of Wisconsin Madison: Therapeutic Physics Resident: Employee  | None   | None   | None  |
| Jason      | Efstathiou | MASSACHUSETTS GENERAL HOSPITAL: Professor/Vice-Chair: Employee   | Angiodynamics: Advisory Board: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Honoraria: ad board member: 6/23/2023<br>Astellas: Education/Meeting Faculty: Honoraria: education faculty: 7/26/2023<br>Blue Earth Diagnostics: Consultant: Honoraria: consultant, prostate cancer: Ongoing<br>Boston Scientific: Consultant: Honoraria: consultant, prostate cancer: Ongoing<br>Elekta: Education/Meeting Faculty: Honoraria: panelist at education meeting: 9/30/2023<br>IBA: Education/Meeting Faculty: Honoraria: speaker at educational conference: 5/14/2023<br>Lantheus: Advisory Board: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Honoraria: ad board, prostate cancer: 10/2/2023<br>Myovant: Advisory Board: Single: Access to company proprietary information or provide your expertise; or any public-facing use of | None   | ACRO: Board member: Board member: Compensation? No<br>Massachusetts Prostate Cancer Coalition (MPCC): patient advocacy: Board member: Board member: Compensation? No<br>NRG Oncology: Vice-Chair GU: Vice-Chair GU, Bladder lead: Compensation? No<br>ROI: Board member: board member: Compensation? No |
| Hans       | Eich       | Department of Radiation Oncology, University Hospital Muenster   | Kyowa Kirin: Advisory Board, Consultant: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Honoraria: Treatment of cutaneous lymphoma: 28.5.24<br>Takeda: Speaker's Bureau: Honoraria: Role of RT in plasmocytoma: 9.11.23   | None   | None  |
| Georges    | El Fakhri  | Yale School of Medicine  | None   | None   | None  |



**ASTRO 2024 Annual Meeting - Faculty and Presenters' Disclosures**

| First Name | Last Name  | Employment Relationships   | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria   | Ownerships/Investments/Intellectual Property   | Leadership/Positions of Authority  |
|------------|------------|--|---|--|--|
| Rami       | El Shafie  | University Medical Center Göttingen, Dept. of Radiotherapy: Deputy Director: Employee  | <b>AstraZeneca:</b> Consultant, Research: Recipient: Me: Salary Support: No: site principal investigator: NSCLC: Grant/research funding, Honoraria, Travel expenses, Compensation/Payment: speaker, consultant, Site PI: Ongoing<br><b>Merck:</b> Advisory Board, Consultant, Research: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Recipient: Me: Salary Support: No: speaker: HNSCC: Honoraria, Travel expenses, Compensation/Payment: speaker, consultant, Site PI: Ongoing<br><b>MSD:</b> Consultant, Research: Recipient: My Institution: Salary Support: No: site principal investigator: NSCLC: Grant/research funding: speaker, consultant, Site PI: Ongoing<br><b>Novocure:</b> Advisory Board, Consultant, Research: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Recipient: Me: Salary Support: No: speaker: GBM, Mesothelioma, NSCLC: Honoraria, Travel expenses, Compensation/Payment: speaker, consultant: Ongoing | None   | None   |
| Baher      | Elgohari   | The University of Pittsburgh: MD: Employee   | None  | None   | None   |
| Dina       | El-Habashy | The university of Texas MD Anderson Cancer Center: Graduate Student-non-UTHSCH: Employee   | None  | None   | None   |
| Andrew     | Elia       | Massachusetts General Hospital: Assistant Professor of Radiation Oncology: Employee  | None  | None   | None   |
| Shekinah   | Elmore     | University of North Carolina   | None  | None   | None   |
| Ronald     | Ennis      | Rutgers Cancer Institute of New Jersey: Professor and Vice Chair: Employee   | None  | None   | None   |
| Beth       | Erickson   | Medical College of Wisconsin: Professor of Radiation Oncology: Employee  | None  | None   | <b>ASTRO:</b> Fellows Committee: Chair: Oversee the selection of ASTRO Fellows: Compensation? No<br><b>ASTRO:</b> ASTRO Board of Directors: Chair of the Education Council: Help to oversee the educational efforts of ASTRO: Compensation? No   |
| Freddy     | Escorcía   | National Cancer Institute: Investigator: Employee  | None  | None   | None   |
| Natia      | Esiashvili | Emory University: Professor: Employee  | None  | None   | None   |
| Suzanne    | Evans      | Yale University: Professor: Employee   | <b>Clarity Patient Safety Organization:</b> Consultant: Honoraria, In-kind donations: analysis of the aapm and ASTRO sponsored incident learning system: Present  | None   | <b>ASTRO:</b> Clinical Affairs and Quality Committee Vice Chair: advisement on matters of quality to ASTRO: Compensation? No   |
| Daniel     | Faden      | Massachusetts Eye and Ear  | None  | None   | None   |
| Jiaqi      | Fan        | Department of Radiation Oncology, Cyberknife and Radiotherapy, Faculty of Medicine and University Hospital Cologne                         | None  | None   | None   |
| Xin-Juan   | Fan        | Department of Radiation Oncology, the First Affiliated Hospital of Zhengzhou University  | None  | None   | None   |
| Michael    | Farris     | Department of Radiation Oncology, Wake Forest University School of Medicine  | None  | <b>Wake Forest hospital:</b> Copyright/Patent/License/Royalty: not related to this project but i have a patent on a 3d printed brachytherapy marker Application No.: 63/601,437 Title: CONTRAST MARKERS FOR USE IN MEDICAL PROCEDURES Inventors: Michael K. Farris, et al. Filing Date: November 21, 2023 Country: United States MCC 2023011145-00204-1M | None   |
| Mark       | Farrugia   | Roswell Park Comprehensive Cancer Center   | None  | None   | None   |
| Bin        | Feng       | Chongqing university cancer hospital: engineer: Employee   | None  | None   | None   |
| Dianne     | Ferguson   | Brigham and Women's: Medical Physicist: Employee   | None  | None   | None   |
| Elena      | Fidarova   | IAEA   | None  | None   | None   |
| Emma       | Fields     | Virginia Commonwealth University: Associate Professor: Employee  | None  | None   | None   |
| Christine  | Fisher     | University of Colorado   | None  | None   | None   |
| Nic        | Fisk       | University of Rhode Island: Assistant Professor: Employee<br>Yale University: Graduate Researcher: Employee: Relationship ended 08/15/2023 | None  | None   | <b>Brown Center for Clinical Cancer Informatics and Data Science:</b> A new center at Brown University/Lifespan Hospital whose focus is on using informatics, machine learning, and data science to advance cancer care and research. It includes researchers, core members, and practicing clinicians.: Faculty Member: I am a new, formal member of the center--one of three faculty not on the leadership (which itself is composed of 3 founding faculty).: Compensation? No |

**ASTRO 2024 Annual Meeting - Faculty and Presenters' Disclosures**

| First Name | Last Name | Employment Relationships  | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria   | Ownerships/Investments/Intellectual Property | Leadership/Positions of Authority   |
|------------|-----------|---|---|--|---|
| Jessica    | Fleming   | The Ohio State University: Radiobiologist: Employee   | FRPT: Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Uncompensated: Advises on content of FRPT annual scientific meeting.: Present   | None   | Advances in Radiation Oncology: Associate Senior Editor: Serve on journal editorial board. Review article submissions and assign necessary reviewers.: Compensation? No   |
| Shannon    | Fogh      | Fred Hutch/UW: Associate Professor: Employee  | None  | None   | None  |
| Eric       | Ford      | University of Washington School of Medicine, Fred Hutch Cancer Center, Department of Radiation Oncology   | None  | None   | None  |
| Idalid     | Franco    | Brigham and Women's Hospital Dana-Farber CC: Radiation Oncologist: Employee   | ASTRO/RTOG NRG Oncology Health Equity Fellowship: Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: Increasing diversity in gynecologic clinical trial: Grant/research funding: PI working on increasing diversity of representation in gynecologic clinical trials.: To present<br>Brigham and Women's Hospital Dana-Farber CC: Research: Recipient: Me: Salary Support: No: Career Development Award: Career Development Award: Grant/research funding: Career Development Award for Minority Faculty: Present<br>Diversity Supplement, National Cancer Institute: Research: Recipient: My Institution: Salary Support: No: site principal investigator: Biomarkers and prostate cancer: Grant/research funding: Biomarker approaches to high-risk prostate cancer: Present<br>NIH/NCI Loan Repayment Program: Research: Recipient: Me: Salary Support: No: site principal investigator: Cost effectiveness treatment in prostate cancer: Grant/research funding: Cost effectiveness for prostate cancer treatment: Present | None   | American Society of Radiation Oncology ASTRO: Vice Chair of the Health Equity Education Committee: Vice Chair: Vice Chair of the Health Equity Education Committee for the Council on Health Equity Diversity and Inclusion of ASTRO: Compensation? No: Relationship ended 10/03/2022<br>Association of Residents in Radiation Oncology: Resident branch of ASTRO: Executive Vice Chair: Executive Vice Chair of overall organization and Chair of the Equity and Inclusion Subcommittee: Compensation? No: Relationship ended 10/03/2022 |
| Laura      | Freedman  | University of Miami: Physician: Employee  | None  | None   | None  |
| Matthew    | Gallitto  | Department of Radiation Oncology, Columbia University Irving Medical Center   | None  | None   | None  |
| Thomas     | Galloway  | Fox Chase Cancer Center: Professor: Employee  | EMD Serono: Consultant: Honoraria: Management of head and neck cancer: To present   | None   | None  |
| Lorenzo    | Galluzzi  | Weill Cornell Medicine: Assistant Professor: Employee   | Onxeo: Advisory Board: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Honoraria: Biotech: 3/31/24<br>Promontory: Advisory Board: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Honoraria: Biotech: 3/31/24   | Promontory: . . .                            | None  |
| Mauricio   | Gamez     | Mayo Clinic: MD: Employee   | None  | None   | None  |
| Gregory    | Gan       | University of Kansas Medical Center: Assistant Professor: Employee  | Genentech: Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: IIT: Grant/research funding, Other-Drug support: IIT PI, translational research: 7/30/23<br>Varian Inc: Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: IIT: Grant/research funding: PI, IIT: 7/31/26  | None   | None  |
| Hao        | Gao       | University of Kansas: Associate Professor: Employee   | None  | None   | None  |
| Lin-ru     | Gao       | Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College | None  | None   | None  |
| Allison    | Garda     | Mayo Clinic: Consultant, Assistant Professor: Employee  | None  | None   | None  |
| Heather    | Gatcombe  | Emory: Associate Professor: Employee  | None  | None   | None  |
| Marc       | Gaudet    | Division of Radiation Oncology, The Ottawa Hospital and the University of Ottawa  | None  | None   | None  |
| Naamit     | Gerber    | NYU Langone Health: Associate Professor: Employee   | Accuray: Advisory Board: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Honoraria: Accuray breast advisory board at ASTRO 2023: 10/3/23<br>John Theurer Cancer Center: Education/Meeting Faculty: Honoraria: SABCS update symposium: To present<br>PreludeDx: Research: Recipient: My Institution: Salary Support: No: Research collaboration: early stage breast cancer: Grant/research funding: early stage breast cancer: To present  | None   | ASTRO: ASTRO APBI Guidelines Committee: member: Serve on ASTRO APBI guidelines committee and chair of one of the key question committees: Compensation? No  |

**ASTRO 2024 Annual Meeting - Faculty and Presenters' Disclosures**

| First Name | Last Name | Employment Relationships   | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria  | Ownerships/Investments/Intellectual Property  | Leadership/Positions of Authority  |
|------------|-----------|--|--|---|--|
| Laila      | Gharzai   | Northwestern University: Physician: Employee   | None   | None  | None   |
| Rohi       | Gheewala  | Hospital of University of Pennsylvania: Resident: Employee                                       | None   | None  | None   |
| Iris       | Gibbs     | Stanford Medicine: Professor: Employee   | Accuray, Inc.: Other-Honoraria for lectures : Honoraria, Travel expenses: To present<br>University of Delaware CAS Dean's Advisory Council: Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Other-None: Alumni advisory board: To present   | None  | American College of Radiology: Medical organization representing diagnostic and interventional radiologists, radiation oncologists, nuclear medicine physicians and medical physicists.: Member and Chapter leader: Serve on multiple chapters and committees including CARROS, CRS, Diversity Committee: Compensation? No<br>ICG Enterprises, Inc.: 501(c)3 non-profit that dispenses educational scholarships and community outreach: Chief Officer: Founder of local non-profit: Compensation? No: Relationship ended 01/06/2023<br>The Radiosurgery Society: The Radiosurgery Society® (RSS) is an international, medical professional, non-profit society consisting of physicians, physicists and healthcare professionals dedicated to advancing the education, science and clinical practice of stereotactic radiosurger: Board of Directors: Member of the Board of Directors: Compensation? No |
| Matthew    | Gil       | University of Strathclyde  | None   | None  | None   |
| Beant      | Gill      | Associates in Radiation Medicine: Physician: Partner<br>Luminis Health: Physician: Employee      | The George Washington University: Other-Faculty: Uncompensated: Clinical role for mentorship and teaching students: Present  | Associates in Radiation Medicine: Ownership equity: Partner:<br>Partnership: Partner: Ownership equity: Partner: Partnership: Partner | American College of Radiology: Organization for radiology and radiation oncology: CAC Representative: Representative for local coverage determination review of radiation oncology services: Compensation? No<br>Chesapeake Potomac Regional Cancer Center: Community practice for radiation oncology services: Medical Director: Medical director for clinical operations: Compensation? No   |
| Gobind     | Gill      | Department of Radiation Oncology and Applied Sciences, Dartmouth Cancer Center, Dartmouth Health | None   | None  | None   |
| Erin       | Gillaspie | Creighton University: Thoracic Surgeon: Employee   | AstraZeneca: Consultant: Honoraria: AZ: present<br>E.R. Squibb & Sons, L.L.C.: Consultant: Honoraria: BMS: present<br>Intuitive Surgical: Consultant: Honoraria: teaching: 10/2022   | None  | None   |
| Erin       | Gillespie | University of Washington: Associate Professor: Employee  | None   | None  | eContour: Free educational website: Co-founder: This is an uncompensated leadership role. The website is funded by external grants to my institution which support programmers and content development.: Compensation? No  |
| John       | Ginn      | Duke University: Assistant Professor: Employee   | None   | None  | None   |
| Frank      | Giordano  | University Medical Center Mannheim   | Biotech, Inc.: Advisory Board, Consultant, Research: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Recipient: My Institution: Salary Support: No: national/overall principal investigator: Oncomagnetic Therapy: Grant/research funding, Honoraria, Travel expenses: Trial PI, Advisor: 01/2028<br>Carl Zeiss Meditec AG: Advisory Board, Consultant, Education/Meeting Faculty, Research, Speaker's Bureau: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Recipient: My Institution: Salary Support: No: national/overall principal investigator: IORT: Grant/research funding, Honoraria, Travel expenses: PI INTRAGO: 01/2027<br>ELEKTA AB: Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: Reference Site: Grant/research funding, Travel expenses: Gamma Knife, IMRT teaching course: 01/2028<br>TME Pharma AG: Advisory Board, Consultant, Research: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Recipient: My Institution: Salary Support: No: national/overall principal investigator: GLORIA Trial: Grant/research funding, Honoraria, Travel expenses: PI GLORIA Phase 1/2 trial: 01/2028<br>Varian Medical Systems, Inc.: Advisory Board, Research: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Recipient: My Institution: Salary Support: No: national/overall principal investigator: ETHOS: Grant/research funding, Honoraria, Travel expenses: Advisor, online adaptive RT: 01/2028 | TME Pharma: Stock: PI GLORIA Trial  | MIISM: Medical Technology: Managing Director: MT institute director: Compensation? No  |
| David      | Gius      | University of Texas Science Center San Antonio: Assistant Dean for Research: Employee            | National Cancer Institute: Research: Recipient: Me: Salary Support: No: site principal investigator: 3 R01's: Grant/research funding: PI: 04/01/2025   | None  | University of Texas Health Science Center San Any: Assistant Dean for Research: Dean for funding portfolio: Compensation? No   |
| Scott      | Glaser    | City of Hope: Radiation Oncologist: Employee   | None   | None  | None   |

**ASTRO 2024 Annual Meeting - Faculty and Presenters' Disclosures**

| First Name  | Last Name   | Employment Relationships  | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria  | Ownerships/Investments/Intellectual Property  | Leadership/Positions of Authority  |
|-------------|-------------|---|--|---|--|
| Carri       | Glide-Hurst | University of Wisconsin Madison: Director, Radiation Oncology Physics: Employee   | <p><b>GE Healthcare:</b> Research: Recipient: My Institution: Salary Support: No: Co-Investigator: Co-I on a research agreement in MR-Simulation: Grant/research funding: Co-I on clinical trial in head and neck MR simulation: To present</p> <p><b>Leo Cancer Care, Ltd:</b> Research: Recipient: My Institution: Salary Support: No: site principal investigator: Preclinical research in upright radiation therapy: In-kind donations: Research agreements on pre-clinical upright radiation therapy: To present</p> <p><b>Medscent:</b> Other-Research collaboration: Uncompensated: Advanced detectors for MRI-guided radiation therapy: To present</p> <p><b>NIH/NCI:</b> Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: Reducing cardiac toxicity with advanced technology: Grant/research funding: PI of NIH R01: To present</p> <p><b>Raysearch:</b> Research: Recipient: My Institution: Salary Support: No: site principal investigator: Treatment planning lab, Master research agreement: Grant/research funding, In-kind donations: Master Research Agreement and Educational Treatment Planning Lab: To present</p>  | <p><b>Flexible Modular Phantom and Method for Medical Applications Using Interchangeable Inserts:</b> Copyright/Patent/License/Royalty: Flexible Modular Phantom and Method for Medical Applications Using Interchangeable Inserts</p> <p><b>GE/GE Healthcare:</b> Stock: Personal investment predating research relationship</p> <p><b>Method and apparatus for categorizing breast density:</b> Copyright/Patent/License/Royalty: Method and apparatus for categorizing breast density</p> <p><b>Patient interface system:</b> Copyright/Patent/License/Royalty: Patient interface system</p> | None   |
| Alexander   | Goglia      | Memorial Sloan Kettering Cancer Center  | None   | None  | None   |
| Encouse     | Golden      | Weill Cornell Medicine: Radiation Oncologist: Employee  | None   | None  | None   |
| Daniel      | Gomez       | Memorial Sloan-Kettering Cancer Center: Attending Physician: Employee   | <p><b>AstraZeneca:</b> Advisory Board, Consultant, Research: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Recipient: Me: Salary Support: No: national/overall principal investigator: PI of Study: Grant/research funding, Honoraria: PI of Study: To present</p> <p><b>GRAIL:</b> Consultant: Honoraria: Consultant: To present</p> <p><b>Johnson and Johnson:</b> Consultant: Honoraria: Consultant: To present</p> <p><b>Medtronic:</b> Advisory Board, Consultant: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Honoraria, Compensation/Payment: Consultant, advisory board (steering committee): To present</p> <p><b>Varian:</b> Consultant: Education/Meeting Faculty: Grant/research</p>  | None  | None   |
| Charlyn     | Gomez       | University of Maryland School of Medicine   | None   | None  | None   |
| Brian       | Gonzalez    | Moffitt Cancer Center: Associate Center Director: Employee  | <p><b>Elly Health:</b> Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Travel expenses: Advisory</p>   | None  | <b>Society of Behavioral medicine:</b> Professional society: Member Delegate: Elected position: Compensation? Yes: Relationship ended 03/31/2024 |
| Christopher | Goodman     | <p>London Health Sciences Centre: Radiation Oncologist: Independent Contractor</p> <p>University of Texas MD Anderson Cancer Center: Adjunct Assistance Professor of Radiation Oncology: Independent Contractor</p> <p>University of Western Ontario: Assistant Professor of Oncology: Independent Contractor</p> | <p><b>AstraZeneca:</b> Advisory Board: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Honoraria: Advisory board: November 2022</p> <p><b>Need Inc.:</b> Consultant: Compensation/Payment: Consultant: Ongoing</p>   | None  | None   |
| Chelain     | Goodman     | University of Texas MD Anderson Cancer Center: Assistant Professor: Employee  | <p><b>ASTRO-BCRF:</b> Research: Recipient: My Institution: Salary Support: Yes: national/overall principal investigator: Circulating tumor cells and breast cancer: Grant/research funding, Salary support: Grant/research funding, Travel expenses, Salary support: Career Development Award: Present</p> <p><b>Menarini Silicon biosystems:</b> Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: CTCs and breast cancer radiotherapy: In-kind donations: In-Kind Materials for Career Development Award: Present</p> <p><b>Menarini Silicon Biosystems:</b> Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: Circulating tumor cells and breast cancer radiotherapy: In-kind donations: In-Kind Materials for Career Development Award: Present</p> <p><b>NIH:</b> Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: Biomarkers and breast cancer radiotherapy: Grant/research funding, Salary support: Principal Investigator: Present</p> <p><b>UT MD Anderson Cancer Center:</b> Research: Recipient: Me: Salary Support: No: national/overall principal investigator: Circulating tumor DNA and breast cancer: Grant/research funding: Principal Investigator: Present</p> | None  | None   |

**ASTRO 2024 Annual Meeting - Faculty and Presenters' Disclosures**

| First Name  | Last Name     | Employment Relationships  | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria   | Ownerships/Investments/Intellectual Property  | Leadership/Positions of Authority   |
|-------------|---------------|---|---|---|---|
| Steven      | Gore          | National Cancer Institute: Acting Branch Chief: Employee  | None  | None  | None  |
| Mary        | Gospodarowicz | University of Toronto   | None  | None  | None  |
| Andre       | Gouveia       | McMaster University   | None  | None  | None  |
| Stephen     | Graves        | University of Iowa: Assistant Professor: Employee   | CDE Dosimetry Inc.: Consultant: Compensation/Payment: Radiopharmaceutical dosimetry calculations and quantitative imaging: To present<br>Fusion Radiopharma: Consultant: Compensation/Payment: Radiopharmaceutical dosimetry calculations and quantitative imaging: To present<br>RayzeBio: Consultant: Compensation/Payment: Radiopharmaceutical dosimetry calculations and quantitative   | None  | None  |
| Michael     | Green         | Ann Arbor Veterans Affairs: Faculty: Employee<br>University of Michigan: Faculty: Employee  | None  | None  | None  |
| Inga        | Grills        | Department of Radiation Oncology, Corewell Health William Beaumont University Hospital  | None  | None  | None  |
| Adam        | Grippin       | MD Anderson Cancer Center: Resident: Employee   | None  | None  | None  |
| Cheryl      | Gross         | ACGME   | None  | None  | None  |
| Craig       | Grossman      | Tampa General Hospital: Staff Physician: Employee<br>University of South Florida: Associate Professor: Employee   | None  | None  | None  |
| Anca        | Grosu         | German Cancer Consortium (DKTK), Partner Site Freiburg  | None  | None  | None  |
| Surbhi      | Grover        | University of Pennsylvania: Associate Professor<br>Radiation Oncology: Employee   | CDRF Global: Consultant: Compensation/Payment: Advising on topics for the dialogue: 12/1/23<br>GenesisCare: Consultant: Compensation/Payment: Advising on global solutions: 11/21/23<br>Lumonus: Consultant: Compensation/Payment: Advising on global solutions: 11/21/23   | Harbinger Health: Stock options: Advising on international data collection  | None  |
| B. Ashleigh | Guadagnolo    | MD Anderson: Professor: Employee  | None  | None  | Connective Tissue Oncology Society: oncology society-non-profit: Board Member: Board member: Compensation? No   |
| Matthias    | Guckenberger  | University Hospital Zurich: Chairman and Full Professor: Employee   | Astra Zeneca: Advisory Board: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Compensation/Payment: Participation in Ad board: 30.06.2024<br>Siemens Healthineers: Research: Recipient: My Institution: Salary Support: No: several projects: radiation oncology: Grant/research funding: professional agreement: 01.01.2026   | None  | ESTRO: President elect: ESTRO: President (elect) and board member: Compensation? No   |
| Susan       | Gueble        | Yale School of Medicine: Assistant Professor: Employee<br>Yale-New Haven Hospital: Radiation Oncology Resident: Employee: Relationship ended 06/30/2023 | National Institutes of Health: Research: Recipient: Me: Salary Support: Yes: national/overall principal investigator: Basic/translational oncology research: Grant/research funding, Salary support: Principal Investigator on NIH Grant 1DPSOD036128 "Therapeutic Potential of a Novel MGMT-Dependent DNA Interstrand Crosslinking Agent in the Treatment of DNA Repair Deficient Cancer": 7/31/2028<br>Spector Family Fund for Clinical Research and Investigation: Research: Recipient: Me: Salary Support: No: Principal Investigator on Internal Award: Basic/translational oncology research: Grant/research funding: Principal Investigator on Spector Family Fund for Clinical Research and Investigation and Yale Physician Scientist Development Internal Award "Overcoming Temozolomide Resistance with a Novel MGMT-Dependent DNA Interstrand Crosslinking Agent in Non-Glioma Cancers": 6/30/2025<br>Yale SPORE in Skin Cancer: Research: Recipient: Me: Salary Support: No: Principal Investigator on Internal Award: Basic/translational oncology research: Grant/research funding: Principal Investigator on Career Enhancement Program Internal Award from Yale SPORE in Skin Cancer "Defining the Interactions of a Novel DNA Modifying Agent with Melanoma-Specific Genetic Features and Molecular Targeted Agents": 8/31/2024 | Modifi Biosciences: Copyright/Patent/License/Royalty: Receive royalty distribution of licensing for "Mechanism of action of KL-50 a lead compound for the treatment of drug-resistant glioblastoma" | Yale Cancer Center: Neuroendocrine Tumor Program Steering Committee: Member: Member of the Yale Cancer Center Neuroendocrine Tumor Program Steering Committee: Compensation? No |
| Mariana     | Guerrero      | Department of Radiation Oncology, University of Maryland School of Medicine   | None  | None  | None  |
| Chandan     | Guha          | Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY: Professor and Vice Chairman: Employee  | Focused Ultrasound Foundation: Education/Meeting Faculty, Other-DSMB: Honoraria: Data Safety Monitoring and Faculty for Immunotherapy and Focused ultrasound: Ongoing<br>Varian: Consultant: Uncompensated: Consult on Immunomodulation and FLASH RT: ongoing   | BioConvergent Health: Limited liability company interest: Co-Founder  | None  |

**ASTRO 2024 Annual Meeting - Faculty and Presenters' Disclosures**

| First Name   | Last Name    | Employment Relationships   | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria  | Ownerships/Investments/Intellectual Property             | Leadership/Positions of Authority  |
|--------------|--------------|--|--|--|--|
| Chengcheng   | Gui          | Memorial Sloan Kettering Cancer Center: Resident Physician: Employee                       | None   | None   | None   |
| Jill         | Gunther      | MD Anderson Cancer Center: Associate Professor: Employee                                   | NIH NCI R25 grant: Education/Meeting Faculty: Grant/research funding: R25 grant to support summer medical student research: To present<br>Osler Institute: Other-I served as an examiner for the Mock Oral board review course.: Honoraria: I served as an examiner for the Mock Oral board review course.: Present<br>The Sterling Foundation: Research: Recipient: Me: Salary Support: No: Researcher: biomarkers for low grade lymphoma: Other-Philanthropic donation: Philanthropic donation: To present<br>University of Maryland Board Review Course: Other-I served as an examiner for the Mock Oral board review course.: Honoraria: I served as an examiner for the Mock Oral board review course.: Present                                 | None   | Rad Onc Education Collaborative Study Group: International group dedicated to promoting rad onc education: Board Member: Serve as on the leadership team of the organization and the co-lead the UME Working Group: Compensation? No   |
| Gaorav       | Gupta        | Memorial Sloan Kettering Cancer Center   | None   | None   | None   |
| Aashish      | Gupta        | Department of Imaging Physics, The University of Texas MD Anderson Cancer Center           | None   | None   | None   |
| Christian    | Guthier      | Brigham and Women's Hospital: Medical Physicist: Employee                                  | None   | None   | None   |
| Jonathan     | Haas         | NYU Langone Hospital-Long Island: Chairman: Employee                                       | Accuray: Education/Meeting Faculty, Speaker's Bureau: Honoraria: speaker: Present  | None   | None   |
| Daphne Adele | Haas-Kogan   | None   | None   | None   | None   |
| Bruce        | Haffty       | Rutgers: Professor and Chair: Employee   | Accuray: Consultant: Compensation/Payment: Reviewed Research: December 2023<br>Johnson and Johnson: Consultant: Compensation/Payment: Review Research: December 2023   | None   | RSNA R&E Foundation: Research and Education Foundation: Trustee: Sit on Board of Trustees: Compensation? No  |
| Lia          | Halasz       | University of Washington: Professor: Employee  | Biomimetix: Research: Recipient: My Institution: Salary Support: No: site principal investigator: Brain metastases clinical trial: Grant/research funding: Site PI for BMX 001 trial for brain metastases, now closed to accrual: February 2024<br>Kuni Foundation: Research: Recipient: My Institution: Salary Support: Yes: national/overall principal investigator: Health access for American Indian/Alaska Native people: Grant/research funding, Salary support: Philanthropic grant to understand and improve barriers to radiation oncology care for American Indian and Alaska Native people in Washington state and surrounding states.: Present<br>UptoDate: Consultant: Compensation/Payment: Section Editor for Neuro Oncology: Present | None   | None   |
| William      | Hall         | Medical College of Wisconsin: Professor: Employee  | Aktis Oncology: Consultant: Compensation/Payment: Consultant for early phase trial design: Present<br>Elekta AB, Stockholm, Sweden: Research: Recipient: My Institution: Salary Support: No: site principal investigator: Research PI: Grant/research funding, Travel expenses: Institutional Research and Travel Support: Present   | Sonoptima: Copyright/Patent/License/Royalty: Shareholder | MR Linac Consortium: Research consortia sponsored by Elekta AB: Vice Chair of the Clinical Steering Committee: I am the Vice Chair of the Clinical Steering Committee, which is a leadership committee for research decisions with the Elekta MR Linac Consortium.: Compensation? No |
| Edward       | Halperin     | New York Medical College: Chancellor/CEO: Employee   | None   | None   | New York Medical College: University: Chancellor/CEO: CEO: Compensation? Yes   |
| Sarah        | Hampson      | University of California, Berkeley: Graduate Student: Student                              | None   | None   | None   |
| Daniel       | Hamstra      | Baylor College of Medicine: Professor and Chairman: Employee                               | Boston Scientific: Consultant: Uncompensated, Other-Meals and payments for presentations: Advisory role: To Present  | None   | None   |
| Chunhui      | Han          | Department of Radiation Oncology, City of Hope National Medical Center                     | ReflExion Medical: Research: Recipient: My Institution: Salary Support: No: site principal investigator: Performance evaluation of the binary MLC system on a novel biology-guided radiotherapy machine using beamlet sequence log data from daily clinical treatments: Grant/research funding: PI for research topic: Performance evaluation of the binary MLC system on a novel biology-guided radiotherapy machine using beamlet sequence log data from daily clinical treatments: 7/2024   | None   | None   |
| Sheela       | Hanasoge     | Emory University: Assistant Professor: Employee  | None   | None   | None   |
| Jean-Michel  | Hannoun-Levi | Antoine La Cassane Cancer Center: MD: Employee   | None   | None   | None   |
| Yao          | Hao          | Washington University School of Medicine: Dr.: Employee                                    | None   | None   | None   |
| Paul         | Harari       | Department of Human Oncology, University of Wisconsin School of Medicine and Public Health | None   | None   | None   |

**ASTRO 2024 Annual Meeting - Faculty and Presenters' Disclosures**

| First Name | Last Name        | Employment Relationships   | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria   | Ownerships/Investments/Intellectual Property | Leadership/Positions of Authority   |
|------------|------------------|--|---|--|---|
| Emily      | Harris           | Duke University, Department of Radiation Oncology: Resident: Employee  | None  | None   | None  |
| Kendra     | Harris           | Tulane Cancer Center   | None  | None   | None  |
| Comron     | Hassanzadeh      | Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center  | Boston Scientific: Other-Participated in device workshop: Travel expenses: Participated in device workshop for new product: 9/2023  | None   | None  |
| Jona       | Hattangadi-Gluth | UC San Diego/Moores Cancer Center: Professor: Employee   | None  | None   | None  |
| Maria      | Hawkins          | University College London: professor: Employee   | None  | None   | CRUK City of London RADNET centre: multiinstitutional programme grant: director: lead and coordinate research in preclinical science research across the teams awarded the grant: Compensation? No  |
| Corbin     | Helis            | US Army: Radiation Oncologist: Employee  | None  | None   | None  |
| Lauren     | Henke            | University Hospitals: Associate Professor of Radiation Oncology: Employee  | Varian Medical Systems: Consultant, Speaker's Bureau: Honoraria: Speaker: Present<br>ViewRay: Advisory Board, Speaker's Bureau: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Honoraria: Speaker: Present   | None   | None  |
| Christina  | Henson           | OU Health: Assistant Professor: Employee   | EMD Serono: Advisory Board: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Compensation/Payment: ad hoc advisory board participation x2: present  | None   | Head and Neck Cancer International Group (HNCIG): Committee Chair: Co-chair of the Young Investigators Committee: Compensation? No  |
| Joseph     | Herman           | Canopy Cancer Collective: CMO: Independent Contractor<br>Histosonics: Medical Director: Employee                                 | None  | Histosonics: Stock: Medical Director         | None  |
| Daniel     | Hicks            | Yale New Haven Hospital: Resident Physician: Employee  | None  | None   | None  |
| Kristin    | Higgins          | City of Hope: Chief Clinical Officer: Employee<br>Emory Healthcare: Medical Director: Employee: Relationship ended 01/23/2024    | Astra Zeneca: Advisory Board, Consultant: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: No remuneration specified: lung cancer consultant: To present<br>Genentech: Consultant: No remuneration specified: lung cancer: To present<br>Janssen Pharmaceuticals: Advisory Board, Consultant: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Compensation/Payment: lung cancer consultant: to present<br>Jazz Pharmaceuticals: Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: small cell lung cancer: Salary support: lung cancer: To present<br>ReflExion Medical: Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Compensation/Payment: Scientific Advisory Board Member: To present | Picture Health: Stock options: advisor       | NRG Oncology: Board of Directors: General Director: Board of Directors: Compensation? No<br>RTOG Foundation: Board Member: Board of Directors: Compensation? No   |
| Luke       | Higgins          | MacNeal Hospital: Resident Physician: Employee: Relationship ended 06/21/2023<br>Michigan Medicine: Resident Physician: Employee | None  | None   | None  |
| Hussam     | Hijazi           | King Abdulaziz University: MD: Employee  | None  | None   | None  |
| Colin      | Hill             | New York University: Faculty Physician: Employee   | None  | None   | None  |
| Christine  | Hill-Kayser      | U Penn: Faculty: Employee  | None  | None   | None  |
| Emily      | Hirata           | University of California, San Francisco: Chief of Clinical Physics, Associate Professor: Employee                                | None  | None   | AAPM: American Association of Physicists in Medicine: Vice Chair, Medical Physics Leadership Academy Community Subcommittee: Vice Chair in AAPM MPLA Community Subcommittee; help develop leadership academy content, material, and programs for AAPM members.: Compensation? No<br>American College of Radiology: ACR: ROPA Committee Member and Physicist Surveyor: Committee member and Physicist surveyor for the ACR Radiation Oncology Practice Accreditation program: Compensation? No |
| Ariel      | Hirsch           | Department of Radiation Oncology, Boston University School of Medicine   | None  | None   | None  |
| David      | Hodgson          | Pediatric Oncology Group of Ontario: Medical Director: Employee<br>University Health Network: oncologist: Employee               | None  | Immvue Therapeutics: Stock: investor         | Pediatric Oncology Group of Ontario: Cancer Agency: Medical Director: lead medical programs: Compensation? Yes  |

**ASTRO 2024 Annual Meeting - Faculty and Presenters' Disclosures**

| First Name | Last Name       | Employment Relationships  | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria   | Ownerships/Investments/Intellectual Property   | Leadership/Positions of Authority  |
|------------|-----------------|---|---|--|--|
| Karen      | Hoffman         | MD Anderson Cancer Center: Professor: Employee  | <b>Janssen:</b> Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: RCT Apa w/ post op RT: Grant/research funding: Research funding to my institution to conduct a multi institutional RCT to evaluate optimal systemic therapy to deliver with post-op RT (Apa monotherapy vs. ADT vs. ADT plus Apa). Funding does not change my salary but buys academic time so checked yes to salary support.: Present<br><b>Varian Medical Systems:</b> Research: Recipient: My Institution: Salary Support: No: site principal investigator: development of plan quality assurance tool: Grant/research funding: Physician co-lead of project to develop a plan quality assurance tool in conjunction with Varian. Funding is to my institution so I checked salary support yes since it did buy some time out of clinic. This project was sunset and we are receiving not additional funding for this project : 2024 | None   | <b>ASTRO:</b> ASTRO representative to the Commission on Cancer: Represents ASTROs interests and sit on the executive committee of the Commission on Cancer.: Compensation? No  |
| Jean       | Hoffman-Censits | The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins: Associate Professor: Employee   | <b>Seagen:</b> Research: Recipient: My Institution: Salary Support: Yes: National/Overall principal investigator: Grant/Research Funding: Salary Support: Present<br><b>Roche Genentech:</b> Research: Recipient: My Institution: Salary Support: Yes: National/Overall principal investigator: Grant/Research Funding: Salary Support: Present   | None   | <b>NCCN:</b> Bladder Cancer Guidelines Committee: Committee Member: collaborate to revise guidelines.: Compensation? No<br><b>AUA:</b> Upper Tract Urothelial Cancer Guidelines: Committee Member: Upper Tract Urothelial Cancer Guidelines.: Compensation? No |
| Jacob      | Hogan           | Washington University School of Medicine  | None  | None   | None   |
| Emma       | Holliday        | UT MD Anderson Cancer Center: Associate Professor, GI Radiation Oncology: Employee  | None  | None   | None   |
| Bo         | Hong            | National Institutes of Health: Officer: Employee  | None  | None   | None   |
| Julian     | Hong            | University of California, San Francisco: Assistant Professor: Employee  | <b>Roche:</b> Research: Recipient: My Institution: Salary Support: No: Coinvestigator: Glioma real world data: Grant/research funding, Salary support: Coinvestigator on study investigating real world data applications in gliomas.: 03/31/2023   | None   | None   |
| Andrew     | Hope            | University Health Network: Radiation Oncologist: Employee   | None  | None   | None   |
| Brad       | Hoppe           | Mayo Clinic: Professor of Radiation Oncology: Employee  | <b>Merck:</b> Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Other-Children's Oncology Group funds my scientific advisory board work into a Mayo research PAU: scientific advisory board for AHOD 1822: Present  | None   | <b>NRG lymphoma working group:</b> Co-Chair: co-chair: Compensation? No<br><b>PTCOG:</b> Secretary: secretary: Compensation? No  |
| Kathleen   | Horst           | Department of Radiation Oncology, Stanford University School of Medicine  | None  | None   | None   |
| Peter      | Hoskin          | East & North Herts NHS Trust: Consultant clinical oncologist: Employee<br>University of Manchester: Professor of Clinical Oncology: Employee  | <b>ASTRO 2023:</b> Education/Meeting Faculty: Travel expenses: Speaker: Present<br><b>GU ASCO 2024:</b> Education/Meeting Faculty, Other-Program Committee: Travel expenses: Program committee: Present   | None   | <b>East of England Cancer Alliance:</b> Main employer reimbursed for time by NHS: Clinical Director: Clinical oncologist: Compensation? No   |
| Michael    | Howard          | ICAD Medical: Consultant medical physicist: Independent Contractor<br>Parkridge Medical Center: Medical Physicist: Employee<br>Tennova Healthcare: VP Oncology and Chief of Physics: Independent Contractor<br>University of Tennessee: Program Director, Medical Physics: Independent Contractor             | None  | <b>HCA:</b> Stock: Stock ownership   | <b>AAPM:</b> Physics professional association: Chair of Specialty Meetings Oversight: Subcommittee chair: Compensation? No   |
| Krishna    | Howell          | Cognito Therapeutics: CCO: Employee<br>GenesisCare: Chief Medical Informatics Officer: Independent Contractor: Relationship ended 06/13/2023<br>Michigan Healthcare Professionals: physician: Employee<br>Temple Health/Fox Chase Cancer Center: Associate Professor: Employee: Relationship ended 04/03/2023 | <b>HAP:</b> Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Compensation/Payment: Board member: To present   | <b>Cognito Therapeutics:</b> Stock: Part of salary/incentive with the position is paid in stock. | None   |
| Jackson    | Howell          | University of Utah: Resident Physician: Employee  | None  | None   | None   |
| Meng-Lun   | Hsieh           | UT Southwestern Medical Center: Resident Physician: Employee  | None  | None   | None   |



**ASTRO 2024 Annual Meeting - Faculty and Presenters' Disclosures**

| First Name | Last Name | Employment Relationships   | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria  | Ownerships/Investments/Intellectual Property | Leadership/Positions of Authority  |
|------------|-----------|--|--|--|--|
| Charles    | Hsu       | <b>Banner-University Medical Center Tucson:</b> Radiology Technologist - Special Vascular Procedures: Partner<br><b>Banner-University of Arizona Medical Center:</b> Associate Professor of Radiation Oncology: Employee | None   | None   | <b>Univ of Arizona Dept of Radiation Oncology:</b> University of Arizona Cancer Center Department of Radiation Oncology Research: Vice Chairman of Clinical Research: head of clinical research within department of radiation oncology: Compensation? No: Relationship ended 06/30/2023<br><b>University of Arizona Cancer Center:</b> Clinical Trials Office: Medical Director: Medical Director of Clinical Trials Office for Cancer Center: Compensation? No |
| Che-yu     | Hsu       | <b>National Taiwan University Cancer Center</b>  | None   | None   | None   |
| Feng-Ming  | Hsu       | <b>National Taiwan University Cancer Center:</b> Attending/Office Chair: Employee  | None   | None   | None   |
| Christina  | Huang     | <b>Department of Radiation Oncology, Duke University Medical Center; Duke University Medical Center</b>  | None   | None   | None   |
| Shao Hui   | Huang     | <b>Department of Radiation Oncology, Princess Margaret Cancer Centre, University of Toronto</b>  | None   | None   | None   |
| Anne       | Hubbard   | <b>ASTRO:</b> Director of Health Policy: Employee  | None   | None   | None   |
| Harper     | Hubbeling | <b>University of Pennsylvania:</b> Physician: Employee   | None   | None   | None   |
| Peter      | Huber     | <b>German Cancer Research Center(DKFZ):</b> Professor, PI: Employee  | None   | None   | None   |
| Emily      | Hubley    | <b>University of Pennsylvania:</b> Medical Physicist: Employee   | None   | None   | None   |
| Ryan       | Hughes    | <b>Department of Radiation Oncology, Wake Forest University School of Medicine</b>   | None   | None   | None   |
| Florence   | Huguet    | <b>AP-HP:</b> Hospital: Employee<br><b>Sorbonne University:</b> University: Employee   | <b>BMS:</b> Consultant, Education/Meeting Faculty: Honoraria, Travel expenses: Head and neck cancer Oesophageal cancer: To present<br><b>Merck Serono:</b> Consultant, Education/Meeting Faculty: Honoraria, Travel expenses: Head and neck cancer: To present<br><b>MSD:</b> Advisory Board, Education/Meeting Faculty: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Honoraria, Travel expenses: Head and neck cancer: To present                                | None   | None   |
| Soon       | Huh       | <b>Department of Radiation Oncology, University of Florida College of Medicine</b>   | None   | None   | None   |
| Zain       | Husain    | <b>Southern California Permanente Medical Group:</b> Physician: Employee   | <b>EMD Serono:</b> Advisory Board: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Honoraria, Travel expenses: Discuss landscape of clinical trials in HN cancer: Jan 2024  | None   | None   |
| Mai Anh    | Huynh     | <b>Brigham and Women's/Dana-Farber Cancer Center:</b> Assistant Professor: Employee  | <b>Immune-Sensor:</b> Research: Recipient: My Institution: Salary Support: Yes: site principal investigator: PULSAR-ICI+/-intratumoral sting agonist: Grant/research funding, Salary support: Site investigator for Phase 2 RCT of PULSAR-ICI+/-intratumoral sting agonist: Ongoing (2026?)<br><b>Novartis:</b> Research: Recipient: My Institution: Salary Support: No: site principal investigator: Pluvicto for oligomet prostate cancer: Grant/research funding, Travel expenses: Site Investigator for Phase 3 PSMA-DC trial: Ongoing (2034?) | None   | None   |
| Badr       | Id Said   | <b>Princess Margaret Cancer Centre, University Health Network, University of Toronto</b>   | None   | None   | None   |

**ASTRO 2024 Annual Meeting - Faculty and Presenters' Disclosures**

| First Name | Last Name         | Employment Relationships   | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria   | Ownerships/Investments/Intellectual Property | Leadership/Positions of Authority   |
|------------|-------------------|--|---|--|---|
| Brandon    | Imber             | Memorial Sloan Kettering Cancer Center: Assistant Attending Radiation Oncologist: Employee | <p><b>AstraZeneca:</b> Research: Recipient: My Institution: Salary Support: No: site principal investigator: : Grant/research funding: site PI for international clinical trial: To present</p> <p><b>Bayer:</b> Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: : No remuneration specified: Grant/research funding: national PI of Radium-223 and SBRT study: To present</p> <p><b>GT Medical Technologies:</b> Advisory Board, Education/Meeting Faculty: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Honoraria: presented research at SNO 2021: To present</p> <p><b>Kazia Therapeutics:</b> Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: : No remuneration specified: Grant/research funding: overall PI for brain metastasis clinical trial: To present</p> <p><b>Novartis:</b> Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: : No remuneration specified: Grant/research funding: PI for IIT where Novartis provided drug: To present</p> <p><b>Telix Pharmaceuticals:</b> Advisory Board: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Honoraria: Advisory Board at SNO 2022: November 2022</p>  | None   | None  |
| Daniel     | Indelicato        | University of Florida: Professor: Employee   | <b>Self:</b> Other-CIRB: Honoraria: Member of the NCI CIRB: To present  | None   | <b>Pediatric Radiation Oncology Society (PROS):</b> Professional Organization: Education Chair- North America: On Executive Committee, responsible for education initiatives throughout North America: Compensation? No |
| Myrsini    | Ioakeim-Ioannidou | Mass General Hospital: Postdoctoral fellow: Employee                                       | None  | None   | None  |
| Jana       | Ivanidze          | Weill Cornell Medicine: Assistant Professor of Radiology: Employee                         | <p><b>GE Health Care:</b> Research: Recipient: My Institution: Salary Support: Yes: national/overall principal investigator: PET guided brain tumor: Grant/research funding: PI, investigator initiated trial grant: Present</p> <p><b>Novartis Pharmaceuticals:</b> Research: Recipient: My Institution: Salary Support: Yes: national/overall principal investigator: PET guided brain tumor: Grant/research funding: PI, investigator</p>  | None   | None  |
| Puneeth    | Iyengar           | MSKCC: Attending and Director: Employee  | <p><b>AstraZeneca:</b> Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Honoraria: Advised on trial design</p> <p><b>Incyte:</b> Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of</p>   | None   | None  |
| Gopakumar  | Iyer              | Memorial Sloan Kettering Cancer Center   | <p><b>Aadi Bioscience:</b> Advisory Board, Research: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Recipient: My Institution: Salary Support: Yes: national/overall principal investigator: Site PI for clinical trial: Grant/research funding, Salary support: Site PI: 2027</p> <p><b>Astra Zeneca:</b> Advisory Board, Research: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Recipient: My Institution: Salary Support: No: site principal investigator: Clinical Trial sub-investigator: Grant/research funding: Clinical Trial: 2026</p> <p><b>EMD Serono:</b> Advisory Board: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Compensation/Payment: Advisory board: 2023</p> <p><b>Flare Therapeutics:</b> Consultant, Research: Recipient: My Institution: Salary Support: Yes: steering committee: Clinical Trial: Grant/research funding, Salary support: Site PI/steering committee member: 2027</p> <p><b>Loxo at Lilly:</b> Advisory Board, Research: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Recipient: My Institution: Salary Support: Yes: site principal investigator: Clinical Trial PI: Grant/research funding, Salary support: Clinical Trial PI: 2028</p> <p><b>Pfizer:</b> Education/Meeting Faculty, Research: Recipient: My Institution: Salary Support: Yes: site principal investigator: Clinical Trial: Grant/research funding, Salary support: Site PI: 2026</p> <p><b>Tyra Biosciences:</b> Research: Recipient: My Institution: Salary</p> | None   | None  |

**ASTRO 2024 Annual Meeting - Faculty and Presenters' Disclosures**

| First Name  | Last Name | Employment Relationships   | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria  | Ownerships/Investments/Intellectual Property   | Leadership/Positions of Authority   |
|-------------|-----------|--|--|--|---|
| Salma       | Jabbour   | Rutgers University: M.D.: Employee   | <b>AstraZeneca:</b> Advisory Board, Consultant: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Travel expenses, Compensation/Payment: Ad Boards lung cancer: 6/2024<br><b>Beigene:</b> Research, Education/Meeting Faculty: Recipient: My Institution: Salary Support: No: site principal investigator: : Grant/research funding: research grant: To present<br><b>Dechert LLC:</b> Other-expert testimony: Compensation/Payment: Expert Testimony-lung & bladder cancer: 7/2023<br><b>Ideology Health:</b> Consultant: Travel expenses: Panel discussions-lung cancer: 6/2024<br><b>IMX Medical:</b> Consultant: Compensation/Payment: review of cases: To present<br><b>Merck &amp; Co, Inc:</b> Consultant, Research: Recipient: My Institution: Salary Support: No: site principal investigator: : Grant/research funding, Compensation/Payment: research consultant: To present<br><b>Radialogica:</b> Consultant: Compensation/Payment: review of RT cases: To present<br><b>Syntact:</b> Consultant: Compensation/Payment: adjudication committee: 2023   | None   | <b>IROBP Deputy Editor D:</b> Deputy Editor: edit articles for IROBP: Compensation? No  |
| Jerry       | Jaboin    | University of Oklahoma Health Sciences Center: Professor: Employee   | None   | None   | None  |
| Christopher | Jackson   | Memorial Sloan Kettering Cancer Center: Resident Physician: Employee   | None   | None   | None  |
| Geraldine   | Jacobson  | Moffitt Cancer and Research Center: Senior Member: Employee  | None   | None   | None  |
| Matthew     | Jacobson  | Dana-Farber Cancer Institute: Instructor: Employee   | None   | None   | <b>MathWorks:</b> Software Company: Advisor: Community Advisory Board: Compensation? No   |
| Reshma      | Jagsi     | Emory University: Chair: Employee<br>NIH: Special govt employee: Employee<br>University of Michigan: Adjunct Professor: unpaid adjunct faculty | <b>Academic Institutions and Societies:</b> Other-one-time talks: Honoraria, Travel expenses: visiting professorships, CME talks: To present<br><b>American Cancer Society:</b> Research: Recipient: My Institution: Salary Support: No: co-investigator: breast cancer: Grant/research funding: Co-investigator on grant to study patient experiences: To present<br><b>Blue Cross Blue Shield Association:</b> Other-Medical Advisor (part of panel who reviews policy): Honoraria: provide expert perspective on insurer policies: To present<br><b>Doris Duke Charitable Foundation:</b> Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: Evaluation of fund to retain clinical scientists: Grant/research funding: lead national program evaluation for fund to support faculty with caregiving demands: To present<br><b>Greenwall Foundation:</b> Other-Faculty scholars program committee: Honoraria, Travel expenses: grant review panel and support for awardees selected for ethics career development program: To present<br><b>Komen Foundation:</b> Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: breast cancer: Grant/research funding, Travel expenses: Komen Senior Scholar award to do research and serve on grant review panels: To present<br><b>NIH:</b> Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: breast ca, bioethics: | <b>Equity Quotient:</b> Stock options: stock options for service as advisor to company that seeks to promote equity in organizations   | <b>JAMA Oncology:</b> Journal: Viewpoints Editor: to begin as editor on March 7, 2023: Compensation? No   |
| Christopher | Jahraus   | Generations Radiotherapy & Oncology PC: Owner & Physician: Partner   | <b>Elekta:</b> Consultant, Advisory Board, Speaker's Bureau: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Honoraria, Travel expenses, Compensation/Payment: I have spoken about their product SmartClinic in numerous venues and served on multiple customer advisory committees.: To Present<br><b>RADformation:</b> Consultant: Other-Provision of software.: I have worked with RADformation to assist them in developing their products in the Elekta OIS environment.: To Present  | <b>Drug Patent:</b> Ownership equity: I am co-maker of a patent for use of rifaximin in radiotherapy patients. Patents have been granted in Canada, the European Union (including Spain specifically), Israel, Japan, Korea, and Russia. I have received no money whatsoever for this intellectual property nor for my rights to it.: Relationship ended 05/08/2024<br><b>Generations Radiotherapy &amp; Oncology PC:</b> Ownership equity: I am | <b>American College of Radiation Oncology:</b> I am a very active member of ACRO (and ASTRO). Within ACRO, I serve multiple roles, including those shown below.: Vice Chair, Gov't Relations & Economics Committee; Vice Chair, PAC; Deputy Editor of Journal Channel (CURIÉ); Chair, ACROPath; RUC-Advisor: I am a member of this organization and actively participate on a voluntary basis, frequently cooperating with ASTRO leadership in my roles at ACRO.: Compensation? No: Relationship ended 05/08/2024 |
| Joanna      | Javor     | Princess Margaret Cancer Centre, University Health Network   | None   | None   | None  |
| Taylor      | Jenkins   | VCU: Assistant Professor: Employee   | None   | None   | None  |
| Krishan     | Jethwa    | Mayo Clinic, Rochester, MN: Physician: Employee  | <b>RadOncQuestions.com, LLC:</b> Other-Editor: Honoraria: GI disease site editor: 2/2023   | None   | <b>American Board of Radiology:</b> Board Examiner: Written board examiner for the American Board of Radiology: Compensation? No  |

| ASTRO 2024 Annual Meeting - Faculty and Presenters' Disclosures |           |  |  |  |  |
|---|-----------|--|--|--|--|
| First Name  | Last Name | Employment Relationships   | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria  | Ownerships/Investments/Intellectual Property | Leadership/Positions of Authority  |
| Anuja   | Jhingran  | The University of Texas MD Anderson Cancer Center: Professor: Employee   | Genentech: Consultant: Travel expenses, Compensation/Payment: Provide advice and feedback on current sponsored and supported trial designs and/or molecule strategies for US Medical Affairs, Product Development Medical Affairs and/or Product Development related to gynecologic program trials: 11/22/23   | None   | None   |
| Angela  | Jia       | University Hospitals, Seidman Cancer Center, Case Western Reserve University: Radiation Oncologist, Assistant Professor in Radiation Oncology: Employee  | Myovant: Advisory Board: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Honoraria, Travel expenses: advisory board: 12/2022   | None   | None   |
| Rachel  | Jimenez   | Massachusetts General Hospital: Attending Physician: Employee  | None   | None   | American Society of Clinical Oncology: Chair Elect, Ethics Committee: I am the Chair for the ASCO Ethics Committee. I coordinate and organize an agenda for the Ethics Committee.: Compensation? No<br>ASTRO: Advances in Radiation Oncology: Editor-in-Chief: Editor-in-Chief: Compensation? No<br>ASTRO: ASTRO: EIC Advances: EIC: Compensation?<br>SurvivingBreastCancer.org: This is a non-profit advocacy organization for patients with breast cancer: Medical Advisory Board, Member: I advise the Director of SBC.org on strategy: Compensation? No              |
| Carlton   | Johnny    | Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network   | None   | None   | None   |
| Cheilonda   | Johnson   | University of Pennsylvania   | None   | None   | None   |
| Candice   | Johnstone | MCW: professor: Employee   | None   | None   | AART: american registry of radiologic technologists: board member/vice president: board member: Compensation? No<br>AAWR: SOCIETY: President elect: Board member: Compensation? No<br>WRS/ACR: WI state chapter of ACR: Councilor: councilor for ACR for the WI chapter: Compensation? No  |
| Peter   | Johnstone | Moffitt Cancer Center: Vice Chair, Radiation Oncology: Employee  | None   | None   | None   |
| Kimberly  | Johung    | Yale University School of Medicine: Associate Professor: Employee  | NCCN: Other-Colorectal Guidelines Panel Member: Travel expenses: Colon, Rectal, Anal, and Small Bowel Cancers – Guidelines Panel Member: Present   | None   | None   |
| Joshua  | Jones     | Children's Hospital of Philadelphia: Pediatrician: Employee: Relationship ended 06/30/2023<br>Pediatric Urgent Car of Rochester: Pediatrician: Employee<br>Rochester Regional Health: Radiation Oncologist: Employee<br>University of Pennsylvania Health System: Associate Professor of Radiation Oncology: Employee: Relationship ended 05/12/2023 | None   | None   | None   |
| Sumanas   | Jordan    | Northwestern University McGaw medical Center   | None   | None   | None   |
| Adedayo   | Joseph    | NSIA-LUTH Cancer Centre, Lagos, Nigeria  | None   | None   | None   |
| Melissa   | Joyner    | M.D. Anderson Cancer Center: Professor: Employee   | None   | None   | MD Anderson Cancer Center: Ancillary site: Associate Director Clinical Operations West Houston: Manage radiation related clinical operations: Compensation? No   |
| Kanta   | KA        | Radiotherapy, Gustave Roussy Institute   | None   | None   | None   |
| Jenna   | Kahn      | Kaiser NW Permanente: Radiation Oncologist: Employee   | None   | None   | ASTRO: Communication Committee: Chair: Communications committee chair: Compensation? No  |
| Anusha  | Kalbasi   | Stanford University: Associate Professor: Employee<br>UCLA: Assistant Professor: Employee: Relationship ended 11/30/2022   | Certis Oncology: Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Other-stock: sarcoma & immunology/immunotherapy: Ongoing<br>Highlight Therapeutics: Research: Recipient: Me: Salary Support: No: site principal investigator: sarcoma immunotherapy: Grant/research funding: research clinical trial investigator: Ongoing<br>T Cure Therapeutics: Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Compensation/Payment: advisory board member; T cell immunotherapy / sarcoma: Ongoing | None   | None   |
| Sophia  | Kamran    | MGH: Assistant Professor of Radiation Oncology: Employee<br>Sanofi: Global Market Access: Employee   | DAVA Oncology: Education/Meeting Faculty: Honoraria, Travel expenses: SBRT in RCC Trimodality Therapy for Muscle-Invasive Bladder Cancer: 11/13/2022<br>NRG Oncology: Research: Recipient: Me: Salary Support: No: national/overall principal investigator: health equity fellowship: Grant/research funding, Travel expenses: health equity fellowship: Present<br>Prostate Cancer Foundation: Research: Recipient: Me: Salary Support: No: national/overall principal investigator: Oligometastatic Prostate Cancer: Grant/research funding: Prostate Cancer Foundation Young Investigator: 12/30/2024   | None   | American Board of Radiology: American Board of Radiology: American Board of Radiology Radiation Oncology Certifying Exam Genitourinary Committee: American Board of Radiology Radiation Oncology Certifying Exam Genitourinary Committee: Compensation? No<br>ASCO: ASCO Annual GU Symposium: Chair- Renal and Rare Tumors Track: Chair of Renal and Rare Tumors Program Track: Compensation? No<br>MGH: MGH Department of Radiation Oncology: Director of Diversity, Equity & Inclusion: Director of Diversity, Equity & Inclusion for the Department: Compensation? No |

**ASTRO 2024 Annual Meeting - Faculty and Presenters' Disclosures**

| First Name     | Last Name  | Employment Relationships  | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria  | Ownerships/Investments/Intellectual Property   | Leadership/Positions of Authority   |
|----------------|------------|---|--|--|---|
| Mitchell       | Kamrava    | Cedars Sinai: Professor: Employee   | <p><b>Adaptiiv:</b> Consultant: Compensation/Payment: 3D printing: Ongoing</p> <p><b>Alessa:</b> Other-DSMB member: Compensation/Payment: DSMB member: Ongoing</p> <p><b>GammaTile:</b> Other-DSMB member: Compensation/Payment: DSMB member: Ongoing</p> <p><b>Springer:</b> Other-book royalties: Compensation/Payment: book royalties: Ongoing</p> <p><b>theragenics:</b> Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Honoraria: advisory board</p>   | None   | <p><b>ABR Gyn examiner:</b> ABR Gyn oral examiner: ABR Gyn oral examiner: Compensation? No</p> <p><b>ABS:</b> Board of Directors, Member-at-large: Board of Directors, president elect: Compensation? No</p> <p><b>ADROP:</b> President: ADROP Immediate Past President: Compensation? No</p>   |
| Thirumala-Devi | Kanneganti | St. Jude Children's Reseach Hospital: Director, Center of Excellence for Innate Immunity and Inflammation, Rose Marie Thomas Endowed Chair, Vice Chair, Member, Immunology Department: Employee | <p><b>American Lebanese Syrian Associated Charities:</b> Research: Recipient: My Institution: Salary Support: Yes: national/overall principal investigator: national/overall principle investigator: Grant/research funding: Principal investigator researching innate immunity: To present</p> <p><b>Immunity:</b> Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Uncompensated: Provide guidance on topics for inclusion in the journal and to shape the future directions of the journal.: To Present</p> <p><b>National Institutes of Health:</b> Research: Recipient: My Institution: Salary Support: Yes: national/overall principal investigator: National/overall principle investigator: Grant/research funding: Principal investigator researching innate immunity: To present</p> <p><b>Pfizer:</b> Advisory Board: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Compensation/Payment: Provide scientific input on topics of mutual interest.: 2023</p> <p><b>Trends in Immunology:</b> Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Uncompensated: Provide guidance on topics for inclusion in the journal and to shape the future directions of the journal.: To Present</p> <p><b>Trends in Molecular Medicine:</b> Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Uncompensated: Act as advisory board member and editorial board member to provide guidance on suitability of articles and topics for inclusion in the journal and to shape the future directions of the journal.: To Present</p> | None   | <p><b>Journal of Experimental Medicine:</b> Scientific journal: Editorial board member: provide guidance on suitability of articles and topics for inclusion in the journal: Compensation? No</p> <p><b>Scientific Reports:</b> Scientific journal: Editorial board member: provide guidance on suitability of articles and topics for inclusion in the journal: Compensation? No</p> |
| Rojano         | Kashani    | University Hospital Seidman Cancer Center: Clinical Chief of Physics and Dosimetry: Employee  | None   | None   | None  |
| Matthew        | Katz       | Radiation Oncology Associates, PA: Partner: Partner   | None   | <p><b>Artiva Biotherapeutics:</b> Stock: Individual stock ownership</p> <p><b>Bavarian Nordic, SA:</b> Stock: Individual stock ownership</p> <p><b>CVS Health:</b> Stock: Individual stock ownership</p> <p><b>Dr Reddy's Laboratories:</b> Stock: Individual stock ownership</p> <p><b>Healthcare Services Group:</b> Stock: Individual stock ownership: Relationship ended 07/01/2024</p> <p><b>Moderna:</b> Stock: Individual stock ownership</p> <p><b>Myomo Inc.:</b> Stock: Individual stock ownership</p> <p><b>Organon:</b> Stock: Individual stock ownership</p> <p><b>Pfizer:</b> Stock: Individual stock ownership</p> <p><b>Rewalk Robotics:</b> Stock: Individual stock ownership</p> <p><b>Siga Technologies:</b> Stock: Individual stock ownership: Relationship ended 01/31/2023</p> | None  |
| Leah           | Katz       | Columbia University Medical Center: Assistant Professor: Employee   | None   | None   | None  |
| Vivek          | Kavadi     | US Oncology: Chief Radiation Oncology Officer: Employee   | None   | None   | None  |

**ASTRO 2024 Annual Meeting - Faculty and Presenters' Disclosures**

| First Name | Last Name | Employment Relationships   | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria   | Ownerships/Investments/Intellectual Property  | Leadership/Positions of Authority   |
|------------|-----------|--|---|---|---|
| Brian      | Kavanagh  | Department of Radiation Oncology, University of Colorado School of Medicine                | None  | None  | None  |
| Florence   | Keane     | Massachusetts General Hospital: Physician: Employee  | <b>DAVA Oncology:</b> Education/Meeting Faculty: Honoraria: Discussion of management of Stage III NSCLC: Ongoing<br><b>Merck:</b> Research: Recipient: My Institution: Salary Support: No: site principal investigator: NSCLC: Grant/research funding, Travel expenses: NSCLC: Ongoing<br><b>Siemens:</b> Education/Meeting Faculty: Honoraria: Honoraria for lecture: Present<br><b>UpToDate:</b> Other-Editor: Other-Royalties: Editor for GE junction section: To present  | None  | None  |
| Emily      | Keit      | University of South Florida: Resident Physician: Employee                                  | None  | None  | None  |
| Sameer     | Keole     | Mayo Clinic: Physician: Employee   | None  | None  | None  |
| Caroline   | Kerr      | University of Wisconsin-Madison: MD/PhD Student: Employee                                  | None  | None  | None  |
| Aparna     | Kesarwala | Emory University School of Medicine: Assistant Professor: Employee                         | <b>Gilead Sciences:</b> Research: Recipient: My Institution: Salary Support: Yes: PI: Radiation Biology: Grant/research funding: PI: Present<br><b>Melanoma Research Alliance:</b> Research: Recipient: My Institution: Salary Support: Yes: PI: Radiation Biology: Grant/research funding: PI: 09/2023<br><b>National Institutes of Health:</b> Research: Recipient: My Institution: Salary Support: Yes: PI: Radiation Biology, Radiation Physics:  | None  | None  |
| Yazeed     | Kesbeh    | Southern California Permanente Medical Group   | None  | None  | None  |
| Atif       | Khan      | Memorial Sloan Kettering Cancer: Attending: Employee                                       | <b>Clovis:</b> Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: PARPi and RT combination: Grant/research funding: combination of rucaparib and RT in high risk adjuvant breast cancer (TNBC): 3/15/2023<br><b>Merck:</b> Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: Combination trial of SBRT, pembro and DDR drugs: Grant/research funding: Combination trial of SBRT, pembro and DDR drugs (olaparib) in metastatic breast cancer: To present<br><b>Varian:</b> Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: Spatial fractionation: Grant/research funding: clinical trial of lattice radiation therapy: Present | <b>Novavax:</b> Stock: Stock holder (company is a COVID vaccine maker, no oncology business)<br><b>Rutgers University:</b> Copyright/Patent/License/Royalty: Rutgers University filed a use patent for the drug riluzole (to be repurposed for cancer treatment) based on my work and I am the named inventor on the patent. The drug has been licensed to and being developed by a company called Biohaven.<br><b>Xtrava Inc:</b> Stock: Company develops at home diagnostics for COVID, flu | <b>American Board of Radiology:</b> US specialty board: Chair of Oral exam committee; Breast section: Oversee creation of the breast oral exam and lead examiners in the delivery of the exam: Compensation? No   |
| Seema      | Khan      | Department of Surgery, Northwestern University Robert H. Lurie Comprehensive Cancer Center | None  | None  | None  |
| Deepak     | Khuntia   | Siemens Healthineers: Chief Medical Officer, Varian: Employee                              | <b>Primum:</b> Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Compensation/Payment: Receive stock.: Present<br><b>ROI:</b> Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Travel expenses: Board of Trustees of ROI.: Present<br><b>We are in this Together:</b> Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or   | None  | None  |
| Elizabeth  | Kidd      | Stanford University: Associate Professor: Employee   | <b>Viewray:</b> Research: Recipient: My Institution: Salary Support: No: site principal investigator: Use of viewray for fractionated radiation: Grant/research funding: Use of viewray for cervix cancer fractionated radiation: Aug. 2023   | None  | <b>ABS Quality &amp; Safety Standard Committee:</b> Co-Leader: Oversee the ABS Quality and Safety Standards Committee.: Compensation? No  |
| Eric       | Kielhorn  | ProMedica Physicians Group: Radiation Oncologist: Employee                                 | None  | None  | <b>ProMedica:</b> Hospital System: Chair of Oncology, ProMedica Cancer Institute: Chair of Oncology: Compensation? Yes<br><b>ProMedica:</b> Hospital System: Chair, Commission on Cancer (CoC): Chair, Commission on Cancer (CoC): Compensation? No<br><b>ProMedica:</b> Hospital: Chair, Radiation Oncology, Flower Hospital: Chair of Radiation Oncology: Compensation? No<br><b>ProMedica:</b> Hospital System: Medical Executive Committee Member: Medical Executive Committee Member: Compensation? Yes<br><b>ProMedica:</b> Hospital System: Peer Review Committee Member: Peer Review Committee Member: Compensation? No |

**ASTRO 2024 Annual Meeting - Faculty and Presenters' Disclosures**

| First Name | Last Name | Employment Relationships  | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria  | Ownerships/Investments/Intellectual Property                      | Leadership/Positions of Authority  |
|------------|-----------|---|--|---|--|
| Ana        | Kiess     | <b>Johns Hopkins University:</b> Associate Professor: Employee  | <b>Bayer:</b> Research: Recipient: My Institution: Salary Support: No: site principal investigator: Phase I trial of HER2-TTC: Grant/research funding: Site PI of phase I trial of HER2-TTC: Present<br><b>Novartis/AAA:</b> Advisory Board, Consultant, Research: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Recipient: My Institution: Salary Support: No: site principal investigator: Phase I/II trial of Lu-PSMA-R2: Grant/research funding, Travel expenses, Uncompensated: Single day advisory boards for Global prostate cancer (7/2023) and RLT xerostomia (10/2023); Ongoing steering committee for phase III study of SBRT +/- Lu-PSMA-617 for oligometastatic prostate cancer.: 2/16/2023<br><b>Progenics Pharmaceuticals:</b> Research: Recipient: My Institution: Salary Support: Yes: national/overall principal investigator: : Grant/research funding: Institutional funding for investigator initiated clinical trial of Lu-PSMA-18T for adenoid cystic carcinoma: | None  | <b>American Board of Radiology:</b> Oral Board Examiner/ Section member: Volunteer member of head and neck/ skin section for Oral Board exam content development and oral examiner: Compensation? No: Relationship ended 07/01/2023  |
| Hyun       | Kim       | <b>Washington University School of Medicine:</b> Associate Professor: Employee  | <b>Novartis:</b> Consultant: Compensation/Payment: Consultant regarding radiopharmaceuticals: 12/2022<br><b>Varian:</b> Education/Meeting Faculty, Research: Recipient: Me: Salary Support: No: site principal investigator: Ethos imaging: Grant/research funding, Honoraria: Ethos imaging (CBCT); adaptive research: To present<br><b>ViewRay:</b> Research: Recipient: Me: Salary Support: No: national/overall principal investigator: Preoperative MR guided RT for gastric cancer: Grant/research funding, Honoraria: Research funding: To present  | <b>GlobalART:</b> Limited liability company interest: Founder/CEO | <b>IJOBP:</b> GI Editorial Board: Associate Editor: Associate Editor: Compensation? No   |
| Ellen      | Kim       | <b>Brigham and Women's Hospital:</b> physician: Employee  | None   | None  | None   |
| Hayeon     | Kim       | <b>UPMC:</b> Medical physicist: Employee  | None   | None  | None   |
| In Ah      | Kim       | <b>Department of Radiation Oncology, Seoul National University Bundang Hospital, Seoul National University College of Medicine</b>  | <b>AstraZeneca:</b> Research: Recipient: Me: Salary Support: No: site principal investigator: AstraZeneca-KHIDI research grant for preclinical study of Akt inhibitor and immune checkpoint inhibitors: Grant/research funding: Principal investigator of Preclinical study for combination strategy of capivasertib, MEDI5752 and radiation therapy in syngenic breast cancer model: December 2024<br><b>KONEC:</b> Research: Recipient: Me: Salary Support: No: site principal investigator: preclinical study for IVAM: Grant/research funding: Principal Investigator of In Vivo Study of In Vitro Abscopal Method: 6-2024   | None  | None   |
| Kathy      | Kim       |   | None   | None  | None   |
| Randall    | Kimble    | Family: <b>Dept of Veterans Affairs:</b> Associate Professor: Employee<br><b>Dept of Veterans Affairs:</b> Associate Professor: Employee<br><b>University of Wisconsin:</b> Associate Professor: Employee | <b>Bridge Bio:</b> Research: Recipient: My Institution: Salary Support: No: lab research: radiosensitization: Grant/research funding: funding to university: 12/31/2022<br><b>Cancer Care Point:</b> Consultant: Travel expenses, Compensation/Payment: physician coverage: To present<br><b>Guidepoint Global:</b> Consultant: Compensation/Payment: KOL discussion regarding drug development: To present  | None  | Family: <b>American Society for Pharmacology and Experimental Therapeutics:</b> National organization/society: Chair Elect - Division for Molecular Pharmacology: Will take over as chair of the division for molecular pharmacology as of July 2023: Compensation? No<br><b>American Society for Pharmacology and Experimental Therapeutics:</b> National organization/society: Chair Elect - Division for Molecular Pharmacology: Will take over as chair of the division for molecular pharmacology as of July 2023: Compensation? No<br><b>International Journal of Radiation Oncology Biology Physics:</b> Journal: Editor: Review editor: Compensation? No<br><b>Radiological Society of North America:</b> National Organization: Chair - RSNA Foundation Radiation Oncology Study Section: I chair the study section within RSNA that reviews radiation oncology seed, resident, fellow, and scholar grants. I am in my 2nd year of a 3 year term.: Compensation? No |
| Tomoki     | Kimura    | <b>Kochi University:</b> Radiation Oncologist: Employee   | None   | None  | None   |
| Martin     | King      | <b>Brigham and Women's Physician's Organization:</b> Physician: Employee  | <b>Bayer Healthcare:</b> Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: Novel hormonal therapy for prostate cancer: Grant/research funding: Principal investigator: Ongoing<br><b>Palette Life Sciences:</b> Grant/research funding, Salary support: Coordinating investigator: To present  | None  | None   |
| Youlia     | Kirova    | <b>Institut Curie:</b> Professor Medical Doctor: Employee   | None   | None  | None   |
| Kendall    | Kiser     | <b>Barnes Jewish Hospital:</b> Resident Physician: Employee   | None   | None  | None   |

**ASTRO 2024 Annual Meeting - Faculty and Presenters' Disclosures**

| First Name       | Last Name     | Employment Relationships   | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria  | Ownerships/Investments/Intellectual Property                      | Leadership/Positions of Authority  |
|------------------|---------------|--|--|---|--|
| Amar             | Kishan        | UCLA: Associate Professor: Employee  | <b>Boston Scientific, Inc.:</b> Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Honoraria: Consulting and ad board: Present<br><b>Department of Defense:</b> Research: Recipient: Me: Salary Support: No: Grant: : Grant/research funding: DOD Grant: Present<br><b>Janssen, Inc.:</b> Advisory Board, Research: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Recipient: My Institution: Salary Support: No: site principal investigator: : Grant/research funding: Trial support: Present<br><b>Point Biopharma:</b> Research: Recipient: My Institution: Salary Support: No: site principal investigator: : No remuneration specified: Research support: Present<br><b>Varian Medical Systems, Inc.:</b> Consultant: Honoraria: Consulting fees: Present<br><b>ViewRay, Inc.:</b> Consultant, Research: Recipient: Me: Salary Support: No: site principal investigator: : Grant/research funding, Honoraria: Research support, honoraria, funding: Present | <b>ViewRay, Inc.:</b> Stock: Low value stock                      | None   |
| Yvonne           | Klaver        | <b>HollandPTC:</b> Radiation Oncologist: Employee<br><b>Leiden University Medical Center:</b> Radiation Oncologist: seconded from HollandPTC   | <b>HollandPTC:</b> Research: Recipient: My Institution: Salary Support: No: site principal investigator: Local investigator for various national and international studies on outcomes of proton therapy in neuro-oncological and esophageal tumors.: Uncompensated: Local investigator for various studies on outcomes of proton therapy in neuro-oncological and esophageal tumors.: To present  | None  | <b>Varian Medical Systems:</b> Radiotherapy equipment and software: FlashForward Consortium Clinical Investigations Working Group: Working Group chair. Discussing ongoing and possible future clinical investigations for FLASH.: Compensation? No    |
| Ann              | Klopp         | <b>Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center</b>   | None   | None  | None   |
| Christin         | Knowlton      | <b>Yale School of Medicine:</b> Associate Professor of Clinical Therapeutic Radiology: Employee  | <b>ASTRO:</b> Other-Surveyor: Travel expenses, Compensation/Payment: APEx surveyor: To present   | <b>Doximity:</b> Stock: Stock owner (limited value)               | None   |
| Jenna            | Kocsis        | <b>Cleveland Clinic:</b> Resident: Employee  | None   | None  | None   |
| Abigail          | Kohut-Jackson | <b>Saint Louis University School of Medicine</b>   | None   | None  | None   |
| Nagendra (Bobby) | Koneru        | <b>Leonard C. Ferguson Cancer Center:</b> Radiation Oncologist: Employee   | <b>IORBC:</b> Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Uncompensated: Board Member: Present   | None  | None   |
| Feng-Ming        | Kong          | <b>The University of Hong Kong, Hong Kong, China:</b> Professor: Employee  | None   | None  | None   |
| Elisa            | Konofagou     | <b>Department of Biomedical Engineering, Columbia University</b>   | None   | None  | None   |
| Bridget          | Koontz        | <b>Duke University School of Medicine:</b> Associate Professor: Employee<br><b>East Carolina University:</b> Affiliate Professor: Independent Contractor<br><b>GenesisCare USA:</b> Chief Medical Officer: Employee: Relationship ended 05/29/2023<br><b>Nova Southeastern University:</b> Consultant: Independent Contractor<br><b>UNC-Chapel Hill:</b> Adjunct Associate Professor: Independent Contractor | <b>Blue Earth Diagnostics:</b> Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Compensation/Payment: proprietary information - yes public facing - no: 5/30/2023<br><b>Lantheus:</b> Advisory Board: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Honoraria, Travel expenses: Advisory board: 5/12/23<br><b>Mirrors of Medicine:</b> Education/Meeting Faculty: Compensation/Payment: Contributor to educational content: 3/1/2023   | <b>Rythera Therapeutics:</b> Ownership equity: Board of Directors | <b>IHE-RO:</b> Non-profit: Co-Chair: Steering committee co-chair: Compensation? No<br><b>IJOBP:</b> Journal: Associate Editor: associate editor, GU: Compensation? No<br><b>NRG Oncology:</b> Co-Chair: Ancillary Projects Committee: Compensation? No |
| Aiden            | Kooyman       | <b>University of British Columbia</b>  | None   | None  | None   |
| Nikhil           | Kotha         | <b>Stanford:</b> Resident: Employee<br><b>Stanford:</b> Resident Physician: Employee   | None   | None  | None   |
| Nataliya         | Kovalchuk     | <b>Department of Radiation Oncology, Stanford University</b>   | None   | None  | None   |



**ASTRO 2024 Annual Meeting - Faculty and Presenters' Disclosures**

| First Name | Last Name | Employment Relationships  | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria  | Ownerships/Investments/Intellectual Property | Leadership/Positions of Authority  |
|------------|-----------|---|--|--|--|
|            |           |   | proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Recipient: My Institution: Salary Support: No: site principal investigator: : Grant/research funding, Compensation/Payment: consultant and co-PI of a study: Ongoing<br><b>castle biosciences:</b> Consultant, Research: Recipient: My Institution: Salary Support: No: site principal investigator: : Grant/research funding: Unpaid consultant and local site PI: Ongoing<br><b>galera therapeutics:</b> Advisory Board: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Compensation/Payment: ad board: Aug 2023<br><b>Merck:</b> Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Grant/research funding, Travel expenses, Compensation/Payment: Consultant and research funding: Ongoing<br><b>Regeneron:</b> Advisory Board, Research: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Recipient: My Institution: Salary Support: No: site principal investigator: : Grant/research funding, Compensation/Payment: participating in study and ad board: Ongoing                                      |  |  |
| Shlomo     | Koyfman   | Cleveland Clinic Foundation: Physician: Employee  | None   | None   | None   |
| Margaret   | Kozak     | Department of Radiation Oncology, University of Texas Southwestern Medical Center                     | None   | None   | None   |
| David      | Kozono    | Brigham and Women's Hospital: Attending Physician: Employee   | Genentech: Consultant: Compensation/Payment: Consultancy, lung cancer clinical trial: Present  | None   | Alliance for Clinical Trials in Oncology: Cooperative group: Executive Officer: Clinical trials operations and scientific leadership: Compensation? No |
| Brittany   | Krekeler  | UC Physicians: Speech-Language Pathologist: Employee<br>University of Cincinnati: Assistant: Employee | None   | None   | Dysphagia Research Society: Professional Organization: Committee Member: Planning committee for annual meeting: Compensation? No                       |
| Conley     | Kriegler  | University of Alberta   | None   | None   | None   |
| Sunil      | Krishnan  | University of Texas Health Houston  | None   | None   | None   |
| David      | Krug      | Saphir Radiosurgery: Lead Physician: Employee<br>UKSH: Deputy Director: Employee                      | <b>Astra Zeneca:</b> Education/Meeting Faculty: Compensation/Payment: RT for breast cancer: Ongoing<br><b>best practice oncologie:</b> Other-Editor: Compensation/Payment: Editor for radiotherapy: Ongoing<br><b>Deutsche Krebshilfe:</b> Research: Recipient: My Institution: Salary Support: No: steering committee: Breast Cancer: Grant/research funding: RT for breast cancer: Ongoing<br><b>ESMO:</b> Education/Meeting Faculty: Travel expenses, Compensation/Payment: Preceptorship for breast cancer: Ongoing<br><b>ESO:</b> Education/Meeting Faculty: Compensation/Payment: Certificate in Competence for breast cancer: Ongoing<br><b>Gilead:</b> Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Compensation/Payment: Radiotherapy and Sacituzumab Govitecan: Ongoing<br><b>med update:</b> Education/Meeting Faculty: Travel expenses, Compensation/Payment: Educational content for radiotherapy: Ongoing<br><b>Merck Sharp &amp; Dohme:</b> Education/Meeting Faculty: Compensation/Payment: Radiotherapy for melanoma: Ongoing<br><b>onkowsissen:</b> Education/Meeting Faculty: Compensation/Payment: Coverage of scientific meetings: Ongoing<br><b>Pfizer:</b> Education/Meeting Faculty: Compensation/Payment: Radiotherapy for breast cancer: Ongoing | None   | None   |
| Stephen    | Kry       | University of Texas MD Anderson Cancer Center: Professor and Director: Employee                       | IAEA: Consultant: Honoraria, Travel expenses: consultancy work: Current<br>Trans-tasman Radiation Oncology Group: Consultant: Honoraria: consultancy work: Present   | None   | None   |
| Ian        | Kudel     | Varian, A Siemens Healthineers Company: Director: Employee  | None   | None   | None   |
| Maggie     | Kuhn      | UC Davis Health: Associate Professor: Employee  | None   | None   | American Broncho-Esophagological Assocation: Secretary: Secretary: secretary for the association: Compensation? No                                     |
| Abhishek   | Kumar     | Department of Radiation Oncology, Duke University Medical Center                                      | None   | None   | None   |

**ASTRO 2024 Annual Meeting - Faculty and Presenters' Disclosures**

| First Name | Last Name  | Employment Relationships   | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria   | Ownerships/Investments/Intellectual Property       | Leadership/Positions of Authority   |
|------------|------------|--|---|--|---|
| Colton     | Ladbury    | City of Hope National Medical Center: Assistant Professor: Employee              | Radiation Oncology Institute: Consultant: Compensation/Payment: Developer of RadOnc Toolbox: Present<br>RefleXion Medical: Research: Recipient: Me: Salary Support: No: national/overall principal investigator: Bridging RT Prior to CAR-T for DLBCL: Grant/research funding: Principal Investigator: Present  | None   | None  |
| David      | Lakomy     | Washington University in St Louis: Resident Physician: Employee                  | None  | None   | None  |
| Rahul      | Lall       | University of California, Berkeley: Graduate Student Researcher: Employee        | None  | None   | None  |
| Brian      | Lally      | Medical university of south carolina: associate professor: Employee              | None  | None   | American College of Radiation Oncology: Similar to ASTRO. Advocate for the profession of radiation oncology: President-Elect: oversee some committees: Compensation? No: Relationship ended               |
| Miranda    | Lam        | Brigham and Women's Hospital: Radiation Oncologist: Employee                     | None  | None   | None  |
| Gerri      | Lamb       | Arizona State University: Professor Emerita: Retired, Emerita Status             | National Committee on Quality Assurance (NCQA): Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Uncompensated: Advisory Committee on Geriatric Measurement and Care Coordination: Present<br>San Carlos Apache Healthcare: Consultant: Compensation/Payment: Advisory Committee on Geriatric Measurement and Care Coordination: Present  | None   | Case Management Society of America: Professional Association: Chair, Strategic Relationships - Academia: Committee chair for strategic plan for relationships with university programs: Compensation? Yes |
| Nayan      | Lamba      | Department of Radiation Oncology, Brigham and Women's Hospital                   | None  | None   | None  |
| Johannes   | Langendijk | University Medical Center Groningen: Professor: Employee                         | IBA: Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Grant/research funding, Honoraria, Travel expenses: advisory board: 2025<br>RaySearch: Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Grant/research funding:   | None   | None  |
| Claire     | Lanier     | Department of Radiation Oncology, Wake Forest University School of Medicine      | None  | None   | None  |
| Michael    | LaRiviere  | University of Pennsylvania: Assistant Professor of Radiation Oncology: Employee  | Merck: Research: Recipient: My Institution: Salary Support: No: Co-I: drug-only funding for lymphoma clinical trial: Other-drug-only funding: drug-only funding for lymphoma clinical trial: To present   | None   | None  |
| Nicole     | Larrier    | Duke University: Associate Professor: Employee                                   | None  | None   | ABR: Board Examiner: Written Question writer: Written question writer: Compensation? No<br>NCCN: Guideline: Committee member: Committee Member: Compensation? No  |
| Susan      | LaRue      | Colorado State University: Professor: Employee                                   | None  | None   | None  |
| Nwamaka    | Lasebikan  | University of nigeria teaching hospital: Oncologist: Employee                    | None  | None   | None  |
| Christine  | Lauro      | University of Tennessee Medical Center Knoxville: Radiation Oncologist: Employee | None  | None   | None  |
| Anna       | LaVigne    | Johns Hopkins University School of Medicine                                      | None  | None   | None  |
| Yaacov     | Lawrence   | Sheba Medical Center: Acting chair , Department of radiation oncology: Employee  | Bristol-Myers Squibb: Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: clinical trial of liver metastases: Grant/research funding: clinical trial of liver metastases: 2022 (end)<br>Checkmate Pharmaceuticals (purchased by Regeneron): Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: clinical trial: Grant/research funding: PI: 2022 (end)<br>Roche Genetech: Consultant: Compensation/Payment: advisory role for clinical trial: Present | Protean Biodiagnostics Inc: Stock: stock ownership | None  |
| Theodore   | Lawrence   | University of Michigan: Professor of Radiation Oncology: Employee                | None  | None   | None  |
| Emily      | Lebow      | University of Pennsylvania: Faculty: Employee                                    | None  | None   | None  |

**ASTRO 2024 Annual Meeting - Faculty and Presenters' Disclosures**

| First Name | Last Name | Employment Relationships  | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria  | Ownerships/Investments/Intellectual Property    | Leadership/Positions of Authority  |
|------------|-----------|---|--|---|--|
| Percy      | Lee       | City of Hope National Medical Center: Professor and Vice-Chair, Medical Director of Orange County and Coastal Regions: Employee<br><b>MD Anderson Cancer Center</b> : Adjunct Professor: non-paid faculty | <b>AstraZeneca, Inc.</b> : Consultant, Education/Meeting Faculty, Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: ENDURE trial: Grant/research funding, Honoraria: funding source for an investigator initiated trial, ad-hoc advisory board member: Present<br><b>Genentech, Inc.</b> : Consultant: Honoraria: IDMC member: Present<br><b>RTOG Foundation</b> : Consultant: Honoraria: Plan reviewer for RTOG 3515: present<br><b>Varian, Inc.</b> : Consultant, Education/Meeting Faculty: Honoraria: advisory role, educational speaker: Present<br><b>Viewray, Inc.</b> : Consultant, Research: Recipient: Me: Salary Support: No: national/overall principal investigator: MR-guided SABR for pancreatic cancer: Grant/research funding, Honoraria, Travel expenses: PI of SMART trial, consulting role in various other engagement : Present   | None  | <b>Radisurgery Society</b> : Board of Director Member: Board of Director Member: Compensation? No  |
| Nancy      | Lee       | <b>Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center</b>   | <b>Elsie Pharmaceuticals</b> : Consultant: Compensation/Payment: Ad Board Member: 12/1/2023<br><b>Galera</b> : Consultant: Compensation/Payment: One time consultant: 12/2023<br><b>LEO SAB</b> : Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Compensation/Payment: Ad Board Member: On-going<br><b>Merck</b> : Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Compensation/Payment: Ad Board Member: On-going<br><b>Merck EMD</b> : Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Compensation/Payment: Ad Board Member: On-going<br><b>Nanobiotix</b> : Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Compensation/Payment: Ad Board Member: On-going<br><b>Shanghai JoAnn Medical Technology Co., Ltd</b> : Consultant: Other-One time consulting: One time consulting: 7/2023<br><b>Varian</b> : Other-One time travel support: Other-One time travel support: One time travel support: 11/2022<br><b>Yinming Consulting</b> : Consultant: Other-One time consulting: One time consultant: 7/2023 | <b>LEO SAB</b> : Stock options: Ad Board Member | None   |
| Grace      | Lee       | <b>Brigham and Women's Hospital</b> : Resident: Employee<br><b>Dana-Farber Cancer Institute</b> : Resident: Employee<br><b>Massachusetts General Hospital</b> : Resident: Employee                        | None   | None  | None   |
| Peter      | Lee       | <b>Department of Radiation Oncology, Fox Chase Cancer Center</b>  | None   | None  | None   |
| Sang Ho    | Lee       | <b>University of Pennsylvania</b> : Senior Research Investigator: Employee  | None   | None  | <b>American Association of Physicists in Medicine (AAPM)</b> : The AAPM is a professional organization dedicated to advancing the application of physics in medicine and healthcare, focusing on areas like medical imaging and radiation therapy. It serves as a key resource for medical physics professionals through educa: Associate Editor: Oversee the peer review process, maintain submission quality and relevance, and guide the editorial strategy in utilizing radiomics, machine learning, and AI to predict outcomes in radiology and radiation oncology.: Compensation? No |
| Shing Fung | Lee       | <b>Department of Radiation Oncology, National University Cancer Institute</b>   | None   | None  | None   |
| Mario      | Levis     | <b>University of Torino, Torino, Italy</b> : Assistant Professor: Employee  | None   | None  | None   |
| Heng       | Li        | <b>Johns Hopkins University</b> : Associate Professor: Employee   | None   | None  | None   |
| Guang      | Li        | <b>Department of Radiation Oncology, Chongqing University Cancer Hospital &amp; Chongqing Cancer Institute &amp; Chongqing Cancer Hospital</b>  | None   | None  | None   |
| Guangjun   | Li        | <b>Radiation Physics Center, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University</b>  | None   | None  | None   |

**ASTRO 2024 Annual Meeting - Faculty and Presenters' Disclosures**

| First Name | Last Name | Employment Relationships   | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria  | Ownerships/Investments/Intellectual Property  | Leadership/Positions of Authority   |
|------------|-----------|--|--|---|---|
| Li         | Li        | Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences | None   | None  | None  |
| Xiang      | Li        | Memorial Sloan Kettering Cancer Center   | None   | None  | None  |
| Xing       | Li        | Inova Schar Cancer Institute: Medical Physicist: Employee  | None   | None  | None  |
| Yun        | Li        | City of Hope: Assistant Professor: Employee  | None   | None  | None  |
| Steven     | Lin       | The University of Texas MD Anderson Cancer Center: Professor: Employee   | <p><b>AstraZeneca:</b> Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Honoraria: Advisory Board member: To present</p> <p><b>Beyond Spring Pharmaceuticals:</b> Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: Dendritic Cell activation: Grant/research funding: Combining activator with radiation: To present</p> <p><b>Creatv Microtech:</b> Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Honoraria: Advisor to the company: To present</p> <p><b>Nektar Therapeutics:</b> Research: Recipient: My Institution: Salary Support: No: site principal investigator: Cytokine therapy: Grant/research funding: PI of the preclinical research/PI of the clinical trial: To present</p> <p><b>STCube Pharmaceuticals:</b> Research: Recipient: My Institution: Salary Support: No: site principal investigator: Novel immunotherapy agent: Grant/research funding: immunotherapy with radiation therapy: To present</p> <p><b>XRAD Therapeutics:</b> Consultant: Compensation/Payment: I serve as consultant for the company: To present</p> | <p><b>Seek Diagnostics:</b> Ownership equity: Co-founder and Scientific Advisor</p>   | None  |
| Chi        | Lin       | NMC Radiation/Oncology/UNMC: Professor and Vice chair of research: Employee  | None   | None  | NMC Radiation/Oncology/UNMC: Vice Chair of Research, Department of Radiation Oncology: Oversee the research activity in the department of Radiation Oncology: Compensation? No  |
| Mu-Han     | Lin       | University of Texas Southwestern Medical Center: Associate Professor/Medical Physicist: Employee   | <p><b>Varian:</b> Research: Recipient: Me: Salary Support: Yes: national/overall principal investigator: Evaluation of RapidPlan in Ethos 2.0: Grant/research funding: Principal investigator: 3/2024</p>  | None  | <p><b>AAPM:</b> Medical Physics society: Member of Working Group on Treatment Planning: Review TG reports, provide plan quality evaluation review lectures.: Compensation? No</p> <p><b>US Taiwanese Medical Physicist Society:</b> Society group manage the social gathering &amp; academic/clinical collaboration among Taiwanese physicists: Board Member: Organize annual events and support medical phys education in Taiwan: Compensation? No</p> |
| Yuting     | Lin       | University of Kansas Medical Center: Lead Proton Physicist: Employee   | None   | None  | None  |
| Wei        | Liu       | Mayo Clinic: Professor: Employee   | None   | <p><b>Mayo Clinic:</b> Copyright/Patent/License/Royalty: I have multiple patents, disclosures, and copyright software. Some are licensed to .Decimal LLC.</p> | <p><b>PTCOG Thoracic SubCommittee:</b> Co-Chair: to lead the PTCOG Thoracic subcommittee, organize the routine meetings, coordinate the efforts to publish guidelines related to the subcommittee, and advocate the research related to the subcommittee.: Compensation? No</p>   |
| Stephen    | Liu       | Georgetown University: Associate Professor: Employee   | <p><b>AstraZeneca Pharmaceuticals LP:</b> Consultant: Compensation/Payment: Consultant: 12/21/2022</p> <p><b>Boehringer Ingelheim International GmbH:</b> Other-Speaker: Compensation/Payment: speaker in education program: 10/28/2022</p> <p><b>F. Hoffmann-La Roche AG:</b> Consultant: Compensation/Payment: Consultant: 10/1/2022</p> <p><b>Janssen Global Services, LLC:</b> Consultant: Compensation/Payment: Consultant: 10/24/2022</p> <p><b>Janssen Scientific Affairs, LLC:</b> Consultant: Compensation/Payment: Consultant: 12/27/2022</p>  | None  | None  |
| Dingchao   | Liu       | Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College        | None   | None  | None  |
| Feng       | Liu       | Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University                                     | None   | None  | None  |
| Hui        | Liu       | State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center           | None   | None  | None  |

**ASTRO 2024 Annual Meeting - Faculty and Presenters' Disclosures**

| First Name | Last Name | Employment Relationships  | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria  | Ownerships/Investments/Intellectual Property | Leadership/Positions of Authority   |
|------------|-----------|---|--|--|---|
| Lianli     | Liu       | Stanford Medicine: Clinical Assistant Professor: Employee   | None   | None   | None  |
| Ya         | Liu       | Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College | None   | None   | None  |
| Yang       | Liu       | National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College                                   | None   | None   | None  |
| Ying       | Liu       | Memorial Sloan Kettering: Assistant Attending: Employee   | <p><b>Artios Pharmaceuticals:</b> Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: therapeutic development: Grant/research funding: PI of study: Present</p> <p><b>AstraZeneca:</b> Research: Recipient: My Institution: Salary Support: No: site principal investigator: therapeutic development: Grant/research funding: PI of study: present</p> <p><b>GSK:</b> Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: immunotherapy:</p> | None   | None  |
| Yufei      | Liu       | Department of Radiation Oncology, City of Hope National Medical Center  | None   | None   | None  |
| Zhihua     | Liu       | Department of Radiation Oncology, Washington University School of Medicine  | None   | None   | None  |
| Andrea     | Lo        | BC Cancer: Radiation Oncologist: Employee   | None   | None   | None  |
| Lina       | Loaiza    | línica Somer: Radiation Oncology: Employee<br>Universidad Pontificia Bolivariana: Docente posgrado: Independent Contractor  | None   | None   | <b>Asociación Colombiana de radioterapia Oncologica:</b> Asociación medica sin animo de lucro: President: Promover desarrollo academico e investigativo en cancer en Colombia: Compensation? No |
| Benjamin   | Lok       | Princess Margaret Cancer Centre: Clinician-Scientist: Employee  | <p><b>AstraZeneca:</b> Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: Radiosensitizers: Grant/research funding: Radiosensitizers - preclinical investigation: Present</p> <p><b>Pfizer:</b> Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: Clinical trial: Grant/research funding: Clinical trial: Present</p>   | None   | <b>ASTRO:</b> Advances in Radiation Oncology Journal: Section Editor - Biology: Section Editor - Biology; Advances in Radiation Oncology: Compensation? Yes                                     |
| Alexander  | Louie     | Sunnybrook Health Science Centre: Radiation Oncologist: Employee  | <b>AstraZeneca:</b> Speaker's Bureau, Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Honoraria: participation in speaker's bureau and advisory board: Ongoing  | None   | None  |
| Bailey     | Loving    | Department of Radiation Oncology, Corewell Health William Beaumont University Hospital  | None   | None   | None  |

**ASTRO 2024 Annual Meeting - Faculty and Presenters' Disclosures**

| First Name | Last Name | Employment Relationships  | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria   | Ownerships/Investments/Intellectual Property   | Leadership/Positions of Authority  |
|------------|-----------|---|---|--|--|
| Daniel     | Low       | UCLA: Professor: Employee   | <p><b>Pulmonum LLC:</b> Other-Founding member: Compensation/Payment: President and founder. Company has not yet obtained funding but will work in the radiation oncology domain, specifically in 4DCT applications.: To present</p> <p><b>TAE Life Sciences:</b> Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Compensation/Payment: SAB member: To present</p> <p><b>Triplet State LLC:</b> Consultant: Grant/research funding: Obtained some funding for graduate student. Funding started roughly 2020 and was used to pay graduate student.: To present</p> <p><b>Ursus Arctos:</b> Other-Founding member: Uncompensated: This LLC is intended to contract with Triplet State LLC. The compensation comes from them and will have its own disclosure entry: To present</p> <p><b>Varian:</b> Research: Recipient: My Institution: Salary Support: No: site principal investigator: Master Research Framework: Grant/research funding, Salary support: I am also the PI of the Varian MRF at UCLA: To present</p> <p><b>ViewRay:</b> Advisory Board, Consultant, Research: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Recipient: My Institution: Salary Support: No: site principal investigator: MR guided Radiation Therapy: Grant/research funding, Travel expenses, Salary support, Compensation/Payment: Co-PI of international clinical trial, consultant, PI of UCLA master research</p> | <p><b>Pulmonum LLC:</b> Limited liability company interest: Founder and owner. Company has not yet received any revenue or investment</p> <p><b>Triplet State LLC:</b> Limited liability company interest: This is currently based on a verbal contract, will be formalized in 2023</p> <p><b>Ursus Arctos LLC:</b> Limited liability company interest: Founder and owner</p>                              | None   |
| Sifan      | Lu        | SUNY Downstate College of Medicine  | None  | None   | None   |
| Michelle   | Ludwig    | <p><b>Baylor College of Medicine:</b> Associate Professor: Employee</p> <p><b>Baylor College of Medicine:</b> Professor: Employee</p> | <p><b>Innovaderm:</b> Consultant: Compensation/Payment: Consultant: Present</p> <p><b>The Immunization Partnership:</b> Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Uncompensated: Serve as a subject matter expert on the role of vaccines in cancer</p>  | None   | None   |
| Join       | Luh       | Eureka Radiation Oncology Consultants: radiation oncologist: Partner  | <p><b>Aptitude Health:</b> Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Travel expenses, Compensation/Payment: various roundtable topics on cancer management: Present</p> <p><b>EMD Serono:</b> Advisory Board: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Honoraria: discuss diagnosis and management of head and neck cancers and review of research on a novel agent: 1/1/2024</p> <p><b>MVision AI:</b> Consultant: Compensation/Payment: validation of auto contours: Present</p>  | <p><b>Accuray:</b> Stock</p> <p><b>Actimatech, Inc.:</b> Ownership equity: Officer</p> <p><b>Astra Zeneca:</b> Stock</p> <p><b>Bridge Oncology:</b> Limited liability company interest: Advisor and investor</p> <p><b>Elekta:</b> Stock</p> <p><b>Genesis Healthcare:</b> Stock</p> <p><b>One Medical:</b> Stock</p> <p><b>Pfizer:</b> Stock</p> <p><b>Siemens:</b> Stoc</p> <p><b>ViewRay:</b> Stock</p> | <p><b>ACR CARROS:</b> Council of Affiliated Regional Radiation Oncology Societies: President: oversee and support CARROS meetings/activities, discuss resolutions relevant to radiation oncology in ACR's Council: Compensation? No: Relationship ended 10/22/2022</p> <p><b>American Cancer Society--Northern California Area:</b> cancer patient advocacy organization: Board Member: participation in meetings, support ACS projects: Compensation? No</p> <p><b>California Radiological Society:</b> economics and policy advocacy organization for radiologists and radiation oncologists: President: engaging with members and resident leadership, staying abreast of state legislative issues: Compensation? No</p> <p><b>Humboldt Del-Norte County Medical Society:</b> medical organization: President: oversee and support medical society activities and issues: Compensation? No: Relationship ended 12/31/2022</p> <p><b>Northern California Radiation Oncology Society:</b> regional radiation oncology organization: President: oversee and support fall and spring meetings: Compensation? No</p> <p><b>Providence Health Radiation Oncology Focus Group:</b> system-wide radiation oncology workgroup addressing RO issues: Co-Chair: lead monthly meetings and provide input on system-wide issues: Compensation? No: Relationship ended 12/31/2022</p> |
| Jason      | Luke      | UPMC Hillman Cancer Center: Physician: Employee   | <p><b>Abbvie, Agenus, Evaxion, Immutep and Shionogi:</b> DSMB</p> <p><b>7 Hills, Affivant, BioCytics, Bright Peak, Exo, Fstar, Inzen, RefleXion, Xilio (stock) Actym, Alphamab Oncology, Arch Oncology, Duke Street Bio, Elipsience, Kanaph, NeoTx, Onc.AI, OncoNano, physIQ, Pyxis, Saros, STipe and Tempest:</b> Scientific Advisory Board: (no stock)</p> <p><b>Abbvie, Agenus, Alnylam, AstraZeneca, Askgene, Atomwise, Bayer, Bristol-Myers Squibb, Castle, Checkmate, Codiak, Crown, Cugene, Curadev, Day One, Eisai, EMD Serono, Endeavor, Flame, G1 Therapeutics, Genentech, Geneos, Gilead, Glenmark, HotSpot, Kadmon, Ko Bio Labs, Krystal, KSQ, Janssen, Ikena, Inzen, Immatics, Immunocore, Incyte, Instil, IO Biotech, LegoChem, Lyvgen, Macrogenics, Merck, Mersana, Nektar, Novartis, Partner, Pfizer, Pioneering Medicines, PsiOxus, Regeneron, Replimmune, Ribon, Roivant, Servier, STINGthera, Storm, Sumoitomo, Synlogic, SyntheKine and Teva:</b> Consultancy with compensation</p> <p><b>AbbVie, Astellas, Astrazeneca, Bristol-Myers Squibb, Corvus, Day One, EMD Serono, Fstar, Genmab, Hot Spot, Ikena, Immatics, Imugene, Incyte, Janux, Kadmon, KAHR, Macrogenics, Merck, Moderna, Nektar, Next Cure, Novartis, Numab, Palleon, Pfizer, Replimmune, Rubius, Servier, Scholar Rock, Synlogic, Takeda,</b></p>  | <p><b>Patents:</b> US-11638728 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)</p>   | None   |
| John       | Lukens    | University of Pennsylvania: Assistant Professor: Employee   | None  | None   | <p><b>NCCN:</b> National Comprehensive Cancer Network: Non-Melanoma Skin Cancer Panelist: Non-Melanoma Skin Cancer Panelist: Compensation? No</p>  |

**ASTRO 2024 Annual Meeting - Faculty and Presenters' Disclosures**

| First Name     | Last Name | Employment Relationships  | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria  | Ownerships/Investments/Intellectual Property | Leadership/Positions of Authority  |
|----------------|-----------|---|--|--|--|
| Alexander      | Lukez     | Fox Chase Cancer Center: Resident Physician: Employee   | None   | None   | None   |
| Leo            | Luo       | Vanderbilt University Medical Center: Assistant Professor: Employee   | GT Medical Technologies: Other-Travel Expenses: Travel expenses: I received travel reimbursement for attendance of an educational conference organized by GT Medical Technologies on the use of GammaTile Brachytherapy for intracranial tumors.:  | None   | None   |
| Ren            | Luo       | Thoracic Oncology Ward, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University   | None   | None   | None   |
| Maryam         | Lustberg  | Yale  | AstraZeneca: Advisory Board, Consultant: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Honoraria, Travel expenses, Salary support, Compensation/Payment: consultant: Ongoing<br>Lilly: Advisory Board, Consultant, Speaker's Bureau: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Honoraria, Travel expenses, Compensation/Payment: CDK 4/6 inhibitors: Ongoing<br>Novartis: Advisory Board, Consultant: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Honoraria, Travel expenses, Compensation/Payment: Early stage breast cancer fibocidib: Ongoing | None   | None   |
| Stephen Thomas | Lutz      | Blanchard Valley Health System: Radiation Oncologist: Employee<br>University of Michigan: Marketing specialist: Employee  | None   | None   | None   |
| Yulia          | Lyatskaya | Brigham and Women's Hospital: Medical Physicist: Employee   | APEX: Other-surveyor: Honoraria, Travel expenses: compensation for being a surveyor  | None   | Brigham and Women's Hospital: Dosimetry Section of the Physics Division: Chief: lead and coordinate QA activities: Compensation? No<br>Harvard Medical Physics Residency Program: teaching program: Associate Director: lead Harvard Medical Physics Residency Program: Compensation? No<br>SDAMPP: Society of Directors of Academic Medical Physics Programs: Chair of Ad Hoc Committee on Surveys: Lead committee activities: Compensation? No |
| Janice         | Lyons     | University Hospitals Seidman Cancer Center: Radiation Oncologist: Employee  | Primum: Other-I serve as a breast cancer expert answering questions posed by the community physicians: Honoraria: I receive compensation for each question answered.: Present  | None   | ABR: ABR exam development: Member: Help develop the ABR oral exam and administer the ABR oral exam: Compensation? No<br>ASTRO: ASTRO PBI guideline: Chair: Chairing the PBI guideline committee: Compensation? No<br>NCCN: NCCN breast cancer guideline committee: Member: Help update the breast cancer guidelines, review the radiation compendium: Compensation? No   |
| Chenyang       | Ma        | The First Affiliated Hospital of Soochow University   | None   | None   | None   |
| Daniel         | Ma        | Mayo Clinic, Department of Radiation Oncology   | None   | None   | None   |
| Jiangjun       | Ma        | Institute of Natural Sciences and School of Mathematics, Shanghai Jiao Tong University  | None   | None   | None   |
| Lin            | Ma        | Department of Radiation Oncology, University of Pennsylvania  | None   | None   | None   |
| Mengmeng       | Ma        | Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences  | None   | None   | None   |
| Shuangshuang   | Ma        | Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences: Master: Employee  | None   | None   | None   |
| Zeliang        | Ma        | Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College | None   | None   | None   |
| Gabriella      | Macchia   | Responsible Research Hospital - Gemelli Molise Hospital: Radiation Oncologist: Employee   | Merck Radiation Oncology: Consultant: Honoraria, Travel expenses: Consultant for KEYNOTE-A18: Present  | None   | None   |
| Emily          | MacDuffie | University of Pennsylvania: Resident Physician: Employee  | None   | None   | None   |

| ASTRO 2024 Annual Meeting - Faculty and Presenters' Disclosures |              |   |   |   |  |
|---|--------------|---|---|---|--|
| First Name  | Last Name    | Employment Relationships  | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria   | Ownerships/Investments/Intellectual Property          | Leadership/Positions of Authority  |
| Brandon   | Mahal        | University of Miami: Assistant Professor: Employee<br>University of Miami: Associate Professor: Employee                              | Foundation Medicine: Speaker's Bureau: Honoraria: Educational series on genomics: August 1, 2024<br>Pfizer: Advisory Board: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: No remuneration specified: Honoraria: Ad Board for Radiation plus systemic therapy: 12/1/22   | None  | None   |
| Umesh   | Mahantshetty | Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai & Homi Bhabha Cancer Hospital & Research Centre                        | None  | None  | None   |
| Raymond   | Mailhot Vega | University of Florida: Associate Professor: Employee  | Florida Department of Health: Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: Scholastic performance of brain tumor survivors: Grant/research funding: PI: 6/30/2024<br>Leukemia and Lymphoma Society: Research: Recipient: My Institution: Salary Support: No: co-investigator: : Grant/research funding: co-I for award seeking to better empower PCPs to advocate for clinical trials: To present<br>NIH/NCATS: Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: Diversity Supplement: Grant/research funding: Evaluating radiotherapy receipt in patients receiving NA chemotherapy for breast cancer: 06/30/2023<br>Robert A Winn Career Development Award: Research: Recipient: My Institution: Salary Support: No: Career Development Award: CDA: Grant/research funding, Salary support: Favorable Wilms Tumor Trial: To present<br>Winn Career Development: Research: Recipient: Me: Salary Support: Yes: award scholar: Wilms Tumor: Salary support: personalizing and de-escalating therapy for favorable histology Wilms tumor: October 2025 | None  | ACR-ARS Appropriateness Criteria Committee: Lymphoma Committee Member: Member: Compensation? No<br>Children's Oncology Group: Steering Committee Member: Member of the Hodgkin Lymphoma Steering Committee: Compensation? No<br>Particle Therapy Co-Operative Group: Co-operative group focusing on particle therapy: Diversity and Inclusion Chair: DEI Chair: Compensation? No |
| Harvey  | Mamon        | BRIGHAM AND WOMEN'S HOSPITAL: radiation oncologist: Employee  | Merck: Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Honoraria: scientific advisory board for a clinical trial of esophageal cancer that includes radiation: Present   | None  | None   |
| Brandon   | Mancini      | BAMF Health: Medical Director: Employee<br>West Michigan Cancer Center: Radiation Oncologist: Employee: Relationship ended 03/13/2022 | GE HealthCare: Advisory Board, Speaker's Bureau: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Honoraria, Travel expenses: Speaker's Bureau with industry presentation at the 2023 SNMMI Annual Meeting on the advancement of radiopharmaceutical treatment/care. Asked to serve on a Theranostics Advisory Board.: To Present<br>GoodRx Health: Consultant: Compensation/Payment: Ad hoc editing/revision of prostate cancer-related educational articles: To Present<br>MCG Health: Consultant: Compensation/Payment: Consultant to evaluate and edit/revise medical guidelines.: To Present  | BAMF Health, Inc.: Ownership equity: Medical Director | BAMF Health: Medical Director: Serve as Medical Director in addition to primary role as a physician providing patient care.: Compensation? No  |
| Gohar   | Manzar       | MD Anderson Cancer Center: Resident Physician (current), incoming Assistant Professor: Employee                                       | None  | None  | None   |
| Ariel   | Marciscano   | Massachusetts General Hospital: Radiation Oncologist: Employee  | None  | None  | None   |
| Danielle  | Margalit     | Brigham & Women's Physician Organization: Physician: Employee   | None  | None  | American Radium Society: Chair, Head/Neck Appropriate Use Criteria Comm.: Chair of Committee: Compensation? No<br>JROBP (Red Journal): Section Editor - Head/Neck: Section Editor: Section editor: Compensation? No: Relationship ended 10/01/2023   |
| Stephanie   | Markovina    | Washington University: Assistant Professor: Employee  | NCCN: Education/Meeting Faculty: Travel expenses: Member of NCCN Thyroid Cancer Panel, recently traveled to in-person panel meeting, received reimbursement for travel expenses for this  | None  | National Cancer Institute, NIH: K08 Career Development Award: Research Grants, Other: PI: Compensation? No<br>Tesaro Inc.: Oncology-focused business within Glasco Smith Kline: Research Grants, Other: PI: Compensation? No   |
| Lawrence  | Marks        | University of North Carolina: Dr. Sidney K. Simon Distinguished Professor of Oncology Research: Employee                              | None  | None  | None   |
| Brian   | Marples      | University of Rochester: Dr. Sidney H. and Barbara L. Sobel Professor in Radiation Oncology: Employee                                 | None  | None  | American Board of Radiology: Member of the Radiation and Cancer Biology Committee: Chair: Resident's certification examination in Radiation and Cancer Biology: Compensation? No   |
| Gustavo   | Marta        | Hospital Sírio-Libanês: Radiation Oncologist: Independent Contractor  | None  | None  | None   |
| Emily   | Martin       | University of California, Los Angeles: Assistant Clinical Professor: Employee   | None  | None  | None   |
| Douglas   | Martin       | The Ohio State University Wexner Medical Center: Professor: Employee  | None  | None  | None   |



**ASTRO 2024 Annual Meeting - Faculty and Presenters' Disclosures**

| First Name     | Last Name  | Employment Relationships  | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria   | Ownerships/Investments/Intellectual Property                              | Leadership/Positions of Authority  |
|----------------|------------|---|---|---|--|
| Anthony        | Mascia     | Cincinnati Children's Hospital: Associate Professor: Employee<br><b>UC Health:</b> Director of Medical Physics: Employee: Relationship ended 08/01/2023                   | <b>Siemens (Varian Medical Systems):</b> Research: Recipient: My Institution: Salary Support: No: PI, co-PI: Trial support: Grant/research funding: PI, co-PI: Present  | None  | None   |
| Masayuki       | Matsuo     | <b>Department of Radiology, Graduate School of Medicine, Gifu University</b>  | None  | None  | None   |
| Malcolm        | Mattes     | <b>Rutgers Cancer Institute of New Jersey:</b> Associate Professor: Employee  | <b>Bristol Myers Squibb Foundation:</b> Research: Recipient: Me: Salary Support: No: Career Development: Career Development: Grant/research funding: Career Development Award: 12/31/2023<br><b>New Jersey Health Foundation:</b> Research: Recipient: Me: Salary Support: No: site principal investigator: Translational Research: Grant/research funding: Research Funding: 2/14/2024<br><b>Radiation Oncology Institute:</b> Research: Recipient: Me: Salary Support: No: national/overall principal investigator: Education Research: Grant/research funding: Research Funding: 10/31/2023  | None  | <b>ASTRO:</b> Communications Committee: Vice Chair: Communications Committee Vice Chair: Compensation? No<br><b>University Hospital Cancer Center:</b> ACOS CoC Cancer Liaison Physician: ACOS CoC Cancer Liaison Physician: ACOS CoC Cancer Liaison Physician: Compensation? No   |
| Martha         | Matuszak   | <b>University of Michigan:</b> Professor: Employee  | <b>Varian:</b> Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: Quality Assurance: Grant/research funding: PI: To present  | <b>Fuse Oncology:</b> Licensing and Collaboration Agreement: Collaborator | <b>AAPM:</b> American Association of Physicists in Medicine: Member, Board of Directors: Board Member at Large: Compensation? No<br><b>MROQC:</b> Radiation Oncology Quality Consortium with Blue Cross Blue Shield of Michigan: Co-Director: Executive Leadership: Compensation? No   |
| Jyoti          | Mayadev    | <b>University of California San Diego:</b> Professor: Employee  | <b>AstraZeneca:</b> Consultant: Honoraria, Compensation/Payment: advisor: ongoing<br><b>KORTUC:</b> Consultant: Honoraria: Clinical trial advisor: Ongoing<br><b>Merck:</b> Advisory Board, Consultant: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Honoraria: advisor: Ongoing<br><b>Primmune:</b> Consultant: Honoraria: advisor: Ongoing<br><b>Varian Medical Systems:</b> Consultant: Honoraria: Advisor to clinical trial development: Ongoing   | None  | <b>American Brachytherapy Society:</b> Board Member: Director-at-large, starting July 2023 for a 3 year term.: Compensation? No<br><b>NRG Oncology:</b> NCI funded cooperative group: Co-Chair: Grant co chair: Compensation? No   |
| Charles        | Mayo       | <b>University of Michigan:</b> Professor: Employee  | <b>CodeX Steering Committee:</b> Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Uncompensated: Member of steering committee having oversight of CodeX projects.: To present<br><b>EPIC Radiation Oncology Steering Board:</b> Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Uncompensated: Advocate for use of standardization methods being developed via professional societies into EPICs interfaces. Coordinate connections between EPIC and other clinical stakeholders regarding standardizations. There is no remuneration or other financial benefit from this participation: To present | None  | <b>American Association of Physicists in Medicine:</b> Professional society representing the role of physics in medicine: Vice Chair Data Science Committee: Vice Chair Data Science Committee: Compensation? No   |
| Sarah          | McAvoy     | <b>Department of Radiation Oncology, University of Maryland School of Medicine</b>  | None  | None  | None   |
| Aliah          | McCalla    | <b>The Ohio State University Wexner Medical Center:</b> Medical Student: Medical Student  | None  | None  | None   |
| Shearwood      | McClelland | <b>University Hospitals Seidman Cancer Center:</b> Director of Spine Oncology: Employee   | <b>Gilmartin Capital:</b> Consultant: Compensation/Payment: Consultant: 05/2024<br><b>GT Medical Technologies:</b> Education/Meeting Faculty: Travel expenses: GammaTile Practitioner Symposium: 2/26/23  | None  | <b>National Medical Association:</b> Section on Radiology and Radiation Oncology: Research Committee: Chair: Compensation? No<br><b>NRG Oncology:</b> Health Disparities Committee: Rural Health Special Interest Group: Chair: Compensation? No   |
| Mark           | McDonald   | <b>Winship Cancer Institute of Emory University:</b> Professor of Radiation Oncology: Employee  | <b>Varian Medical Systems:</b> Education/Meeting Faculty: Honoraria: moderator, Varian Users Meeting, PTCOG 2022  | None  | <b>Georgia ProtonCare Center, Inc.:</b> d/b/a Emory Proton Therapy Center, a not-for-profit cancer treatment center providing proton radiation therapy services: Medical Director: approve, direct and provide oversight, evaluate and set standards for patient care at the center: Compensation? No  |
| Andrew         | McDonald   | <b>Department of Radiation Oncology, University of Alabama at Birmingham</b>  | None  | None  | None   |
| Lachlan Joseph | McDowell   | <b>Peter MacCallum Cancer Centre:</b> Radiation Oncologist: Employee: Relationship ended 10/07/2022<br><b>Princess Alexandra Hospital:</b> Radiation Oncologist: Employee | <b>MSD:</b> Advisory Board: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Compensation/Payment: Advisory board for study design; Paid to institution: April 2023  | None  | <b>Head and Neck Cancer International Group:</b> International collaboration of Head and Neck research groups: Co-Chair Young Investigator subcommittee: Co-Chair of Young Investigator subcommittee: Compensation? No<br><b>Head and Neck Cancer International group:</b> International collaboration of Head and Neck research groups: Deputy Chair Guidelines and Protocols Committee: Co-chair of subcommittee: Compensation? No<br><b>Trans Tasman Radiation Oncology Group:</b> Research Group: Deputy Chair Head and Neck/Skin Working Party: Organisation, no compensation: Compensation? No |
| Susan          | McDuff     | <b>Duke Cancer Center Department of Radiation Oncology:</b> Assistant Professor: Employee   | None  | None  | None   |

**ASTRO 2024 Annual Meeting - Faculty and Presenters' Disclosures**

| First Name | Last Name   | Employment Relationships  | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria  | Ownerships/Investments/Intellectual Property | Leadership/Positions of Authority |
|------------|-------------|---|--|--|-----------------------------------|
| Rana       | Mckay       | UCSD: Associate Professor: Employee   | <p><b>Ambrx:</b> Advisory Board, Consultant: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Compensation/Payment: GU malignancies</p> <p><b>AstraZeneca:</b> Advisory Board, Consultant: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Compensation/Payment: GU Malignancies</p> <p><b>Aveo:</b> Advisory Board: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Compensation/Payment: GU malignancies</p> <p><b>Bayer:</b> Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Compensation/Payment: GU malignancies</p> <p><b>BMS:</b> Advisory Board: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Compensation/Payment: GU malignancies</p> <p><b>Caris:</b> Consultant: Compensation/Payment: GU malignancies</p> <p><b>Dendreon:</b> Advisory Board: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Compensation/Payment: GU malignancies</p> <p><b>Eisai:</b> Consultant: Compensation/Payment: GU malignancies</p> <p><b>Exelixis:</b> Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Compensation/Payment: GU malignancies</p> <p><b>JNJ:</b> Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Compensation/Payment: GU malignancies</p> <p><b>Lilly:</b> Consultant: Compensation/Payment: GU Malignancies</p> | None   | None                              |
| Elizabeth  | McKenzie    | Cedars Sinai Medical Center: Medical Physicist: Employee  | None   | None   | None                              |
| William    | McLaughlin  | University of Michigan: Professor: Employee   | None   | None   | None                              |
| Shauna     | McVorrn     | Geisel School of Medicine at Dartmouth and the Dartmouth Cancer Center: Assistant Professor: Employee | None   | None   | None                              |
| Minesh     | Mehta       | Baptist Health: Chief of Radiation Oncology: Employee   | <p><b>Kazia Therapeutics:</b> Consultant: Compensation/Payment: Consulted on protocol development: 10/15/2022</p> <p><b>Mevion:</b> Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Compensation/Payment: Advisory board on general needs and developments in proton therapy: Ongoing</p>   | None   | None                              |
| Teresa     | Meier       | University of Cincinnati: Assistant Professor: Employee   | None   | None   | None                              |
| Stavros    | Melemenidis | Department of Radiation Oncology, Stanford University School of Medicine                              | None   | None   | None                              |
| Loren      | Mell        | UC San Diego: Professor: Employee   | <p><b>Astra-Zeneca:</b> Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: head/neck cancer: Grant/research funding: head/neck cancer: 12/31/24</p> <p><b>Castle Biosciences:</b> Speaker's Bureau: Honoraria: Skin cancer diagnostics: Oct 15, 2022</p> <p><b>Cel-Sci:</b> Advisory Board: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Honoraria: Advisory Board: 11/1/22</p> <p><b>EMD Serono:</b> Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: head/neck cancer: Grant/research funding: head/neck cancer: Present</p> <p><b>Merck:</b> Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: head/neck cancer: Grant/research funding: head/neck cancer: Present</p> <p><b>Pfizer:</b> Advisory Board: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Honoraria: Scientific Advisory Board: October 1, 2022</p>   | None   | None                              |
| Eric       | Mellon      | University of Miami: Associate Professor: Employee  | None   | None   | None                              |

**ASTRO 2024 Annual Meeting - Faculty and Presenters' Disclosures**

| First Name | Last Name     | Employment Relationships   | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria  | Ownerships/Investments/Intellectual Property | Leadership/Positions of Authority  |
|------------|---------------|--|--|--|--|
| Yu         | Men           | Department of VIP Medical Services & Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College | None   | None   | None   |
| Cynthia    | Menard        | CHUM: Department Chief: Employee   | None   | None   | None   |
| Alejandra  | Mendez Romero | Erasmus MC: Dr.: Employee  | None   | None   | None   |
| Marc       | Mendonca      | Indiana University School of Medicine  | None   | None   | None   |
| Nipun      | Merchant      | UNIVERSITY OF MIAMI: SURGEON: Employee   | None   | None   | None   |
| Kenneth    | Merrell       | Mayo Clinic: MD: Employee<br>Mayo Clinic: Physician: Employee  | <b>AstraZeneca:</b> Research: Recipient: My Institution: Salary Support: Yes: site principal investigator: SBRT + IO for lung cancer: Other-Clinical trial funding based on effort: Other-Clinical trial funding paid to institution: PI, IO and SBRT for lung cancer: 2025<br><b>Galera:</b> Research: Recipient: My Institution: Salary Support: Yes: site principal investigator: SBRT + SOD for pancreas cancer: Other-Clinical trial funding based on effort: Other-Clinical trial funding paid to institution: SBRT + SOD for pancreas cancer: 2024<br><b>Novartis:</b> Research: Recipient: My Institution: Salary Support: Yes: national/overall principal investigator: PRRT for meningioma: Other-Clinical trial funding based on effort: Other-Clinical trial funding paid to institution: PI, PRRT for meningioma: 2026<br><b>Pfizer:</b> Education/Meeting Faculty: Other-Clinical trial funding based on effort: Other-Clinical trial funding paid to institution: Global oncology education, Medical Director: 2028<br><b>Varian:</b> Research: Recipient: My Institution: Salary Support: Yes: site principal investigator: CRA for VT: Other-Clinical trial funding based on effort: Other-Clinical trial funding paid to institution: CRA for VT: 2028 | None   | <b>GACC:</b> NPO: Chairman: Oversee global outreach and education programs: Compensation? No<br><b>Global Access to Cancer Care Foundation:</b> Non-profit organization: Chairman: Chairman of the board, NPO to support cancer care and access globally: Compensation? No   |
| Shane      | Mesko         | Scripps Cancer Center: Radiation Oncologist: Employee  | <b>Oscar Health:</b> Consultant: Compensation/Payment: Independent Consultant for coverage guidelines: To Present  | None   | None   |
| Omar       | Mian          | Cleveland Clinic: Staff: Employee  | <b>Bayer:</b> Consultant: Compensation/Payment: Consultant Prostate Cancer: Jan 2023<br><b>Gilead:</b> Research: Recipient: My Institution: Salary Support: No: site principal investigator: Bladder Cancer: Grant/research funding: PI Research (Clinical Trial): Dec 2025<br><b>Varian:</b> Research: Recipient: My Institution: Salary Support: No: site principal investigator: Bladder Cancer: Grant/research funding: PI Research Grant: Dec 2025  | None   | <b>NCCN:</b> Guidelines: Panel Member: NCCN Panel Member: Compensation? No   |
| Jeff       | Michalski     | Washington University School of Medicine: Professor: Employee  | <b>Michalski and Associates:</b> Consultant: Travel expenses, Compensation/Payment: Consultatn: To present<br><b>NCI:</b> Research: Recipient: My Institution: Salary Support: No: co-investigator: Radium-223; Improving Response and Toxicities: Grant/research funding: Coinvestigator: To present  | None   | <b>NCI:</b> GU Steering Committee: Co-Chair: Oversee portfolio of NCI NCTN clinical trials in genitourinary cancers.: Compensation? No<br><b>RTOG Foundation:</b> nonprofit organization dedicated to improving outcomes for cancer patients through the conduct of practice changing clinical trials.: Treasurer: Treasurer and board of directors: Compensation? No  |
| Michelle   | Mierzwa       | University of Michigan: Associate Professor of Radiation Oncology: Employee  | <b>Adaptimmune:</b> Advisory Board: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Honoraria: interaction of drug   | None   | <b>MROQC:</b> Michigan Radiation Oncology Quality Consortium: Behavioral Health Committee co-lead: subcommittee co-lead: Compensation? No  |
| Dimitris   | Mihailidis    | University of Pennsylvania: Associate Professor: Employee  | None   | None   | <b>AAPM:</b> Therapy Physics Committee: Vice Chair: Manage therapy physics subcommittees, working groups and task groups.: Compensation? No: Relationship ended 05/26/2023<br><b>AAPM Task Group 261: management of dental and maxillofacial CBCT technologies:</b> Provide document with recommendations and guidelines to manage dental and maxillofacial CBCT technologies: Chair: manage and produce the guidelines: Compensation? No<br><b>AAPM Task Group 359: FLASH beam dosimetry:</b> Manage and coordinate expert investigation on FLASH beam dosimetry issues, make recommendations and provide guidance in FLASH beam dosimetry.: Chair: Manage and coordinate, guide the group to producing recommendations and guidance through a manuscript: Compensation? No<br><b>Doody Enterprise Inc:</b> Source, expert reviews of newly published books, print and electronic, in the health sciences.: Member of the Editorial Board: Book review editor for Medical Physics division: Compensation? No<br><b>The American Board of Medical Physics:</b> Board certification for medical and radiological physicists: Member of the Board of Directors: Representative of the AAPM and voting member of the board of directors: Compensation? No |
| George     | Mikhaeel      | Guy's & St Thomas NHS Hospital: Clinical Oncologist: Employee  | <b>Kite:</b> Education/Meeting Faculty: Honoraria, Travel expenses: Invited speaker about Role of radiotherapy with CAR-T: 5 October   | None   | None   |
| Sarah      | Milgrom       | University of Colorado: Associate Professor: Employee  | <b>Bristol Myers Squibb:</b> Consultant: Uncompensated: Provided advice to researchers at Bristol Myers Squibb regarding PET volumetric research for a pediatric Hodgkin lymphoma study:   | None   | <b>American Radium Society:</b> Appropriate Use Criteria Lymphoma Committee: Vice Chair: work with a committee to develop guidelines regarding lymphoma sub-topics: Compensation? No   |

**ASTRO 2024 Annual Meeting - Faculty and Presenters' Disclosures**

| First Name | Last Name | Employment Relationships  | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria  | Ownerships/Investments/Intellectual Property   | Leadership/Positions of Authority   |
|------------|-----------|---|--|--|---|
| Matthew    | Mille     | National Cancer Institute, National Institutes of Health: Staff Scientist: Employee   | None   | None   | <p><b>Baltimore-Washington Chapter of the Health Physics Society:</b> Local chapter of the Health Physics Society: Webmaster: Maintain the organization website: Compensation? No</p> <p><b>Council on Ionizing Radiation Measurements and Standards:</b> An independent, non-profit council that draws together stakeholders from industry, academia, and government involved in all ionizing radiation disciplines to provide leadership, focus, and action on important developments and needs: Co-chair of Medical Radiation Subcommittee: Co-chair the conference organizing subcommittee on medical radiation topics: Compensation? No</p> <p><b>Council on Ionizing Radiation Measurements and Standards:</b> An independent, non-profit council that draws together stakeholders from industry, academia, and government involved in all ionizing radiation disciplines to provide leadership, focus, and action on important developments and needs: Past President: Advisor to the conference organizing committee: Compensation? No: Relationship ended 04/19/2023</p> <p><b>Council on Ionizing Radiation Measurements and Standards:</b> An independent, non-profit council that draws together stakeholders from industry, academia, and government involved in all ionizing radiation disciplines to provide leadership, focus, and action on important developments and needs: Past President: Chair the conference organizing committee: Compensation? No: Relationship ended 04/13/2022</p> <p><b>Council on Ionizing Radiation Measurements and Standards:</b> An independent, non-profit council that draws together stakeholders from industry, academia, and government involved in all ionizing radiation disciplines to provide leadership, focus, and action on important developments and needs: Webmaster: Maintain the organization website: Compensation? No</p> <p><b>International Society of Radiation Epidemiology and Dosimetry:</b> ISoRED is the first international society of scientists interested in radiation, epidemiology and dosimetry: Chair of Communications Working Group: To create and maintain a dedicated ISoRED website and social media platforms to communicate the society's activities: Compensation? No</p> |
| Jessica    | Miller    | University of Wisconsin - Madison: Associate Professor: Employee  | <p><b>GE Healthcare Collaboration:</b> Research: Recipient: My Institution: Salary Support: No: collaborator: Bone Marrow Imaging: Grant/research funding: Collaborator/Bone Marrow: To present</p> <p><b>Siemens Healthiness Collaboration:</b> Research: Recipient: My Institution: Salary Support: No: site principal investigator: CT for radiation therapy: Grant/research funding: PI/DECT: To present</p> <p><b>UWADCL Advisory Board:</b> Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Uncompensated: Board Member: To present</p>   | None   | None  |
| Jacob      | Miller    | Cleveland Clinic Foundation: Associate Staff: Employee  | None   | None   | None  |
| Rachel     | Minne     | Department of Human Oncology, University of Wisconsin   | None   | None   | None  |
| Bruce      | Minsky    | MD Anderson Cancer Center: Professor: Employee  | None   | None   | None  |
| Darrion    | Mitchell  | The Ohio State University: Assistant Professor: Employee  | None   | None   | None  |
| Timur      | Mitin     | Oregon Health and Science University: Associate Professor: Employee   | <p><b>AstraZeneca:</b> Education/Meeting Faculty, Research, Speaker's Bureau: Recipient: My Institution: Salary Support: No: national/overall principal investigator: Pneumonitis in Stage III NSCLC VA patients: Grant/research funding, Honoraria, Travel expenses: Radiation Oncology in management of Stage III NSCLC: To present</p> <p><b>Bioprotect Ltd.:</b> Other-Clinical Events Committee (CEC) for clinical study BP-007: Honoraria: CEC primary reviewer: To present</p> <p><b>Novocure, Inc.:</b> Speaker's Bureau, Research, Education/Meeting Faculty, Consultant, Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Recipient: My Institution: Salary Support: No: national/overall principal investigator: Prophylactic TTF in SCLC: Grant/research funding, Honoraria, Travel expenses, Compensation/Payment: Prophylactic TTF in SCLC: To present</p> <p><b>UpToDate Inc.:</b> Other-Chapter author: Other-Royalties: Chapter Author: "Radiation therapy techniques in cancer treatment": To</p> | None   | None  |
| Devarati   | Mitra     | University of Texas MD Anderson Cancer Center: Assistant Professor: Employee  | None   | None   | None  |
| Kathryn    | Mittauer  | Florida International University: Associate Professor: Academic affiliate<br>Miami Cancer Institute: Senior Medical Physicist: Employee | <p><b>ViewRay Inc:</b> Consultant, Research, Speaker's Bureau: Recipient: Me: Salary Support: No: national/overall principal investigator: LAP-ABLATE, SRS MR Linac benchmarking: Grant/research funding, Honoraria, Travel expenses, Compensation/Payment: Honoraria for speaking engagement on A3i UI, travel and compensation for consulting for A3i UI: 10/25/2023</p>   | <p><b>MR Guidance LLC:</b> Limited liability company interest: Dr. Mittauer reports ownership interest in a company that provides consulting services on image guided radiation therapy technology (MR Guidance, LLC.): Relationship ended</p> | None  |
| David      | Miyamoto  | Massachusetts General Hospital: Physician Investigator: Employee  | None   | None   | None  |
| Masashi    | Mizumoto  | University of Tsukuba: Assistant Professor: Employee  | None   | None   | None  |

**ASTRO 2024 Annual Meeting - Faculty and Presenters' Disclosures**

| First Name | Last Name | Employment Relationships   | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria  | Ownerships/Investments/Intellectual Property  | Leadership/Positions of Authority |
|------------|-----------|--|--|---|-----------------------------------|
| Everett    | Moding    | Stanford University: Assistant Professor: Employee   | Gerson Lehrman Group: Consultant: Compensation/Payment: Consulted on projects related to oncology and genomic technologies.: To Present<br>Guidepoint: Consultant: Compensation/Payment: Consulted on projects related to oncology and genomic technologies.: To   | None  | None                              |
| Nuverah    | Mohsin    | Fox Chase Cancer Center  | None   | None  | None                              |
| Shalini    | Moningi   | Brigham and Women's Hospital: Attending Physician: Employee  | None   | None  | None                              |
| Steven     | Montalvo  | Department of Radiation Oncology, University of Texas Southwestern Medical Center  | None   | None  | None                              |
| Dominic    | Moon      | UT Southwestern Medical Center: Assistant Professor: Employee  | Gateway For Cancer Research: Research: Recipient: Me: Salary Support: No: national/overall principal investigator: Phase I trial: Grant/research funding: Research funding for phase I trial: To present<br>The Cary Council: Research: Recipient: Me: Salary Support: No: national/overall principal investigator: Circulating tumor cells as a biomarker: Grant/research funding: Research funding for a   | None  | None                              |
| Bill       | Moore     | NYU Langone Health   | None   | None  | None                              |
| Fabio Ynoe | Moraes    | Department of Oncology, Division of Radiation Oncology, Queen's University   | None   | None  | None                              |
| Jean       | Moran     | Department of Medical Physics, Memorial Sloan Kettering Cancer Center  | None   | None  | None                              |
| Takayuki   | Mori      | Department of Radiology, Graduate School of Medicine, Gifu University  | None   | None  | None                              |
| Zachary    | Morris    | University of Wisconsin-Madison: Associate Professor: Employee   | Archeus Technologies: Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Compensation/Payment: Scientific Advisory Board Member: Present<br>Cali Biomedical: Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Compensation/Payment: Member of scientific advisory board: To Present<br>Johnson & Johnson: Consultant: Compensation/Payment: Consulting on radiation - intratumoral approaches: To Present<br>Northstar Medical Radioisotopes: Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Honoraria, Travel expenses: Scientific Advisory Board Member: To present<br>Point Biopharma: Research: Recipient: My Institution: Salary Support: No: site principal investigator: : Grant/research funding: Theranostics research: To Present<br>Seneca Therapeutics: Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Compensation/Payment: Scientific Advisory Board Member: Present<br>Telix Pharmaceuticals: Research: Recipient: My Institution: Salary | Archeus Technologies: Stock options: Scientific Advisory Board Member<br>Seneca Therapeutics: Stock options: Scientific Advisory Board Member<br>Wisconsin Alumni Research Foundation: Copyright/Patent/License/Royalty: Inventor on various patents related to radiation therapy and/or immunotherapy for cancer | None                              |
| Sabin      | Motwani   | RWJBarnabas Health Medical Group: Radiation Oncologist: Employee   | None   | None  | None                              |
| Kent       | Mouw      | Brigham & Women's Hospital: Assistant Professor of Radiation Oncology: Employee<br>Dana-Farber Cancer Institute: Assistant Professor of Radiation Oncology: Employee | Pfizer: Research, Consultant: Recipient: My Institution: Salary Support: No: national/overall principal investigator: bladder cancer: Grant/research funding, Compensation/Payment: bladder cancer clinical trial: To present<br>Riva Therapeutics: Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Compensation/Payment: drug development consultant: To present<br>UpToDate: Education/Meeting Faculty: Honoraria: bladder cancer professional media: To present<br>UroGen: Advisory Board, Consultant: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Honoraria: device and drug development consultant: 10/2021   | Riva Therapeutics: Ownership equity: co-founder   | None                              |

**ASTRO 2024 Annual Meeting - Faculty and Presenters' Disclosures**

| First Name    | Last Name           | Employment Relationships  | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria  | Ownerships/Investments/Intellectual Property | Leadership/Positions of Authority   |
|---------------|---------------------|---|--|--|---|
| Yvonne        | Mowery              | <b>Duke Health:</b> Assistant Professor of Radiation Oncology: Employee: Relationship ended 05/31/2023<br><b>UPMC Hillman Cancer Center/University of Pittsburgh:</b> Associate Professor of Radiation Oncology: Employee | <b>Bayer:</b> Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: preclinical studies with BAY 1895344: In-kind donations: Supports research evaluating radiosensitizing and immunomodulatory effects of ATR inhibitor BAY 1895344: December 2023<br><b>Catalys Pacific LLC:</b> Consultant: Compensation/Payment: Reviewed slides from Galera Therapeutics regarding Avasopasem, related literature, and literature related to potential competitor. Summarized these findings and provided input on potential for FDA approval and clinical benefit for Avasopasem: 1/16/2023<br><b>Damon Runyon Cancer Foundation:</b> Research: Recipient: : Salary Support: No: national/overall principal investigator: Duke Clinical Investigator Award: Grant/research funding, Travel expenses: Basic, translational and clinical research focused on studying radiation resistance in head and neck cancer: To present<br><b>John R. Flanagan Charitable Foundation:</b> Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: postdoc support: Grant/research funding: supports postdoc salary: To present<br><b>Merck:</b> Research: Recipient: My Institution: Salary Support: No: Radiation Oncology PI: SU2C-SARC032 clinical trial: Grant/research funding: MISP funding for SU2C-SARC032, trial evaluating addition of pembrolizumab to neoadjuvant radiation and surgery for high-risk soft tissue sarcoma: 11/2021<br><b>NCI/NIH:</b> Research: Recipient: My Institution: Salary Support: No: 823 825 826: steering committee and collaborator: Grant/research funding: Oncology Co-Clinical Imaging Research Resources to Encourage Consensus on Quantitative Imaging Methods and Precision Medicine (U124) - preclinical experiments | None   | <b>Center for Cancer Immunotherapy:</b> Duke Cancer Institute Center for Cancer Immunotherapy: Associate Center Director for Radioimmunotherapy: To identify cancer immunotherapy discoveries related to radiation therapy that show promise and facilitate a team to translate the finding into a drug that can be tested in a clinical trial.: Compensation? No: Relationship ended 05/31/2023  |
| John          | Mulhall             | <b>Memorial Sloan Kettering Cancer Center:</b> Professor: Employee  | <b>Firm Tech:</b> Consultant: Other-stock: on steering committee: Current<br><b>Ro:</b> Consultant: Other-stock: on steering committee: Current  | None   | <b>Journal of Sexual Medicine:</b> journal: Editor in Chief: Editor: Compensation? Yes<br><b>SMSNA:</b> Medical Society: Board of Directors: Non voting member: Compensation? Yes   |
| Philipose     | Mulugeta            | <b>Hospital of University of PA:</b> Associate Professor of Clinical Radiology: Employee  | None   | None   | None  |
| Pablo         | Munoz Schuffenegger | <b>Pontificia Universidad Catolica de Chile:</b> Assistant Professor: Employee  | None   | None   | <b>International Association for the Study of Lung Cancer:</b> Member of the Advanced Radiotherapy (ART) Committee at IASLC as a Latin America representative: Member of the Advanced Radiotherapy (ART) Committee at IASLC as a Latin America representative: Compensation? No<br><b>Latin American Cooperative Oncology Group:</b> Radiation Oncology Research Group - Steering Committee Member: Radiation Oncology Research Group - Steering Committee Member: Compensation? No   |
| Louise        | Murray              | <b>University of Leeds:</b> Associate Professor: Employee   | None   | None   | None  |
| Vedang        | Murthy              | <b>Tata Memorial Centre:</b> Professor: Employee  | <b>Varian Medical Systems:</b> Research: Recipient: Me: Salary Support: No: site principal investigator: trial: Grant/research funding: PI of a trial: Present   | None   | None  |
| Nima          | Nabavizadeh         | <b>OREGON HEALTH &amp; SCIENCE UNIVERSITY:</b> Associate Professor of Radiation Oncology, Residency Program Director: Employee  | <b>Freonome:</b> Advisory Board: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Compensation/Payment: Early lung detection advisory board: Present<br><b>GRAIL LLC:</b> Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Compensation/Payment: Specialist Advisory Board: Present<br><b>Pharmacy Times:</b> Education/Meeting Faculty: Compensation/Payment: Helped develop educational material on multi-cancer early detection tests: Present   | None   | None  |
| Arash         | Naghavi             | <b>Moffitt Cancer Center:</b> Associate Member: Employee  | <b>Viewray:</b> Research: Recipient: My Institution: Salary Support: No: site principal investigator: HEAT trial: Grant/research funding: Principal investigator: 2023   | None   | <b>Cancer Control:</b> Journal: Editorial board: Editorial board: Compensation? No  |
| Justyn        | Nakashima           | <b>University of South Florida:</b> Resident: Employee  | None   | None   | None  |
| Ansel         | Nalin               | <b>Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center</b>  | None   | None   | None  |
| Lakshmi Rekha | Narra               | <b>Rutgers Cancer Institute of New Jersey:</b> Resident Physician: Employee   | None   | None   | None  |
| Haidy         | Nasief              | <b>Froedtert and Medical college of Wisconsin:</b> Faculty: Employee  | None   | None   | <b>AAPM:</b> AAPM north central chapter meeting: Social media representative: Social media representative: Compensation? No<br><b>Astro:</b> Astro early career committee: Member: Compensation? No<br><b>ASTRO:</b> ASTRO Early career medical physics subcommittee: Chair: Compensation? No<br><b>ASTRO SWRO:</b> Vice Chair, Medical Physics SWRO Subcommittee: Vice Chair, Medical Physics Subcommittee: Compensation? No<br><b>NRG oncology:</b> Early career and new investigator committee: Member: Compensation? No |

**ASTRO 2024 Annual Meeting - Faculty and Presenters' Disclosures**

| First Name | Last Name  | Employment Relationships  | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria  | Ownerships/Investments/Intellectual Property  | Leadership/Positions of Authority   |
|------------|------------|---|--|---|---|
| Kingsley   | Ndoh       | Hurone AI: Founder & CEO: Employee<br>University of Washington: Project Director: Employee  | None   | None  | None  |
| Kevin      | Nead       | University of Texas MD Anderson Cancer Center: Assistant Professor: Employee  | None   | None  | None  |
| Beth       | Neilsen    | UCLA: Resident Physician: Employee  | ViewRay: Consultant: Compensation/Payment: Consulting for VR regarding MRI-guided RT: 12/2022  | None  | None  |
| Taindra    | Neupane    | Thomas Jefferson University   | None   | None  | None  |
| Andrea     | Ng         | Brigham and Women's Hospital and Dana Farber Cancer Institute: Professor of Radiation Oncology: Employee  | UptoDate: Other-Royalty: Other-Royalty: Publishing: Ongoing  | None  | American Board of Radiology: Medical Board: Trustee: Exam management: Compensation? No  |
| Hieu       | Nguyen     | UCSD School of Medicine   | None   | None  | None  |
| Triet      | Nguyen     | Johns Hopkins Bloomberg School of Public Health: PhD Candidate: PhD Candidate<br>University of Maryland School of Medicine: Research Affiliate: Research Affiliate              | None   | None  | None  |
| Alan       | Nichol     | Department of Radiation Oncology, BC Cancer   | Varian Medical Systems Ltd: Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: Clinical trial for brain metastases: Grant/research funding: Principal investigator Phase 2 clinical trial: 2026   | None  | None  |
| John       | Nikitas    | UCLA: Resident Physician: Employee  | None   | None  | None  |
| Matthew    | Ning       | UT MD Anderson Cancer Center: Assistant Professor: Employee   | None   | None  | None  |
| Mizuki     | Nishino    | Brigham and Women's Hospital and Dana-Farber Cancer Institute   | None   | None  | None  |
| Joshua     | Niska      | Department of Radiation Oncology, Mayo Clinic   | None   | None  | None  |
| Georgios   | Ntentas    | Guy's and St Thomas' NHS Foundation Trust: Senior Radiotherapy Physicist: Employee  | None   | None  | None  |
| Bismarck   | Odei       | Huntsman Cancer Hospital: Assistant Professor: Employee   | Bristol Myers Squibb: Other-Award Recipient: Grant/research funding: Career Development Award: 1/2026  | Eli Lilly: Stock: Stock holder<br>Novo Nordisk: Stock: Stock holder   | None  |
| Michael    | Oertel     | University Hospital Muenster: Consultant: Employee  | None   | None  | None  |
| Danielle   | Ofri       | Bellevue Hopsital   | None   | None  | None  |
| Joy        | Ogunmuyiwa | New York Presbyterian: Resident: Employee   | None   | None  | None  |
| William    | Oh         | Icahn School of Medicine at Mount Sinai: Clinical Professor of Medicine: Employee<br>Prostate Cancer Foundation: Chief Medical Officer: Employee: Relationship ended 04/30/2024 | Cytogen: Consultant: Compensation/Payment: Consultant: To present<br>Pfizer: Consultant: Compensation/Payment: Consultant: To present  | Archetype Therapeutics: Stock options: Founding Chair, SAB<br>Sema4/GeneDx: Stock options: Chief Medical Officer: Relationship ended 11/01/2022 | Chemotherapy Foundation: Medical Charity: Chair, Medical Advisory Council: Chair, Medical Advisory Council: Compensation? Yes |
| Nitin      | Ohri       | Albert Einstein College of Medicine, Montefiore Me: Associate Professor, Attending Physician: Employee: Relationship ended 10/07/2023   | AstraZeneca: Consultant, Research: Recipient: My Institution: Salary Support: No: site principal investigator: Lung Cancer: Grant/research funding, Honoraria: Lung Cancer: Present<br>Genentech: Consultant: Compensation/Payment: Consultant: To present<br>Regeneron: Consultant: No remuneration specified: Consulting: To present | None  | None  |
| Eric       | Ojerholm   | University of Pennsylvania: Radiation Oncologist: Employee  | None   | None  | None  |
| Carol      | Oliveira   | McGill University Health Centre: Radiation Oncologist: Independent Contractor   | None   | None  | None  |
| Kenneth    | Olivier    | Department of Radiation Oncology, Mayo Clinic   | None   | None  | None  |
| Adam       | Olson      | UPMC Hillman Cancer Center: Assistant Professor: Employee   | None   | None  | None  |
| Eenas      | Omari      | The Medical College of Wisconsin: Assistant Professor: Employee   | The Medical College of Wisconsin: Education/Meeting Faculty: Travel expenses: Research presentations travel funds: To present  | None  | None  |
| Chavon     | Onumah     | George Washington SMHS: Program Director: Employee  | None   | None  | None  |
| Emily      | O'Reilly   | Vancouver Coastal Health: Resident Physician: Employee  | None   | None  | None  |
| Megan      | Orr        | UC San Diego: Resident Physician: Employee  | None   | None  | None  |

**ASTRO 2024 Annual Meeting - Faculty and Presenters' Disclosures**

| First Name | Last Name  | Employment Relationships  | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria  | Ownerships/Investments/Intellectual Property | Leadership/Positions of Authority  |
|------------|------------|---|--|--|--|
| Joe        | O'Sullivan | Northern Ireland Cancer Centre  | <p><b>AAA:</b> Advisory Board, Consultant, Speaker's Bureau: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Honoraria: Prostate cancer: 01/01/2025</p> <p><b>Bayer:</b> Advisory Board, Speaker's Bureau: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Honoraria: Prostate Cancer: 01/01/2025</p> <p><b>Janssen:</b> Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Honoraria: Prostate Cancer: 01/01/26</p> <p><b>Monrol:</b> Consultant, Speaker's Bureau: Honoraria: Prostate Cancer: 01/01/2025</p> <p><b>Novartis:</b> Advisory Board, Consultant, Speaker's Bureau: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Honoraria: Prostate: 01/01/26</p> | None   | None   |
| Hiba       | Othman     | Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network  | None   | None   | None   |
| Harald     | Paganetti  | Massachusetts General Hospital: Director of Physics Research in Radiation Oncology: Employee  | <p><b>Particle Therapy Co-operative Group (PTCOG):</b> Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Uncompensated: PTCOG - North America - Board of Directors: To present</p> <p><b>Physics in Medicine and Biology:</b> Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Travel expenses: Executive Editorial Board: To present</p>   | None   | <p><b>ICRU:</b> International Commission on Radiation Units and Measurements: Committee member: Committee on prescribing and reporting dose in proton therapy: Compensation? No</p> <p><b>NCRP:</b> National Council on Radiation Protection &amp; Measurements: Council Member: Advisory: Compensation? No</p> <p><b>University of Manchester, UK:</b> INfraStructure in Proton International Research (INSPIRE); European Union research infrastructure project: Head; Scientific Advisory Board: Advisory Board: Compensation? No</p> |
| Joshua     | Palmer     | The Ohio State University: Associate Professor: Employee  | <p><b>Carbofix:</b> Speaker's Bureau: Honoraria: honoraria for speaking: Present</p> <p><b>ICOTEC:</b> Consultant: Honoraria: Consultant and honoraria for speaking.: Present</p> <p><b>The Ohio State University:</b> Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: Neuro oncology: Grant/research funding, Salary support: Trial funding: Present</p> <p><b>Varian Medical Systems:</b> Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: Radiation therapy: Grant/research funding, Salary support: Present</p>   | None   | None   |
| Manisha    | Palta      | Duke University: Associate Professor: Employee  | <p><b>Merck:</b> Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: Esophago-gastric cancer: Grant/research funding: PI for study esophago-gastric cancer CRT with immunotherapy: Present</p> <p><b>Syntactx:</b> Consultant: Compensation/Payment: clinical trial AE adjudication: 2023</p> <p><b>UpToDate:</b> Other-section editor: Honoraria: section editor: Present</p> <p><b>Varian Medical Systems:</b> Consultant, Advisory Board: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Grant/research funding, Compensation/Payment: expert opinion: Present</p> <p><b>Voxelmetric:</b> Consultant: Compensation/Payment: clinical trial protocol review and imaging review for clinical trial: 2022</p>  | None   | <p><b>ASCO GI Cancers Symposium Leadership Committee:</b> Planning Committee: Planning committee for GI ASCO meetings: Compensation? No</p> <p><b>ASTRO Education Committee:</b> Member: CME; Educational session CME question and justification review.: Compensation? No</p>   |
| Jinghui    | Pan        | Department of Radiation Oncology, Renmin Hospital, Wuhan University   | None   | None   | None   |
| Kamal      | Pandey     | UT Southwestern Medical Center at Dallas  | None   | None   | None   |
| Qingsong   | Pang       | Department of Radiation oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention Therapy | None   | None   | None   |
| Evangelos  | Pappas     | Dept of Biomedical Sciences, University of West Attica, Greece: Associate Professor: Employee   | None   | None   | None   |
| Kelly      | Paradis    | Michigan Medicine: Associate Professor: Employee  | <p><b>Varian Medical Systems:</b> Consultant, Research: Recipient: My Institution: Salary Support: No: Co-I: Advanced treatment planning: Grant/research funding, Honoraria: Running a series of webinars highlighting the roles of women in radiation oncology:</p>   | None   | None   |



**ASTRO 2024 Annual Meeting - Faculty and Presenters' Disclosures**

| First Name | Last Name | Employment Relationships  | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria   | Ownerships/Investments/Intellectual Property  | Leadership/Positions of Authority   |
|------------|-----------|---|---|---|---|
| Parag      | Parikh    | Henry Ford Health - Cancer: Senior Staff Physician: Employee  | Galera: Research: Recipient: My Institution: Salary Support: No: RT QA lead: Radioprotector in pancreatic cancer: Grant/research funding: I am the RTQA lead for an international study for their radioprotector in pancreatic cancer.: 11/1/2023<br>Viewray Inc: Consultant, Education/Meeting Faculty, Research, Speaker's Bureau: Recipient: My Institution: Salary Support: No: national/overall principal investigator: Pancreatic Cancer: Grant/research funding, Honoraria, Travel expenses, Salary support: I serve as the national PI for the SMART trial. I perform educational classes at Henry Ford for Viewray. I have spoken at meetings on Viewray's behalf.: 10/1/2023  | Nuvaira: Stock: Stockholder - this is a COPD company without an oncology product  | None  |
| Rahul      | Parikh    | Rutgers Cancer Institute of New Jersey: Professor: Employee   | Mevion Medical Systems: Speaker's Bureau: Honoraria: Speaker fee: 2021<br>MyCareGorithm, LLC: Consultant: Honoraria: Development of Patient Educational Materials: Ongoing  | None  | None  |
| Simul      | Parikh    | Lake Huron Medical Center: Radiation Oncologist: Employee   | None  | None  | None  |
| Claire     | Park      | Department of Radiation Oncology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Harvard Medical School | None  | None  | None  |
| Jung Bin   | Park      | Department of Radiation Oncology, Seoul National University Hospital  | None  | None  | None  |
| Sean       | Parker    | Cleveland Clinic: Resident Physician: Employee  | None  | None  | None  |
| Jeannette  | Parkes    | Groote Schuur Hospital and University of Cape Town: MD: Employee  | None  | None  | None  |
| Jared      | Pasetsky  | New York Presbyterian - Columbia: Resident Physician: Employee  | None  | None  | None  |
| Alexander  | Pastuszak | University of Utah: Associate Professor: Employee   | Contraline: Consultant: Compensation/Payment: biotech company developing male contraceptive: Current  | None  | Paterna Biosciences: Biotech company: CEO: CEO of a biotech company: Compensation? Yes  |
| Chirayu    | Patel     | MGH: Radiation Oncologist: Employee   | Varian: Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: Adaptive Radiation in Lymphoma: Grant/research funding: Adaptive Radiation in Lymphoma: To present  | None  | None  |
| Krishnan   | Patel     | National Cancer Institute (NIH): Physician: Employee  | None  | None  | None  |
| Ravi       | Patel     | University of Pittsburgh Hillman Cancer Center: Assistant Professor: Employee   | Merck: Research: Recipient: My Institution: Salary Support: No: Rad Onc PI.: Neoadjuvant immunotherapy trial in NMSC.: Salary support: I'm the radiation oncology co-investigator for this trial.: Present<br>NIH: Research: Recipient: My Institution: Salary Support: No: site principal investigator: NIH grant PI and co-investigator.: Grant/research funding: I have a certain percentage of my academic University of Pittsburgh Salary supported by research grant funding.: Present<br>NIH R01 nanotech Study Section: Other-Grant Reviewer.: Honoraria, Travel expenses: Review NIH Grants: 3/3/2023<br>Voximetry: Research: Recipient: My Institution: Salary Support: No: Software MTA: Software MTA: Grant/research funding, Uncompensated: I have a research agreement where the company provides software and my lab will provide services in software testing and application development.: Present | Wisconsin Alumni Research Foundation: Copyright/Patent/License/Royalty: I have two patents for which I'm a listed inventor awarded to the Wisconsin Alumni Research Foundation. There are no licensing fees or royalties to date associated with these patents. | Elsevier Clinical Pathways: Clinical Treatment Pathways Development Committee: Co-Chair of the Skin Cancer Pathway: I am responsible of developing and reviewing skin cancer treatment pathways.: Compensation? No      |
| Reema      | Patel     | University of Virginia School of Medicine   | None  | None  | None  |
| Sagar      | Patel     | Emory University: Physician: Employee   | None  | None  | None  |
| Luke       | Pater     | U Cincinnati: Faculty: Employee   | None  | None  | None  |
| Smriti     | Patodia   | The Lancet Oncology: Senior Editor: Employee  | None  | None  | None  |
| Eric       | Paulson   | Medical College of Wisconsin: Professor: Employee   | Elekta Instruments AB: Research: Recipient: My Institution: Salary Support: Yes: site principal investigator: MR-guided online adaptive RT: Grant/research funding: PI, Co-I: 12/31/2025<br>Siemens Healthineers: Research: Recipient: My Institution: Salary Support: Yes: site principal investigator: MR-guided RT: Grant/research funding: PI: 9/30/2024  | Sonoptima Inc: Ownership equity: Co-Founder   | None  |
| Lauren     | Pedersen  | Washington University School of Medicine  | ASTRO: Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: ASTRO Seed Resident/Fellow grant PI: Grant/research funding, Travel expenses: Direct support of research in submitted abstract: 2024   | None  | Radiation Research Society: Organization of researchers in radiation field: Scholar In Training Committee Chair: leader of committee charged with advocating for trainees within broader organization: Compensation? No |

**ASTRO 2024 Annual Meeting - Faculty and Presenters' Disclosures**

| First Name | Last Name | Employment Relationships   | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria  | Ownerships/Investments/Intellectual Property   | Leadership/Positions of Authority  |
|------------|-----------|--|--|--|--|
| Chen       | Peng      | Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences | None   | None   | None   |
| Haley      | Perlow    | Department of Radiation Oncology, The Ohio State University Wexner Medical Center                                  | None   | None   | None   |
| Subha      | Perni     | The University of Texas MD Anderson Cancer Center: Assistant Professor: Employee                                   | None   | None   | None   |
| Andrew     | Peterson  | Duke: Professor of Urology: Employee   | <b>Boston Scientific:</b> Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: medical device: Grant/research funding, Honoraria: AUS Clinical Outcomes Trial AUSCO: Present  | None   | None   |
| Jennifer   | Peterson  | Mayo Clinic: MD: Employee  | None   | None   | None   |
| Katherine  | Peterson  | Phoenix VA Health Care System: AP Oncology Dietitian: Employee   | None   | None   | None   |
| Ha         | Pham      | Department of Radiation Oncology, Vanderbilt University Medical Center   | None   | None   | None   |
| John       | Phillips  | Tennessee Oncology: Radiation Oncologist: Partner  | <b>Monteris:</b> Consultant: Grant/research funding, Compensation/Payment: I do research and consulting work around Monteris' laser thermotherapy platform for CNS malignancies. I give lectures and help programs (academics and community) setup best practices for LITT in their hospital.: To Present<br><b>OneOncology:</b> Consultant: Uncompensated: I help OneOncology develop strategy around Radiation Oncology quality and delivery:                        | None   | <b>ABR OLA Committee:</b> ABR OLA program for RO Maintenance of Certification: Senior Editor: I am one of 3 senior editors which develop, review and approve the materials for the ABR OLA program for RO Maintenance of Certification: Compensation? No<br><b>ASTRO MDQA:</b> ASTRO MDQA Committee: Member: I serve as an MD member of the ASTRO MDQA committee.: Compensation? No  |
| Chelsea    | Pinnix    | MD Anderson Cancer Center: Associate Professor: Employee   | <b>Lancet Haematology:</b> Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Uncompensated: Member of the International Advisory Editorial Board: Present<br><b>Merck:</b> Research: Recipient: My Institution: Salary Support: No: site principal investigator: Pembrolizumab for relapsed and refractory DLBCL: Grant/research funding: Clinical trial support: Present | None   | <b>American Radium Society:</b> Member at Large: member at large on the executive committee: Compensation? No: Relationship ended 05/01/2023<br><b>International Lymphoma Radiation Oncology Group:</b> Steering Committee: Steering Committee Member: Steering committee member since 2019: Compensation? No<br><b>National Cancer Institute Lymphoma Steering Committee:</b> LYSC is one of 18 steering committees formed in response to the recommendations of the Clinical Trials Working Group mandated by the National Cancer Advisory Board. These committees involve the broad oncology community to address the design and prioritiza: NRG Representative on the committee: Joined the committee 3/1/2022 as NRG representative. Potential honoraria for meeting attendance.: Compensation? No<br><b>NRG Hematologic Malignancies Core Working Group:</b> Core Working Group: Co-Chair: Co-Chair as of October 2022: Compensation? No<br><b>Society of Immunotherapy of Cancer:</b> DEI Task Force: Task force member as of October 2022: Compensation? No<br><b>SWOG:</b> Myeloma Committee: Radiation Oncology Chair: Myeloma committee: Compensation? No |
| Valentina  | Pinzi     | Fondazione IRCCS Istituto neurologico C. Besta: Senior consultant: Employee  | <b>ESTRO - ACROP:</b> Research: Recipient: My Institution: Salary Support: No: Participant: neurooncology: Uncompensated: neurooncology: 12/2024   | None   | None   |
| Asya       | Pitre     | Texas College of Osteopathic Medicine  | None   | None   | None   |
| Sean       | Pitroda   | University of Chicago: Associate Professor: Employee   | None   | <b>PersonaDx:</b> Ownership equity: Co-founder | None   |
| Patricia   | Pius      | University of Oklahoma College of Medicine: Resident Physician: Employee   | None   | None   | None   |
| John       | Plastaras | University of Pennsylvania: Professor: Employee  | <b>IBA Proton Therapy:</b> Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Honoraria: attend 2 meeting per year, occasionally present on roles of proton therapy for  | None   | <b>ASTRO:</b> Board: Treasurer/Secretary: Board member for ASTRO, elected position: Compensation? No: Relationship ended 10/01/2023  |
| Tarun      | Podder    | SUNY Upstate Medical University  | None   | None   | None   |

**ASTRO 2024 Annual Meeting - Faculty and Presenters' Disclosures**

| First Name       | Last Name  | Employment Relationships  | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria   | Ownerships/Investments/Intellectual Property  | Leadership/Positions of Authority  |
|------------------|------------|---|---|---|--|
| Kelli            | Pointer    | Dartmouth-Hitchcock Medical Center: Assistant Professor: Employee<br>Government of Vermont: Civil Engineer: Employee<br>USG Corporation: Staff Researcher: Partner: Relationship ended 11/01/2022 | ACS-IRG grant: Research: Recipient: Me: Salary Support: No: national/overall principal investigator: Defining a Molecular Signature of Glioblastoma: Grant/research funding: Defining a Molecular Signature of Glioblastoma Cancer Stem Cell Acquired Radiation Resistance: To present<br>Dartmouth Cancer Center Shared Resources: Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Uncompensated: advisory board member for shared resources: To present<br>Lab start up funding: Research: Recipient: Me: Salary Support: No: site principal investigator: overcoming radiation resistance: Grant/research funding: Overcoming radiation resistance in cancer.: To present<br>Radiation Research Foundation: Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: radiation resistance in gliomas: Grant/research funding: research funding for radiation resistance in glioma: | None  | ASTRO: 2022 - 2023 Annual Meeting Track - Biology and CNS tracks: abstract reviewer: abstract reviewer: Compensation? No   |
| Adela            | Poitevin   | Medica Sur: Chief of department: Employee   | None  | None  | None   |
| Daniel           | Polan      | University of Michigan: Assistant Professor: Employee   | None  | None  | Winter Insitute of Medical Physics: Co-Director: Co-Director of Conference: Compensation? No   |
| Erqi             | Pollom     | Stanford: Associate Professor: Employee   | GT Medical Technologies: Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Compensation/Payment: serve on ad board for use of gamma tiles for brain tumors: Present<br>Varian: Honoraria: honoraria for being an instructor at Varian school: Present<br>Vysioneer: Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: No remuneration specified: Honoraria: Advisory Board: CNS executive: Ongoing  | None  | None   |
| Christopher Hays | Pope       | CARTI   | None  | None  | None   |
| Matthew          | Poppe      | Huntsman Cancer Institute: Professor: Employee<br>University of Utah: Professor: Employee   | None  | PEEL Therapeutics: Stock: Stock ownership in startup biotech company. Currently there are no possible conflicts with ASTRO or any radiation oncology concepts, as this company is still lab-based only.<br>PEEL Therapeutics: Stock: Investor | Alliance: Trial cooperative group: Breast Vice Chair and Local Regional Working Group co-chair: Leader of the breast group for clinical trial development: Compensation? No<br>Alliance: Trial cooperative group: Member of the Board of Directors and Executive Committee: voting member: Compensation? No<br>Alliance for Clinical Trials in Oncology: cooperative group network: Vice Chair breast committee: Vice chair as above and chair of the local regional committee.: Compensation? No<br>NCCN: Panel Member: Soft Tissue Sarcoma guideline committee: member: Compensation? No<br>NCI: BOLD Task for of the Breast Cancer Steering Committee: Member: Help to develop and give recommendations for local regional concepts of NCI funded trials: Compensation? No<br>NCI BOLD task force of the breast committee: Member, Alliance representative: Member: Review CTEP concepts with local regional components: Compensation? No |
| Kari             | Postlewait | University of Oklahoma Health Sciences Center   | None  | None  | None   |
| Douglas          | Prah       | Medical College of Wisconsin: Associate Professor, Director of Advanced Care & Technology: Employee   | Swanson, Martin & Bell, LLP: Consultant: Compensation/Payment: Expert Witness for a Malpractice Lawsuit: To present   | None  | None   |
| Yolanda          | Prezado    | French National Research Center: Research Director: Employee  | None  | None  | Task Group TG 359: AAPM: Vice-Chair: Vice-Chair of the task group: Compensation? No  |
| Alex             | Price      | University Hospitals: Physicist IV: Employee  | ASTRO: Education/Meeting Faculty: Uncompensated: Faculty at ASTRO annual meeting: Oct 2023  | None  | None   |
| James            | Price      | Division of Cancer Sciences, The University of Manchester   | None  | None  | None   |
| Nicolas          | Prionas    | University of California San Francisco: Assistant Professor: Employee   | None  | None  | None   |
| Lindsay          | Puckett    | Clement J Zablocki Milwaukee VA Medical Center: Physician: Employee<br>Medical College of Wisconsin: Physician: Employee  | None  | None  | Medical College of Wisconsin: Interim Chair of Thoracic Disease Oriented Team: Chair of Thoracic Disease Team: Compensation? No  |
| Juhi             | Purswani   | New York University Grossman School of Medicine, Department of Radiation Oncology   | None  | None  | None   |
| Shunan           | Qi         | Chinese Academy of Medical Sciences Cancer Hospital, Beijing, China: Professor of Radiation Oncology: Employee  | None  | None  | None   |

**ASTRO 2024 Annual Meeting - Faculty and Presenters' Disclosures**

| First Name | Last Name    | Employment Relationships  | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria   | Ownerships/Investments/Intellectual Property                | Leadership/Positions of Authority  |
|------------|--------------|---|---|---|--|
| Xin        | Qi           | Department of Radiation Oncology, Peking University First Hospital  | None  | None  | None   |
| Alexander  | Qian         | Department of Radiation Oncology, University of California San Francisco  | None  | None  | None   |
| Xiaxi      | Qiao         | State Key Laboratory of Molecular Oncology and Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (PUMC) | None  | None  | None   |
| Shang-Bin  | Qin          | Department of Radiation Oncology, Peking University First Hospital  | None  | None  | None   |
| Morten     | Quist        | Copenhagen University Hospital: Associate Professor: Employee   | None  | None  | IASLC: Board of Directors: Board Member: Board Member: Compensation? No  |
| Asal       | Rahimi       | Department of Radiation Oncology, University of Texas Southwestern Medical Center   | None  | None  | None   |
| Malolan    | Rajagopalan  | Mount Carmel Health System; Radiology, Inc.   | None  | None  | None   |
| Greeshma   | Rajeev-Kumar | University of Chicago   | None  | None  | None   |
| Silpa      | Raju         | Barnes Jewish Hospital: Resident Physician: Employee  | None  | None  | None   |
| Ann        | Raldow       | UCLA Health: Assistant Professor: Employee  | <b>Intelligent Automation:</b> Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: Symptom self-reporting using mobile application: Grant/research funding: Symptom self-reporting using mobile application: To present<br><b>Viewray, Inc.:</b> Consultant, Research: Recipient: My Institution: Salary Support: No: site principal investigator: Vaginal sparing for females with anal cancer: Compensation/Payment: Consulting and   | None  | None   |
| David      | Raleigh      | UCSF: Associate Professor: Employee   | <b>Gamma Tile:</b> Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Honoraria: Advisor: Present<br><b>Tippling Point:</b> Consultant: Honoraria: Consultant: Present  | None  | None   |
| Avani      | Rao          | Radiation Oncology Associates of the National Capital Region: Associate: Employee   | None  | None  | None   |
| Shyam      | Rao          | University Of California, Davis: Professor: Employee  | None  | None  | None   |
| Sana       | Raouf        | Memorial Sloan Kettering Cancer Center  | <b>Exact:</b> Consultant: Compensation/Payment: Consult on multi-cancer early detection clinical studies.: Present<br><b>Grail:</b> Consultant: Compensation/Payment: Consult on multi-cancer early detection clinical studies.: Present<br><b>Verily:</b> Consultant: Compensation/Payment: Consult on real world clinical studies.: Present   | <b>illumina:</b> Stock: own stocks only: Relationship ended | None   |
| Dominique  | Rash         | UCSD Health: Radiation oncologist: Employee   | <b>Radformation:</b> Other-Speaker re:Radformation products: Honoraria: Discussed EZ fluence and other products at vendor booth: 10/27/22<br><b>VisionRT:</b> Speaker's Bureau: Honoraria, Travel expenses: discussed   | None  | None   |
| Kristin    | Redmond      | Johns Hopkins University: physician: Employee   | <b>Accuray:</b> Research: Recipient: My Institution: Salary Support: No: site principal investigator: SRS hypophysectomy for painful bone mets: Grant/research funding, Honoraria, Travel expenses: I am the PI for a small single arm pilot study receiving modest support from Accuray. In addition they covered travel expenses and gave an honorarium for participation at the AERO meeting a few years ago: Present<br><b>Biomimetix:</b> Other-Data safety monitoring board for a trial: Compensation/Payment: data safety monitoring board for a trial: 2024<br><b>Canon:</b> Research: Recipient: My Institution: Salary Support: Yes: site principal investigator: radiogenomics: Grant/research funding, Other-patent pending with Canon: radiogenomics for chordoma: Present | None  | <b>Camp Kesem:</b> Camp for children whose parent has cancer: Advisory board: advisory board: Compensation? No |
| Tamer      | Refaat       | Edward Hines Jr. VA Hospital: Radiation Oncologist: Employee<br>Loyola University Medical Center: Professor: Employee   | None  | None  | None   |
| Samuel     | Regan        | University of Michigan: Resident Physician: Employee  | None  | None  | None   |

**ASTRO 2024 Annual Meeting - Faculty and Presenters' Disclosures**

| First Name | Last Name | Employment Relationships   | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria   | Ownerships/Investments/Intellectual Property  | Leadership/Positions of Authority   |
|------------|-----------|--|---|---|---|
| Lei        | Ren       | University of Maryland: Professor: Employee  | None  | None  | None  |
| Amar       | Rewari    | Luminis Health: Chief of Radiation Oncology: Employee  | None  | None  | <p><b>ACR:</b> Chair, Radiation Oncology Economics Committee: Chair, Radiation Oncology Economics Committee: Compensation? No</p> <p><b>ASTRO:</b> Chair, Health Policy Committee: Chair, Health Policy Committee: Compensation? No</p> <p><b>DIS Alumni Community Board:</b> Alumni Board for Study Abroad Provider: Vice chair of the Board: Vice chair of the Board: Compensation? No</p> <p><b>Fund for Education Abroad:</b> Study Abroad Scholarship Provider: Chairman of the Board: Chairman of the Board: Compensation? No</p> |
| Nadeem     | Riaz      | MSKCC: Assistant Attending: Employee   | <p><b>AZ:</b> Advisory Board: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Honoraria: hn io advisory board: 9/2023</p> <p><b>Pfizer:</b> Research: Recipient: My Institution: Salary Support: No: translational research: translational research: Grant/research funding: translational biomarkers: Ongoing</p> <p><b>REPARE Therapeutics:</b> Research: Recipient: My Institution: Salary Support: No: basic research: drug rt combination: Grant/research funding: research funding: Ongoing</p>   | None  | JNCI: Journal: Deputy Editor: journal editor: Compensation? Yes   |
| Umberto    | Ricardi   | University of Turin: Full Professor: Employee  | None  | None  | None  |
| Shayna     | Rich      | <p>Haven Hospice: Associate Medical Director: Employee</p> <p>Veterans Administration: Hospice and Palliative Medicine Section Head: Employee: Relationship ended 10/13/2023</p> | <p>University of Central Florida: Education/Meeting Faculty: Uncompensated: Honorary Professor: To present</p>  | None  | Fast Facts: Reviewer: Review blinded versions of proposed Fast Facts: Compensation? No  |
| Anupam     | Rishi     | Department of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute  | None  | None  | None  |
| Amanda     | Rivera    | University of Miami: Assistant Professor: Employee   | None  | None  | None  |
| Paul       | Riviere   | University of California San Diego Department of Radiation Medicine and Applied Sciences   | None  | None  | None  |
| Mack       | Roach     | University of California, San Francisco: Professor: Employee   | ACCURAY: Education/Meeting Faculty: Honoraria: ASTRO 2023: Oct 1, 2023  | None  | None  |
| Jared      | Robbins   | <p>Banner Health System: Radiation Oncologist: Employee</p> <p>University of Arizona - College of Medicine: Professor, Residency Program Director: Employee</p>                  | <p>Arizona Dental Association: Education/Meeting Faculty: Honoraria: Gave a lecture on managing head and neck cancers: 9/8/2024</p> <p>Rowpar Pharmaceutical: Research: Recipient: My Institution: Salary Support: No: site principal investigator: Impact of CloSYS mouth rinse on oral mucositis: Grant/research funding: PI for the study, oversaw the operations and analyzed the data.: Nov 2022</p> <p>Western Regional Dental Experience, Spring 2023: Education/Meeting Faculty: Honoraria: Preventing radiation-</p>   | None  | None  |
| Hannah     | Roberts   | Massachusetts General Brigham: Instructor of Radiation Oncology: Employee  | None  | None  | None  |
| Tyler      | Robin     | University of Colorado School of Medicine: Assistant Professor of Radiation Oncology: Employee   | None  | None  | None  |
| Clifford   | Robinson  | Washington University School of Medicine in St. Louis: Professor: Employee   | <p>AstraZeneca: Consultant, Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: PACIFIC-4 ICI: Grant/research funding, Honoraria: PACIFIC-4 ICI: To present</p> <p>EMD Serono: Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Honoraria: Ad hoc advisory boards: To present</p> <p>EmpNia: Consultant: Compensation/Payment: Consulting: To present</p> <p>Merck: Research: Recipient: My Institution: Salary Support: No: site principal investigator: Esophageal brachy + pembro: Grant/research funding: Esophageal brachy + pembro phase I trial: To present</p> <p>Quantaras: Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Other-Stock: Ad hoc advisory boards: To present</p> <p>Radialogica: Consultant: Honoraria, Other-Stock: Chief Medical Officer: To present</p> | <p>EmpNia: Stock options: Chief Medical Officer, stock options</p> <p>Quantaras: Stock options: Advisory board, stock options</p> <p>Radialogica: Stock options: Chief Medical Officer, phantom equity</p> <p>Varian: Copyright/Patent/License/Royalty: 2 patents through Washington University licensed to Varian for cardiac radioablation work</p> | <p>EmpNia: Chief Medical Officer: Chief Medical Officer: Compensation? Yes</p> <p>Radialogica: Chief Medical Officer: Chief Medical Officer: Compensation? No</p>   |

**ASTRO 2024 Annual Meeting - Faculty and Presenters' Disclosures**

| First Name  | Last Name             | Employment Relationships   | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria  | Ownerships/Investments/Intellectual Property  | Leadership/Positions of Authority  |
|-------------|-----------------------|--|--|---|--|
| Timothy     | Robinson              | Yale: Assistant Professor: Employee  | Kite Pharma: Consultant: Honoraria: Invited guest lecturer on CAR T-cell therapy and radiation in Diffuse Large B-Cell Lymphoma: Ongoing   | Duke University: Copyright/Patent/License/Royalty: Patents related to splicing-based therapeutics with potential implications for EGFR-related therapies<br>H. Lee Moffitt Cancer Center: Copyright/Patent/License/Royalty: Patents related to splicing-based therapeutics with potential implications for EGFR-related therapies | Yale: Yale University, Cancer Prevention and Control Program: Co-Leader: Wife is co-leader of Yale's Cancer Prevention and Control (CPC) program: Compensation? No |
| Danielle    | Rodin                 | Family: Scarborough Health Network: Physician: Independent Contractor<br>University Health Network: Radiation Oncologist: Employee | Need Inc: Consultant: Compensation/Payment: provide expertise on breast cancer management: Present<br>Union for International Cancer Control: Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Travel expenses, Uncompensated: Elected member of Board of Directors: | None  | None   |
| Carlos      | Rodriguez-Russo       | Icahn School of Medicine at Mount Sinai  | None   | None  | None   |
| Kara        | Romano                | University of Virginia: Associate Professor: Employee  | Merck Pharmaceuticals: Advisory Board, Consultant: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Honoraria: immunotherapy for cervical cancer: Present   | None  | None   |
| Gabriela    | Roque Oliveira Nomura | Department of Biomedical Engineering, The University of Texas at Austin  | None   | None  | None   |
| Abby        | Rosenberg             | Dana-Farber Cancer Institute   | None   | None  | None   |
| Kenneth     | Rosenzweig            | City of Englewood: Councilman: Employee<br>Mount Sinai: Physician and Chair: Employee  | None   | None  | NRG Data Monitoring Committee: Monitors NRG protocols: Member: Member of Committee: Compensation? No   |
| Dylan       | Ross                  | HCA Riverside Community Hospital: Resident Physician: Employee   | None   | None  | None   |
| Michael     | Roumeliotis           | Johns Hopkins School of Medicine   | None   | None  | None   |
| David       | Routman               | Mayo Clinic: Radiation Oncologist: Employee  | None   | Exact Sciences: Copyright/Patent/License/Royalty: Patent and Other Intellectual   | None   |
| Soumyajit   | Roy                   | Rush University Medical Centre   | None   | None  | None   |
| Trevor      | Royce                 | ArteraAI: Medical Director: Employee<br>Flatiron Health: Medical Director: Employee: Relationship ended 10/01/2023                 | Agilix: Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Travel expenses: Advisory Board: To present   | Agilix Health: Stock options: Options holder; advisor<br>Lumata Health: Ownership equity: Minority investor<br>mPATH: Stock options: Options holder<br>Roche: Stock: Stock/Options holder<br>Sonovascular: Ownership equity: Minority investor<br>VitriVax: Ownership equity: Minority investor                                   | None   |
| Patrick     | Rucker                | Capital Forum  | None   | None  | None   |
| Andrea      | Russo                 | Massachusetts General Hospital: Radiation Oncologist: Employee   | British Medical Journal: Other-Author of clinical guidelines: Compensation/Payment: Author of treatment of cervical cancer: Present<br>UpToDate: Other-Medical guidelines: Compensation/Payment: Author - Treatment of vulvar cancer: Present  | None  | None   |
| Maliazurina | Saad                  | The University of Texas MD Anderson Cancer Center: Postdoctoral Fellow: Employee   | None   | None  | None   |
| Hina        | Saeed                 | Lynn Cancer Institute, Boca Raton Regional Hospital, Baptist Health South Florida  | None   | None  | None   |
| Omran       | Saifi                 | Mayo Clinic: Resident Physician: Employee  | None   | None  | None   |

**ASTRO 2024 Annual Meeting - Faculty and Presenters' Disclosures**

| First Name | Last Name | Employment Relationships  | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria  | Ownerships/Investments/Intellectual Property   | Leadership/Positions of Authority   |
|------------|-----------|---|--|--|---|
| April      | Salama    | Duke Health: Associate Professor of Medicine: Employee  | <p><b>BMS:</b> Consultant, Research: Recipient: My Institution: Salary Support: No: Skin Cancer Research: Skin Cancer: Grant/research funding: Skin Cancer: Current</p> <p><b>Ideaya:</b> Research: Recipient: My Institution: Salary Support: No: Skin Cancer Research: Skin Cancer: Grant/research funding: Skin Cancer: Current</p> <p><b>Immunocore:</b> Research: Recipient: My Institution: Salary Support: No: Skin Cancer Research: Skin Cancer: Grant/research funding: Skin Cancer: Current</p> <p><b>Iovance:</b> Consultant: Honoraria: Skin Cancer: Current</p> <p><b>Merck:</b> Research: Recipient: My Institution: Salary Support: No: Skin Cancer Research: Skin Cancer: Grant/research funding: Skin Cancer: Current</p> <p><b>Novartis:</b> Consultant: Honoraria: Skin Cancer: Current</p> <p><b>Oleatec Therapeutics:</b> Research: Recipient: My Institution: Salary Support: No: Skin Cancer Research: Skin Cancer: Grant/research funding: Skin Cancer: Current</p> <p><b>Pfizer:</b> Consultant: Honoraria: Skin Cancer: Current</p> <p><b>Regeneron:</b> Consultant, Research: Recipient: My Institution: Salary Support: No: Skin Cancer Research: Skin Cancer: Grant/research funding: Skin cancer: Current</p> <p><b>Replimune:</b> Research: Recipient: My Institution: Salary Support: No: Skin Cancer Research: Skin Cancer: Grant/research funding: Skin Cancer: Current</p> <p><b>Seagen:</b> Research: Recipient: My Institution: Salary Support: No: Skin Cancer Research: Skin Cancer: Grant/research funding: Skin Cancer: Current</p>   | None   | None  |
| Kilian     | Salerno   | <p>Department of Defense: Project Analyst: Employee</p> <p>National Cancer Institute: Staff Clinician, Associate Research Physician: Employee</p> | None   | None   | <p><b>ACR:</b> TXIT Annual In-Service Exam: TXIT Committee Chair: Committee Chair: Compensation? No</p> <p><b>AJCC:</b> member of the Breast Panel: panel member: Compensation? No</p> <p><b>IJOBP:</b> Senior Editor: Senior Editor for Sarcoma and Pediatrics: Compensation? No</p> <p><b>Journal of Surgical Oncology:</b> Associate Editor: Associate Editor of the Radiation Therapy Section: Compensation? No</p>   |
| Bill       | Salter    | Huntsman Cancer Institute at the University of Utah: Professor and Chief, Division of Medical Physics: Employee                                   | <p><b>ASTRO, RO-HAC-/RO-ILS, ASRT Annual Meeting:</b> Other-Speaker; Safety Errors: What Therapists Can Learn from RO-ILS, American Society of Radiologic Technologists, ASRT 2022 Annual Meeting, San Antonio, Texas: Uncompensated: ASTRO, RO-HAC-/RO-ILS, ASRT Annual Meeting Speaker; Safety Errors: What Therapists Can Learn from RO-ILS, American Society of Radiologic Technologists, ASRT 2022 Annual Meeting, San Antonio, Texas: 10.23.2022</p> <p><b>Clarity PSO/RO-ILS RO-HAC:</b> Advisory Board, Consultant: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Honoraria: RO-HAC members must sign a contract with Clarity PSO. RO-HAC members receive an honorarium. Service on RO-HAC is sponsored by ASTRO and AAPM.: To present</p> <p><b>Elekta Clarit:</b> Research: Recipient: My Institution: Salary Support: No: site principal investigator: Proton Ultrasound Research: Grant/research funding: Elekta Clarity, Proton Ultrasound Research, Principal Investigator: To present</p> <p><b>Mevion Medical System:</b> Advisory Board, Other-Speaker: CTOR Image Guidance for Protons: Implementation and initial experience, Mevion Medical Systems, Nucleus User Meeting, 63rd ASTRO Annual Meeting, Chicago, IL: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Honoraria, Uncompensated: Mevion Medical System, FLASH Alliance, committee member: To present</p> <p><b>RaySearch Labs:</b> Research: Recipient: My Institution: Salary Support: No: site principal investigator: Hybrid Modulated Arc Therapy: Grant/research funding: RaySearch Labs, Hybrid Modulated Arc Therapy, Principal Investigator, Research Grant: To</p> | None   | <p><b>AAPM:</b> AAPM WGIMRT: Committee Member: AAPM WGIMRT: Compensation? No</p> <p><b>ACR:</b> ACR Economic Committee Member: Committee Member: ACR Economic Committee Member: Compensation? No</p> <p><b>ASTRO:</b> RO-HAC Liaison, ASTRO Clinical Affairs and Quality Council, CAQC Steering Committee: Committee Member: Committee Member, RO-HAC Liaison, ASTRO Clinical Affairs and Quality Council, CAQC Steering Committee: Compensation? No</p> <p><b>University of Utah:</b> CORI, Computational Oncology Research Initiative- Committee co-leader: Committee co-leader: University of Utah, CORI, Computational Oncology Research Initiative- Committee co-leader: Compensation? No</p> <p><b>Varian, a Siemens Healthineers company:</b> Intelligent Imaging Consortium: Committee Member: Varian, a Siemens Healthineers company, Intelligent Imaging Consortium, Committee Member: Compensation? No</p> |
| Rohan      | Salunkhe  | Princess Margaret Cancer Centre: Radiation Oncology Fellow: Employee  | None   | None   | None  |
| Robert     | Samstein  | Department of Radiation Oncology, Icahn School of Medicine, Mount Sinai   | <p><b>Merck:</b> Research: Recipient: My Institution: Salary Support: No: site principal investigator: MSI-H endometrial cancer: Grant/research funding: Co-PI on research effort studying response of MSI-H endometrial tumors: 08/2025</p>   | <p><b>Memorial Sloan Kettering:</b> Copyright/Patent/License/Royalty: Patent related to TMB as biomarker for immunotherapy</p> | None  |
| Howard     | Sandler   | Cedars-Sinai Medical Center: Chair of Department of Radiation Oncology: Employee  | <p><b>Janssen:</b> Consultant: Uncompensated: Member, clinical trial steering committee: 9/23/2023</p>   | None   | None  |

**ASTRO 2024 Annual Meeting - Faculty and Presenters' Disclosures**

| First Name | Last Name    | Employment Relationships  | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria  | Ownerships/Investments/Intellectual Property  | Leadership/Positions of Authority   |
|------------|--------------|---|--|---|---|
| Nina       | Sanford      | University of Texas Southwestern: Assistant Professor: Employee   | AstraZeneca: Education/Meeting Faculty: Honoraria, Compensation/Payment: Educational lecture, consulting fees: 12/21/23<br>Total Health Conferencing: Education/Meeting Faculty: Honoraria: Speaker in Best of GI conference: 2/15/23  | None  | None  |
| Noelia     | Sanmamed     | Hospital Clinico San Carlos   | None   | None  | None  |
| Patricia   | Santos       | Emory University School of Medicine: Assistant Professor: Employee  | Conquer Cancer: Research: Recipient: My Institution: Salary Support: Yes: national/overall principal investigator: Emergency Medicaid and Access to Cancer Care: Grant/research funding, Salary support: PI: 12/2024<br>The Commonwealth Fund: Research: Recipient: My Institution: Salary Support: Yes: national/overall principal investigator: Emergency Medicaid and Access to Cancer Care: Grant/research funding, Salary support: PI: 2/2025   | None  | None  |
| Anurag     | Saraf        | Brigham Womens Hospital: Resident Physician: Employee   | None   | None  | None  |
| Gustavo    | Sarria       | University Hospital Bonn: Radiation Oncologist: Employee  | rl Zeiss Meditec AG: Speaker's Bureau: Honoraria, Travel expenses: Present   | None  | None  |
| Stephanie  | Schaub       | University of Washington: Assistant Professor: Employee   | CarboFix: Other-Honoraria for a Webinar: Honoraria: Speaker on Webinar for the use of proton therapy with carbon fiber hardware: 2/2024  | None  | None  |
| Naomi      | Schechter    | South Florida Proton Therapy Institute: Radiation Oncologist: Employee  | None   | None  | American College of Radiology (ACR): American College of Radiology: Past Chair & member Practice Parameters Committee, Rad Onc: Practice Parameters Committee, Radiation Oncology: Compensation? No |
| Joshua     | Schiff       | Barnes Jewish Hosptial: Resident Physician: Employee  | Varian Medical Systems: Research: Recipient: My Institution: Salary Support: No: site principal investigator: : Grant/research funding: Co-PI and primary protocol/grant author for IIT evaluating CT-guided adaptive SBRT for early stage ultra-central NSCLC.:   | None  | None  |
| Jonathan   | Schoenfeld   | Brigham and Women's Hospital: Radiation Oncologist: Employee  | Bristol Myers Squibb: Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: Immunotherapy for head and neck cancer: Grant/research funding: Immunotherapy for head and neck cancer - overall PI: To present<br>EMD Serono: Advisory Board, Consultant, Education/Meeting Faculty: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Grant/research funding, Compensation/Payment: Consulting, speaking: To present<br>Genentech: Advisory Board, Consultant: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Compensation/Payment: Radiation and immune therapy: 2022<br>Immunitas: Advisory Board, Consultant: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Compensation/Payment: Scientific Advisory board: To present<br>Intrigel: Advisory Board, Consultant: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Compensation/Payment: SAB: To present<br>Merck: Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: Immunotherapy and radiation: Grant/research funding: Investigator initiated clinical trial: To present<br>Merck KGaA: Advisory Board, Consultant: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: | Immunitas: Stock options: Stock options   | None  |
| Caitlin    | Schonewolf   | DELFI Diagnostics, Inc: Medical Director: Employee<br>Gral: Medical Director: Employee: Relationship ended 04/25/2023 | None   | Delfi Diagnostics, Inc: Stock options: Medical Director with employee stock ownership in DELFI Diagnostics. | None  |
| Aronne     | Schottstaedt | Department of Radiation Oncology, Medical College of Wisconsin  | None   | None  | None  |
| Benjamin   | Schrank      | The University of Texas MD Anderson Cancer Center: Resident Physician: Employee                                       | The Radiological Society of North America: Research: Recipient: Me: Salary Support: No: national/overall principal investigator: Macrophage biology: Grant/research funding: Basic science research: 06/30/2024  | None  | None  |
| Thilo      | Schuler      | NSW Health: Radiation Oncology Advanced Trainee: Employee   | None   | None  | None  |
| Madeline   | Schumacher   | University of Cincinnati College of Medicine  | None   | None  | None  |



**ASTRO 2024 Annual Meeting - Faculty and Presenters' Disclosures**

| First Name | Last Name        | Employment Relationships  | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria  | Ownerships/Investments/Intellectual Property  | Leadership/Positions of Authority   |
|------------|------------------|---|--|---|---|
| Jacob      | Scott            | Cleveland Clinic: Physician-Scientist: Employee   | <b>Cvergenx:</b> Consultant, Other-co-founder: Compensation/Payment: co-founder and inventor: Present<br><b>empyrean medical systems:</b> Advisory Board, Consultant: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Travel expenses, Compensation/Payment: scientific and medical advisor/medical director: Present<br><b>resistance bio:</b> Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Compensation/Payment: chairman of advisory board: Present<br><b>skincure oncology:</b> Advisory Board, Consultant: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Compensation/Payment: advisor and consultant: present<br><b>vironexis:</b> Consultant: Compensation/Payment: consultant: Present | <b>Cvergenx:</b> Copyright/Patent/License/Royalty: co-founder<br><b>empyrean medical systems:</b> Ownership equity: medical director and chief advisor<br><b>resistance bio:</b> Ownership equity: advisory board chair<br><b>vironexis:</b> Ownership equity: advisor and consultant | None  |
| Francinna  | Scott-Jones      | Northside Hospital Cancer Institute   | None   | None  | None  |
| Kriithikaa | Sekar            | HCG Hospitals   | None   | None  | None  |
| Ugur       | Selek            | American Hospital, Department of Radiation Oncology, Istanbul, Turkey: Department Chair: Employee<br>Koc University, School of Medicine, Department of Radiation Oncology, Istanbul, Turkey: Professor, Founding Past Chair: Employee<br>U.T. M.D. Anderson Cancer Center, Department of Radiation Oncology, Houston, TX: Adjunct Faculty, Professor: Employee: Relationship ended 12/31/2022 | <b>Abdi Ibrahim:</b> Consultant, Education/Meeting Faculty: Honoraria, Travel expenses: Consultant, Lecturer as education/meeting Faculty: To present<br><b>Elekta:</b> Education/Meeting Faculty: Honoraria: Lecturer as education/meeting Faculty: 11.09.2022<br><b>MSD:</b> Advisory Board: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Honoraria: Advisory Role in Cost Effectiveness and Public Health Impact of Implementing Gender-Neutral Vaccination with the 9-Valent Human Papillomavirus Vaccine in Turkiye: To present<br><b>ViewRay:</b> Education/Meeting Faculty: Honoraria: Lecturer as education/meeting Faculty: 11.09.2022   | <b>FSD Pharma Inc:</b> Stock: Stock   | <b>Turkish Society for Radiation Oncology:</b> Turkish Society for Radiation Oncology: President: President for the term of 03.27.2023-03.27.2025: Compensation? No |
| Aaron      | Seo              | University of Texas MD Anderson Cancer Center: Resident Physician: Employee   | None   | None  | None  |
| Yun Jeong  | Seo              | Mount Sinai West Hospital   | None   | None  | None  |
| Jan        | Seuntjens        | Department of Radiation Oncology, Princess Margaret Cancer Centre, University of Toronto  | None   | None  | None  |
| Bryan      | Sexton           | Duke University Health System   | <b>HRSA:</b> Research: Recipient: My Institution: Salary Support: Yes: site principal investigator: Well-being: Grant/research funding: PI: 2024<br><b>Vizient Safe &amp; Reliable:</b> Consultant: Salary support: Ongoing  | None  | None  |
| Laleh      | Seyyed-Kalantari | York University: Assistant Professor: Employee  | <b>CFREF:</b> Research: Recipient: Me: Salary Support: No: national/overall principal investigator: AI fairness in medical imaging: Grant/research funding: Principle investigator and topic: AI fairness in medical imaging: 04/2028<br><b>Google:</b> Research: Recipient: Me: Salary Support: No: national/overall principal investigator: AI fairness in medical imaging: Grant/research funding, In-kind donations: Principle investigator and topic: AI fairness in medical imaging: 04/2028<br><b>NSERC Discovery Grant:</b> Research: Recipient: Me: Salary Support: No: national/overall principal investigator: AI fairness in medical imaging: Grant/research funding: Principle investigator and topic: AI fairness in medical imaging: 04/2028  | None  | None  |
| Chirag     | Shah             | Cleveland Clinic: Physician: Employee   | <b>Impedimed:</b> Consultant: Compensation/Payment: scientific consultant: To Present<br><b>PreludeDX:</b> Consultant: Compensation/Payment: Scientific consultant: To Present<br><b>Viderra Surgical:</b> Consultant: Compensation/Payment: Scientific consultant: To present   | None  | None  |
| Manav      | Shah             | Northwell Health  | None   | None  | None  |
| Syed       | Shah             | Department of Radiation Oncology, Mayo Clinic   | None   | None  | None  |

**ASTRO 2024 Annual Meeting - Faculty and Presenters' Disclosures**

| First Name | Last Name   | Employment Relationships   | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria   | Ownerships/Investments/Intellectual Property   | Leadership/Positions of Authority   |
|------------|-------------|--|---|--|---|
| Simona     | Shaitelman  | UT MD Anderson Cancer Center: Associate Professor: Employee  | <p><b>Alpha Tau:</b> Research: Recipient: Me: Salary Support: No: co-investigator: : Grant/research funding: Alpha irradiation research: 2022</p> <p><b>Artios Pharma:</b> Research: Recipient: Me: Salary Support: No: co-investigator: : Grant/research funding: DNA repair inhibitor plus radiation research: 2022</p> <p><b>Becton, Dickinson and Company (BD):</b> Consultant: Compensation/Payment: Providing breast radiation oncology input on the development of clinical trials to evaluate a device to be used for breast reconstruction.: To present</p> <p><b>Exact Sciences:</b> Research: Recipient: Me: Salary Support: No: in kind research testing: oncotype testing for research patients: Grant/research funding: Provide Oncotype testing for patients to determine eligibility on a clinical trial: Present</p> <p><b>NIH:</b> Research: Recipient: Me: Salary Support: No: national/overall principal investigator: : Grant/research funding: examining PARP inhibitor with radiation: 8/31/2023</p>   | None   | <p><b>Elekta:</b> linear accelerator manufacturer: Breast Representative: Breast representative from UTMACC to MR Linac Consortium group of breast rad oncs meet to discuss how using MRLinac, guidelines on how to contour breast targets using MRI (agnostic of themachine): Compensation? No</p> |
| Stephen    | Shang       | South Florida Proton Therapy Institute: Data Scientist: Employee   | None  | None   | None  |
| Yasamin    | Sharifzadeh | Mayo Clinic: Resident Physician: Employee  | None  | None   | <b>American College of Radiation Oncology (ACRO):</b> ACRO Resident Communications Subcommittee Member: Help manage ACRO's resident committee social media pages.: Compensation? No   |
| Narek      | Shaverdian  | Memorial Sloan Kettering: Radiation Oncologist: Employee   | <p><b>Amgen:</b> Research: Recipient: Me: Salary Support: No: national/overall principal investigator: Lung Cancer: Grant/research funding: Stage III Lung and sotorasib: 2028</p> <p><b>Novartis:</b> Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: Lung Cancer: Grant/research funding: Lung Cancer: 2026</p>   | None   | None  |
| Xinglei    | Shen        | University of Kansas Medical Center: Associate Professor: Employee   | <p><b>Myovant pharmaceuticals:</b> Advisory Board, Research: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Recipient: My Institution: Salary Support: No: national/overall principal investigator: relugolix in prostate cancer: Grant/research funding, Honoraria: Advisory board for relugolix also conduct of a clinical trial using relugolix in prostate cancer: To present</p> <p><b>Pfizer pharmaceuticals:</b> Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: Relugolix in prostate cancer: Grant/research funding: Conduct of a clinical trial using relugolix in prostate cancer: To present</p>   | None   | <b>ASTRO:</b> Practical Radiation Oncology Journal: Associate Editor: Associate Editor: Compensation? No  |
| Colette    | Shen        | University of North Carolina-Chapel Hill: Assistant Professor: Employee  | <p><b>AstraZeneca:</b> Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: SRS, PARP inhibition, immunotherapy for brain mets: Grant/research funding: Sponsor-investigator for multi-institutional study of combination therapy with radiosurgery, PARP inhibition, and immunotherapy for patients with breast cancer brain metastasis: To present</p> <p><b>GT Medical Technologies:</b> Consultant: Compensation/Payment: Participate as a consortium member for the trial titled A Multicenter Observational Study of GammaTile™ Surgically Targeted Radiation Therapy (STaRT) in Intracranial Brain Neoplasms. Consortium members will be asked to participate in quarterly meetings to discuss trial progress, review data reports and consider ideas brought forward for additional analysis and publications. Consortium members will also be asked to support publication/presentation planning efforts for the trial.: To present</p> <p><b>Johnson and Johnson:</b> Consultant: Compensation/Payment: Consulting agreement with Interventional Oncology division regarding NBTXR3 hafnium oxide nanoparticle: To present</p> <p><b>Nanobiotix:</b> Consultant: Travel expenses: Consultant: To present</p> | None   | None  |
| Wen Bin    | Shen        | Radiotherapy Department, the Fourth Hospital of Hebei Medical University   | None  | None   | None  |
| Ke         | Sheng       | University of California, San Francisco: Professor and Vice Chair: Employee  | None  | <b>Celestial Oncology:</b> Ownership equity: I am a founder of Celestial Oncology, an SBIR company.                  | None  |
| Jenni      | Sheng       | Johns Hopkins School of Medicine: Assistant Professor: Employee  | None  | None   | None  |
| Annemarie  | Shepherd    | Federal Government: Project Manager: Employee<br>Memorial Sloan Kettering-Cancer Center: Assistant Attending: Employee | None  | <p><b>ArcellX:</b> Stock: I own stock in this company</p> <p><b>Doximity:</b> Stock: I own stock in this company</p> | <b>ITMIG:</b> International Thymic Malignancy Interest Group: Tumor Board Chair: I chair the tumor board sessions for this group: Compensation? No  |

**ASTRO 2024 Annual Meeting - Faculty and Presenters' Disclosures**

| First Name | Last Name    | Employment Relationships  | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria  | Ownerships/Investments/Intellectual Property | Leadership/Positions of Authority  |
|------------|--------------|---|--|--|--|
| David      | Sher         | University of Texas Southwestern Medical Center: Professor: Employee  | Varian Medical Center: Research: Recipient: My Institution: Salary Support: No: site principal investigator: Adaptive radiotherapy: Grant/research funding: Principal Investigator; randomized study of adaptive radiotherapy: 03/01/2024  | None   | None   |
| Tracy      | Sherertz     | Washington Permanente Medical Group: Director of Brachytherapy: Employee                                      | None   | None   | American Radium Society: ARS promotes the multi-disciplinary and collegial study of all aspects of cancer: Chair, AUC Gyn Committee: The ARS Appropriate Use Committees (AUC) are a panel of experts tasked with publishing updated treatment guidelines relevant to Radiation Oncology. I serve as the Chair of the Gyn AUC Committee of ARS.: Compensation? No   |
| Zohaib     | Sherwani     | Rutgers CINJ: Resident: Employee  | None   | None   | None   |
| Arshin     | Sheybani     | UnityPoint Health: Physician: Employee  | None   | None   | ASTRO: Nominating Committee: community practice physician: member of ASTRO nominating committee for leadership appointments: Compensation? No<br>ASTRONews: magazine publication for ASTRO: editorial board member: select topics for publication: Compensation? No<br>IWORC-NCORP: review NCORP grant: board member: voting member to designate inclusion of cancer centers and providers into our NCORP: Compensation? No<br>Rectal Anal Task Force: a subcommittee of the NCI GI steering committee: community oncologist representative: a member of the committee with 3 year term. we have monthly meetings to discuss development of clinical trials for rectal and anal cancers: Compensation? No                                  |
| Juanli     | Shi          | Department of Radiation Oncology, Xijing Hospital, Fourth Military Medical University.                        | None   | None   | None   |
| Stephen    | Shiao        | Cedars-Sinai Medical Center: Associate Professor: Employee  | Merck: Advisory Board, Research: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Recipient: Me: Salary Support: No: national/overall principal investigator: Single-cell Sequencing for HER2+ Breast Cancer: Grant/research funding, Honoraria: TNBC and RT, Her2+ Breast Cancer, Neoadjuvant RT (Ongoing Trial): To present   | None   | ASTRO Scientific Review Committee: American Society of Radiation Oncology: Vice-Chair: Co-Lead grant review for ASTRO science projects: Compensation? No<br>Cedars-Sinai Cancer Center: Cedars-Sinai Cancer Center is part of the Cedars-Sinai Medical Center and is responsible for all cancer related activity in the medical center.: Co-Leader, Experimental Therapeutic Program: I Co-Lead one of the three main programs for the Cedars-Sinai Cancer Center. My program is in charge of the clinical translational research carried out by the Cancer Center.: Compensation? No<br>Department of Veterans Affairs (VA): VA ONCC Review Panel: Chair: I chair the Oncology C committee for the VA Research Program.: Compensation? No |
| Takuya     | Shimizuguchi | Department of Radiation Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital | None   | None   | None   |
| Timothy    | Showalter    | Artera, Inc: Chief Medical Officer: Employee<br>University of Virginia: Professor: Employee                   | None   | None   | None   |
| Ravi       | Shridhar     | Advent Health Cancer Institute: Radiation Oncologist: Employee  | Astrazeneca: Speaker's Bureau: Compensation/Payment: Speaker's Bureau: 04/24<br>Boston Scientific: Consultant, Speaker's Bureau: Compensation/Payment: Consultant/Speaker's Bureau: 4/2024   | None   | None   |
| Muhammad   | Shuja        | Mayo Clinic: Resident Physician: Employee   | None   | None   | None   |
| Rebecca    | Shulman      | Fox Chase Cancer Center: Attending physician: Employee: Relationship ended 06/30/2023                         | None   | None   | None   |
| Nie        | Shulun       | Cheeloo College of Medicine, Shandong University  | None   | None   | None   |
| Farzan     | Siddiqui     | Henry Ford Health System: Vice-Chair, Radiation Oncology: Employee  | Varian Medical Systems Inc: Advisory Board, Research, Speaker's Bureau: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Recipient: My Institution: Salary Support: No: site principal investigator: Use of radiomics in head and neck cancers: Grant/research funding, Honoraria, Travel expenses: Varian Clinical School- Head and neck instructor Varian Noona-Medical Advisory Board member: To present | None   | Henry Ford Cancer Institute: Department of Radiation Oncology: Vice-Chair: Vice-Chair of radiation oncology operations: Compensation? No<br>Henry Ford Health: Henry Ford Medical Group: Chair-Elect, HFMG Board of Governors: Conducting board meetings: Compensation? No   |
| Malika     | Siker        | Medical College of Wisconsin: Professor and Associate Dean: Employee  | Advancing Healthier Wisconsin: Research: Recipient: Me: Salary Support: No: PI: Community outreach in education: Grant/research funding: Community outreach in education. I serve as PI: December 2024   | None   | None   |
| Scott      | Silva        | University of Louisville: Assistant Professor: Employee   | None   | None   | None   |

**ASTRO 2024 Annual Meeting - Faculty and Presenters' Disclosures**

| First Name | Last Name | Employment Relationships   | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria  | Ownerships/Investments/Intellectual Property    | Leadership/Positions of Authority   |
|------------|-----------|--|--|---|---|
| Austin     | Sim       | <b>Boston Children's Hospital:</b> Fellow Physician: Employee<br><b>Nationwide Children's Hospital:</b> Fellow Physician: Employee: Relationship ended 06/30/2024<br><b>The Ohio State University:</b> Assistant Professor: Employee | <b>ViewRay, Inc.:</b> Research: Recipient: My Institution: Salary Support: No: Co-Investigator: delta MR radiomics in non small cell lung cancer: Grant/research funding: delta MR radiomics in non small cell lung cancer: 2022   | None  | <b>ACRO Government Relations and Economics Committee:</b> ACRO Government Relations and Economics Committee: Committee Member: Committee Member: Compensation? No: Relationship ended 09/22/2023<br><b>American Academy of Pediatrics:</b> American Academy of Pediatrics: Fellow District Representative, District 5: Fellow District Representative, District 5: Compensation? No<br><b>Applied Radiation Oncology:</b> Journal: Editorial Advisory Board: Editorial Advisory Board: Compensation? No<br><b>ARRO:</b> Association of Residents in Radiation Oncology: Immediate Past Chair: Junior Member 2020-2021 Chair 2021-2022 Immediate Past Chair 2022-Present: Compensation? No: Relationship ended 05/01/2023<br><b>ILROG:</b> International Lymphoma Radiation Oncology Group: Council Member: Council Member: Compensation? No<br><b>NRG Oncology:</b> Gastrointestinal Non-Colorectal Cancer Core SubcommitteeGastrointestinal Cancer CommitteeRadiation Oncology Committee: Committee Member: Gastrointestinal Non-Colorectal Cancer Core Subcommittee Gastrointestinal Cancer Committee Radiation Oncology Committee: Compensation? No<br><b>SWOG:</b> Radiation Oncology, Lymphoma, and Bone Marrow Transplant committees: Committee Member: Radiation Oncology, Lymphoma, and Bone Marrow Transplant committees: Compensation? No |
| Aaron      | Simon     | <b>UC Irvine Health/Chao Family Comprehensive Cancer:</b> Assistant Professor: Employee  | None   | None  | None  |
| Charles    | Simone    | <b>New York Proton Center, Memorial Sloan Kettering:</b> Research Professor and Chief Medical Officer: Employee  | None   | None  | <b>American Radium Society:</b> Chair, Thoracic Appropriate Use Criteria Committee: Chair, Thoracic Appropriate Use Criteria Committee: Compensation? No<br><b>American Society for Radiation Oncology:</b> Chair, Lung Resource Panel; Vice Chair, Lung Track: Chair, Lung Resource Panel; Vice Chair, Lung Track: Compensation? No<br><b>Annals of Palliative Medicine:</b> Editor-in-Chief: Editor-in-Chief: Compensation? No<br><b>NRG Oncology:</b> Chair, Particle Therapy Work Group: Chair, Particle Therapy Work Group: Compensation? No<br><b>Proton Collaborative Group:</b> President of the Board ; Chair, Lung Committee: President of the Board ; Chair, Lung Committee: Compensation? No  |
| Lisa       | Singer    | <b>University of California, San Francisco:</b> Assistant Professor: Employee  | <b>UCSF PIPE:</b> Research: Recipient: Me: Salary Support: Yes: site principal investigator: Simulation-Based Education: Grant/research funding: Simulation-Based Education: 6/30/2023   | None  | <b>American Board of MR Safety:</b> Board of Directors: Board of Directors: Board of Directors: Compensation? No  |
| Gagandeep  | Singh     | <b>City of Hope Los Angeles</b>  | None   | None  | None  |
| Raj        | Singh     | <b>The Ohio State University Wexner Medical Center:</b> Assistant Professor/Physician: Employee<br><b>Virginia Commonwealth University Health System:</b> Resident Physician: Employee: Relationship ended 06/30/2023                | None   | None  | None  |
| Benjamin   | Sintay    | <b>Cone Health:</b> Executive Director & Chief Physicist: Employee<br><b>Fuse Oncology:</b> Chief Innovation Officer: Employee   | None   | <b>Fuse Oncology:</b> Ownership equity: Founder | <b>Fuse Oncology:</b> Board Member: Board Member: Compensation? No  |
| Terence    | Sio       | <b>Mayo Clinic Arizona:</b> Radiation Oncologist: Employee   | None   | None  | <b>Advances in Radiation Oncology:</b> Associate Editor, Education Editor: Associate Editor, Education Editor: Associate Editor, Education Editor: Compensation? No<br><b>Alliance Symptom Intervention Health Disparities Subcommittee:</b> Co-chair, Alliance SI Health Disparities: Co-chair, Alliance SI Health Disparities: Compensation? No<br><b>American Board of Radiology (ABR):</b> GI oral board examiner: GI oral board examiner: GI oral board examiner: Compensation? No   |
| Shankar    | Siva      | <b>Peter MacCallum Cancer Centre:</b> Radiation Oncologist: Employee   | <b>AstraZeneca:</b> Advisory Board, Education/Meeting Faculty: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Other-Payment to institution: Lung cancer advisory and educational meetings: Present<br><b>Reflexion Medical Systems:</b> Research: Recipient: My Institution: Salary Support: No: site principal investigator: SABR: Other-payment to institution: SABR for metastases: 2022<br><b>Varian Medical Systems:</b> Education/Meeting Faculty, Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: SABR: Other-Payment to institution: for clinical research activities, educational talks, Present | None  | <b>ART committee of IASLC:</b> Advanced Radiotherapy Techniques (ART) committee of the International Association for the Study of Lung Cancer (IASLC): committee member: advisory role: Compensation? No<br><b>Radisurgery Society (RSS):</b> Board of Directors of the Radisurgery Society (RSS): Board Directoy: volunteer role for advisory of the board: Compensation? No   |
| Heath      | Skinner   | <b>University of Pittsburgh:</b> Chair: Employee<br><b>UPMC Hillman Cancer Center:</b> Chair: Employee   | <b>EMD Sereno:</b> Research: Recipient: My Institution: Salary Support: No: Contact for the grant: Oncodisparities in Head and Neck cancer: Grant/research funding: This grant provides salary support and research funds for 2 fellows performing research in disparities in head and neck cancer. These funds go to the institution and the fellows.: To present<br><b>NIDCR:</b> Research: Recipient: My Institution: Salary Support: Yes: national/overall principal investigator: p16 and radioresponse: Grant/research funding: This is a grant from the NIH.: To present  | None  | <b>Department of Defense:</b> Department of Defense Congressionally Directed Medical Research Program (CDMRP): Programmatic Review Committee Member: Group that provides final decisions for DOD funding of Peer Reviewer Cancer Research Projects and sets goals and funding mechanisms.: Compensation? Yes<br><b>NCI:</b> National Cancer Institute: Member of Head and Neck Steering Committee: Serve on committee to evaluate cooperative group clinical trials: Compensation? No<br><b>UPMC Hillman Cancer Center:</b> Chair of Department: Chair: I run the radiation oncology department: Compensation? No   |

**ASTRO 2024 Annual Meeting - Faculty and Presenters' Disclosures**

| First Name | Last Name | Employment Relationships  | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria   | Ownerships/Investments/Intellectual Property                     | Leadership/Positions of Authority  |
|------------|-----------|---|---|--|--|
| Lindsey    | Sloan     | University of Minnesota: Assistant Professor: Employee  | <b>Arena (a wholly owned subsidiary of Pfizer):</b> Other-PI for clinical trial: Salary support: PI for clinical trial: To present<br><b>GT Medical Technologies:</b> Research: Recipient: My Institution: Salary Support: No: site principal investigator: GammaTile Clinical Trials: Salary support: GammaTile Clinical Trials: To present<br><b>Medtronic:</b> Consultant: Honoraria: consulting, contract held but no consulting services provided: To present<br><b>Sanofi-Regeneron:</b> Advisory Board, Speaker's Bureau: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Honoraria, Travel expenses: Serves on regional advisory board: To present   | None   | None   |
| Alicia     | Smart     | Mass General Brigham: Resident Physician: Employee  | None  | <b>Cardinal Health:</b> Stock: Stock<br><b>CVS:</b> Stock: Stock | None   |
| Kimberly   | Smith     | Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai   | <b>Elekta:</b> Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Travel expenses, Compensation/Payment: Serve as member on advisory board providing operational feedback to assist company in the production of software to assist in workflow efficiencies.: Present  | None   | None   |
| Shannon    | Smith     | Henry Ford Health Jackson Radiation Oncology: NP: Employee  | None  | None   | None   |
| Quaovi     | Sodji     | University of Wisconsin-Madison: Assistant Professor: Employee  | None  | None   | None   |
| Abhishek   | Solanki   | Edward Hines Jr. VA Hospital: Radiation Oncologist: Employee<br>Loyola University Medical Center: Attending Physician: Employee   | <b>United States Department of Veterans Affairs:</b> Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: Prostate Cancer Oligometastasis: Grant/research funding: I am the national PI of the VA STARPORT trial, funded by VA ORD: To present   | None   | <b>American College of Radiology:</b> Council of Regional Radiation Oncology Societies Caucus: Councilor, Executive Committee Member: I serve as the councilor for CARROS in the ACR: Compensation? No |
| Lilja      | Solnes    | Johns Hopkins: Professor: Employee  | <b>Lantheus:</b> Research: Recipient: My Institution: Salary Support: Yes: site principal investigator: Research: Grant/research funding: Research: To Present<br><b>Novartis:</b> Consultant, Research: Recipient: My Institution: Salary Support: Yes: site principal investigator: Consultant/Research: Grant/research funding, Compensation/Payment: Consultant/Research: To Present  | None   | None   |
| Scott      | Soltys    | Stanford University: Professor: Employee  | <b>Accuray, Inc.:</b> Advisory Board, Education/Meeting Faculty: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Honoraria, Travel expenses: Speaker at meeting. 1 hour advisory board.: Nov 2022<br><b>Brainlab, Inc.:</b> Education/Meeting Faculty: Travel expenses: Speaker at Medical Meeting: Sept 2023<br><b>Novocure, Inc.:</b> Advisory Board, Research: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Recipient: My Institution: Salary Support: No: national/overall principal investigator: Glioblastoma: Grant/research funding, Honoraria: Research support to institution, Honoraria to self: To present | None   | None   |
| Yang       | Song      | Department of Radiation Oncology, Division of Translational Radiation Sciences, University of Maryland Baltimore, School of Medicine,   | None  | None   | None   |
| Yash       | Soni      | UT Southwestern Medical Center: Resident Physician: Employee  | None  | None   | None   |
| Mateusz    | Spalek    | Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Skłodowska-Curie National Research Institute of Oncology   | None  | None   | None   |
| Joseph     | Sparano   | <b>Astra Zeneca:</b> Consultant: Consultant<br><b>Cytel:</b> DSMB Member: DSMB MEMBER<br><b>Genentech/Roche:</b> DSMB member: DSMB member<br><b>Icahn School of Medicine at Mount Sinai:</b> Chief, Division of Hematology and Medical Oncology: Employee<br><b>Novartis:</b> AMALEE Steerig Committee member and consultant: Consultant<br><b>Pfizer:</b> DSMB member: DSMB member | <b>Astra Zeneca, Cytel, Seagen, Novartis, Genentech, Pfizer:</b> Consultant: Honoraria: Site PI, study drug: 10/1/24<br><b>Olema:</b> Research: Recipient: My Institution: Salary Support: No: site principal investigator: Study drug: Honoraria: Site PI, study drug: 10/1/24   | None   | None   |

**ASTRO 2024 Annual Meeting - Faculty and Presenters' Disclosures**

| First Name | Last Name     | Employment Relationships   | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria   | Ownerships/Investments/Intellectual Property | Leadership/Positions of Authority   |
|------------|---------------|--|---|--|---|
| Patricia   | Spears        | University of North Carolina at Chapel Hill: Patient Advocate and Scientific Research Manager: Employee  | Pfizer, Inc: Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Honoraria: Advocate Advisory CARE Committee member. Advocate participation on a breast cancer Real World Evidence (RWE) Advisory Committee: 12/2022   | None   | None  |
| Lena       | Specht        | Institute of Clinical Medicine, University of Copenhagen, Denmark: Professor of Oncology: Employee<br>Rigshospitalet, Copenhagen University Hospital: Chief Oncologist: Employee | Kyowa Kirin Co. Ltd: Speaker's Bureau, Research, Education/Meeting Faculty, Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Recipient: My Institution: Salary Support: No: national/overall principal investigator: Mogamulizumab for mycosis fungoides: Honoraria: advisor, speaker at webinar: Ongoing<br>Takeda: Advisory Board: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Honoraria: advisor, speaker at webinar: Ongoing  | None   | Danish Lymphoma Group: Non-profit organization, national: Board Member: board member, makes national guidelines for lymphoma treatment: Compensation? No<br>Danish Lymphoma Radiation Oncology Group: Non-profit organization, national: Chairman: Chairman, radiation therapy of hematological malignancies: Compensation? No<br>International Lymphoma Radiation Oncology Group: Non-profit organization, worldwide: Vice-Chairman: vice-chairman of worldwide organization of lymphoma radiation oncologists: Compensation? No |
| Corey      | Speers        | University Hospitals: Vice Chair of Research: Employee   | Exact Sciences: Consultant: Compensation/Payment: paid consultant for Exact Sciences: To present  | None   | None  |
| Daphna     | Spiegel       | Beth Israel Deaconess Medical Center: Assistant Professor: Employee  | None  | None   | None  |
| Catherine  | Spina         | Columbia University College of Physicians and Surgeons   | None  | None   | None  |
| Michael    | Spiotto       | MD Anderson Cancer Center: Assoc Prof: Employee  | None  | None   | None  |
| Daniel     | Spratt        | University Hospitals Seidman Cancer Center: Chair and Professor: Employee  | Astellas: Advisory Board: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Honoraria: advisory board: Ongoing<br>AstraZeneca: Advisory Board: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Honoraria: Advisory board: 6/1/2023<br>Bayer: Advisory Board: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Honoraria: advisory board: Ongoing<br>Boston Scientific: Advisory Board, Consultant: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Honoraria: consultant for spacer gels: Ongoing<br>Janssen: Advisory Board: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Honoraria: advisory board: Ongoing<br>Myovant/Pfizer: Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Honoraria: Advisory board: | None   | None  |
| Teo        | Stanescu      | University of Toronto: Assistant Professor: Employee   | None  | None   | None  |
| Michael    | Steinberg     | Department of Radiation Oncology, University of California, Los Angeles  | None  | None   | None  |
| Richard    | Stock         | Ichan School of Medicine at Mount Sinai: Professor: Employee   | Accuray: Education/Meeting Faculty: Honoraria: gave talk at company sponsored symposium given during ASTRO 2023: 12/1/23<br>Ground Rounds in Urology: Education/Meeting Faculty:  | None   | None  |
| Jonathan   | Strauss       | Department of Radiation Oncology, Northwestern University Feinberg School of Medicine  | None  | None   | None  |
| Eric       | Stutheit-Zhao | Princess Margaret Cancer Centre, University Health Network   | None  | None   | None  |
| Tingshi    | Su            | The University of Texas MD Anderson Cancer Center  | None  | None   | None  |

**ASTRO 2024 Annual Meeting - Faculty and Presenters' Disclosures**

| First Name    | Last Name | Employment Relationships  | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria  | Ownerships/Investments/Intellectual Property   | Leadership/Positions of Authority  |
|---------------|-----------|---|--|--|--|
| Lisa          | Sudmeier  | Emory University Winship Cancer Institute:<br>Assistant Professor: Employee   | <b>Melanoma Research Alliance:</b> Research: Recipient: Me: Salary Support: Yes: site principal investigator: The effect of neuronal signaling and radiation therapy on the brain immune microenvironment: Grant/research funding, Salary support: PI for Young Investigator Award: Harnessing the Microenvironment to Achieve a More Robust Anti-Tumor Immune Response in the Brain: Jun 30, 2027<br><b>Merck:</b> Research: Recipient: Me: Salary Support: Yes: site principal investigator: Peripheral immune cell phenotypes in patients with brain metastases on Pembrolizumab: Grant/research funding, Salary support: PI for Oncology Translational Studies Program Grant: Defining radiation and pembrolizumab activated T cells with anti-tumor activity in the brain.: October 1, 2026<br><b>NIH/NIAID:</b> Research: Recipient: Me: Salary Support: Yes: site principal investigator: Studying tumor-specific CD8+ T cells in brain metastases: Grant/research funding, Salary support: PI for K08 "Characterization of Brain Metastasis-specific CD8+ T Cells": July | None   | None   |
| Hongfei       | Sun       | Department of Radiation Oncology, Xijing Hospital, Fourth Military Medical University   | None   | None   | None   |
| Devaki Shilpa | Surasi    | The University of Texas MD Anderson Cancer Center: Associate Professor: Employee  | <b>Blue earth diagnostics:</b> Research: Recipient: My Institution: Salary Support: Yes: principle investigator for an investigator initiated trial: F18 rhPSMA PETMRI in prostate cancer: Grant/research funding: principle investigator: 2024  | None   | The University of Texas MD Anderson Cancer Center: Patient safety and quality officer: Patient safety and quality officer: Patient safety and quality officer: Compensation? Yes       |
| Murat         | Surucu    | Stanford University: Clinical Assoc. Prof & Chief of Clinical Physics: Employee   | <b>Reflexion Medical Inc.:</b> Research: Recipient: My Institution: Salary Support: Yes: site principal investigator: medical device vendor: Grant/research funding, Honoraria: master research agreement and speaker: Present   | None   | None   |
| Philip        | Sutera    | Johns Hopkins: Resident: Employee<br>Johns Hopkins University: Resident: Employee   | None   | None   | None   |
| Elsa          | Sutton    | Mayo Clinic: Resident physician: Employee   | None   | None   | None   |
| Yoshiyuki     | Suzuki    | Department of Radiation Oncology, Fukushima Medical University School of Medicine   | None   | None   | None   |
| Becki         | Swanson   | AdventHealth: Executive Director Cancer Institute: Employee   | None   | None   | None   |
| Paul          | Swiecicki | University of Michigan: Associate Professor: Employee   | <b>Ascentage Pharma:</b> Grant/research funding, Salary support: Funding to institution for investigator initiated clinical trial in metastatic salivary gland cancer: To present<br><b>Astellas:</b> Advisory Board: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Honoraria: Participated in an advisory board discussing treatment landscape of head and neck squamous cell carcinoma and trial designs: Spring 2023<br><b>Remix Therapeutics:</b> Advisory Board: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Honoraria: Participated in an advisory board meeting to discuss the treatment landscape of adenoid cystic carcinoma and potential clinical trial designs: Spring 2023  | <b>Patent for HPV ctDNA assay:</b> Copyright/Patent/License/Royalty: Co-developer of institutional novel ctDNA assay, patent pending | None   |
| Martin        | Swinton   | The Christie NHS Foundation Trust: Urology Research Fellow: Employee  | None   | None   | None   |
| Alasdair      | Syme      | Dalhousie University: Assistant Professor: non-salaried staff<br>DoseCloud Solutions, Inc.: CEO: Owner<br>Nova Scotia Health: Medical Physicist: Employee | <b>ABK Biomedical:</b> Consultant: Compensation/Payment: ad hoc study of radiation dosimetry questions for glass microspheres in radioembolization: 2024   | <b>DoseCloud Solutions, Inc.:</b> Ownership equity: Founder, CEO   | Dalhousie University: University: Program Director, graduate medical physics program: Administration of the graduate medical physics program at Dalhousie university: Compensation? No |
| Jazmyne       | Tabb      | Brookwood Baptist Health: Resident: Employee<br>University of California San Diego: Resident: Employee  | None   | None   | None   |
| Vinita        | Takiar    | Cincinnati VA Medical Center: Physician: Employee<br>University of Cincinnati: Professor: Employee  | None   | None   | None   |
| Wesley        | Talcott   | Northwell Health: Radiation Oncologist: Employee  | <b>OncoLive:</b> Other-Speaker: Honoraria: Received an honorarium to speak at an OncoLive State of Science Summit on topic of my choosing ("Radiation considerations for elderly breast cancer patients"): 9/11/23<br><b>Varian:</b> Other-Panelist: Honoraria, Travel expenses: Speaking at Varian Users Meeting at the 2023 ASTRO Annual Meeting   | None   | None   |

**ASTRO 2024 Annual Meeting - Faculty and Presenters' Disclosures**

| First Name | Last Name | Employment Relationships   | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria  | Ownerships/Investments/Intellectual Property   | Leadership/Positions of Authority  |
|------------|-----------|--|--|--|--|
| Vivian     | Tan       | London Health Sciences Center: Resident: Employee  | None   | None   | None   |
| Chad       | Tang      | MD Anderson Cancer Center: Hospital: Employee  | <p><b>Boston Scientific:</b> Consultant: Honoraria, Travel expenses: Participate in device development workshop: 9/25/23</p> <p><b>Diffusion Pharmaceutical:</b> Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Honoraria: Member of scientific advisory board: Ongoing</p> <p><b>Lantheus:</b> Advisory Board: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Honoraria, Travel expenses: Member of advisory board: 5/12/23</p> <p><b>Merck:</b> Research: Recipient: Me: Salary Support: No: national/overall principal investigator: Radiation and Pembrolizumab: Grant/research funding: Received research drug for a study: Ongoing</p> <p><b>Molli Surgical:</b> Advisory Board: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Honoraria: Advisory board meeting: 10/2/23</p> <p><b>Siemen Helathineer:</b> Advisory Board: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Honoraria, Travel expenses: Member of advisory board: 1/11/23</p> <p><b>Telix:</b> Advisory Board: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Honoraria: Advisory board with multiple</p> | <p><b>Osler:</b> Copyright/Patent/License/Royalty: Gave a number of lectures and receive royalties</p> <p><b>Stanford Office of Technology Licensing:</b> Copyright/Patent/License/Royalty: I receive royalties from a patent that I received as a medical student</p> <p><b>Wolter Kluwer:</b> Copyright/Patent/License/Royalty: I receive royalties for a book I wrote</p> | None   |
| Linglong   | Tang      | Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine | None   | None   | None   |
| Patrick    | Tang      | Erasmus MC: PhD-candidate: Employee  | None   | None   | None   |
| Neil       | Taunk     | University of Pennsylvania: Assistant Professor of Radiation Oncology and Radiology: Employee  | <p><b>Boston Scientific:</b> Advisory Board, Consultant, Education/Meeting Faculty: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Honoraria, Travel expenses, Compensation/Payment: Consulting, Advisory Board: Ongoing</p> <p><b>Point BioPharma:</b> Advisory Board, Consultant: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Grant/research funding, Honoraria, Compensation/Payment: Consulting, Advisory Board: Ongoing</p> <p><b>Telix Pharmaceuticals:</b> Advisory Board: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Travel expenses: Advisory: Ongoing</p> <p><b>Varian Medical Systems:</b> Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: SBRT, IGRT, O-Ring LINAC: Grant/research funding: PI, Research Grant:</p>   | None   | <p><b>ABR:</b> American Board of Radiology: MOC Committee: Committee Member: Compensation? No</p> <p><b>CAMPEP:</b> Commission on Accreditation of Medical Physics Education Programs (CAMPEP): Board of Governors: Board of Governors: Compensation? No</p> |
| Leila      | Tchelebi  | Northwell Health: Attending Physician: Employee  | <p><b>American College of Radiation Oncology:</b> Other-Chart reviewer for facilities seeking ACRO accreditation: Compensation/Payment: I review charts relevant to GI oncology for completeness/accuracy as part of the process by which facilities seek ACRO accreditation.</p>  | None   | None   |
| Sewit      | Teckie    | New York City Health and Hospitals: System Chief of Radiation Oncology: Employee   | None   | None   | None   |
| Rahul      | Tendulkar | Cleveland Clinic: Staff: Employee  | <p><b>Varian Medical Systems:</b> Education/Meeting Faculty: Honoraria: Honoraria for educational talks: To present</p>  | None   | None   |
| Feifei     | Teng      | Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences                         | None   | None   | None   |



**ASTRO 2024 Annual Meeting - Faculty and Presenters' Disclosures**

| First Name      | Last Name       | Employment Relationships   | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria   | Ownerships/Investments/Intellectual Property  | Leadership/Positions of Authority   |
|-----------------|-----------------|--|---|---|---|
| Boon-Keng Kevin | Teo             | University of Pennsylvania: Associate Professor: Employee  | <b>Therapanacea:</b> Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: Development of AI model for autocontouring: Grant/research funding: PI for grant, "Development of an auto-contouring model for MRI in Brachtherapy": June 2024<br><b>Varian Medical Systems:</b> Research: Recipient: My Institution: Salary Support: No: Investigator: Planning study on Halycon linac: Grant/research funding: Investigator in grant "Biologically-guided Online Adaptive Multisite Ablative Radiation Using an O-ring   | None  | None  |
| Welela          | Tereffe         | MD Anderson Cancer Center: Chief Medical Executive: Employee: Relationship ended 09/01/2024                        | None  | None  | ASCO: Professional Society: Committee Chair: Ethics Committee: Compensation? No   |
| Stephanie       | Terezakis       | University of Minnesota: Professor and Chair: Employee   | None  | None  | American Radium Society: Vice President: Vice President: Compensation? No   |
| Nikhil          | Thaker          | Capital Health: Medical Director: Employee   | None  | None  | None  |
| Laura           | Thevenot        | ASTRO: CEO: Employee   | None  | None  | None  |
| Kundan          | Thind           | Henry Ford Health: Senior Physicist, Radiation Oncology: Employee  | None  | None  | None  |
| Charles         | Thomas          | AMA: Deputy Editor: Independent Contractor   | None  | None  | None  |
| Rehema          | Thomas          | MD Anderson Cancer Center: Resident: Employee  | None  | None  | None  |
| Alastair        | Thompson        | Baylor College of Medicine: Professor and Chief, Section of Breast Surgery: Employee                               | <b>PER:</b> Other-Speaker: Honoraria: Speaker Miami Breast Meeting: 3/8/2024<br><b>San Antonio Breast Cancer Symposium:</b> Other-Speaker: Honoraria: Meeting Speaker, 2-23 San Antonio Breast Cancer Symposium: 12/9/2023  | None  | <b>Breast Oncology Local Disease Task Force:</b> NCI Task Force: Co-Chair: Co-chair of Task Force: Compensation? No<br><b>Translational Breast Cancer Research Consortium:</b> Cooperative Research Group: Co-Chair, Locoregional Working Group: Co-Lead of working group: Compensation? No |
| Keith           | Thraen-Borowski | Loras College: Associate Professor: Employee   | None  | None  | None  |
| Baoqing         | Tian            | Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences | None  | None  | None  |
| Lee             | Tomlinson       | None   | None  | None  | None  |
| Mylin           | Torres          | Emory University: Professor: Employee  | <b>Genentech:</b> Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: Atezo & radiation metastatic breast cancer: Grant/research funding: PI: 8/2023<br><b>Oncohealth:</b> Consultant: Compensation/Payment: Utilization management, consultant on radiotherapy toxicity management: 5/2023<br><b>Pfizer:</b> Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: Talaoparib/XRT in metastatic breast cancer: Grant/research funding: PI of Phase II trial: To present  | None  | None  |
| Phuoc           | Tran            | University of Maryland School of Medicine: Professor & Vice Chair: Employee  | <b>Bayer Healthcare:</b> Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Honoraria: SAB: Present<br><b>Janssen:</b> Advisory Board, Consultant: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Honoraria: SAB: Present<br><b>Lantheus:</b> Advisory Board: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Compensation/Payment: Ad board: 6/1/23<br><b>Natsar Pharmaceuticals:</b> Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Honoraria: SAB: Present<br><b>Pfizer:</b> Advisory Board: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Honoraria: Relugolix: 12/1/23<br><b>ReflerXion Medical Inc:</b> Advisory Board, Consultant: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Honoraria, Travel expenses: SAB: Present<br><b>Regeneron:</b> Advisory Board: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Compensation/Payment: Ad | <b>Natsar Pharmaceuticals:</b> Copyright/Patent/License/Royalty: Compounds and Methods of Use in Ablative Radiotherapy. PCT/US2012/028475. PCT/WO/2012/122471. Patent awarded 5/25/2015. Patent#: 9114158. Licensed to Natsar Pharmaceuticals | <b>AACR:</b> Radiation Science and Medicine Working Group Steering Committee: Member: Compensation? No<br><b>Cancer Resesarch:</b> Senior Editor: Senior Editor: Compensation? No<br><b>NRG Oncology:</b> GU TS Chair: GU TS Chair: Compensation? No  |

**ASTRO 2024 Annual Meeting - Faculty and Presenters' Disclosures**

| First Name | Last Name       | Employment Relationships   | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria   | Ownerships/Investments/Intellectual Property | Leadership/Positions of Authority   |
|------------|-----------------|--|---|--|---|
| Alison     | Tree            | <b>The Royal Marsden NHS Foundation Trust:</b><br>Doctor: Employee   | <b>Accuray:</b> Research, Speaker's Bureau: Recipient: My Institution: Salary Support: No: site principal investigator: PACE trials: Grant/research funding: PACE trial: Present<br><b>Bayer:</b> Speaker's Bureau: Honoraria: Prostate cancer educational meeting - I spoke on SBRT: 2024<br><b>Elekta:</b> Education/Meeting Faculty, Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: MR guided radiotherapy: Grant/research funding, Honoraria, Travel expenses, Salary support: I am chair of the MR Linac consortium Clinical Steering Committee. My employer (the NHS) receives financial support to free me up from clinical duties for this role: Present<br><b>Janssen:</b> Speaker's Bureau: Honoraria: Prostate cancer update: Present<br><b>Varian:</b> Research: Recipient: My Institution: Salary Support: No: site principal investigator: PACE trials: Grant/research funding: PACE trials: Present | None   | <b>IJOBP:</b> Journal: Section Editor GU: Lead editor for GU at the red journal, which is financially compensated: Compensation? Yes<br><b>MR Linac consortium:</b> Academic industrial partnership focussed on radiotherapy research and education: Chair: I receive no direct compensation but my employer receives financial compensation to back fill my clinical duties: Compensation? No<br><b>National Prostate Cancer Audit (UK):</b> Body to monitor prostate cancer management in the UK: Oncology lead: Receives multiple sources of national data, we set priorities for driving up standards nationally: Compensation? Yes<br><b>Prostate Cancer UK:</b> Charity: Clinical Advisory Group member and grant review committee member: Clinical advice on charity's priorities and reviewing grants for their research innovation programme: Compensation? No<br><b>UK SABR consortium:</b> Voluntary organisation supporting radiotherapy education in the UK: Steering committee member: Committee member: Compensation? No |
| Minh Tam   | Truong          | <b>Boston Medical Center:</b> Radiation Oncologist: Employee<br><b>Boston University:</b> Chair of Radiation Oncology: Employee  | None  | None   | None  |
| C Jillian  | Tsai            | <b>Department of Radiation Oncology, University of Toronto</b>   | None  | None   | None  |
| Chia-Lin   | Tseng           | <b>University of Toronto:</b> Assistant Professor: Faculty Appointment   | <b>Abbvie:</b> Education/Meeting Faculty: Honoraria: Educational Seminars: To present<br><b>Elekta:</b> Education/Meeting Faculty: Honoraria, Travel expenses: Educational Seminars: To present   | None   | <b>Elekta MR-Linac Consortium:</b> An International Research Group: Brain Tumor Site Group Lead: Lead for Brain Tumor Site Group: Compensation? No  |
| Slavisa    | Tubin           | <b>Medaustrom - the Center for Ion Therapy and Research</b>  | None  | None   | None  |
| Neelam     | Tyagi           | <b>Memorial Sloan-Kettering Cancer Center:</b><br>Attending Physicist: Employee  | <b>Elekta:</b> Education/Meeting Faculty: Honoraria, Travel expenses: Healthcare - faculty: Present   | None   | None  |
| Jessalyn   | Ubellacker      | <b>Harvard T.H. Chan School of Public Health:</b><br>Assistant Professor: Employee   | <b>University of Michigan:</b> Education/Meeting Faculty: Honoraria, Travel expenses: Ferroptosis: March 2023   | None   | None  |
| Jean-Luc   | Urbain          | <b>Roswell Park Cancer Center:</b> Associate Chair<br>Theranostics: Employee: Relationship ended 11/30/2023<br><b>Wake Forest University:</b> Professor: Employee: Relationship ended 02/28/2023 | None  | None   | <b>CANM:</b> CANM: Board Member: Board Member: Compensation? No<br><b>SNMMI:</b> SNMMI: President Elect: President Elect: Compensation? No  |
| Alfredo    | Urdaneta        | <b>Virginia Commonwealth University:</b> Assistant Professor: Employee   | None  | None   | None  |
| Nicholas   | van As          | <b>The Royal Marsden NHS Foundation Trust</b>  | <b>Accuray:</b> Education/Meeting Faculty, Speaker's Bureau: Grant/research funding: Chief investigator: 2025   | None   | None  |
| Frederique | van Gameren     | <b>Department of Radiotherapy, University Medical Center Utrecht</b>   | None  | None   | None  |
| Tina       | Vaziri          | <b>Johns Hopkins Hospital:</b> Resident: Employee<br><b>MedStar Washington Hospital Center:</b> Resident: Employee: Relationship ended 06/25/2024  | None  | None   | None  |
| Tanooha    | Veeramachandani | <b>UT Southwestern Medical School</b>  | None  | None   | None  |
| Ioannis    | Verginadis      | <b>University of Pennsylvania:</b> Research Assistant Professor: Employee  | <b>Flash Radiotherapy and Particle Therapy:</b> Other-Travel expenses: Travel expenses: Presenter: 12/2/2022  | None   | None  |
| Tamara     | Vern-Gross      | <b>Mayo Clinic:</b> Consultant: Employee: Relationship ended 11/01/2023  | None  | None   | None  |
| Janny      | Villa-Pulgarin  | <b>Department of Urology, NewYork-Presbyterian/Weill Cornell Medical Center</b>  | None  | None   | None  |
| Akila      | Viswanathan     | <b>Johns Hopkins University School of Medicine:</b><br>Department Chair: Employee  | None  | None   | <b>Elsevier:</b> Seminars in Radiation Oncology: Editor in Chief: run journal intellectual content: Compensation? No  |
| Te         | Vuong           | <b>Jewish General Hospital:</b> Professor: Employee  | None  | None   | None  |
| Melissa    | Vyfhuis         | <b>University of Maryland, School of Medicine:</b><br>Associate Professor of Radiation Oncology: Employee  | None  | None   | None  |

**ASTRO 2024 Annual Meeting - Faculty and Presenters' Disclosures**

| First Name | Last Name | Employment Relationships  | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria  | Ownerships/Investments/Intellectual Property  | Leadership/Positions of Authority |
|------------|-----------|---|--|---|-----------------------------------|
| Gary       | Walker    | Banner MD Anderson Cancer Center: Radiation Oncologist: Employee  | None   | None  | None                              |
| Chao       | Wang      | None  | None   | None  | None                              |
| Da         | Wang      | University of Chicago: Assistant Professor: Employee: Relationship ended 12/31/2023<br>UT Southwestern Medical Center: Assistant Professor: Employee  | None   | None  | None                              |
| Guangyu    | Wang      | Department of radiation oncology, Peking Union Medical College Hospital. Chinese Academy of Medical Sciences & Peking Union Medical College   | None   | None  | None                              |
| Haohua     | Wang      | Shandong University Cancer Center, Cheeloo College of Medicine, ShanDong University   | None   | None  | None                              |
| Jing       | Wang      | UT Southwestern Medical Center: Professor: Employee   | Varian: Research: Recipient: My Institution: Salary Support: No: site principal investigator: CBCT enhancement: Grant/research funding: PI, CBCT enhancement: To present   | None  | None                              |
| Li         | Wang      | The University of Texas MD Anderson Cancer Center   | None   | None  | None                              |
| Qian       | Wang      | University Hospitals Seidman Cancer Center: Assistant Professor: Employee   | None   | None  | None                              |
| Rong       | Wang      | Department of Radiation Oncology, Xijing Hospital, Fourth Military Medical University.  | None   | None  | None                              |
| Shang      | Wang      | Department of Radiation Oncology, Division of Abdominal Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University   | None   | None  | None                              |
| Siwei      | Wang      | Department of Radiation Oncology, Zhongshan Hospital, Fudan University  | None   | None  | None                              |
| Tony       | Wang      | Columbia University: Professor: Employee  | <b>Cancer Panels:</b> Consultant: Honoraria: Serve on a glioblastoma cancer panel: 08/20/2023<br><b>Elekta:</b> Consultant: Honoraria, Travel expenses: Speaker: 10/04/2022<br><b>Genentech:</b> Consultant, Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: related to glioblastoma: Grant/research funding: Principal investigator of a glioblastoma clinical trial: To present<br><b>Iylon Precision:</b> Advisory Board, Consultant: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Honoraria, Compensation/Payment: Consultant/Advisory Board: To present<br><b>Merck:</b> Research: Recipient: My Institution: Salary Support: No: Investigator: related to glioma: Uncompensated: Co-Investigator: To present<br><b>Varian:</b> Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: related to glioma: Grant/research funding, Salary support: Principal investigator of an adaptive radiotherapy clinical trial for glioblastoma patients: To present<br><b>Wolters Kluwer:</b> Other-Editor: Other-Royalties: Royalties for textbook: To present | <b>Doximity:</b> Stock options: Stock Options | None                              |
| Xin        | Wang      | Department of Radiation Oncology, Division of Abdominal Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University   | None   | None  | None                              |
| Xinyue     | Wang      | Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College | None   | None  | None                              |
| Yan        | Wang      | Department of Radiation Oncology, Fudan University Shanghai Cancer Center   | None   | None  | None                              |

**ASTRO 2024 Annual Meeting - Faculty and Presenters' Disclosures**

| First Name | Last Name    | Employment Relationships  | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria   | Ownerships/Investments/Intellectual Property   | Leadership/Positions of Authority  |
|------------|--------------|---|---|--|--|
| Laura      | Warren       | Brigham and Women's Physician Organization: Physician: Employee   | None  | None   | None   |
| William    | Watkins      | City of Hope: Physicist: Employee   | None  | None   | None   |
| Emily      | Weg          | University of Washington: Assistant Professor: Employee   | None  | None   | Fred Hutch Proton Center: Proton Center for the Fred Hutch Cancer Center / University of Washington: Associate Medical Director: Associate Medical Director of the Proton Center: Compensation? No                           |
| Yuchun     | Wei          | Department of Radiation Oncology and Shandong Provincial Key Laboratory of Radiation Oncology, Shandong First Medical University and Shandong Academy of Medical Sciences | None  | None   | None   |
| Joanne     | Weidhaas     | Department of Radiation Oncology, University of California, Los Angeles   | None  | MiraDx: Ownership equity: Founder  | MiraKind: Non-profit: founder: I founded mirakind as a non-profit to educate patients.: Compensation? No   |
| Stephanie  | Weiss        | Fox Chase Cancer Center: Professor of Radiation Oncology: Employee  | None  | AstraZeneca: Stock<br>Pfizer: Stoc<br>Regeneron: Stock   | Vice Chair of Graduate Medical Education: Lead educational programs within radiation oncology at TUH: Vice Chair of Graduate Medical Education: Lead educational programs within radiation oncology at TUH: Compensation? No |
| James      | Welsh        | University of Texas MD Anderson Cancer Center: Professor: Employee  | Alkermes: Research: Recipient: Me: Salary Support: Yes: national/overall principal investigator: Radiotherapy combination with IL 2: Grant/research funding: Principal Investigator: 10 2027<br>Alpine Immune Science: Advisory Board, Consultant: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Compensation/Payment: consultant: 12 2022<br>Artidis: Research: Recipient: Me: Salary Support: Yes: national/overall principal investigator: The nanomechanical signature of response to therapy in lung cancers: Grant/research funding: Principal Investigator: 9 2029<br>Astra Zeneca: Research: Recipient: Me: Salary Support: Yes: Co-PI: LCT and Durvalumab clinical studies: Grant/research funding: Co-PI: 6 2028<br>Bayer Healthcare: Research: Recipient: Me: Salary Support: Yes: national/overall principal investigator: modulate the tumor stromal microenvironment by specifically targeting and depleting a highly suppressive immune cell population: Grant/research funding: Principal Investigator: 11 2025<br>Bristol Meyer Squibb: Research: Recipient: Me: Salary Support: Yes: national/overall principal investigator: Pre-clinical and clinical studies on immunotherapy: Grant/research funding: Principal Investigator: 12 2027<br>Gilead: Research: Recipient: Me: Salary Support: Yes: national/overall principal investigator: Combination of Radiotherapy with anti-CCR8: Grant/research funding: Principal Investigator: 5 2029<br>Hotspot: Research: Recipient: Me: Salary Support: Yes: national/overall principal investigator: Combination of | Alpine Immune Science: Ownership equity: Equity: Relationship ended<br>Checkmate Pharmaceuticals: Ownership equity: Financial Relationship<br>Molecular Match: Ownership equity: Financial Relationship<br>Oligo Immune: Ownership equity: Financial Relationship<br>OncoResponse: Ownership equity: Equity: Relationship ended<br>Reflexion: Ownership equity: Financial Relationship | None   |
| Weitao     | Wen          | Department of Radiation Oncology and Shandong Provincial Key Laboratory of Radiation Oncology, Shandong First Medical University and Shandong Academy of Medical Sciences | None  | None   | None   |
| Maria      | Werner-Wasik | Thomas Jefferson University: Professor: Employee  | None  | None   | NRG Oncology: NCI-sponsored clinical research group: Chair: Chair, Protocol Operations Management Committee: Compensation? No  |
| Gabriella  | Wernicke     | Northwell Health: Physician: Employee   | None  | None   | None   |
| Zachary    | White        | Stanford University: Resident Physician: Employee   | None  | None   | Association of Residents in Radiation Oncology (ARRO): Executive Committee Member: Representative for residents in radiation oncology: Compensation? No  |
| N. Ari     | Wijetunga    | Radiation Oncology, Memorial Sloan Kettering Cancer Center  | None  | None   | None   |
| Vonetta    | Williams     | Memorial Sloan Kettering Cancer Center: Assistant Attending: Employee   | None  | None   | None   |
| Casey      | Williamson   | Oregon Health & Science University: Assistant Professor: Employee   | None  | None   | None   |
| Lydia      | Wilson       | St. Jude Children's Research Hospital: Instructor: Employee: Relationship ended 06/01/2023<br>Thomas Jefferson University: Assistant Professor: Employee                  | None  | None   | None   |

**ASTRO 2024 Annual Meeting - Faculty and Presenters' Disclosures**

| First Name | Last Name | Employment Relationships  | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria  | Ownerships/Investments/Intellectual Property  | Leadership/Positions of Authority  |
|------------|-----------|---|--|---|--|
| Brian      | Winey     | Massachusetts General Hospital: Associate Professor of Medical Physics: Employee  | NIH: Research: Recipient: My Institution: Salary Support: No: Investigator: PI of Grant: Harald Paganetti: Salary support: Researching adaptive proton therapy. I help lead the aim looking at CBCT correction methods.: To present  | Patent: US8855738: Copyright/Patent/License/Royalty: Patent: US8855738 "Acoustically induced blood stasis and in vivo optical spectroscopy" No royalties or | ASTRO: ASTRO: Vice-Chair of SEPD Subcommittee: Help to organize the subcommittee business and assist with annual meeting program development.: Compensation? No  |
| Jeff       | Winter    | University Health Network: Medical Physicist: Employee  | None   | None  | None   |
| Jennifer   | Wo        | Massachusetts General Hospital: Associate Professor: Employee   | Genentech: Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: Hepatocellular Cancer: Grant/research funding: Phase IB SBRT and Atezo/Bev for Unresectable HCC: Present  | None  | None   |
| Jeffrey    | Wong      | City of Hope Medical Group: Physician: Employee   | Accuray, Inc.: Education/Meeting Faculty, Research: Recipient: My Institution: Salary Support: No: site principal investigator: clinical trial: Grant/research funding, Uncompensated: 1. single institution grant for a clinical trial 2. speaker to User group. Honorarium offered but declined: Present<br>Blue Earth Diagnostic: Advisory Board, Research: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Recipient: My Institution: Salary Support: No: site principal investigator: clinical trial: Grant/research funding, Uncompensated: 1. single institution grant for a clinical trial 2. Advisory board. Compensation offered but declined: Present<br>Fusion, Inc: Research: Recipient: My Institution: Salary Support: No: site principal investigator: clinical trial: Grant/research funding: site PI of industry sponsored trial: Present<br>Imaginab: Research: Recipient: My Institution: Salary Support: No: site principal investigator: clinical trial: Grant/research funding: site PI: Present<br>Janssen: Research: Recipient: My Institution: Salary Support: No: site principal investigator: clinical trial: Grant/research funding: site PI of multi-center trial: Present<br>Novartis: Research: Recipient: My Institution: Salary Support: No: site principal investigator: clinical trial: Grant/research funding: site PI: Present<br>Reflexion, Inc.: Advisory Board, Consultant, Education/Meeting Faculty, Research: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Recipient: My Institution: Salary Support: No: site principal investigator: clinical trial: Grant/research | None  | None   |
| Rebecca    | Wong      | University health network: Radiation oncologist: Employee   | International cancer expert Corp: Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Uncompensated: Board member: ongoing  | None  | None   |
| Kristina   | Woodhouse | Merck: Oncology Clinical Director: Employee   | None   | Merck: Stock: stock   | None   |
| Amanda     | Woods     | University of Mississippi Medical Center: Nurse Practitioner/Faculty Administrator: Employee  | None   | None  | None   |
| William    | Woods     | Department of Radiation Oncology, University of Mississippi Medical Center  | None   | None  | None   |
| Jean       | Wright    | Johns Hopkins University: Associate Professor, Radiation Oncology: Employee<br>National Institutes of Health: Associate Director, NINDS: Employee | ASTRO: Other-APEX surveyor: Honoraria: survey radiation oncology departments for accreditation: Present<br>Elsevier Journals: Other-Editor: Honoraria: Editor of breast section of journal: Present<br>Oncospace: Research: Recipient: My Institution: Salary Support: No: site principal investigator: development of a novel peer review platform: Grant/research funding, Salary support: research on utility of platform to identify radiation treatment planning errors: Present<br>Physicians Education Resource: Education/Meeting Faculty: Honoraria, Travel expenses: speaker on hypofractionated radiotherapy for breast cancer: 3/3/2023<br>Prostate Cancer Foundation: Research: Recipient: My Institution: Salary Support: No: site principal investigator: Identification of radiation deserts: Grant/research funding, Salary support: Data analysis to identify underserved areas of country with respect to radiation oncology services.: Present<br>Up To Date: Other-royalties: Compensation/Payment: Etiology, clinical manifestations, and diagnosis of vascular dementia: Present<br>Wicker Smith: Consultant: Compensation/Payment: Expert witness in defense of clinical radiation oncologist: 11/20/23  | None  | American Board of Radiology: Testing for board certification for radiation oncology: Oral Board Examiner: Conduct oral examinations of trainees 1-2 x per year: Compensation? No<br>ASTRO: Chair, Clinical Affairs and Quality Committee: chair of committee that oversees guidelines, MDQA and APEX committees.: Compensation? No |

**ASTRO 2024 Annual Meeting - Faculty and Presenters' Disclosures**

| First Name | Last Name | Employment Relationships  | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria   | Ownerships/Investments/Intellectual Property   | Leadership/Positions of Authority   |
|------------|-----------|---|---|--|---|
| Abraham    | Wu        | Memorial Sloan Kettering Cancer Center: Associate Attending: Employee   | CivaTech Oncology, Inc.: Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: clinical trial of brachytherapy device: Grant/research funding: Research grant for study involving company product (CivaSheet) paid to institution: To present | Simphotek, Inc.: Stock options: Restricted stock, as compensation for advisory board service | None  |
| Albert     | Wu        | Johns Hopkins University: Professor: Employee<br>World Health Organization: Consultant: Independent Contractor  | Siemens Healthineers: Education/Meeting Faculty: Honoraria: healthcare speaker: 6/6/2023<br>Vizient: Education/Meeting Faculty: Honoraria: Speaker: 6/6/2023  | None   | Baltimore CONNECT Inc: Network of community based on social service organizations: Board President: President of Board of Directors: Compensation? No |
| Hui        | Wu        | The Affiliated Cancer Hospital of Zhengzhou University  | None  | None   | None  |
| Xin        | Wu        | Duke University Medical Center  | None  | None   | None  |
| Yuan       | Wu        | Hubei Cancer Hospital   | None  | None   | None  |
| WeiWei     | Xiao      | State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer   | None  | None   | None  |
| Ying       | Xiao      | University of Pennsylvania: Prof.: Employee   | None  | None   | None  |
| Yahui      | Xie       | Kansas College of Osteopathic Medicine  | None  | None   | None  |
| Lei        | Xing      | Stanford University Hospital: Professor: Employee   | None  | None   | None  |
| Xinyan     | Xu        | The University of Texas MD Anderson Cancer Center: Research Assistant: Employee   | None  | None   | None  |
| Zhuang     | Xue       | Department of Radiation Oncology, Shandong First Medical University and Shandong Academy of Medical Sciences  | None  | None   | None  |
| Robin      | Yabroff   | American Cancer Society   | National Comprehensive Cancer Network: Other-Honoraria for Health-Related Social Needs workgroup: Honoraria: Workgroup:   | None   | None  |
| Joachim    | Yahalom   | Radiation Oncology, Memorial Sloan Kettering Cancer Center  | None  | None   | None  |
| Kosj       | Yamoah    | H. Lee Moffitt Cancer Center & Research Institute: Physician Scientist: Employee<br>Jame Haley VA Medical Center: Lead Site Investigator, VA Center of Excellence, Prostate Cancer: Employee<br>Moffitt Cancer Center: Department Chair- Radiation Oncology: Employee | None  | None   | H. Lee Moffitt Cancer Center: Academic Center: Chairman. Department of Radiation Oncology: Departmental chair: Compensation? Yes                      |
| Michael    | Yan       | University Health Network: Radiation Oncologist: Employee   | Need Inc.: Consultant: Compensation/Payment: Steering Committee: Present  | None   | None  |
| Bining     | Yang      | Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College   | None  | None   | None  |
| Dongrong   | Yang      | Duke University Medical Center  | None  | None   | None  |
| Hua        | Yang      | Department of Radiation Oncology, First Affiliated Hospital of Air Force Medical University   | None  | None   | None  |

**ASTRO 2024 Annual Meeting - Faculty and Presenters' Disclosures**

| First Name | Last Name | Employment Relationships   | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria   | Ownerships/Investments/Intellectual Property   | Leadership/Positions of Authority   |
|------------|-----------|--|---|--|---|
| Jonathan   | Yang      | New York University School of Medicine: Attending: Employee<br>University of Washington: Associate Professor: Employee   | <b>AstraZeneca:</b> Advisory Board: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Compensation/Payment: Grant/research funding: overall PI, site PI: Ongoing<br><b>Cantex Therapeutics:</b> Research: Recipient: My Institution: Salary Support: No: site principal investigator: : Grant/research funding: GBM clinical trial: Present<br><b>Debiopharm:</b> Research: Recipient: My Institution: Salary Support: No: site principal investigator: : Grant/research funding: research funding for prospective trial: To present<br><b>Galera Therapeutics:</b> Consultant: Compensation/Payment: consultant for drug and radiotherapy development: Ongoing<br><b>Kazia Therapeutics:</b> Advisory Board: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Compensation/Payment: Grant/research funding, Compensation/Payment: Grant/research funding: overall PI, site PI: Ongoing<br><b>Nanocan Therapeutics:</b> Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Compensation/Payment: Other-stock options: advisory board for drug and radiotherapy development: Ongoing<br><b>Plus Therapeutics:</b> Consultant: Compensation/Payment: DSMC member: Present | <b>Nanocan:</b> Stock options: advisory board for drug and radiotherapy development<br><b>Nanocan Therapeutics:</b> Stock options: advisory board for drug development | None  |
| Wen-Chi    | Yang      | Department of Radiation Oncology, National Taiwan University Cancer Center   | None  | None   | None  |
| Wensha     | Yang      | University of California, San Francisco: Associate Professor: Employee   | None  | None   | None  |
| Xiaofeng   | Yang      | Emory University: Associate Professor: Employee  | None  | None   | None  |
| Xiaojing   | Yang      | Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine  | None  | None   | None  |
| Yuexin     | Yang      | Department of Radiation Oncology , National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College | None  | None   | None  |
| Zhi        | Yang      | Department of Radiation Oncology, Xijing Hospital, Fourth Military Medical University  | None  | None   | None  |
| Zi         | Yang      | Department of Radiation Oncology, Stanford University School of Medicine   | None  | None   | None  |
| Weiguang   | Yao       | University of Maryland School of Medicine: Associate Professor: Employee   | None  | None   | None  |
| Orly       | Yariv     | National Institutes of Health: Research fellow: Employee   | None  | None   | None  |
| Catheryn   | Yashar    | University of California San Diego: Professor, Radiation Oncology and Chief Medical Officer: Employee  | None  | None   | <b>ABR:</b> American Board of Radiology: Trustee for Breast and GYN: Oversee examinations of written and oral for breast and gynecology: Compensation? No<br><b>kukuna o ka la:</b> small educational organization: chairman of the board: give yearly meeting in hawaii: Compensation? No<br><b>UCSD:</b> University: Chief Medical Officer: quality and safety oversight: Compensation? Yes |

**ASTRO 2024 Annual Meeting - Faculty and Presenters' Disclosures**

| First Name | Last Name | Employment Relationships  | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria  | Ownerships/Investments/Intellectual Property   | Leadership/Positions of Authority  |
|------------|-----------|---|--|--|--|
| Debra      | Yeboa     | Univ of Texas MD Anderson Cancer Center: Associate Professor: Employee  | <b>Brockman Foundation/ Medical research Grant:</b> Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: brain mets: Grant/research funding: Medical research foundation grant: Present<br><b>MD Anderson Institutional Research Grant Funding:</b> Research: Recipient: My Institution: Salary Support: No: site principal investigator: Institutional Research Grant, Shirley Stein Award, and/or Division of RadOnc Grants: Grant/research funding: Institutional Research Grant, Shirley Stein Award, and/or Division of RadOnc Grants: To present<br><b>Novartis:</b> Research: Recipient: My Institution: Salary Support: No: collaborator: radonc collaborator at local site: Other-1 percent effort paid to the MD Anderson institution, not personally, as a potential Radonc collaborator for a clinical trial. The neurologist is the site PI, and we are not the lead site.: 1 percent effort paid to the MD Anderson institution, not personally, as a potential Radonc collaborator for a clinical trial. The neurologist is the site PI, and we are not the lead site.: To present<br><b>Practical Radiation Oncology Journal:</b> Other-Academic journal associate editor: Uncompensated: academic journal associate editor: Present<br><b>Robert Wood Johnson:</b> Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: clinical trials: Grant/research funding: Medical research foundation grant: Present | None   | <b>ACR Radiation Oncology In-Training Exam:</b> Text writing committee: In service test writing: Compensation? No: Relationship ended 12/01/2022<br><b>American Radium Society:</b> Annual Meeting Planning Committee member: Annual Meeting Planning Committee member for review of abstracts: Compensation? No: Relationship ended 09/01/2023<br><b>ASCO/SNO Brain Mets Conference:</b> Annual Meeting Planning Committee member: Annual Meeting Planning Committee member/ abstract reviewer: Compensation? No<br><b>Radiosurgery Society (RSS):</b> Annual Planning Committee member & MD Anderson liaison: Annual Planning Committee: Compensation? No<br><b>Society of Neuro-Oncology:</b> Radiation Sciences Co-chair: Co-chair for radiation sciences education track and part of planning committee: Compensation? No |
| Ferah      | Yildiz    | Hacettepe University Faculty of Medicine, Department of Radiation Oncology  | None   | None   | None   |
| Torunn     | Yock      | Massachusetts General Hospital: Professor: Employee   | <b>Mim Software:</b> Research: Recipient: My Institution: Salary Support: Yes: site principal investigator: RT and Radiology Software: Salary support: They help pull RT plans from other institutions for the registry.: 2025   | None   | None   |
| Sue        | Yom       | ASTRO: EIC IROBP: Independent Contractor<br><b>Bristol Meyers:</b> Investigator: Independent Contractor<br><b>Springer_UpToDate:</b> author: Independent Contractor<br><b>University of California San Francisco:</b> Professor: Employee | <b>ASTRO:</b> Other-editor: Honoraria: Compensation/Payment: publishing: Present<br><b>Bristol Myers Squibb:</b> Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: nasopharyngeal cancer: Grant/research funding: nasopharynx cancer: To present<br><b>Elsevier:</b> Other-editor for ClinicalKey: Honoraria: oncology topics: To present<br><b>EMD Serono:</b> Research: Recipient: My Institution: Salary Support: No: site principal investigator: head and neck cancer: Grant/research funding: head and neck cancer: To present<br><b>Merck:</b> Grant/research funding: lung cancer: To present<br><b>Nanobiotix:</b> Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: : Grant/research funding: head and neck cancer: Present  | <b>Springer:</b> Book chapter royalty: author: Relationship ended<br><b>Springer:</b> Book chapter royalty: author<br><b>Up To Date:</b> Book chapter royalty: author: Relationship ended<br><b>Up To Date:</b> Book chapter royalty: author | ASTRO: ASTRO: EIC IROBP: EIC   |
| Stephanie  | Yoon      | City of Hope Medical Center: Assistant Professor: Employee  | None   | None   | None   |
| Afua       | Yorke     | University of Washington: Assistant Professor: Employee   | None   | None   | None   |
| Jing       | You       | Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital and Institute  | None   | None   | None   |
| Kristina   | Young     | The Oregon Clinic: Radiation Oncologist: Partner  | <b>Bicara:</b> Research: Recipient: My Institution: Salary Support: Yes: Sponsored research agreement: Combination BCA101 + RT: Grant/research funding, Salary support: PI: 1/1/26<br><b>BMS:</b> Research: Recipient: Me: Salary Support: No: SRA PI: CD8 T Cell-Specific TGFβ: Grant/research funding: PI: Present<br><b>Corbus Therapeutics:</b> Consultant, Research: Recipient: My Institution: Salary Support: No: SRA PI: Combination Radiation and CRB-622: Grant/research funding, Salary support, Compensation/Payment: 1) Clinical trial design consultant. 2) SRA for pre-clinical work with some salary support testing combination radiation and CRB-622: Present<br><b>IMV Inc:</b> Research: Recipient: My Institution: Salary Support: No: IIT PI: Survivac in Breast Cancer: Grant/research funding: IIT PI: Present<br><b>Synthis Bio:</b> Advisory Board: Ongoing: Access to company proprietary information or provide your expertise: or any public-   | <b>Kristina Young:</b> Copyright/Patent/License/Royalty: Patent holder   | <b>Synthis Therapeutics:</b> Biotech Startup: Scientific Advisor: TGFB in cancer: Compensation? No<br><b>The Oregon Clinic:</b> Medical Practice: Medical Director and Managing Partner: Medical Director and Managing Partner: Compensation? No   |



**ASTRO 2024 Annual Meeting - Faculty and Presenters' Disclosures**

| First Name | Last Name | Employment Relationships  | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria  | Ownerships/Investments/Intellectual Property | Leadership/Positions of Authority   |
|------------|-----------|---|--|--|---|
| Melissa    | Young     | Department of Therapeutic Radiology, Yale University School of Medicine   | Xequel Bio: Consultant: Compensation/Payment: Advisory board member: to present  | None   | None  |
| Irini      | Youssef   | Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center  | None   | None   | None  |
| David      | Yu        | Emory University: Professor: Employee<br>Emory University School of Medicine: Professor: Employee   | City of Hope: Speaker's Bureau: Honoraria, Travel expenses: Speaker: 2024<br>Cleveland Clinic Foundation: Speaker's Bureau: Travel expenses: Speaker: 2023<br>Columbia: Speaker's Bureau: Travel expenses: Speaker: 2023<br>DOD: Other-Reviewer: Grant/research funding, Honoraria, Travel expenses, Salary support: PI and Reviewer: Present<br>MCW: Speaker's Bureau: Travel expenses: Speaker: 2022<br>MGH: Speaker's Bureau: Honoraria: Speaker: 2023<br>NIH: Other-Reviewer: Grant/research funding, Honoraria, Travel expenses, Salary support: PI and Reviewer: Present<br>University of Kentucky: Speaker's Bureau: Honoraria, Travel expenses: Speaker: 2022<br>University of Maryland: Speaker's Bureau: Honoraria, Travel expenses: Speaker: 2023<br>University of Miami: Speaker's Bureau: Honoraria, Travel expenses: Speaker: 2023                                     | None   | Cancer Research: Journal: Editorial Board: Editorial Board: Compensation? No<br>International Journal of Radiation Biology: Journal: Associate Editor: Associate Editor: Compensation? No<br>Journal of Molecular Cell Biology: Journal: Editorial Board: Editorial Board: Compensation? No |
| James      | Yu        | Connecticut Radiation Oncology: Radiation Oncologist: Employee  | Boston Scientific: Advisory Board, Speaker's Bureau: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Honoraria, Compensation/Payment: Ongoing advisory board. Past speaking on behalf of the company.: To present<br>Pfizer / Myovant: Advisory Board, Research, Speaker's Bureau: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Recipient: Me: Salary Support: No: national/overall principal investigator: ASTRO/Pfizer/Myovant Challenge grant: Grant/research funding, Honoraria: Served on an advisory board and was compensated. Spoke in an educational panel and compensated by Pfizer/Myovant. PI of a funded trial as part of the Pfizer/Myovant funded 2022 ASTRO/Pfizer/Myovant challenge grant - Present | Modifi Bio: Stock: Stock ownership           | None  |
| Ning       | Yue       | Rutgers University: Professor, Executive Vice Chair and Chief of Physics: Employee  | None   | None   | SANTRO: Radiation oncology network between US and China: Board member: Board Member: Compensation? No   |
| Michael    | Yunes     | American Board of Radiology: Associate Executive Director: Employee<br>Pioneer Valley Radiation Oncology: President: Partner<br>University of Massachusetts Chan Medical School: Associate Professor: Academic Position | Elekta: Consultant: Honoraria, Travel expenses: Presented workflow optimization for Mosaik Voice, SmartClinic and SmartForms. SRS, SBRT with Monaco and Elekta VersaHD: Present  | None   | None  |
| Gelareh    | Zadeh     | Division of Neurosurgery, Toronto Western Hospital - University of Toronto  | None   | None   | None  |
| Nicholas   | Zaorsky   | University Hospitals: Radiation Oncologist: Employee  | American Cancer Society: Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: EXERT for metastatic prostate cancer: Grant/research funding: Tri State CEOs Against Cancer Clinician Scientist Development Grant, CSDG-20-013-01-CCE: present<br>American College of Radiation Oncology: Consultant: Compensation/Payment: chart review and accreditation of radiation oncology facilities nationally: present<br>NIH: Research: Recipient: Me: Salary Support: No: national/overall principal investigator: LRP 1 L30 CA231572-01: Grant/research funding: LRP 1 L30 CA231572-01: 2022  | None   | None  |
| Sondos     | Zayed     | Department of Radiation Oncology, Western University, London Health Sciences Centre   | None   | None   | None  |
| Michael    | Zelesky   | Memorial Sloan Kettering Cancer Center: Attending Physician: Employee: Relationship ended 04/01/2024<br>NYU Langone Medical Center: Attending Physician: Employee   | Boston Scientific: Consultant: Compensation/Payment: Consultant: Present   | None   | Brachytherapy Journal: Journal: Editor in Chief: Editor/Manuscripts: Compensation? Yes  |

**ASTRO 2024 Annual Meeting - Faculty and Presenters' Disclosures**

| First Name | Last Name | Employment Relationships  | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria  | Ownerships/Investments/Intellectual Property | Leadership/Positions of Authority |
|------------|-----------|---|--|--|-----------------------------------|
| Jing       | Zeng      | University of Washington: Professor: Employee   | <b>AstraZeneca:</b> Advisory Board, Consultant, Research: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Recipient: My Institution: Salary Support: No: national/overall principal investigator: Trial for small cell lung cancer: Grant/research funding, Honoraria, Compensation/Payment: Radiation and immunotherapy for lung cancer: To present<br><b>Gilead:</b> Research: Recipient: My Institution: Salary Support: No: national/overall principal investigator: Radiation with immunotherapy in mouse model: Grant/research funding: Testing radiation with immunotherapy in mouse model: To present<br><b>IBA:</b> Advisory Board, Consultant, Education/Meeting Faculty, Research: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Recipient: My Institution: Salary Support: No: national/overall principal investigator: FLASH research at proton center: Grant/research funding, Honoraria, Compensation/Payment: Proton radiation for cancer treatment: To present | None   | None                              |
| Zheng      | Zeng      | Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College   | None   | None   | None                              |
| Tianyou    | Zhan      | Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC)     | None   | None   | None                              |
| Helen      | Zhang     | Memorial Sloan-Kettering Cancer Center: Resident Physician: Employee  | None   | None   | None                              |
| Ran        | Zhang     | Shandong University Cancer Center ; Department of Radiation Oncology and Shandong Provincial Key Laboratory of Radiation Oncology, Shandong First Medical University and Shandong Academy of Medical Sciences | None   | None   | None                              |
| Rongxiao   | Zhang     | Westchester Medical Center: Chief, Section of Physics: Employee   | None   | None   | None                              |
| Samuel     | Zhang     | Department of Radiation Oncology, Cedars-Sinai Medical Center   | None   | None   | None                              |
| Ying       | Zhang     | Department of Radiation Oncology, First Affiliated Hospital of Air Force Medical University   | None   | None   | None                              |
| Zengfu     | Zhang     | Shandong Cancer Hospital and Institute  | None   | None   | None                              |
| Jingtong   | Zhao      | Duke University   | None   | None   | None                              |
| Michelle   | Zhao      | Bakar Computational Health Sciences Institute, University of California San Francisco   | None   | None   | None                              |
| Yue        | Zhao      | Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center; Cancer Hospital affiliate to University of Electronic Science and Technology of China                           | None   | None   | None                              |
| Dandan     | Zheng     | University of Rochester: Professor: Employee  | None   | None   | None                              |
| Siyue      | Zheng     | Department of Radiation Oncology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine  | None   | None   | None                              |
| Jim        | Zhong     | Department of Radiation Oncology, Winship Cancer Institute of Emory University  | None   | None   | None                              |
| Xin        | Zhou      | St Jude Children's Research Hospital: Assistant member: Employee  | None   | None   | None                              |
| Yue        | Zhou      | Shanghai Medical College, Fudan University  | None   | None   | None                              |

**ASTRO 2024 Annual Meeting - Faculty and Presenters' Disclosures**

| <b>First Name</b> | <b>Last Name</b> | <b>Employment Relationships</b>   | <b>Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria</b> | <b>Ownerships/Investments/Intellectual Property</b> | <b>Leadership/Positions of Authority</b> |
|-------------------|------------------|---|--|---|--|
| Ruiqiu            | Zhu              | Department of Radiotherapy and Oncology, The Second Affiliated Hospital of Soochow University | None   | None  | None                                     |
| Lin               | Zhu              | Harvard Radiation Oncology Program  | None   | None  | None                                     |
| Anthony           | Zietman          | Massachusetts General Hospital: Professor:<br>Employee  | None   | None  | None                                     |
| Jacqueline        | Zoberi           | Washington University School of Medicine:<br>Professor of Radiation Oncology: Employee        | None   | None  | None                                     |